


**CUMULATIVE
SUPPLEMENT 7**
July 2025



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

45th EDITION

Department of Health and Human Services

Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

45th EDITION

**Cumulative Supplement 7
July 2025**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi

DRUG PRODUCT LISTS

Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Products Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

45th EDITION

**CUMULATIVE SUPPLEMENT 7
July 2025**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section

2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
DR REDDYS LABORATORIES INC (DR REDDYS LABS INC)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
DR REDDYS LABORATORIES LTD (DR REDDYS)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
DR REDDYS LABORATORIES LTD (DR REDDYS LABS LTD)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
ENDO OPERATIONS LTD (ENDO OPERATIONS)	PH HEALTH LTD (PH HEALTH)
ICU MEDICAL INC (ICU MEDICAL INC)	OTSUKA ICU MEDICAL LLC (OTSUKA ICU MEDCL)
MYLAN INSTITUTIONAL LLC (MYLAN INSTITUTIONAL)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)

MYLAN LABORATORIES LTD (MYLAN LABS LTD)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN TECHNOLOGIES INC (MYLAN TECHNOLOGIES)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)	PHARMBEDIENT CONSULTING LLC (PHARMBEDIENT)
RUBICON RESEARCH PRIVATE LTD (RUBICON)	RUBICON RESEARCH LTD (RUBICON RESEARCH)
STERISCIENCE SPECIALITIES PTE LTD (STERISCIENCE SPECLTS)	ONESOURCE SPECIALTY PTE LTE (ONESOURCE SPECIALTY)
STRIDES SOFTGELS PTE LTD (STRIDES SOFTGELS)	ONESOURCE SPECIALTY PTE LTD (ONESOURCE SPECIALTY)
WOCKHARDT LTD (WOCKHARDT)	WOCKHARDT BIO AG (WOCKHARDT BIO AG)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	App1 No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	–	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2024</u>	<u>MAR 2025</u>	<u>JUN 2025</u>	<u>SEP 2025</u>	<u>DEC 2025</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23856 2772 (11.8%)	23679 2740 (11.6%)	23798 2744 (11.5%)		
MULTISOURCE	20814 (88.2%)	20939 (88.4%)	21054 (88.5%)		
THERAPEUTICALLY EQUIVALENT	20741 (87.9%)	20826 (88%)	20952 (88%)		
NOT THERAPEUTICALLY EQUIVALENT	73 (0.3%)	113 (0.5%)	102 (0.4%)		
EXCEPTIONS ⁴	47 (0.2%)	47 (0.2%)	47 (0.2%)		
NEW MOLECULAR ENTITIES APPROVED	43	13	7		
NUMBER OF APPLICANTS	1197	1209	1226		

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB	HETERO LABS LTD V	EQ 600MG BASE;300MG	A205412	001	Apr 16, 2025	Apr NEWA
@	MACLEODS PHARMS LTD	EQ 600MG BASE;300MG	A212663	001	Dec 19, 2024	Jun DISC

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

@	TEVA PHARMS USA	250MG	A208432	001	Oct 31, 2018	Mar DISC
@		500MG	A210726	001	Jan 26, 2023	Mar DISC

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB	GLENMARK PHARMS LTD	333MG	A202229	001	Jul 16, 2013	Mar CMFD
----	---------------------	-------	---------	-----	--------------	----------

>A> ACECLIDINE HYDROCHLORIDE

>A> SOLUTION/DROPS;OPHTHALMIC

>A> VIZZ

>A>	+!	LENZ THERAP	EQ 1.44% BASE	N218585	001	Jul 31, 2025	Jul NEWA
-----	----	-------------	---------------	---------	-----	--------------	----------

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP1	ASPIRO	1GM/100ML (10MG/ML)	A216617	001	Jul 27, 2022	Mar CTEC
AP	+! B BRAUN MEDICAL	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021	Mar CFTG
AP2	+!	1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021	Mar CFTG
	! BAXTER HLTHCARE CORP	650MG/65ML (10MG/ML)	A214331	002	May 21, 2025	May NEWA
AP1		1GM/100ML (10MG/ML)	A214331	001	Sep 17, 2021	Mar CTEC
AP1	EUGIA PHARMA	1GM/100ML (10MG/ML)	A210969	001	Oct 21, 2020	Mar CTEC
AP	GLAND	500MG/50ML (10MG/ML)	A219215	001	Apr 02, 2025	Mar NFTG
AP2		1GM/100ML (10MG/ML)	A219215	002	Apr 02, 2025	Mar NFTG
AP1	HIKMA	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Mar CTEC
AP1	INFORLIFE	1GM/100ML (10MG/ML)	A215403	001	May 03, 2023	Mar CTEC
AP1	MYLAN	1GM/100ML (10MG/ML)	A213255	001	Aug 07, 2020	Mar CTEC
AP1	! SANDOZ	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar CTEC
AP1	WOCKHARDT BIO AG	1GM/100ML (10MG/ML)	A205746	001	Apr 18, 2023	Mar CTEC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

@	AVIV PHARMA	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	May CAHN
---	-------------	----------------------	---------	-----	--------------	----------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@	CHARTWELL	120MG/5ML;12MG/5ML	A089450	001	Oct 27, 1992	Feb DISC
!	GENUS LIFESCIENCES	120MG/5ML;12MG/5ML	A087508	001		Feb CTEC
@	XTTRIUM LABS INC	120MG/5ML;12MG/5ML	A087006	001		Feb CAHN

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@	ANI PHARMS	300MG;15MG	A088629	002	Mar 06, 1985	May CAHN
@		300MG;30MG	A088629	003	Mar 06, 1985	May CAHN
@ +		300MG;60MG	A088629	001	Mar 06, 1985	May CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@	CHARTWELL	325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Feb DISC
AA	! WES PHARMA INC	325MG/15ML;7.5MG/15ML	A211023	001	Mar 08, 2019	Feb CHRS

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@	CHARTWELL	300MG;5MG	A040658	001	Jan 19, 2006	Feb DISC
@		300MG;7.5MG	A040658	002	Mar 24, 2006	Feb DISC
@		300MG;10MG	A040658	003	Jun 23, 2004	Feb DISC
@		325MG;7.5MG	A040432	001	Jan 22, 2003	Feb DISC
@	RHODES PHARMS	300MG;5MG	A207808	001	Mar 30, 2018	Jan DISC
@		300MG;7.5MG	A207808	002	Mar 30, 2018	Jan DISC
@		300MG;10MG	A207808	003	Mar 30, 2018	Jan DISC

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
AA	!	SPECGX LLC	300MG;5MG	A206718	001	Mar 31, 2017	Feb CHRS
AA	!		300MG;7.5MG	A206718	002	Mar 31, 2017	Feb CHRS
AA	!		300MG;10MG	A206718	003	Mar 31, 2017	Feb CHRS

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN							
AA		SANKALP LIFECARE	325MG/5ML;5MG/5ML	A201448	001	Aug 26, 2021	Apr CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN							
	@	CHARTWELL	325MG;5MG	A207834	001	Aug 15, 2019	Feb DISC
	@		325MG;7.5MG	A207834	002	Aug 15, 2019	Feb DISC
	@		325MG;10MG	A207834	003	Aug 15, 2019	Feb DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN							
	@	MPP PHARMA	325MG;37.5MG	A078778	001	Apr 07, 2014	Jun CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE							
AB		MPP PHARMA	500MG	A204691	001	Mar 29, 2016	May CAHN

TABLET;ORAL

ACETAZOLAMIDE							
AB		AUROBINDO PHARMA LTD	125MG	A212089	001	May 30, 2025	May NEWA
AB			250MG	A212089	002	May 30, 2025	May NEWA
		DIAMOX					
	@ +	TEVA BRANDED PHARM	125MG	N008943	001		Feb CAHN
	@ +		250MG	N008943	002		Feb CAHN

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM							
AP		GLAND	EQ 500MG BASE/VIAL	A219775	001	Jun 17, 2025	Jun NEWA

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE							
AN		CONBA USA	10%	A214177	001	Mar 14, 2025	Mar NEWA
AN			20%	A214177	002	Mar 14, 2025	Mar NEWA
AN		SOMERSET THERAPS LLC	10%	A219194	001	Feb 12, 2025	Jan NEWA
AN			20%	A219194	002	Feb 12, 2025	Jan NEWA

>D> ACETYLCYSTEINE LYSINE

>D> FOR SOLUTION;ORAL

>D> LEGUBETI

>D>	+!	GALEPHAR	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jul DISC
>A>	@ +		EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jul DISC
	+!		EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jun CMFD
>D>	+!		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jul DISC
>A>	@ +		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jul DISC
	+!		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jun CMFD

ACITRETIN

CAPSULE;ORAL

ACITRETIN							
	@	MYLAN	17.5MG	A203707	001	Sep 10, 2015	Apr CAHN
	@		22.5MG	A203707	002	Sep 10, 2015	Apr CAHN

ACOLTREMONE

SOLUTION/DROPS;OPHTHALMIC

TRYPTYR							
	+!	ALCON LABS INC	0.003%	N217370	001	May 28, 2025	May NEWA

ACYCLOVIR

CREAM; TOPICAL

ACYCLOVIR

	@	CIPLA	5%	A212981	001	May 02, 2025	May DISC
AB			5%	A212981	001	May 02, 2025	Apr NEWA
BX		ZYDUS LIFESCIENCES	5%	A206770	001	Feb 28, 2023	Mar CTEC

OINTMENT; TOPICAL

ACYCLOVIR

	@	APOTEX	5%	A210774	001	Sep 06, 2019	Jan DISC
	@	CHARTWELL MOLECULAR	5%	A206437	001	Jul 31, 2017	Feb CAHN
	@	CIPLA	5%	A211794	001	Jan 18, 2019	May DISC
BX			5%	A211794	001	Jan 18, 2019	Mar CTEC

>D> TABLET; BUCCAL

>D> SITAVIG

>D>	+	LIGAND PHARMS	50MG	N203791	001	Apr 12, 2013	Jul DISC
>A>	@	+	50MG	N203791	001	Apr 12, 2013	Jul DISC
	+	!	50MG	N203791	001	Apr 12, 2013	Jun CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP		FRESENIUS KABI USA	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	May CMFD
	@		EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Feb DISC

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

ALBUTEROL SULFATE

AB2		PADAGIS US	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Mar CMFD
-----	--	------------	--------------------	---------	-----	--------------	----------

POWDER, METERED; INHALATION

PROAIR DIGIHALER

@ + TEVA BRANDED PHARM

PROAIR RESPICLICK

+! TEVA BRANDED PHARM

			EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Feb CAHN
			EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015	Feb CAHN

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN		RITEDOSE CORP	EQ 0.5% BASE	A218386	001	Mar 12, 2025	Feb NEWA
----	--	---------------	--------------	---------	-----	--------------	----------

SYRUP; ORAL

ALBUTEROL SULFATE

@ COSETTE

			EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Jan DISC
--	--	--	-----------------	---------	-----	--------------	----------

TABLET; ORAL

ALBUTEROL SULFATE

AB		ACERTIS PHARMS	EQ 2MG BASE	A211397	001	Oct 26, 2018	May CAHN
----	--	----------------	-------------	---------	-----	--------------	----------

AB			EQ 4MG BASE	A211397	002	Oct 26, 2018	May CAHN
----	--	--	-------------	---------	-----	--------------	----------

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

>D> AB		GLENMARK PHARMS LTD	0.05%	A079061	001	Jun 23, 2009	Jul DISC
>A>	@		0.05%	A079061	001	Jun 23, 2009	Jul DISC

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

>D> AB		GLENMARK PHARMS LTD	0.05%	A079227	001	Jul 30, 2009	Jul DISC
>A>	@		0.05%	A079227	001	Jul 30, 2009	Jul DISC

ALCOHOL

SOLUTION; INTRA-ARTERIAL

ABLYSINOL

AP	+	BPI LABS	99% (5ML)	N207987	002	Jun 21, 2018	Jun CFTG
		DEHYDRATED ALCOHOL					

AP		ACCORD HLTHCARE	99% (5ML)	A217845	001	Jun 23, 2025	Jun NFTG
----	--	-----------------	-----------	---------	-----	--------------	----------

AP		BRECKENRIDGE	99% (5ML)	A219444	001	Jun 23, 2025	Jun NFTG
----	--	--------------	-----------	---------	-----	--------------	----------

AP		INGENUS PHARMS LLC	99% (5ML)	A219569	001	Jul 09, 2025	Jun NEWA
----	--	--------------------	-----------	---------	-----	--------------	----------

AP		XGEN PHARMS	99% (5ML)	A219400	001	Jun 23, 2025	Jun NFTG
----	--	-------------	-----------	---------	-----	--------------	----------

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

@ APOTEX

@

@

			EQ 5MG BASE	A077982	001	Aug 04, 2008	Mar DISC
			EQ 10MG BASE	A077982	002	Aug 04, 2008	Mar DISC
			EQ 35MG BASE	A077982	003	Aug 04, 2008	Mar DISC

TABLET;ORAL

ALENDRONATE SODIUM

@

EQ 70MG BASE

A077982 004 Aug 04, 2008 Mar DISC

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB	AUROBINDO PHARMA LTD	100MG	A215091	001	Apr 14, 2025	Apr	NEWA
AB		300MG	A215091	002	Apr 14, 2025	Apr	NEWA
AB	INDOCO	200MG	A204467	003	May 22, 2025	May	NEWA
AB	ZYDUS PHARMS	200MG	A210117	003	Jun 13, 2025	Jun	NEWA

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

	@	APOTEX INC	0.25MG	A077741	001	Jan 19, 2007	Mar	DISC
	@		0.5MG	A077741	002	Jan 19, 2007	Mar	DISC
	@		1MG	A077741	003	Jan 19, 2007	Mar	DISC
	@		2MG	A077741	004	Jan 19, 2007	Mar	DISC
>D> AB		SUN PHARM	0.25MG	A090082	001	Jun 17, 2010	Jul	DISC
>A>	@		0.25MG	A090082	001	Jun 17, 2010	Jul	DISC
>D> AB			0.5MG	A090082	002	Jun 17, 2010	Jul	DISC
>A>	@		0.5MG	A090082	002	Jun 17, 2010	Jul	DISC
>D> AB			1MG	A090082	003	Jun 17, 2010	Jul	DISC
>A>	@		1MG	A090082	003	Jun 17, 2010	Jul	DISC
>D> AB			2MG	A090082	004	Jun 17, 2010	Jul	DISC
>A>	@		2MG	A090082	004	Jun 17, 2010	Jul	DISC

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

@ APOTEX INC

@

@

@

0.5MG

1MG

2MG

3MG

A078449 001 Nov 12, 2008 Mar DISC

A078449 004 Dec 23, 2015 Mar DISC

A078449 002 Nov 12, 2008 Mar DISC

A078449 003 Nov 12, 2008 Mar DISC

ALPROSTADIL

SUPPOSITORY;URETHRAL

MUSE

@ + VIATRIS

@ +

@ +

@ +

0.125MG

0.25MG

0.5MG

1MG

N020700 001 Nov 19, 1996 Feb CAHN

N020700 002 Nov 19, 1996 Feb CAHN

N020700 003 Nov 19, 1996 Feb CAHN

N020700 004 Nov 19, 1996 Feb CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

AMANTADINE HYDROCHLORIDE

@ ZYDUS

GOCOVRI

+ SUPERNUS PHARMS

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

@ BAJAJ

EQ 68.5MG BASE

EQ 68.5MG BASE

50MG/5ML

A214897 001 Aug 26, 2024 May DISC

N208944 001 Aug 24, 2017 May CTEC

A075819 001 Sep 11, 2002 Mar CAHN

AMCINONIDE

LOTION;TOPICAL

AMCINONIDE

! SOLUBIOMIX

0.1%

A076329 001 Nov 06, 2002 Feb CAHN

AMINOCAPROIC ACID

SOLUTION;ORAL

AMINOCAPROIC ACID

AA	AJENAT PHARMS	0.25GM/ML
AA	APOZEAL PHARMS	0.25GM/ML

0.25GM/ML

0.25GM/ML

A213825 001 Apr 08, 2021 Jan CAHN

A213216 001 May 19, 2025 May NEWA

AMINOPHYLLINE

INJECTABLE;INJECTION

AMINOPHYLLINE

+! HOSPIRA

25MG/ML

A087242 001 Oct 26, 1983 Jun CRLD

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

BX	RUBICON	10MG	A215376	001	May 01, 2023	Mar CTEC
BX		25MG	A215376	002	May 01, 2023	Mar CTEC
BX		50MG	A215376	003	May 01, 2023	Mar CTEC
BX		75MG	A215376	004	May 01, 2023	Mar CTEC
BX		100MG	A215376	005	May 01, 2023	Mar CTEC
BX		150MG	A215376	006	May 01, 2023	Mar CTEC
AB	UNIQUE PHARM	10MG	A218389	001	Jun 23, 2025	Jun NEWA
AB		25MG	A218389	002	Jun 23, 2025	Jun NEWA
AB		50MG	A218389	003	Jun 23, 2025	Jun NEWA
AB		75MG	A218389	004	Jun 23, 2025	Jun NEWA
AB		100MG	A218389	005	Jun 23, 2025	Jun NEWA
AB		150MG	A218389	006	Jun 23, 2025	Jun NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@	MICRO LABS	EQ 12.5MG BASE;5MG	A211925	001	Feb 02, 2022	Apr DISC
@		EQ 25MG BASE;10MG	A211925	002	Feb 02, 2022	Apr DISC
	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Apr CTEC
!		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Apr CTEC

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@	CHARTWELL RX	50MG;4MG	A071863	001	Dec 21, 1987	Jun CAHN
---	--------------	----------	---------	-----	--------------	----------

AMLODIPINE BESYLATE

FOR SOLUTION;ORAL

SDAMLO

>A>	+!	BRILLIAN PHARMA	EQ 2.5MG BASE/BOT	N219531	001	Jul 24, 2025	Jul NEWA
>A>	+!		EQ 5MG BASE/BOT	N219531	002	Jul 24, 2025	Jul NEWA
>A>	+!		EQ 10MG BASE/BOT	N219531	003	Jul 24, 2025	Jul NEWA

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	ALEMBIC	EQ 2.5MG BASE;EQ 10MG BASE	A217279	001	May 22, 2025	May NEWA
AB		EQ 2.5MG BASE;EQ 20MG BASE	A217279	002	May 22, 2025	May NEWA
AB		EQ 2.5MG BASE;EQ 40MG BASE	A217279	003	May 22, 2025	May NEWA
AB		EQ 5MG BASE;EQ 10MG BASE	A217279	004	May 22, 2025	May NEWA
AB		EQ 5MG BASE;EQ 20MG BASE	A217279	005	May 22, 2025	May NEWA
AB		EQ 5MG BASE;EQ 40MG BASE	A217279	006	May 22, 2025	May NEWA
AB		EQ 5MG BASE;EQ 80MG BASE	A217279	007	May 22, 2025	May NEWA
AB		EQ 10MG BASE;EQ 10MG BASE	A217279	008	May 22, 2025	May NEWA
AB		EQ 10MG BASE;EQ 20MG BASE	A217279	009	May 22, 2025	May NEWA
AB		EQ 10MG BASE;EQ 40MG BASE	A217279	010	May 22, 2025	May NEWA
AB		EQ 10MG BASE;EQ 80MG BASE	A217279	011	May 22, 2025	May NEWA
AB	APDM PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Feb CAHN
AB		EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Feb CAHN
AB		EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Feb CAHN
AB		EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Feb CAHN
AB		EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Feb CAHN
AB		EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Feb CAHN
AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb CAHN
AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb CAHN
AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb CAHN
AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb CAHN
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	CHARTWELL RX	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010	Apr CAHN
@		EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010	Apr CAHN
@		EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010	Apr CAHN
@		EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010	Apr CAHN
@		EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010	Apr CAHN
@		EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010	Apr CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

>A>	AB	MACLEODS PHARMS LTD	EQ 5MG BASE;12.5MG;20MG	A207088	001	Jul 18, 2025	Jul	NEWA
>A>	AB		EQ 5MG BASE;12.5MG;40MG	A207088	002	Jul 18, 2025	Jul	NEWA
>A>	AB		EQ 5MG BASE;25MG;40MG	A207088	003	Jul 18, 2025	Jul	NEWA
>A>	AB		EQ 10MG BASE;12.5MG;40MG	A207088	004	Jul 18, 2025	Jul	NEWA
>A>	AB		EQ 10MG BASE;25MG;40MG	A207088	005	Jul 18, 2025	Jul	NEWA
	AB	PIRAMAL	EQ 5MG BASE;12.5MG;20MG	A210718	001	May 14, 2025	May	NEWA
	AB		EQ 5MG BASE;12.5MG;40MG	A210718	002	May 14, 2025	May	NEWA
	AB		EQ 5MG BASE;25MG;40MG	A210718	003	May 14, 2025	May	NEWA
	AB		EQ 10MG BASE;12.5MG;40MG	A210718	004	May 14, 2025	May	NEWA
	AB		EQ 10MG BASE;25MG;40MG	A210718	005	May 14, 2025	May	NEWA
	@	TORRENT	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016	Jun	DISC
	@		EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016	Jun	DISC
	@		EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016	Jun	DISC

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

TABLET; ORAL

WIDAPLIK

@ +	GEORGE MEDICINES	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Jun	DISC
+		EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Jun	NEWA
@ +		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Jun	DISC
+		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Jun	NEWA
@ +		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Jun	DISC
+		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Jun	NEWA

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	HETERO LABS LTD V	EQ 5MG BASE;20MG	A209591	001	Feb 14, 2025	Feb	NEWA
AB		EQ 5MG BASE;40MG	A209591	002	Feb 14, 2025	Feb	NEWA
AB		EQ 10MG BASE;20MG	A209591	003	Feb 14, 2025	Feb	NEWA
AB		EQ 10MG BASE;40MG	A209591	004	Feb 14, 2025	Feb	NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	SOFIE	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Mar	CAHN
----	-------	------------------------------------	---------	-----	--------------	-----	------

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

ADZENYS XR-ODT

>D>	+	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jul	CTEC
>A>	AB	+	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jul	CTEC
>D>	+		EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jul	CTEC
>A>	AB	+	EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jul	CTEC
>D>	+		EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jul	CTEC
>A>	AB	+	EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jul	CTEC
>D>	+		EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jul	CTEC
>A>	AB	+	EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jul	CTEC
>D>	+		EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jul	CTEC
>A>	AB	+	EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jul	CTEC
>D>	+		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jul	CTEC
>A>	AB	+	EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jul	CTEC

AMPHETAMINE

>D>	@	ACTAVIS LABS FL INC	EQ 3.1MG BASE	A209253	001	Jun 22, 2023	Jul	CMFD
>A>	AB		EQ 3.1MG BASE	A209253	001	Jun 22, 2023	Jul	CMFD
>D>	@		EQ 6.3MG BASE	A209253	002	Jun 22, 2023	Jul	CMFD
>A>	AB		EQ 6.3MG BASE	A209253	002	Jun 22, 2023	Jul	CMFD
>D>	@		EQ 9.4MG BASE	A209253	003	Jun 22, 2023	Jul	CMFD
>A>	AB		EQ 9.4MG BASE	A209253	003	Jun 22, 2023	Jul	CMFD
>D>	@		EQ 12.5MG BASE	A209253	004	Jun 22, 2023	Jul	CMFD
>A>	AB		EQ 12.5MG BASE	A209253	004	Jun 22, 2023	Jul	CMFD
>D>	@		EQ 15.7MG BASE	A209253	005	Jun 22, 2023	Jul	CMFD
>A>	AB		EQ 15.7MG BASE	A209253	005	Jun 22, 2023	Jul	CMFD
>D>	@		EQ 18.8MG BASE	A209253	006	Jun 22, 2023	Jul	CMFD
>A>	AB		EQ 18.8MG BASE	A209253	006	Jun 22, 2023	Jul	CMFD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	CEDIPROF INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210754	001	Jul 05, 2022	Jan CMFD
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210754	002	Jul 05, 2022	Jan CMFD
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210754	003	Jul 05, 2022	Jan CMFD
AB		5MG; 5MG; 5MG; 5MG	A210754	004	Jul 05, 2022	Jan CMFD
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210754	005	Jul 05, 2022	Jan CMFD

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

@	RHODES PHARMS	5MG	A213852	001	Sep 07, 2021	Jan DISC
@		10MG	A213852	002	Sep 07, 2021	Jan DISC

AMPHOTERICIN B

INJECTABLE, LIPOSOMAL; INJECTION

AMPHOTERICIN B

AB	AVET LIFESCIENCES	50MG/VIAL	A215354	001	Jun 02, 2025	May NEWA
AB	MYLAN LABS LTD	50MG/VIAL	A212967	001	Jun 30, 2025	Jun NEWA

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

@	HIKMA	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Mar DISC
@		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Mar DISC

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

@	BARR LABS	EQ 0.5MG BASE	A076530	001	Apr 18, 2005	Mar CAHN
@		EQ 1MG BASE	A076530	002	Apr 18, 2005	Mar CAHN

ANGIOTENSIN II ACETATE

SOLUTION; INTRAVENOUS

ANGIOTENSIN II ACETATE

AP	GLAND	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	A216966	001	Jun 03, 2025	May NFTG
AP	GIAPREZA					
AP	+! LA JOLLA PHARMA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	May CFTG

APALUTAMIDE

TABLET; ORAL

APALUTAMIDE

AB	ZYDUS	60MG	A217113	001	Mar 17, 2025	Mar NFTG
AB	ERLEADA					
AB	+ JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Mar CFTG

APIXABAN

FOR SUSPENSION; ORAL

ELIQUIS SPRINKLE

+!	BRISTOL	0.15MG	N220073	001	Apr 17, 2025	Apr NEWA
----	---------	--------	---------	-----	--------------	----------

TABLET; ORAL

APIXABAN

@	HETERO LABS LTD V	2.5MG	A210066	001	Nov 21, 2023	Apr DISC
@		5MG	A210066	002	Nov 21, 2023	Apr DISC
>D> AB	IMPAX	2.5MG	A209810	001	Feb 14, 2025	Jul DISC
>A>	@	2.5MG	A209810	001	Feb 14, 2025	Jul DISC
AB		2.5MG	A209810	001	Feb 14, 2025	Feb NEWA
>D> AB		5MG	A209810	002	Feb 14, 2025	Jul DISC
>A>	@	5MG	A209810	002	Feb 14, 2025	Jul DISC
AB		5MG	A209810	002	Feb 14, 2025	Feb NEWA
@	MACLEODS PHARMS LTD	2.5MG	A210067	001	Feb 27, 2025	Jun DISC
AB		2.5MG	A210067	001	Feb 27, 2025	Feb NEWA
@		5MG	A210067	002	Feb 27, 2025	Jun DISC
AB		5MG	A210067	002	Feb 27, 2025	Feb NEWA
@	TORRENT	2.5MG	A210156	001	Dec 17, 2024	Jun DISC
@		5MG	A210156	002	Dec 17, 2024	Jun DISC

TABLET, FOR SUSPENSION;ORAL
ELIQUIS

+! BRISTOL MYERS SQUIBB 0.5MG N202155 003 Apr 17, 2025 Apr NEWA

APOMORPHINE HYDROCHLORIDE

SOLUTION;SUBCUTANEOUS
ONAPGO

+! MDD US 98MG/20ML (4.9MG/ML) N214056 001 Feb 03, 2025 Feb NEWA

APREMILAST

TABLET;ORAL
APREMILAST

	@	GLENMARK PHARMS LTD	10MG	A211674	001	Oct 16, 2023	Jun DISC
	@		20MG	A211674	002	Oct 16, 2023	Jun DISC
	@		30MG	A211674	003	Oct 16, 2023	Jun DISC
	@	MACLEODS PHARMS LTD	10MG	A211788	001	Nov 25, 2024	Jun DISC
	@		20MG	A211788	002	Nov 25, 2024	Jun DISC
	@		30MG	A211788	003	Nov 25, 2024	Jun DISC
>D>	AB	TORRENT	10MG	A211834	001	Jun 20, 2025	Jul DISC
>A>	@		10MG	A211834	001	Jun 20, 2025	Jul DISC
	AB		10MG	A211834	001	Jun 20, 2025	Jun NEWA
>D>	AB		20MG	A211834	002	Jun 20, 2025	Jul DISC
>A>	@		20MG	A211834	002	Jun 20, 2025	Jul DISC
	AB		20MG	A211834	002	Jun 20, 2025	Jun NEWA
>D>	AB		30MG	A211834	003	Jun 20, 2025	Jul DISC
>A>	@		30MG	A211834	003	Jun 20, 2025	Jul DISC
	AB		30MG	A211834	003	Jun 20, 2025	Jun NEWA

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION
ARFORMOTEROL TARTRATE

AN	AUCTA	EQ 0.015MG BASE/2ML	A218380	001	Feb 03, 2025	Jan NEWA
AN	MICRO LABS	EQ 0.015MG BASE/2ML	A218555	001	Mar 07, 2025	Feb NEWA
AN	SABA ILAC SANAYI	EQ 0.015MG BASE/2ML	A218429	001	Apr 25, 2025	Apr NEWA

ARGATROBAN

INJECTABLE;INJECTION
ARGATROBAN

>D>	AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Jul DISC
>A>	@		250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Jul DISC

INJECTABLE;INTRAVENOUS
ARGATROBAN IN SODIUM CHLORIDE

AP	+!	PLANO PHARMS	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	Mar CAHN
----	----	--------------	----------------------	---------	-----	--------------	----------

ARIPIPIRAZOLE

FILM;ORAL
MEZOFY

	+	CMG PHARM CO LTD	5MG	N211448	001	Apr 15, 2025	Apr NEWA
	+!		10MG	N211448	002	Apr 15, 2025	Apr NEWA
	+		15MG	N211448	003	Apr 15, 2025	Apr NEWA

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY MAINTENA KIT

	+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013	Jan CTEC
	+!		400MG/VIAL	N202971	002	Feb 28, 2013	Jan CTEC
>D>	+		400MG	N202971	004	Sep 29, 2014	Jul CHRS
>A>	+!		400MG	N202971	004	Sep 29, 2014	Jul CHRS

ARIPIPIRAZOLE

	@	MYLAN	300MG/VIAL	A216608	001	Dec 03, 2024	Jan DISC
	@		400MG/VIAL	A216608	002	Dec 03, 2024	Jan DISC

SOLUTION;ORAL
ARIPIPIRAZOLE

AA		VISTAPHARM LLC	1MG/ML	A212870	001	Dec 26, 2019	Jan CAHN
----	--	----------------	--------	---------	-----	--------------	----------

ARMODAFINIL

TABLET;ORAL
NUVIGIL

AB	+	NUVO PHARMS	50MG	N021875	001	Jun 15, 2007	Jan CAHN
	@ +		100MG	N021875	002	Mar 26, 2009	Jan CAHN
AB	+		150MG	N021875	003	Jun 15, 2007	Jan CAHN
AB	+		200MG	N021875	005	Mar 26, 2009	Jan CAHN
AB	+!		250MG	N021875	004	Jun 15, 2007	Jan CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA	MPP PHARMA	325MG;50MG;40MG	A 078149	001	Jun 13, 2007	May CAHN
----	------------	-----------------	----------	-----	--------------	----------

ATENOLOL

TABLET;ORAL

ATENOLOL

>A>	AB	AIPING PHARM INC	25MG	A 072304	002	Jul 31, 1992	Jul CAHN
>A>	AB		50MG	A 072304	003	Jul 18, 1988	Jul CAHN
>A>	AB		100MG	A 072304	001	Jul 15, 1988	Jul CAHN
>D>	AB	TWI PHARMS	25MG	A 072304	002	Jul 31, 1992	Jul CAHN
>D>	AB		50MG	A 072304	003	Jul 18, 1988	Jul CAHN
>D>	AB		100MG	A 072304	001	Jul 15, 1988	Jul CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

>A>	AB	AIPING PHARM INC	50MG;25MG	A 072302	002	May 31, 1990	Jul CAHN
>A>	AB		100MG;25MG	A 072302	001	May 31, 1990	Jul CAHN
>D>	AB	TWI PHARMS	50MG;25MG	A 072302	002	May 31, 1990	Jul CAHN
>D>	AB		100MG;25MG	A 072302	001	May 31, 1990	Jul CAHN

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	APOTEX	EQ 10MG BASE	A 214969	001	Sep 02, 2021	Jun CAHN
AB		EQ 20MG BASE	A 214969	002	Sep 02, 2021	Jun CAHN
AB		EQ 40MG BASE	A 214969	003	Sep 02, 2021	Jun CAHN
AB		EQ 80MG BASE	A 214969	004	Sep 02, 2021	Jun CAHN
@	SUN PHARM INDS LTD	EQ 10MG BASE	A 076477	001	Nov 30, 2011	Mar DISC
@		EQ 20MG BASE	A 076477	002	Nov 30, 2011	Apr DISC
@		EQ 40MG BASE	A 076477	003	Nov 30, 2011	Apr DISC
@		EQ 80MG BASE	A 076477	004	Nov 30, 2011	Apr DISC

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

@	APOTEX	750MG/5ML	A 209750	001	Oct 11, 2017	Mar DISC
AB	PAI HOLDINGS	750MG/5ML	A 214272	001	Oct 25, 2021	Jun CAHN

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

>D>	AP	EUGIA PHARMA	10MG/ML	A 206011	001	Apr 08, 2015	Jul DISC
>A>	@		10MG/ML	A 206011	001	Apr 08, 2015	Jul DISC
		ATRACURIUM BESYLATE PRESERVATIVE FREE					
>D>	AP	EUGIA PHARMA	10MG/ML	A 206010	001	Apr 08, 2015	Jul DISC
>A>	@		10MG/ML	A 206010	001	Apr 08, 2015	Jul DISC

ATRASENTAN HYDROCHLORIDE

TABLET;ORAL

VANRAFIA

+	NOVARTIS	EQ 0.75MG BASE	N 219208	001	Apr 02, 2025	Apr NEWA
---	----------	----------------	----------	-----	--------------	----------

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D>	!	HIKMA	0.025MG/5ML; 2.5MG/5ML	A 087708	001	May 03, 1982	Jul CRLD
>A>	+	!	0.025MG/5ML; 2.5MG/5ML	A 087708	001	May 03, 1982	Jul CRLD

AVANAFIL

TABLET;ORAL

STENDRA

>D>	AB	+	METUCHEN PHARMS	50MG	N 202276	001	Apr 27, 2012	Jul CAHN
>D>	AB	+		100MG	N 202276	002	Apr 27, 2012	Jul CAHN
>D>	AB	+	!	200MG	N 202276	003	Apr 27, 2012	Jul CAHN
>A>	AB	+	VIVUS LLC	50MG	N 202276	001	Apr 27, 2012	Jul CAHN
>A>	AB	+		100MG	N 202276	002	Apr 27, 2012	Jul CAHN
>A>	AB	+	!	200MG	N 202276	003	Apr 27, 2012	Jul CAHN

AVATROMBOPAG MALEATE

>A> GRANULE;ORAL
 >A> DOPTLET SPRINKLE
 >A> +! AKARX INC EQ 10MG BASE N219696 001 Jul 24, 2025 Jul NEWA

AVIBACTAM SODIUM; AZTREONAM

POWDER;INTRAVENOUS
 EMBLAVEO
 +! ABBVIE EQ 0.5GM BASE/VIAL;1.5GM/VIAL N217906 001 Feb 07, 2025 Feb NEWA

AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE

CAPSULE, TABLET;ORAL
 AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
 +! VERASTEM INC EQ 0.8MG BASE;EQ 200MG BASE N219616 001 May 08, 2025 May NEWA

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS
 AZACITIDINE
 AP RELIANCE LIFE 100MG/VIAL A217453 001 May 20, 2025 May NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL
 ASTEPRO
 @ + NORVIUM BIOSCIENCE 0.137MG/SPRAY N022203 001 Oct 15, 2008 Jan CAHN
 @ 0.2055MG/SPRAY N022203 002 Aug 31, 2009 Jan CAHN
 @ + VIATRIS 0.137MG/SPRAY N022203 001 Oct 15, 2008 Apr CAHN
 @ 0.2055MG/SPRAY N022203 002 Aug 31, 2009 Apr CAHN
 AZELASTINE HYDROCHLORIDE
 @ BIONPHARMA 0.137MG/SPRAY A090176 001 Jul 28, 2015 Jan DISC
 AB PADAGIS US 0.137MG/SPRAY A202609 001 Mar 17, 2017 Jun CAHN

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL
 AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE
 AB TEVA PHARMS USA INC 0.137MG/SPRAY;0.05MG/SPRAY A208436 001 Apr 08, 2025 Mar NEWA

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL
 AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE
 AB ALKEM LABS LTD EQ 40MG MEDOXOMIL;12.5MG A217490 001 Jan 21, 2025 Jan NFTG
 AB EQ 40MG MEDOXOMIL;25MG A217490 002 Jan 21, 2025 Jan NFTG
 EDARBYCLOR
 AB + AZURITY EQ 40MG MEDOXOMIL;12.5MG N202331 001 Dec 20, 2011 Jan CFTG
 AB +! EQ 40MG MEDOXOMIL;25MG N202331 002 Dec 20, 2011 Jan CFTG

AZITHROMYCIN

FOR SUSPENSION;ORAL
 AZITHROMYCIN
 AB CHARTWELL RX EQ 100MG BASE/5ML A065488 001 May 15, 2015 Feb CMFD
 AB EQ 200MG BASE/5ML A065488 002 May 15, 2015 Feb CMFD
 AB ZHEJIANG POLY PHARM EQ 100MG BASE/5ML A217036 001 Jul 27, 2023 Mar CAHN
 AB EQ 200MG BASE/5ML A217036 002 Jul 27, 2023 Mar CAHN
 ZITHROMAX
 @ + PFIZER EQ 1GM BASE/PACKET N050693 001 Sep 28, 1994 Apr DISC
 INJECTABLE;INJECTION
 AZITHROMYCIN
 @ HOSPIRA EQ 500MG BASE/VIAL A065511 001 Jun 26, 2009 Apr DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
 LUMI-SPORYN
 AT + CASPER PHARMA LLC 400 UNITS/GM;EQ 3.5MG N050417 001 Feb CPOT
 BASE/GM;10,000 UNITS/GM

BACLOFEN

GRANULES;ORAL
 LYVISPAH
 @ + AMNEAL 5MG/PACKET N215422 001 Nov 22, 2021 Jun DISC
 @ + 10MG/PACKET N215422 002 Nov 22, 2021 Jun DISC
 @ + 20MG/PACKET N215422 003 Nov 22, 2021 Jun DISC

SOLUTION; ORAL									
BACLOFEN									
AA	RUBICON RESEARCH			5MG/5ML	A214445	001	Dec 06, 2024	May	CAHN
				10MG/5ML	A214445	002	Jun 03, 2025	May	NFTG
AA	OZOBAX DS								
AA	+! METACEL PHARMS LLC			10MG/5ML	N208193	002	Oct 12, 2023	May	CFTG
TABLET; ORAL									
BACLOFEN									
AB	APPCO			5MG	A090334	003	Jan 31, 2025	Jan	NEWA
>D>	AB	! RUBICON		5MG	A209102	001	Nov 28, 2017	Jul	CAHN
>D>	AB			10MG	A209102	002	Nov 28, 2017	Jul	CAHN
>D>	AB			15MG	A209102	004	Feb 05, 2024	Jul	CAHN
>D>	AB			20MG	A209102	003	Nov 28, 2017	Jul	CAHN
>A>	AB	! RUBICON RESEARCH		5MG	A209102	001	Nov 28, 2017	Jul	CAHN
>A>	AB			10MG	A209102	002	Nov 28, 2017	Jul	CAHN
>A>	AB			15MG	A209102	004	Feb 05, 2024	Jul	CAHN
>A>	AB			20MG	A209102	003	Nov 28, 2017	Jul	CAHN
	AB	YILING		10MG	A074584	001	Aug 19, 1996	Jun	CAHN
	AB			20MG	A074584	002	Aug 19, 1996	Jun	CAHN
<u>BALOXAVIR MARBOXIL</u>									
FOR SUSPENSION; ORAL									
XOFLUZA									
	+ GENENTECH INC			30MG/PACKET	N214410	002	May 30, 2025	Jun	NEWA
	+!			40MG/PACKET	N214410	003	May 30, 2025	Jun	NEWA
<u>BALSALAZIDE DISODIUM</u>									
CAPSULE; ORAL									
BALSALAZIDE DISODIUM									
AB	CARNEGIE			750MG	A219422	001	Apr 03, 2025	Mar	NEWA
<u>BECLOMETHASONE DIPROPIONATE</u>									
AEROSOL, METERED; INHALATION									
QVAR 40									
	@ + TEVA BRANDED PHARM			0.04MG/INH	N020911	002	Sep 15, 2000	Mar	CAHN
QVAR 80									
	@ + TEVA BRANDED PHARM			0.08MG/INH	N020911	001	Sep 15, 2000	Mar	CAHN
AEROSOL, METERED; NASAL									
QNASL									
	+ TEVA BRANDED PHARM			0.04MG/ACTUATION	N202813	002	Dec 17, 2014	Feb	CAHN
	+!			0.08MG/ACTUATION	N202813	001	Mar 23, 2012	Feb	CAHN
<u>BENDAMUSTINE HYDROCHLORIDE</u>									
POWDER; INTRAVENOUS									
BENDAMUSTINE HYDROCHLORIDE									
	@ APOTEX			25MG/VIAL	A204230	001	Jun 05, 2023	May	DISC
	@			100MG/VIAL	A204230	002	Jun 05, 2023	May	DISC
SOLUTION; INTRAVENOUS									
BENDAMUSTINE HYDROCHLORIDE									
>A>	+! DR REDDYS			100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Jul	NEWA
>A>	@ +			100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Jul	DISC
<u>BENZOYL PEROXIDE</u>									
CREAM; TOPICAL									
EPSOLAY									
	+! MAYNE PHARMA			5%	N214510	001	Apr 22, 2022	May	CAHN
<u>BENZOYL PEROXIDE; TRETINOIN</u>									
CREAM; TOPICAL									
TWYNEO									
	+! MAYNE PHARMA			3%; 0.1%	N214902	001	Jul 26, 2021	May	CAHN
<u>BENZTROPINE MESYLATE</u>									
TABLET; ORAL									
BENZTROPINE MESYLATE									
AA	QUAGEN			0.5MG	A212694	001	Feb 11, 2025	Jan	NEWA
AA				1MG	A212694	002	Feb 11, 2025	Jan	NEWA
AA				2MG	A212694	003	Feb 11, 2025	Jan	NEWA

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

	@	CHARTWELL MOLECULAR	EQ 0.05% BASE	A076603	001	Jan 23, 2004	Feb CAHN
>D> AB	!	GLENMARK PHARMS INC	EQ 0.05% BASE	A078930	001	Sep 23, 2008	Jul DISC
>A>	@		EQ 0.05% BASE	A078930	001	Sep 23, 2008	Jul DISC
>D> AB		TARO	EQ 0.05% BASE	A076543	001	Dec 09, 2003	Jul CHRS
>A> AB	!		EQ 0.05% BASE	A076543	001	Dec 09, 2003	Jul CHRS

OINTMENT; TOPICAL
BETAMETHASONE DIPROPIONATE

>D> AB		TARO	EQ 0.05% BASE	A074271	001	Sep 15, 1994	Jul DISC
>A>	@		EQ 0.05% BASE	A074271	001	Sep 15, 1994	Jul DISC

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION; TOPICAL
CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE
@ PADAGIS ISRAEL 0.064%; 0.005%

A212367	001	Sep 11, 2020	Jan DISC
---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
BETAXOLOL HYDROCHLORIDE

@	RENOVA PHARMS	EQ 0.5% BASE	A075386	001	Jun 30, 2000	Jun CAHN
---	---------------	--------------	---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

>D>	@	HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Jul CMFD
>A> AA			5MG	A091256	001	May 04, 2010	Jul CMFD
>D>	@		10MG	A091256	002	May 04, 2010	Jul CMFD
>A> AA			10MG	A091256	002	May 04, 2010	Jul CMFD
>D>	@		25MG	A091256	003	May 04, 2010	Jul CMFD
>A> AA			25MG	A091256	003	May 04, 2010	Jul CMFD
>D>	@		50MG	A091256	004	May 04, 2010	Jul CMFD
>A> AA			50MG	A091256	004	May 04, 2010	Jul CMFD

BEXAROTENE

CAPSULE; ORAL
BEXAROTENE

@	CIPLA	75MG	A210352	001	Dec 10, 2024	Jan DISC
---	-------	------	---------	-----	--------------	----------

BICALUTAMIDE

TABLET; ORAL
BICALUTAMIDE

@	APOTEX	50MG	A200274	001	May 21, 2015	Mar DISC
---	--------	------	---------	-----	--------------	----------

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC
BIMATOPROST

AB		MANKIND PHARMA	0.01%	A218196	001	Mar 17, 2025	Mar NFTG
		LUMIGAN					
AB	+	ABBVIE	0.01%	N022184	001	Aug 31, 2010	Mar CFTG

BISOPROLOL FUMARATE

TABLET; ORAL
BISOPROLOL FUMARATE

		RUBICON	2.5MG	A075643	003	Mar 07, 2025	Mar NEWA
AB		UNIQUE PHARM	5MG	A219044	001	Apr 16, 2025	Apr NEWA
AB			10MG	A219044	002	Apr 16, 2025	Apr NEWA
		ZEBETA					
	@ +	TEVA BRANDED PHARM	5MG	N019982	002	Jul 31, 1992	Apr CAHN
	@ +		10MG	N019982	001	Jul 31, 1992	Apr CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ZIAC

AB	+	TEVA BRANDED PHARM	2.5MG; 6.25MG	N020186	003	Mar 26, 1993	Apr CAHN
AB	+		5MG; 6.25MG	N020186	001	Mar 26, 1993	Apr CAHN
AB	+	!	10MG; 6.25MG	N020186	002	Mar 26, 1993	Apr CAHN

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
BORTEZOMIB

	@	BAXTER HLTHCARE CORP	3.5MG/VIAL	A213823	001	May 02, 2022	May DISC
AP		MEDICAMEN BIOTECH	3.5MG/VIAL	A218688	001	Jun 02, 2025	May NEWA

BOSENTAN

TABLET, FOR SUSPENSION;ORAL
BOSENTAN

AB		NATCO PHARMA LTD	32MG	A213154	001	Feb 05, 2025	Jan NFTG
		TRACLEER					
AB	+	ACTELION	32MG	N209279	001	Sep 05, 2017	Jan CFTG

BOSUTINIB MONOHYDRATE

TABLET;ORAL
BOSULIF

AB	+	PF PRISM CV	EQ 100MG BASE	N203341	001	Sep 04, 2012	May CFTG
AB	+		EQ 500MG BASE	N203341	002	Sep 04, 2012	May CFTG
		BOSUTINIB MONOHYDRATE					
AB		ALEMBIC	EQ 100MG BASE	A209543	001	May 23, 2025	May NFTG
AB			EQ 500MG BASE	A209543	002	May 23, 2025	May NFTG

BREXANOLONE

SOLUTION;INTRAVENOUS
ZULRESSO

	@ +	SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jan DISC
--	-----	-------------	---------------------	---------	-----	--------------	----------

BREXPIRAZOLE

TABLET;ORAL
BREXPIRAZOLE

AB		ALEMBIC	0.25MG	A213683	001	Jan 13, 2025	Jan NEWA
AB			0.5MG	A213683	002	Jan 13, 2025	Jan NEWA
AB			1MG	A213683	003	Jan 13, 2025	Jan NEWA
AB			2MG	A213683	004	Jan 13, 2025	Jan NEWA
AB			3MG	A213683	005	Jan 13, 2025	Jan NEWA
AB			4MG	A213683	006	Jan 13, 2025	Jan NEWA
	@	APOTEX	0.25MG	A213731	001	Feb 24, 2025	Mar DISC
AB			0.25MG	A213731	001	Feb 24, 2025	Feb NEWA
	@		0.5MG	A213731	002	Feb 24, 2025	Mar DISC
AB			0.5MG	A213731	002	Feb 24, 2025	Feb NEWA
	@		1MG	A213731	003	Feb 24, 2025	Mar DISC
AB			1MG	A213731	003	Feb 24, 2025	Feb NEWA
	@		2MG	A213731	004	Feb 24, 2025	Mar DISC
AB			2MG	A213731	004	Feb 24, 2025	Feb NEWA
	@		3MG	A213731	005	Feb 24, 2025	Mar DISC
AB			3MG	A213731	005	Feb 24, 2025	Feb NEWA
		REXULTI					
AB	+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Jan CTEC
AB	+		0.5MG	N205422	002	Jul 10, 2015	Jan CTEC
AB	+		1MG	N205422	003	Jul 10, 2015	Jan CTEC
AB	+		2MG	N205422	004	Jul 10, 2015	Jan CTEC
AB	+		3MG	N205422	005	Jul 10, 2015	Jan CTEC
AB	+		4MG	N205422	006	Jul 10, 2015	Jan CTEC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC
BRIMONIDINE TARTRATE

>A>	AB		UPSHER SMITH LABS	0.1%	A217599	001	Jul 30, 2025	Jul NEWA
-----	----	--	-------------------	------	---------	-----	--------------	----------

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

	@	AMNEAL	0.2%;EQ 0.5% BASE	A217288	001	Dec 30, 2024	Jan DISC
AB		CAPLIN	0.2%;EQ 0.5% BASE	A219093	001	Feb 25, 2025	Feb NEWA

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC
BRINZOLAMIDE

>D>	AB		PADAGIS US	1%	A211914	001	Jul 28, 2023	Jul DISC
>A>		@		1%	A211914	001	Jul 28, 2023	Jul DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

AA	+	XTTRIUM LABS INC	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Feb CAHN
		BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE					
AA		BIONPHARMA	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	May CMFD

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

@	SANDOZ	0.25MG/2ML	A201966	003	Sep 27, 2013	Feb DISC
@		0.5MG/2ML	A201966	002	Sep 27, 2013	Feb DISC
@		1MG/2ML	A201966	001	Sep 27, 2013	Feb DISC

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP		ASPIRO	0.25MG/ML	A218746	001	Feb 27, 2025	Feb NEWA
		TABLET; ORAL					
		BUMETANIDE					

>A>	AB	JUBILANT GENERICS	0.5MG	A212470	001	Aug 05, 2025	Jul NEWA
>A>	AB		1MG	A212470	002	Aug 05, 2025	Jul NEWA
>A>	AB		2MG	A212470	003	Aug 05, 2025	Jul NEWA
	AB	MANKIND PHARMA	0.5MG	A219291	001	Apr 03, 2025	Mar NEWA
	AB		1MG	A219291	002	Apr 03, 2025	Mar NEWA
	AB		2MG	A219291	003	Apr 03, 2025	Mar NEWA

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP		SOMERSET THERAPS LLC	EQ 0.3MG BASE/ML	A219302	001	Jan 30, 2025	Jan NEWA
		TABLET; SUBLINGUAL					
		BUPRENORPHINE HYDROCHLORIDE					
	@	PHARMOBEDIENT	EQ 2MG BASE	A201066	001	Mar 06, 2015	Jun CAHN
	@		EQ 8MG BASE	A201066	002	Mar 06, 2015	Jun CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		DIFGEN PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A212756	003	Feb 13, 2025	Feb NEWA
AB			EQ 4MG BASE;EQ 1MG BASE	A212756	004	Feb 13, 2025	Feb NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1		IPCA LABS LTD	100MG	A207874	001	May 02, 2025	Apr NEWA
AB1			150MG	A207874	002	May 02, 2025	Apr NEWA
AB1			200MG	A207874	003	May 02, 2025	Apr NEWA
	@	SUN PHARM	150MG	A200216	001	Nov 30, 2020	Feb DISC
	@		300MG	A203650	001	Dec 31, 2020	Feb DISC
		FORFIVO XL					
	@ +	TWI PHARMS	450MG	N022497	001	Nov 10, 2011	Jun DISC

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPIRONE HYDROCHLORIDE

>D>		EPIC PHARMA LLC	7.5MG	A218628	001	Mar 13, 2025	Jul CAHN
			7.5MG	A218628	001	Mar 13, 2025	Feb NEWA
>D>			10MG	A218628	002	Mar 13, 2025	Jul CAHN
			10MG	A218628	002	Mar 13, 2025	Feb NEWA
>D>			15MG	A218628	003	Mar 13, 2025	Jul CAHN
			15MG	A218628	003	Mar 13, 2025	Feb NEWA
>A>		PANGEA	7.5MG	A218628	001	Mar 13, 2025	Jul CAHN
>A>			10MG	A218628	002	Mar 13, 2025	Jul CAHN
>A>			15MG	A218628	003	Mar 13, 2025	Jul CAHN

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	15MG	A202557	004	Dec 30, 2014	Apr CHRS
AB		AIPING PHARM INC	7.5MG	A202087	005	Jul 03, 2025	Jun NEWA
BX		EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Mar CTEC
BX			7.5MG	A208972	002	Apr 16, 2019	Mar CTEC

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE							
BX		10MG	A208972	003	Apr 16, 2019	Mar	CTEC
BX		15MG	A208972	004	Apr 16, 2019	Mar	CTEC
BX		30MG	A208972	005	Apr 16, 2019	Mar	CTEC
BX	INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Mar	CTEC
BX		7.5MG	A209696	002	May 03, 2018	Mar	CTEC
BX		10MG	A209696	003	May 03, 2018	Mar	CTEC
BX		15MG	A209696	004	May 03, 2018	Mar	CTEC
BX		30MG	A209696	005	May 03, 2018	Mar	CTEC
AB	! UNICHEM	15MG	A210907	003	Nov 14, 2019	Apr	CHRS

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN							
@	APOTEX	6MG/ML	A210448	001	May 07, 2019	Jan	DISC

BUTORPHANOL TARTRATE

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE							
AB	! HIKMA	1MG/SPRAY	A075824	001	Mar 12, 2002	May	CHRS
@	RISING	1MG/SPRAY	A075759	001	Aug 08, 2001	May	DISC
STADOL							
@ +	BRISTOL MYERS SQUIBB	1MG/SPRAY	N019890	001	Dec 12, 1991	May	CRLD

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFFEINE CITRATE							
>D> AP	EUGIA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A205013	001	Sep 22, 2015	Jul	DISC
>A>	@	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A205013	001	Sep 22, 2015	Jul	DISC
SOLUTION; ORAL							
CAFFEINE CITRATE							
@	SUN PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090357	001	Sep 30, 2009	Feb	DISC

CALCITONIN SALMON

INJECTABLE; INJECTION

CALCITONIN-SALMON							
AP	SAGENT	200 IU/ML	A219196	001	Jul 09, 2025	Jun	NEWA

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL							
AB	ONESOURCE SPECIALTY	0.25MCG	A091356	001	Dec 12, 2014	Jun	CAHN
AB	!	0.5MCG	A091356	002	Dec 12, 2014	Jun	CAHN

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE							
AB	MPP PHARMA	667MG	A203179	001	Oct 26, 2015	May	CAHN

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER							
@ +	VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Feb	CAHN
PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Feb	CAHN
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER							
+!	VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Feb	CAHN
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER							
@ +	VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML	N021703	013	Oct 10, 2008	Feb	CAHN

INJECTABLE; INJECTION

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

GM/1000ML; 2.21GM/1000ML; 7.07GM
/1000ML (5000ML)

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Feb CAHN
---	---	---------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Feb CAHN
---	---	---------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Feb CAHN
---	---	---------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Feb CAHN
---	--	---------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Feb CAHN
---	---	---------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Feb CAHN
---	---	---------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Feb CAHN
---	--	---------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Feb CAHN
---	--	---------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Feb CAHN
---	---	---------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

@	+	VANTIVE US HLTHCARE	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Feb CAHN
---	---	---------------------	---	---------	-----	--------------	----------

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Feb CAHN
---	--	---------------------	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

+	!	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	001	Nov 30, 1984	Feb CTEC
---	---	-----------------	---	---------	-----	--------------	----------

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

+	!	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	002	Nov 30, 1984	Feb CTEC
---	---	-----------------	---	---------	-----	--------------	----------

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

+	!	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	003	Nov 30, 1984	Feb CTEC
---	---	-----------------	--	---------	-----	--------------	----------

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	001		Feb CAHN
---	--	---------------------	---	---------	-----	--	----------

SOLUTION;INTRAPERITONEAL									
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
	@	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML	N017512	003			Feb	CAHN
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
	@	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	002			Feb	CAHN
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	001	Dec 04, 1992		Feb	CAHN
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	002	Dec 04, 1992		Feb	CAHN
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
	@ +	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	003	Dec 04, 1992		Feb	CAHN
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	004	Dec 04, 1992		Feb	CAHN
DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	012	Jan 10, 1989		Feb	CAHN
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	013	Jul 11, 1990		Feb	CAHN
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER									
	+	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	014	Jul 11, 1990		Feb	CTEC
AT	+		18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	014	Jul 11, 1990		Feb	CAHN
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	015	Jul 11, 1990		Feb	CAHN
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
	@	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	007	Jul 09, 1984		Feb	CAHN
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
	@	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	008	Jul 09, 1984		Feb	CAHN
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
	@	VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985		Feb	CAHN
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
	@	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	009	Jul 09, 1984		Feb	CAHN
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	004			Feb	CAHN
AT	+		25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	001	Dec 04, 1992		Feb	CAHN
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	005			Feb	CAHN
AT	+		25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	002	Dec 04, 1992		Feb	CAHN
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
	@ +	VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985		Feb	CAHN

SOLUTION;INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N017512	006			Feb	CAHN
AT	+		25.7MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N020163	003	Dec 04, 1992		Feb	CAHN

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

	+	VANTIVE US HLTHCARE	N/A/1000ML;3.05GM/1000ML;0.314 GM/1000ML;2.21GM/1000ML;6.95GM /1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015		Feb	CAHN
--	---	---------------------	--	---------	-----	--------------	--	-----	------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

	+	VANTIVE US HLTHCARE	3.68GM/1000ML;3.05GM/1000ML;0. 314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0 .187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015		Feb	CAHN
--	---	---------------------	--	---------	-----	--------------	--	-----	------

CANDESARTAN CILEXETIL

TABLET;ORAL

CANDESARTAN CILEXETIL

AB		ZYDUS LIFESCIENCES	4MG	A091390	001	Aug 23, 2017		Jan	CMFD
AB			8MG	A091390	002	Aug 23, 2017		Jan	CMFD
AB			16MG	A091390	003	Aug 23, 2017		Jan	CMFD
AB			32MG	A091390	004	Aug 23, 2017		Jan	CMFD

CAPECITABINE

TABLET;ORAL

CAPECITABINE

BX		TEYRO LABS	150MG	A217237	001	Oct 23, 2023		Mar	CTEC
BX			500MG	A217237	002	Oct 23, 2023		Mar	CTEC

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

>A>	AB	AIPING PHARM INC	12.5MG	A214442	001	Jan 27, 2023		Jul	CAHN
>A>	AB		25MG	A214442	002	Jan 27, 2023		Jul	CAHN
>A>	AB		50MG	A214442	003	Jan 27, 2023		Jul	CAHN
>A>	AB		100MG	A214442	004	Jan 27, 2023		Jul	CAHN
>D>	AB	CHANGZHOU PHARM	12.5MG	A214442	001	Jan 27, 2023		Jul	CAHN
>D>	AB		25MG	A214442	002	Jan 27, 2023		Jul	CAHN
>D>	AB		50MG	A214442	003	Jan 27, 2023		Jul	CAHN
>D>	AB		100MG	A214442	004	Jan 27, 2023		Jul	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		ANI PHARMS	100MG	A076697	001	May 20, 2011		May	CAHN
AB			200MG	A076697	002	May 20, 2011		May	CAHN
AB			300MG	A076697	003	May 20, 2011		May	CAHN

TABLET;ORAL

CARBAMAZEPINE

AB		ALEMBIC	200MG	A216623	001	Apr 16, 2025		Apr	NEWA
----	--	---------	-------	---------	-----	--------------	--	-----	------

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

>A>	AB	ALEMBIC	100MG	A219939	001	Jul 25, 2025		Jul	NEWA
>A>	AB		200MG	A219939	002	Jul 25, 2025		Jul	NEWA
>A>	AB		400MG	A219939	003	Jul 25, 2025		Jul	NEWA
	AB	ALKEM LABS LTD	100MG	A217277	001	Jan 14, 2025		Jan	NEWA
	AB		200MG	A217277	002	Jan 14, 2025		Jan	NEWA
	AB		400MG	A217277	003	Jan 14, 2025		Jan	NEWA
	@	OSMOTICA PHARM US	100MG	A215664	001	Oct 22, 2024		Apr	DISC
	@		200MG	A215664	002	Oct 22, 2024		Apr	DISC
	@		400MG	A215664	003	Oct 22, 2024		Apr	DISC
	AB	SCIECURE PHARMA INC	100MG	A216235	001	Mar 02, 2023		Jun	CAHN
	AB		200MG	A216235	002	Mar 02, 2023		Jun	CAHN
	AB		400MG	A216235	003	Mar 02, 2023		Jun	CAHN
	AB	TORRENT	100MG	A212524	001	Jan 13, 2025		Jan	NEWA
	AB		200MG	A212524	002	Jan 13, 2025		Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL
CARBAMAZEPINE

AB		400MG	A212524	003	Jan 13, 2025	Jan NEWA
AB	YICHANG HUMANWELL	100MG	A219072	001	Jan 16, 2025	Jan NEWA
AB		200MG	A219072	002	Jan 16, 2025	Jan NEWA
AB		400MG	A219072	003	Jan 16, 2025	Jan NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	MACLEODS PHARMS LTD	12.5MG;200MG;50MG	A214495	001	Apr 15, 2025	Apr NEWA
AB		18.75MG;200MG;75MG	A214495	002	Apr 15, 2025	Apr NEWA
AB		25MG;200MG;100MG	A214495	003	Apr 15, 2025	Apr NEWA
AB		31.25MG;200MG;125MG	A214495	004	Apr 15, 2025	Apr NEWA
AB		37.5MG;200MG;150MG	A214495	005	Apr 15, 2025	Apr NEWA
AB		50MG;200MG;200MG	A214495	006	Apr 15, 2025	Apr NEWA
>D> AB	SUN PHARM	25MG;200MG;100MG	A079085	001	May 10, 2012	Jul DISC
>A>	@	25MG;200MG;100MG	A079085	001	May 10, 2012	Jul DISC
>D> AB		37.5MG;200MG;150MG	A079085	002	May 10, 2012	Jul DISC
>A>	@	37.5MG;200MG;150MG	A079085	002	May 10, 2012	Jul DISC

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

	@	APOTEX INC	10MG;100MG	A077120	001	Jun 02, 2008	Mar DISC
	@		25MG;100MG	A077120	002	Jun 02, 2008	Mar DISC
	@		25MG;250MG	A077120	003	Jun 02, 2008	Mar DISC
AB		ASCENT PHARMS INC	10MG;100MG	A218939	001	Jan 14, 2025	Jan NEWA
AB			25MG;100MG	A218939	002	Jan 14, 2025	Jan NEWA
AB			25MG;250MG	A218939	003	Jan 14, 2025	Jan NEWA
>D> AB		NORVIUM BIOSCIENCE	10MG;100MG	A090324	001	Sep 28, 2009	Jul DISC
>A>	@		10MG;100MG	A090324	001	Sep 28, 2009	Jul DISC
	@		25MG;250MG	A090324	003	Sep 28, 2009	Jun DISC

TABLET, EXTENDED RELEASE;ORAL
CARBIDOPA AND LEVODOPA

	@	APOTEX	25MG;100MG	A076212	001	Jun 16, 2004	Mar DISC
	@		50MG;200MG	A076212	002	Jun 16, 2004	Mar DISC

CARBINOXAMINE MALEATE

TABLET;ORAL

CARBINOXAMINE MALEATE

	@	SENORES PHARMS	4MG	A090435	001	Apr 15, 2010	Jan CAHN
--	---	----------------	-----	---------	-----	--------------	----------

CARFILZOMIB

POWDER;INTRAVENOUS

KYPROLIS

	+	ON YX PHARMS AMGEN	10MG/VIAL	N202714	003	Jun 07, 2018	Jun CHRS
	+		30MG/VIAL	N202714	002	Jun 03, 2016	Jun CHRS

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AA	FOSUN WANBANG	350MG	A081025	001	Apr 13, 1989	Jan CAHN
AB	HERITAGE	250MG	A205126	001	Jul 08, 2015	Jun CAHN
AA		350MG	A205126	002	Jul 08, 2015	Jun CAHN
AB	INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun CAHN
AA		350MG	A205126	002	Jul 08, 2015	Jun CAHN
AB	MPP PHARMA	250MG	A207237	001	May 11, 2017	May CAHN
AA		350MG	A207237	002	Sep 21, 2020	May CAHN
AA	POINTVIEW HLDINGS	350MG	A211789	001	Oct 20, 2021	Apr CAHN

CARVEDILOL

TABLET;ORAL

CARVEDILOL

AB		GRAVITI PHARMS	3.125MG	A076649	001	Sep 05, 2007	Feb CAHN
AB			6.25MG	A076649	002	Sep 05, 2007	Feb CAHN
AB			12.5MG	A076649	003	Sep 05, 2007	Feb CAHN
AB			25MG	A076649	004	Sep 05, 2007	Feb CAHN
	@	NORVIUM BIOSCIENCE	3.125MG	A077316	001	Sep 05, 2007	Feb CAHN
	@		6.25MG	A077316	002	Sep 05, 2007	Mar DISC
AB			6.25MG	A077316	002	Sep 05, 2007	Feb CAHN
	@		12.5MG	A077316	003	Sep 05, 2007	Apr DISC

TABLET;ORAL									
CARVEDILOL									
AB		12.5MG	A077316	003	Sep 05, 2007	Feb	CAHN		
	@	25MG	A077316	004	Sep 05, 2007	Apr	DISC		
AB		25MG	A077316	004	Sep 05, 2007	Feb	CAHN		
<u>CARVEDILOL PHOSPHATE</u>									
CAPSULE, EXTENDED RELEASE;ORAL									
COREG CR									
AB	+ WAYLIS THERAP	10MG	N022012	001	Oct 20, 2006	Jun	CMFD		
AB	+	20MG	N022012	002	Oct 20, 2006	Jun	CMFD		
AB	+	40MG	N022012	003	Oct 20, 2006	Jun	CMFD		
AB	+	80MG	N022012	004	Oct 20, 2006	Jun	CMFD		
<u>CASPOFUNGIN ACETATE</u>									
POWDER; INTRAVENOUS									
CASPOFUNGIN ACETATE									
>A>	AP	HANGZHOU ZHONGMEI	50MG/VIAL	A216506	001	Jul 18, 2025	Jul	NEWA	
>A>	AP		70MG/VIAL	A216506	002	Jul 18, 2025	Jul	NEWA	
<u>CEDAZURIDINE; DECITABINE</u>									
TABLET;ORAL									
INQOVI									
	+! TAIHO ONCOLOGY	100MG;35MG	N212576	001	Jul 07, 2020	Feb	CAHN		
<u>CEFAZOLIN SODIUM</u>									
INJECTABLE; INJECTION									
CEFAZOLIN SODIUM									
	QILU ANTIBIOTICS	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan	CAHN		
AP		EQ 1GM BASE/VIAL	A203661	001	Dec 28, 2015	Jan	CAHN		
		EQ 2GM BASE/VIAL	A203661	002	Mar 11, 2022	Jan	CAHN		
AP	!	EQ 10GM BASE/VIAL	A209217	001	Oct 17, 2018	Jan	CAHN		
<u>CEFEPIME HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
CEFEPIME HYDROCHLORIDE									
	! QILU ANTIBIOTICS	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan	CAHN		
AP	!	EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan	CAHN		
AP	!	EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan	CAHN		
<u>CEFIXIME</u>									
FOR SUSPENSION;ORAL									
CEFIXIME									
>A>	AB	AJENAT PHARMS	100MG/5ML	A206938	001	Feb 06, 2017	Jul	CAHN	
>A>	AB		200MG/5ML	A206938	002	Feb 06, 2017	Jul	CAHN	
>A>	AB		500MG/5ML	A206939	001	Feb 06, 2017	Jul	CAHN	
>D>	AB	BELCHER	100MG/5ML	A206938	001	Feb 06, 2017	Jul	CAHN	
>D>	AB		200MG/5ML	A206938	002	Feb 06, 2017	Jul	CAHN	
>D>	AB		500MG/5ML	A206939	001	Feb 06, 2017	Jul	CAHN	
TABLET;ORAL									
CEFIXIME									
>D>	!	FDC LTD	400MG	A206358	001	Dec 17, 2024	Jul	DISC	
>A>	@		400MG	A206358	001	Dec 17, 2024	Jul	DISC	
<u>CEFPODOXIME PROXETIL</u>									
FOR SUSPENSION;ORAL									
VANTIN									
	@ + PFIZER	EQ 50MG BASE/5ML	N050675	001	Aug 07, 1992	Mar	CAHN		
	@ +	EQ 100MG BASE/5ML	N050675	002	Aug 07, 1992	Mar	CAHN		
TABLET;ORAL									
VANTIN									
	@ + PFIZER	EQ 100MG BASE	N050674	001	Aug 07, 1992	Mar	CAHN		
	@ +	EQ 200MG BASE	N050674	002	Aug 07, 1992	Mar	CAHN		
<u>CEFPROZIL</u>									
FOR SUSPENSION;ORAL									
CEFPROZIL									
	@ APOTEX INC	125MG/5ML	A065351	001	Feb 29, 2012	Mar	DISC		
	@	250MG/5ML	A065351	002	Feb 29, 2012	Mar	DISC		

TABLET;ORAL

CEFPROZIL

@ APOTEX INC

250MG

A065327 001 Mar 26, 2008 Mar DISC

@

500MG

A065327 002 Mar 26, 2008 Mar DISC

CEFTIBUTEN DIHYDRATE

CAPSULE;ORAL

CEDAX

>A> @ BURKE THERAP

EQ 400MG BASE

N050685 002 Dec 20, 1995 Jul CAHN

>D> @ SI PHARMS

EQ 400MG BASE

N050685 002 Dec 20, 1995 Jul CAHN

FOR SUSPENSION;ORAL

CEDAX

>A> @ + BURKE THERAP

EQ 90MG BASE/5ML

N050686 001 Dec 20, 1995 Jul CAHN

>A> @ +

EQ 180MG BASE/5ML

N050686 002 Dec 20, 1995 Jul CAHN

>D> @ + SI PHARMS

EQ 90MG BASE/5ML

N050686 001 Dec 20, 1995 Jul CAHN

>D> @ +

EQ 180MG BASE/5ML

N050686 002 Dec 20, 1995 Jul CAHN

CEFTOBIPROLE MEDOCARIL SODIUM

POWDER;INTRAVENOUS

ZEVTERA

+! ISTX

667MG/VIAL

N218275 001 Apr 03, 2024 Apr CMFD

@ +

667MG/VIAL

N218275 001 Apr 03, 2024 Mar CAHN

CEFTRIAZONE SODIUM

INJECTABLE;INJECTION

CEFTRIAZONE

AP QILU ANTIBIOTICS

EQ 10GM BASE/VIAL

A209218 001 Oct 17, 2018 Jan CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAZONE

AP QILU ANTIBIOTICS

EQ 250MG BASE/VIAL

A203702 001 Jun 29, 2016 Jan CAHN

AP

EQ 500MG BASE/VIAL

A203702 002 Jun 29, 2016 Jan CAHN

AP

EQ 1GM BASE/VIAL

A203702 003 Jun 29, 2016 Jan CAHN

AP

EQ 2GM BASE/VIAL

A203702 004 Jun 29, 2016 Jan CAHN

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

@ APOTEX

EQ 250MG BASE

A065069 001 Oct 02, 2002 Mar DISC

@

EQ 500MG BASE

A065069 002 Oct 02, 2002 Mar DISC

CELECOXIB

CAPSULE;ORAL

CELECOXIB

@ PANGEA

200MG

A212925 001 Dec 09, 2020 Feb CAHN

@

400MG

A212925 002 Dec 09, 2020 Feb CAHN

>D> AB STRIDES PHARMA

100MG

A213127 001 Apr 29, 2025 Jul DISC

>A> @

100MG

A213127 001 Apr 29, 2025 Jul DISC

AB

100MG

A213127 001 Apr 29, 2025 Apr NEWA

>D> AB

200MG

A213127 002 Apr 29, 2025 Jul DISC

>A> @

200MG

A213127 002 Apr 29, 2025 Jul DISC

AB

200MG

A213127 002 Apr 29, 2025 Apr NEWA

>D> AB

400MG

A213127 003 Apr 29, 2025 Jul DISC

>A> @

400MG

A213127 003 Apr 29, 2025 Jul DISC

AB

400MG

A213127 003 Apr 29, 2025 Apr NEWA

>A> AB ZYDUS PHARMS

50MG

A205938 001 Jul 14, 2025 Jul NEWA

>A> AB

100MG

A205938 002 Jul 14, 2025 Jul NEWA

>A> AB

200MG

A205938 003 Jul 14, 2025 Jul NEWA

>A> AB

400MG

A205938 004 Jul 14, 2025 Jul NEWA

>A> SUSPENSION;ORAL

>A> VYSCOXIA

>A> +! CODADOSE INC

10MG/ML

N211759 001 Jul 29, 2025 Jul NEWA

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

>A> AB AJENAT PHARMS

EQ 250MG BASE

A062713 001 Jul 15, 1988 Jul CAHN

>A> AB

EQ 500MG BASE

A062713 002 Jul 15, 1988 Jul CAHN

>D> AB BELCHER PHARMS

EQ 250MG BASE

A062713 001 Jul 15, 1988 Jul CAHN

>D> AB

EQ 500MG BASE

A062713 002 Jul 15, 1988 Jul CAHN

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CETIRIZINE HYDROCHLORIDE

AA	BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	May CMFD
	ZYRTEC					
	@ + J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb CRLD

CETRORELIX ACETATE

POWDER;SUBCUTANEOUS

CETRORELIX ACETATE

AP	XIROMED	EQ 0.25MG BASE/VIAL	A218061	001	Jun 03, 2025	May NEWA
----	---------	---------------------	---------	-----	--------------	----------

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB	RUBICON	30MG	A216682	001	Apr 06, 2023	Jun CTEC
BX		30MG	A216682	001	Apr 06, 2023	Mar CTEC

CHENODIOL

TABLET;ORAL

CTEXLI

	+! MIRUM	250MG	N219488	001	Feb 21, 2025	Feb NEWA
--	----------	-------	---------	-----	--------------	----------

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

AP	SUN PHARM	EQ 500MG BASE/VIAL	A091546	001	Jul 26, 2011	Jun CMFD
----	-----------	--------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	APOZEAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017	Apr CAHN
---	----------------	--------------------------	---------	-----	--------------	----------

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

SONAZINE

>A>	@ ALLIED	30MG/ML	A080983	004		Jul CAHN
>A>	@	100MG/ML	A080983	005		Jul CAHN
>D>	@ FOSUN PHARMA	30MG/ML	A080983	004		Jul CAHN
>D>	@	100MG/ML	A080983	005		Jul CAHN

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	10MG	A216788	001	Apr 25, 2025	Apr NEWA
AB		25MG	A216788	002	Apr 25, 2025	Apr NEWA
AB		50MG	A216788	003	Apr 25, 2025	Apr NEWA
AB		100MG	A216788	004	Apr 25, 2025	Apr NEWA
AB		200MG	A216788	005	Apr 25, 2025	Apr NEWA
>D> AB	SUN PHARM	10MG	A214256	001	Oct 26, 2020	Jul DISC
>A>	@	10MG	A214256	001	Oct 26, 2020	Jul DISC
>D> AB		25MG	A214256	002	Oct 26, 2020	Jul DISC
>A>	@	25MG	A214256	002	Oct 26, 2020	Jul DISC
>D> AB		50MG	A214256	003	Oct 26, 2020	Jul DISC
>A>	@	50MG	A214256	003	Oct 26, 2020	Jul DISC
>D> AB		100MG	A214256	004	Oct 26, 2020	Jul DISC
>A>	@	100MG	A214256	004	Oct 26, 2020	Jul DISC
>D> AB		200MG	A214256	005	Oct 26, 2020	Jul DISC
>A>	@	200MG	A214256	005	Oct 26, 2020	Jul DISC
AB	ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Feb CAHN
AB		25MG	A212630	002	Nov 29, 2021	Feb CAHN
AB		50MG	A212630	003	Nov 29, 2021	Feb CAHN
AB		100MG	A212630	004	Nov 29, 2021	Feb CAHN
AB		200MG	A212630	005	Nov 29, 2021	Feb CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

@	AIPING PHARM INC	25MG	A087380	001		Jan CAHN
@		50MG	A087381	001		Jan CAHN
	HEMICLOR					
	+! PRM PHARMA	12.5MG	N218647	001	Mar 17, 2025	Mar NEWA

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA		AJENAT PHARMS	250MG	A215540	001	Jan 24, 2023	Jan CAHN
AB		APPCO	375MG	A212047	001	Jan 27, 2023	Mar CAHN
AB			750MG	A212047	002	Jan 27, 2023	Mar CAHN
	@	CHARTWELL RX	250MG	A087981	001	Sep 20, 1983	Apr CAHN

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

>A>	@	AIPING PHARM INC	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Jul CAHN
>A>	@		EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Jul CAHN
>D>	@	UPSHER SMITH LABS	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Jul CAHN
>D>	@		EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Jul CAHN
		CHOLESTYRAMINE LIGHT					
	@	MACLEODS PHARMS LTD	EQ 4GM RESIN/SCOOPFUL	A209109	001	Oct 31, 2024	Jun DISC
	@		EQ 4GM RESIN/PACKET	A209109	002	Oct 31, 2024	Jun DISC
AB		PHARMOBEDIENT CNSLTG	EQ 4GM RESIN/PACKET	A209599	001	Nov 12, 2020	Apr CAHN
AB			EQ 4GM RESIN/SCOOPFUL	A209599	002	Nov 12, 2020	Apr CAHN
		PREVALITE					
>A> AB		AIPING PHARM INC	EQ 4GM RESIN/PACKET	A073263	001	Feb 22, 1996	Jul CAHN
>A> AB			EQ 4GM RESIN/SCOOPFUL	A073263	002	Oct 30, 1997	Jul CAHN
>D> AB		UPSHER SMITH LABS	EQ 4GM RESIN/PACKET	A073263	001	Feb 22, 1996	Jul CAHN
>D> AB			EQ 4GM RESIN/SCOOPFUL	A073263	002	Oct 30, 1997	Jul CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB	!	AUROBINDO PHARMA LTD	EQ 135MG FENOFIBRIC ACID	A212598	002	Jul 25, 2019	Apr CHRS
>D>		TRILIPIX					
>D> AB	+	ABBVIE	EQ 45MG FENOFIBRIC ACID	N022224	001	Dec 15, 2008	Jul DISC
>A>	@ +		EQ 45MG FENOFIBRIC ACID	N022224	001	Dec 15, 2008	Jul DISC
	@ +		EQ 135MG FENOFIBRIC ACID	N022224	002	Dec 15, 2008	Apr DISC

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT	!	PADAGIS US	1%	A078594	001	Feb 16, 2010	Mar CHRS
		LOPROX					
	@ +	BAUSCH	1%	N021159	001	Feb 28, 2003	Mar DISC

CIDOFOVIR

SOLUTION; INTRAVENOUS

CIDOFOVIR

AP		AVET LIFESCIENCES	EQ 75MG BASE/ML	A202501	001	Jul 26, 2012	May CDFR
AP			EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	A202501	001	Jul 26, 2012	May CPOT
AP	!	MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May CDFR
AP	!		EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	A201276	001	Jun 27, 2012	May CPOT
		VISTIDE					
	@ +	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May CDFR
	@ +		EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	N020638	001	Jun 26, 1996	May CPOT

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

	@	SANKALP LIFECARE	50MG	A077708	001	Sep 28, 2009	Apr CAHN
	@		100MG	A077708	002	Sep 28, 2009	Apr CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

	@	HIKMA	200MG	A074890	001	Dec 18, 1998	Jun CAHN
	@		300MG	A074890	002	Dec 18, 1998	Jun CAHN
	@		400MG	A074890	003	Dec 18, 1998	Jun CAHN
	@		800MG	A074890	004	Dec 18, 1998	Jun CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

AB	PIRAMAL	EQ 30MG BASE	A210207	001	Aug 01, 2018	Jan CAHN
AB		EQ 60MG BASE	A210207	002	Aug 01, 2018	Jan CAHN
AB		EQ 90MG BASE	A210207	003	Aug 01, 2018	Jan CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OTIC

CIPROFLOXACIN HYDROCHLORIDE

>D> AB	IDENTIRX	EQ 0.2% BASE	A217887	001	Nov 05, 2024	Jul CAHN
>A> AB	NEW HEIGHTSRX	EQ 0.2% BASE	A217887	001	Nov 05, 2024	Jul CAHN

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

CIPROFLOXACIN AND DEXAMETHASONE

AB	AMNEAL	0.3%;0.1%	A216501	001	Mar 22, 2024	Apr CTNA
----	--------	-----------	---------	-----	--------------	----------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

>D> AP	EUGIA PHARMA	EQ 2MG BASE/ML	A209144	001	May 08, 2020	Jul DISC
>A>	@	EQ 2MG BASE/ML	A209144	001	May 08, 2020	Jul DISC
AP	GLAND	EQ 2MG BASE/ML	A215516	001	May 24, 2022	Mar CAHN
AP		EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar CAHN
AP		EQ 10MG BASE/ML	A215516	002	May 24, 2022	Mar CAHN
	@	EQ 2MG BASE/ML	A216538	001	Mar 08, 2024	Feb DISC
AP	HAINAN POLY	EQ 2MG BASE/ML	A204960	003	Aug 30, 2017	Feb CMS1
	HENGRUI PHARMA	EQ 2MG BASE/ML				
	CISATRACURIUM BESYLATE PRESERVATIVE FREE					
>D> AP	EUGIA PHARMA	EQ 2MG BASE/ML	A209665	001	Oct 27, 2020	Jul DISC
>A>	@	EQ 2MG BASE/ML	A209665	001	Oct 27, 2020	Jul DISC
	@	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Feb DISC
	@	EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Feb DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@	APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004	Mar DISC
@		EQ 20MG BASE	A077046	002	Nov 24, 2004	Mar DISC
@		EQ 40MG BASE	A077046	003	Nov 24, 2004	Mar DISC

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

@	JUBILANT CADISTA	250MG	A206714	001	Apr 25, 2019	Apr CAHN
@		500MG	A206714	002	Apr 25, 2019	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB	MPP PHARMA	500MG	A203243	001	Feb 29, 2016	May CAHN
----	------------	-------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

@	ALMAJECT	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Feb DISC
@		EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Feb DISC
@	FRESENIUS KABI USA	EQ 150MG BASE/ML	A065346	001	Mar 29, 2007	Jun DISC
@		EQ 150MG BASE/ML	A065347	001	May 09, 2007	Jun DISC

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT	CARNEGIE	EQ 1% BASE	A219612	001	Jun 13, 2025	Jun NEWA
----	----------	------------	---------	-----	--------------	----------

CLOBAZAM

SUSPENSION; ORAL

CLOBAZAM

@	VISTAPHARM LLC	2.5MG/ML	A210746	001	Jul 10, 2019	Jan CAHN
---	----------------	----------	---------	-----	--------------	----------

TABLET; ORAL

CLOBAZAM

@	ESJAY PHARMA	5MG	A209308	003	Oct 19, 2021	Feb CAHN
>D> AB		10MG	A209308	001	Oct 22, 2018	Jul DISC
>A>	@	10MG	A209308	001	Oct 22, 2018	Jul DISC
AB		10MG	A209308	001	Oct 22, 2018	Feb CAHN

TABLET;ORAL
CLOBAZAM

@	20MG	A209308	002	Oct 22, 2018	Feb CAHN
---	------	---------	-----	--------------	----------

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

>D> AB1	GLENMARK SPECLT	0.05%	A209095	001	May 10, 2018	Jul DISC
>A>	@	0.05%	A209095	001	May 10, 2018	Jul DISC

LOTION;TOPICAL

CLOBETASOL PROPIONATE

@ BEACH PRODS

IMPEKLO

@ + NORVIUM BIOSCIENCE

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

>D> AB	GLENMARK SPECLT	0.05%	A208933	001	Mar 20, 2017	Jul DISC
>A>	@	0.05%	A208933	001	Mar 20, 2017	Jul DISC

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

>D> AT	GLENMARK PHARMS LTD	0.05%	A210190	001	Apr 18, 2018	Jul DISC
>A>	@	0.05%	A210190	001	Apr 18, 2018	Jul DISC

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

>D> AT	GLENMARK SPECLT	0.05%	A209004	001	Mar 26, 2018	Jul DISC
>A>	@	0.05%	A209004	001	Mar 26, 2018	Jul DISC
	@ MACLEODS PHARMS LTD	0.05%	A214345	001	Dec 02, 2024	Jun DISC

SUSPENSION/DROPS;OPHTHALMIC

BYQLOVI

+! FORMOSA

+!

N218158	001	Mar 04, 2024	May CTNA
N218158	001	Mar 04, 2024	Feb CAHN

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

>D> AP	MEITHEAL	20MG/20ML (1MG/ML)	A213461	001	Oct 23, 2020	Jul CHRS
>A> AP	!	20MG/20ML (1MG/ML)	A213461	001	Oct 23, 2020	Jul CHRS
>D>	CLOLAR					
>D> AP	+! GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Jul DISC
>A>	@ +	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Jul DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	LEADING	25MG	A211364	001	Feb 07, 2020	Jun CAHN
AB		50MG	A211364	002	Feb 07, 2020	Jun CAHN
AB		75MG	A211364	003	Feb 07, 2020	Jun CAHN

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

@ SUN PHARM INDS INC

@

@

@

@

@

A078654	001	Aug 27, 2014	Jan DISC
A078654	002	Aug 27, 2014	Jan DISC
A078654	003	Aug 27, 2014	Jan DISC
A078654	004	Aug 27, 2014	Jan DISC
A078654	005	Aug 27, 2014	Jan DISC

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

@

AB1	RUBICON RESEARCH	0.1MG	A210680	001	Apr 30, 2018	Apr CAHN
	SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018	Mar CMFD

CLOZAPINE

TABLET;ORAL

CLOZAPINE

@ SUN PHARM INDS INC

@

@

@

@

A075713	001	Nov 15, 2002	Apr DISC
A075713	003	Aug 19, 2005	Apr DISC
A075713	002	Nov 15, 2002	Apr DISC
A075713	004	Nov 07, 2017	Apr DISC

COBICISTATTABLET; ORAL
TYBOST

>A>	+	GILEAD SCIENCES INC	90MG	N203094	002	Jun 20, 2025	Jul NEWA
-----	---	---------------------	------	---------	-----	--------------	----------

COBICISTAT; DARUNAVIR ETHANOLATETABLET; ORAL
PREZCOBIX

	+	JANSSEN PRODS	150MG; EQ 675MG BASE	N205395	002	Mar 21, 2025	Mar NEWA
	+	!	150MG; EQ 800MG BASE	N205395	001	Jan 29, 2015	Mar CPOT
	+	!	150MG; 800MG	N205395	001	Jan 29, 2015	Mar CAIN

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDESYRUP; ORAL
PROMETH VC W/ CODEINE

@	CHARTWELL RX	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A088764	001	Oct 31, 1984	Apr CAHN
---	--------------	-------------------------------	---------	-----	--------------	----------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDESYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		CHARTWELL RX	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010	Apr CAHN
AA	!	COSETTE	10MG/5ML; 6.25MG/5ML	A200386	001	Jun 29, 2012	May CAHN
AA		XTTRIUM LABS INC	10MG/5ML; 6.25MG/5ML	A088875	001	Dec 17, 1984	Feb CAHN
		PROMETHAZINE WITH CODEINE					
@		PHARM ASSOC	10MG/5ML; 6.25MG/5ML	A040650	001	Jan 31, 2006	Jan DISC

CODEINE SULFATESOLUTION; ORAL
CODEINE SULFATE

@	HIKMA	30MG/5ML	N202245	001	Jun 30, 2011	Jun CAHN
---	-------	----------	---------	-----	--------------	----------

TABLET; ORAL
CODEINE SULFATE

AB	+	HIKMA	15MG	N022402	001	Jul 16, 2009	Jun CAHN
AB	+		30MG	N022402	002	Jul 16, 2009	Jun CAHN
AB	+	!	60MG	N022402	003	Jul 16, 2009	Jun CAHN

COLESEVELAM HYDROCHLORIDETABLET; ORAL
COLESEVELAM HYDROCHLORIDE

>D>	AB		MACLEODS PHARMS LTD	625MG	A204893	001	Apr 18, 2025	Jul DISC
>A>		@		625MG	A204893	001	Apr 18, 2025	Jul DISC
	AB			625MG	A204893	001	Apr 18, 2025	Apr NEWA

COLISTIMETHATE SODIUMINJECTABLE; INJECTION
COLISTIMETHATE SODIUM

>D>	AP		ADRASTEIA PHARMA	EQ 150MG BASE/VIAL	A064216	001	Feb 26, 1999	Jul DISC
>A>		@		EQ 150MG BASE/VIAL	A064216	001	Feb 26, 1999	Jul DISC
		@	NEXUS	EQ 150MG BASE/VIAL	A065177	001	Mar 19, 2004	Apr DISC

COPPERSYSTEM; INTRAUTERINE
MIUDELLA

+	!	SEBELA WOMENS HLTH	N/A	N218201	001	Feb 24, 2025	Feb NEWA
---	---	--------------------	-----	---------	-----	--------------	----------

COPPER CU-64 DOTATATESOLUTION; INTRAVENOUS
DETECTNET

+	!	CURIUM	4mL (1mCi/ML)	N213227	001	Sep 03, 2020	Jan CAHN
---	---	--------	---------------	---------	-----	--------------	----------

CROMOLYN SODIUMCONCENTRATE; ORAL
GASTROCROM

AA		+	!	VIATRIS SPECIALTY	100MG/5ML	N020479	001	Feb 29, 1996	Feb CAHN
----	--	---	---	-------------------	-----------	---------	-----	--------------	----------

SOLUTION; INHALATION
CROMOLYN SODIUM

AN				FERA PHARMS LLC	10MG/ML	A075437	001	Apr 21, 2000	Apr CAHN
	@			HIKMA	10MG/ML	A075333	001	Apr 30, 2002	Jun CAHN

CUPRIC SULFATE

INJECTABLE;INJECTION
CUPRIC SULFATE

!	AM REGENT	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022	Jan CTEC
@	APOTEX CORP	EQ 0.4MG COPPER/ML	A218745	001	Aug 19, 2024	Jan DISC

CYANOCOBALAMIN

INJECTABLE;INJECTION
CYANOCOBALAMIN

AP	MEITHEAL	1MG/ML	A214316	001	Nov 15, 2024	Apr CAHN
	DODEX					
@	ACCORD HLTHCARE	1MG/ML	A083022	001		Jan DISC
	SPRAY, METERED;NASAL					
	CALOMIST					
>D>	@ ENDO OPERATIONS	25MCG/SPRAY	N022102	001	Jul 27, 2007	Jul CAHN
>A>	@ PH HEALTH	25MCG/SPRAY	N022102	001	Jul 27, 2007	Jul CAHN

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CYCLOMYDRIL

+	ALCON LABS INC	0.2%;1%	A084300	001		May CRLD
---	----------------	---------	---------	-----	--	----------

CYCLOPHOSPHAMIDE

CAPSULE;ORAL
CYCLOPHOSPHAMIDE

AB	TRI-SOURCE PHARMA	25MG	A218282	001	Dec 03, 2024	Apr CAHN
AB		50MG	A218282	002	Dec 03, 2024	Apr CAHN

CYCLOSPORINE

EMULSION;OPHTHALMIC
CYCLOSPORINE

	@ APOTEX	0.05%	A207606	001	Jan 12, 2023	Apr DISC
BX		0.05%	A207606	001	Jan 12, 2023	Mar CTEC

SOLUTION;ORAL
CYCLOSPORINE

@	ABBVIE	100MG/ML	A065025	001	Mar 03, 2000	Feb DISC
---	--------	----------	---------	-----	--------------	----------

CYTARABINE; DAUNORUBICIN

POWDER;INTRAVENOUS
VYXEOS

>D>	+	CELATOR PHARMS	100MG;44MG	N209401	001	Aug 03, 2017	Jul CAHN
>A>	+	JAZZ PHARMS THERAP	100MG;44MG	N209401	001	Aug 03, 2017	Jul CAHN

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

DABIGATRAN ETEXILATE MESYLATE

AB	AUROBINDO PHARMA	EQ 75MG BASE	A208039	001	May 14, 2025	May NEWA
AB		EQ 110MG BASE	A208039	002	May 14, 2025	May NEWA
AB		EQ 150MG BASE	A208039	003	May 14, 2025	May NEWA
	@ BRECKENRIDGE	EQ 75MG BASE	A207922	001	Dec 19, 2024	Jun DISC
	@	EQ 110MG BASE	A207922	003	Dec 19, 2024	Jun DISC
	@	EQ 150MG BASE	A207922	002	Dec 19, 2024	Jun DISC
AB	DR REDDYS	EQ 75MG BASE	A208048	001	Jan 28, 2025	Jan NEWA
AB		EQ 110MG BASE	A208048	002	Jan 28, 2025	Jan NEWA
AB		EQ 150MG BASE	A208048	003	Jan 28, 2025	Jan NEWA
AB	MYLAN	EQ 75MG BASE	A208067	001	Feb 03, 2025	Jan NEWA
AB		EQ 150MG BASE	A208067	002	Feb 03, 2025	Jan NEWA

DACARBAZINE

INJECTABLE;INJECTION
DACARBAZINE

@	HOSPIRA	200MG/VIAL	A075940	001	Oct 18, 2001	Mar DISC
---	---------	------------	---------	-----	--------------	----------

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL
AMPYRA

AB	+	MERZ	10MG	N022250	001	Jan 22, 2010	Feb CAHN
----	---	------	------	---------	-----	--------------	----------

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

QTERN

@ +	ASTRAZENECA AB	5MG;EQ 5MG BASE	N209091	002	May 02, 2019	Jun DISC
@ +		10MG;EQ 5MG BASE	N209091	001	Feb 27, 2017	Jun DISC

DAPSONE

GEL; TOPICAL

DAPSONE

AB	AUROBINDO PHARMA LTD	5%	A218457	001	Apr 04, 2025	Mar NEWA
----	----------------------	----	---------	-----	--------------	----------

TABLET; ORAL

DAPSONE

AB	SOLIS PHARMS	25MG	A203887	001	May 06, 2016	Apr CAHN
AB		100MG	A203887	002	May 06, 2016	Apr CAHN

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPTOMYCIN

@	FRESENIUS KABI USA	350MG/VIAL	A213396	001	Aug 01, 2024	Jan DISC
@	HANGZHOU ZHONGMEI	500MG/VIAL	A215215	001	Nov 26, 2021	Jun DISC
@ +	MAIA PHARMS INC	350MG/VIAL	N217630	001	Nov 21, 2024	May DISC
+		500MG/VIAL	N217630	002	Nov 21, 2024	Jun CHRS
+		500MG/VIAL	N217630	002	Nov 21, 2024	Jun CMFD
@ +		500MG/VIAL	N217630	002	Nov 21, 2024	May DISC

DARUNAVIR

TABLET; ORAL

DARUNAVIR

AB	ANNORA PHARMA	600MG	A216168	001	Jan 21, 2025	Jan NEWA	
AB		800MG	A216168	002	Jan 21, 2025	Jan NEWA	
>D>	HETERO LABS LTD III	400MG	A202083	001	Sep 14, 2023	Jul CTEC	
>A> AB		400MG	A202083	001	Sep 14, 2023	Jul CTEC	
>A> AB	MYLAN	75MG	A202136	001	Jul 22, 2025	Jul NFTG	
>A> AB		150MG	A202136	002	Jul 22, 2025	Jul NFTG	
>A>		300MG	A202136	003	Jul 22, 2025	Jul NFTG	
>A> AB		400MG	A202136	004	Jul 22, 2025	Jul NEWA	
>A> AB		600MG	A202136	005	Jul 22, 2025	Jul NEWA	
>D> AB	TEVA PHARMS USA	600MG	A202118	001	Nov 21, 2017	Jul DISC	
>A>	@	600MG	A202118	001	Nov 21, 2017	Jul DISC	
	PREZISTA						
>D>	+	JANSSEN PRODS	75MG	N021976	004	Dec 18, 2008	Jul CFTG
>A> AB	+		75MG	N021976	004	Dec 18, 2008	Jul CFTG
>D>	+		150MG	N021976	005	Dec 18, 2008	Jul CFTG
>A> AB	+		150MG	N021976	005	Dec 18, 2008	Jul CFTG

DASATINIB

TABLET; ORAL

DASATINIB

AB	BIOCON PHARMA	20MG	A217217	001	Mar 03, 2025	Feb NEWA
AB		50MG	A217217	002	Mar 03, 2025	Feb NEWA
AB		70MG	A217217	003	Mar 03, 2025	Feb NEWA
AB		80MG	A217217	004	Mar 03, 2025	Feb NEWA
AB		100MG	A217217	005	Mar 03, 2025	Feb NEWA
AB		140MG	A217217	006	Mar 03, 2025	Feb NEWA
AB	DR REDDYS	20MG	A213383	001	Mar 03, 2025	Feb NEWA
AB		50MG	A213383	002	Mar 03, 2025	Feb NEWA
AB		70MG	A213383	003	Mar 03, 2025	Feb NEWA
AB		80MG	A213383	004	Mar 03, 2025	Feb NEWA
AB		100MG	A213383	005	Mar 03, 2025	Feb NEWA
AB		140MG	A213383	006	Mar 03, 2025	Feb NEWA
AB	EUGIA PHARMA	20MG	A216547	001	Apr 22, 2025	Apr NEWA
AB		50MG	A216547	002	Apr 22, 2025	Apr NEWA
AB		70MG	A216547	003	Apr 22, 2025	Apr NEWA
AB		80MG	A216547	004	Apr 22, 2025	Apr NEWA
AB		100MG	A216547	005	Apr 22, 2025	Apr NEWA
AB		140MG	A216547	006	Apr 22, 2025	Apr NEWA
AB	ZYDUS PHARMS	20MG	A218719	001	Mar 03, 2025	Feb NEWA
AB		50MG	A218719	002	Mar 03, 2025	Feb NEWA
AB		70MG	A218719	003	Mar 03, 2025	Feb NEWA
AB		80MG	A218719	004	Mar 03, 2025	Feb NEWA
AB		100MG	A218719	005	Mar 03, 2025	Feb NEWA
AB		140MG	A218719	006	Mar 03, 2025	Feb NEWA

TABLET; ORAL

PHYRAGO

+	HANDA THERAP	20MG	N216099	001	Dec 05, 2023	Jan CAHN
+		50MG	N216099	002	Dec 05, 2023	Jan CAHN
+		70MG	N216099	003	Dec 05, 2023	Jan CAHN
+		80MG	N216099	004	Dec 05, 2023	Jan CAHN
+	!	100MG	N216099	005	Dec 05, 2023	Jan CAHN
+		140MG	N216099	006	Dec 05, 2023	Jan CAHN

DECITABINE

INJECTABLE; INTRAVENOUS

DECITABINE

AP	ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Apr CHRS
AP	! DR REDDYS	50MG/VIAL	A203131	001	Jul 11, 2013	Apr CHRS

DEFERASIROX

TABLET; ORAL

DEFERASIROX

AB	JUBILANT GENERICS	90MG	A211660	001	Apr 11, 2025	Apr NEWA
AB		180MG	A211660	002	Apr 11, 2025	Apr NEWA
AB		360MG	A211660	003	Apr 11, 2025	Apr NEWA
@	SUN PHARM	90MG	A211641	001	Jan 02, 2020	Apr DISC
@		180MG	A211641	003	Jun 15, 2020	Apr DISC
@		360MG	A211641	002	Jan 02, 2020	Apr DISC

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

@	TORRENT	125MG	A209426	001	Nov 05, 2024	Jun DISC
@		250MG	A209426	002	Nov 05, 2024	Jun DISC
@		500MG	A209426	003	Nov 05, 2024	Jun DISC

DEFLAZACORT

SUSPENSION; ORAL

PYQUVI

AB	AUCTA	22.75MG/ML	A219417	001	Jun 30, 2025	Jun NEWA
----	-------	------------	---------	-----	--------------	----------

TABLET; ORAL

DEFLAZACORT

AB	SUN PHARM	6MG	A217741	001	Mar 18, 2025	Mar NEWA
AB		18MG	A217741	002	Mar 18, 2025	Mar NEWA
AB		30MG	A217741	003	Mar 18, 2025	Mar NEWA
AB		36MG	A217741	004	Mar 18, 2025	Mar NEWA

JAYTHARI

AB	ZYDUS LIFESCIENCES	6MG	A219254	001	Apr 08, 2025	Mar NEWA
AB		18MG	A219254	002	Apr 08, 2025	Mar NEWA
AB		30MG	A219254	003	Apr 08, 2025	Mar NEWA
AB		36MG	A219254	004	Apr 08, 2025	Mar NEWA

>A> DELGOCITINIB

>A> CREAM; TOPICAL

>A> ANZUPGO

>A>	! LEO PHARMA AS	2%	N219155	001	Jul 23, 2025	Jul NEWA
-----	-----------------	----	---------	-----	--------------	----------

DESLORATADINE

TABLET; ORAL

DESLORATADINE

AB	AJENAT PHARMS	5MG	A078355	001	Apr 19, 2012	Jan CAHN
----	---------------	-----	---------	-----	--------------	----------

DESMOPRESSIN ACETATE

TABLET; ORAL

DESMOPRESSIN ACETATE

@	GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May DISC
@		0.2MG	A201831	002	May 28, 2015	May DISC

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

AVERI

	AVION PHARMS	0.15MG; 0.03MG	A218933	001	May 02, 2025	Apr NEWA
--	--------------	----------------	---------	-----	--------------	----------

TABLET; ORAL-28

AVERI

AB	AVION PHARMS	0.15MG; 0.03MG	A218933	002	May 02, 2025	Apr NEWA
----	--------------	----------------	---------	-----	--------------	----------

DESONIDECREAM; TOPICAL
DESONIDE

>D>	AB	CADILA	0.05%	A210198	001	Nov 20, 2019	Jul CHRS
>A>	AB	!	0.05%	A210198	001	Nov 20, 2019	Jul CHRS
>D>	AB	GLENMARK SPECLT	0.05%	A209729	001	Jul 24, 2017	Jul DISC
>A>	@		0.05%	A209729	001	Jul 24, 2017	Jul DISC
>D>	AB	+! PADAGIS US	0.05%	N017010	001		Jul DISC
>A>	@ +		0.05%	N017010	001		Jul DISC

LOTION; TOPICAL
DESONIDE

>D>	AB	GLENMARK SPECLT	0.05%	A209494	001	Sep 26, 2017	Jul DISC
>A>	@		0.05%	A209494	001	Sep 26, 2017	Jul DISC

OINTMENT; TOPICAL
DESONIDE

>D>	AB	GLENMARK PHARMS LTD	0.05%	A209996	001	Sep 15, 2017	Jul DISC
>A>	@		0.05%	A209996	001	Sep 15, 2017	Jul DISC
		DESOWEN					
	@	GALDERMA LABS LP	0.05%	A071425	001	Jun 15, 1988	May DISC

DESOXIMETASONEOINTMENT; TOPICAL
DESOXIMETASONE

>D>	AB	! GLENMARK PHARMS LTD	0.25%	A202838	001	Sep 20, 2013	Jul DISC
>A>	@		0.25%	A202838	001	Sep 20, 2013	Jul DISC
>D>	AB	ZYDUS LIFESCIENCES	0.25%	A205206	001	Sep 19, 2017	Jul CHRS
>A>	AB	!	0.25%	A205206	001	Sep 19, 2017	Jul CHRS

DESVENLAFAXINE SUCCINATETABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE SUCCINATE

AB	MACLEODS PHARMS LTD	EQ 50MG BASE	A211427	001	Jan 15, 2025	Jan NEWA
AB		EQ 100MG BASE	A211427	002	Jan 15, 2025	Jan NEWA
AB	MEDICAP LABS	EQ 50MG BASE	A204805	001	May 07, 2019	Feb CAHN
AB		EQ 100MG BASE	A204805	002	May 07, 2019	Feb CAHN

DEUTETRABENAZINETABLET; ORAL
AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Feb CAHN
+		6MG	N208082	001	Apr 03, 2017	Jan CTEC
+		9MG	N208082	002	Apr 03, 2017	Feb CAHN
+		9MG	N208082	002	Apr 03, 2017	Jan CTEC
+!		12MG	N208082	003	Apr 03, 2017	Feb CAHN
+!		12MG	N208082	003	Apr 03, 2017	Jan CTEC

DEUTETRABENAZINE

@	AUROBINDO PHARMA LTD	6MG	A215971	001	Dec 26, 2024	Jan DISC
@		9MG	A215971	002	Dec 26, 2024	Jan DISC
@		12MG	A215971	003	Dec 26, 2024	Jan DISC

TABLET, EXTENDED RELEASE; ORAL
AUSTEDO XR

>D>	+!	TEVA	24MG	N216354	003	Feb 17, 2023	Jul CHRS
>A>	+		24MG	N216354	003	Feb 17, 2023	Jul CHRS
>D>	+		48MG	N216354	007	May 29, 2024	Jul CHRS
>A>	+!		48MG	N216354	007	May 29, 2024	Jul CHRS

DEXAMETHASONETABLET; ORAL
DEXAMETHASONE

AB	+	HIKMA	0.5MG	A084612	002		Apr CMS1
AB	+		0.75MG	A084612	003		Apr CMS1
AB	+!		1MG	A084612	004	Sep 15, 1983	Apr CMS1
AB	+		1.5MG	A084612	005		Apr CMS1
AB	+!		2MG	A084612	006		Apr CMS1
AB	+!		6MG	A084612	007	Sep 15, 1983	Apr CMS1

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

>D>	AP	EUGIA PHARMA	EQ 4MG PHOSPHATE/ML	A206781	001	Dec 01, 2015	Jul DISC
>A>	@		EQ 4MG PHOSPHATE/ML	A206781	001	Dec 01, 2015	Jul DISC

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

POLMON

!	CARWIN PHARM ASSOC	2MG/5ML	A202520	001	Jul 16, 2018	Mar CAHN
!	CARWIN PHARMS	2MG/5ML	A202520	001	Jul 16, 2018	Feb CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	HIKMA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	A206407	003	May 30, 2025	May NFTG
AP		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	May CAHN
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	May CAHN
AP	PRECEDEX +! HOSPIRA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020	May CFTG

DESMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DESMETHYLPHENIDATE HYDROCHLORIDE

AB	MEDICAP LABS	5MG	A078992	001	Nov 23, 2021	Feb CAHN	
AB		10MG	A078992	002	Nov 23, 2021	Feb CAHN	
AB		15MG	A078992	003	Nov 18, 2013	Feb CAHN	
AB		30MG	A078992	004	Nov 18, 2013	Feb CAHN	
AB		20MG	A078992	005	Nov 23, 2021	Feb CAHN	
AB		40MG	A078992	006	Nov 23, 2021	Feb CAHN	
>D>	AB	SUN PHARM INDS INC	5MG	A206734	001	Nov 05, 2021	Jul DISC
>A>	@	5MG	A206734	001	Nov 05, 2021	Jul DISC	
>D>	AB	10MG	A206734	002	Nov 05, 2021	Jul DISC	
>A>	@	10MG	A206734	002	Nov 05, 2021	Jul DISC	
>D>	AB	15MG	A206734	003	Nov 05, 2021	Jul DISC	
>A>	@	15MG	A206734	003	Nov 05, 2021	Jul DISC	
>D>	AB	20MG	A206734	004	Nov 05, 2021	Jul DISC	
>A>	@	20MG	A206734	004	Nov 05, 2021	Jul DISC	
>D>	AB	25MG	A206734	005	Nov 05, 2021	Jul DISC	
>A>	@	25MG	A206734	005	Nov 05, 2021	Jul DISC	
>D>	AB	30MG	A206734	006	Nov 05, 2021	Jul DISC	
>A>	@	30MG	A206734	006	Nov 05, 2021	Jul DISC	
>D>	AB	35MG	A206734	007	Nov 05, 2021	Jul DISC	
>A>	@	35MG	A206734	007	Nov 05, 2021	Jul DISC	
>D>	AB	40MG	A206734	008	Nov 05, 2021	Jul DISC	
>A>	@	40MG	A206734	008	Nov 05, 2021	Jul DISC	

TABLET; ORAL

DESMETHYLPHENIDATE HYDROCHLORIDE

@	RHODES PHARMS	2.5MG	A208756	001	Nov 20, 2017	Jan DISC
@		5MG	A208756	002	Nov 20, 2017	Jan DISC
@		10MG	A208756	003	Nov 20, 2017	Jan DISC

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP	MSN	EQ 250MG BASE/VIAL	A216748	001	Mar 26, 2025	Mar NEWA
AP		EQ 500MG BASE/VIAL	A216748	002	Mar 26, 2025	Mar NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE DM

AA	!	PAI HOLDINGS	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Apr CAHN
AA		PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE		A091687	001	Jun 28, 2012	May CAHN
AA		COSETTE	15MG/5ML; 6.25MG/5ML	A091687	001	Jun 28, 2012	May CAHN
AA		PROMETHAZINE W/ DEXTROMETHORPHAN		A088864	001	Jan 04, 1985	Feb CAHN
AA		XTTRIUM LABS INC	15MG/5ML; 6.25MG/5ML	A088864	001	Jan 04, 1985	Feb CAHN

DIAZEPAMINJECTABLE; INJECTION
DIAZEPAM

AP	GALENICUM HLTH	50MG/10ML (5MG/ML)	A216422	001	May 19, 2025	May	NEWA
----	----------------	--------------------	---------	-----	--------------	-----	------

DIAZOXIDE CHOLINETABLET, EXTENDED RELEASE; ORAL
VYKAT XR

+	SOLENO THERAP	25MG	N216665	001	Mar 26, 2025	Mar	NEWA
+		75MG	N216665	002	Mar 26, 2025	Mar	NEWA
+	!	150MG	N216665	003	Mar 26, 2025	Mar	NEWA

DICLOFENAC POTASSIUMCAPSULE; ORAL
DICLOFENAC POTASSIUM

AB	ONESOURCE SPECIALTY	25MG	A210078	001	Dec 03, 2019	Jun	CAHN
----	---------------------	------	---------	-----	--------------	-----	------

FOR SOLUTION; ORAL
DICLOFENAC POTASSIUM

AB	TORRENT	50MG	A215891	001	Jan 22, 2025	Jan	NEWA
----	---------	------	---------	-----	--------------	-----	------

TABLET; ORAL
DICLOFENAC POTASSIUM

AB	RK PHARMA	50MG	A075463	001	Jul 26, 1999	Mar	CHRS
AB	!	RUBICON	A075229	001	Nov 20, 1998	Mar	CHRS
AB	UMEDICA	25MG	A215750	002	Jun 30, 2025	Jun	NEWA

DICLOFENAC SODIUMGEL; TOPICAL
DICLOFENAC SODIUM

BX	ALEMBIC	3%	A212351	001	Jul 27, 2022	Mar	CTEC
----	---------	----	---------	-----	--------------	-----	------

SOLUTION; TOPICAL
DICLOFENAC SODIUM

AB	ENCUBE	2%	A217646	001	Apr 09, 2025	Mar	NEWA
----	--------	----	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM

AB	AUROBINDO PHARMA USA	50MG	A075281	002	Feb 12, 2002	Apr	CMFD
AB		75MG	A075281	003	Feb 12, 2002	Apr	CMFD

TABLET, EXTENDED RELEASE; ORAL
DICLOFENAC SODIUM

AB	NOVAST LABS	100MG	A216275	001	Sep 23, 2022	Apr	CAHN
----	-------------	-------	---------	-----	--------------	-----	------

DICYCLOMINE HYDROCHLORIDECAPSULE; ORAL
DICYCLOMINE HYDROCHLORIDE

AB	RISING	10MG	A219242	001	Jun 23, 2025	Jun	NEWA
----	--------	------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION
DICYCLOMINE HYDROCHLORIDE

@	NEXUS	10MG/ML	A206468	001	Feb 01, 2019	Apr	DISC
---	-------	---------	---------	-----	--------------	-----	------

TABLET; ORAL
DICYCLOMINE HYDROCHLORIDE

AB	PRINSTON INC	20MG	A218310	001	Jun 06, 2025	May	NEWA
AB	RUBICON RESEARCH	20MG	A216736	001	Dec 14, 2022	Mar	CAHN
	!	40MG	A216736	002	Mar 25, 2025	Mar	NEWA

DIETHYLPROPION HYDROCHLORIDETABLET; ORAL
TENUATE

@	+	MPP PHARMA	25MG	N011722	002		Jun	CAHN
---	---	------------	------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE; ORAL
TENUATE DOSPAN

@	+	ANI PHARMS	75MG	N012546	001		Apr	CAHN
---	---	------------	------	---------	-----	--	-----	------

DIFELIKEFALIN ACETATESOLUTION; INTRAVENOUS
KORSUVA

+	!	VIFOR INTL	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021	Apr	CAHN
---	---	------------	---	---------	-----	--------------	-----	------

DIFLUPREDNATE

EMULSION;OPHTHALMIC
DIFLUPREDNATE

AB	MYLAN LABS LTD	0.05%	A212566	001	Mar 20, 2025	Mar NEWA
AB	UPSHER SMITH LABS	0.05%	A218191	001	Feb 11, 2025	Jan NEWA

DIGOXIN

ELIXIR;ORAL
DIGOXIN

AA	+! HIKMA	0.05MG/ML	N021648	001	Aug 26, 2004	Jun CAHN
----	----------	-----------	---------	-----	--------------	----------

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION
DIHYDROERGOTAMINE MESYLATE

@	BAXTER HLTHCARE CORP	1MG/ML	A216747	001	Jan 07, 2025	Jun DISC
@	CIPLA	1MG/ML	A212334	001	Sep 20, 2024	Jan DISC

POWDER;NASAL
ATZUMI

+!	SATSUMA PHARMS	EQ 5.2MG BASE	N217901	001	Apr 30, 2025	Apr NEWA
----	----------------	---------------	---------	-----	--------------	----------

SOLUTION;SUBCUTANEOUS
BREKIYA (AUTOINJECTOR)

+!	AMNEAL	1MG/ML	N215400	001	May 14, 2025	May NEWA
----	--------	--------	---------	-----	--------------	----------

SPRAY, METERED;NASAL
DIHYDROERGOTAMINE MESYLATE

AB	AGGREGA	0.5MG/SPRAY	A215228	001	Feb 26, 2025	Feb NEWA
----	---------	-------------	---------	-----	--------------	----------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB1	AMTA	60MG	A219073	001	Mar 24, 2025	Mar NEWA
AB1		90MG	A219073	002	Mar 24, 2025	Mar NEWA
AB1		120MG	A219073	003	Mar 24, 2025	Mar NEWA
AB1	NOVAST LABS	60MG	A218032	001	Jul 02, 2025	Jun NEWA
AB1		90MG	A218032	002	Jul 02, 2025	Jun NEWA
AB1		120MG	A218032	003	Jul 02, 2025	Jun NEWA
@	SUN PHARM	120MG	A203023	001	Jun 08, 2017	Apr DISC
@		180MG	A203023	002	Jun 08, 2017	Mar DISC
@		240MG	A203023	003	Jun 08, 2017	Mar DISC
@		300MG	A203023	004	Jun 08, 2017	Feb DISC
AB1	UTOPIIC PHARMS	60MG	A219073	001	Mar 24, 2025	Apr CAHN
AB1		90MG	A219073	002	Mar 24, 2025	Apr CAHN
AB1		120MG	A219073	003	Mar 24, 2025	Apr CAHN

SOLUTION;INTRAVENOUS

DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE
+! HQ SPCLT PHARMA 100MG/100ML (1MG/ML)
+! 250MG/250ML (1MG/ML)

N218038	001	Feb 21, 2025	Feb NEWA
N218038	002	Feb 21, 2025	Feb NEWA

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

@	CIPLA	120MG	A210305	001	Sep 24, 2020	Feb DISC
@		240MG	A210305	002	Sep 24, 2020	Feb DISC
@	TORRENT	120MG	A210390	001	Jan 06, 2025	Jun DISC
@		240MG	A210390	002	Jan 06, 2025	Jun DISC

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP	AVET LIFESCIENCES	50MG/ML	A205336	001	Jun 24, 2025	Jun NEWA
AP	! NORVIUM BIOSCIENCE	50MG/ML	A040498	001	Jul 12, 2005	Feb CAHN

DIPYRIDAMOLE

TABLET;ORAL
DIPYRIDAMOLE

AB	BARR LABS	75MG	A087717	001	Oct 03, 1990	Mar CAHN
----	-----------	------	---------	-----	--------------	----------

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

@	APOTEX	EQ 125MG VALPROIC ACID	A077615	003	Jul 29, 2008	Mar	DISC
@		EQ 250MG VALPROIC ACID	A077615	002	Jul 29, 2008	Mar	DISC
@		EQ 500MG VALPROIC ACID	A077615	001	Jul 29, 2008	Mar	DISC

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

>A>	AB	SCIEGEN PHARMS INC	EQ 250MG VALPROIC ACID	A078705	002	Feb 10, 2009	Jul	CAHN
>A>	AB		EQ 500MG VALPROIC ACID	A078705	001	Aug 04, 2009	Jul	CAHN
>D>	@	UTOPIC PHARMS	EQ 250MG VALPROIC ACID	A214462	001	Mar 15, 2021	Jul	CAHN
>D>	@		EQ 500MG VALPROIC ACID	A214462	002	Mar 15, 2021	Jul	CAHN
>D>	AB	WOCKHARDT BIO AG	EQ 250MG VALPROIC ACID	A078705	002	Feb 10, 2009	Jul	CAHN
>D>	AB		EQ 500MG VALPROIC ACID	A078705	001	Aug 04, 2009	Jul	CAHN
>A>	@	YICHANG HUMANWELL	EQ 250MG VALPROIC ACID	A214462	001	Mar 15, 2021	Jul	CAHN
>A>	@		EQ 500MG VALPROIC ACID	A214462	002	Mar 15, 2021	Jul	CAHN

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

AP	!	AMNEAL	20MG/ML (20MG/ML)	A209640	001	Jan 19, 2018	Apr	CHRS
AP	!		80MG/4ML (20MG/ML)	A209640	002	Jan 19, 2018	Apr	CHRS
AP	!		160MG/8ML (20MG/ML)	A209640	003	Jan 19, 2018	Apr	CHRS
AP		GUANGDONG SUNHO	20MG/ML (20MG/ML)	A213768	001	May 13, 2025	May	NEWA
AP			80MG/4ML (20MG/ML)	A213768	002	May 13, 2025	May	NEWA
		TAXOTERE						
	@ +	SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449	003	Aug 03, 2010	Apr	DISC
	@ +		80MG/4ML (20MG/ML)	N020449	004	Aug 02, 2010	Apr	DISC
AP	+		160MG/8ML (20MG/ML)	N020449	005	Apr 13, 2012	Apr	CHRS

SOLUTION;INTRAVENOUS

BEIZRAY

@ +	ZHUHAI	80MG/4ML (20MG/ML)	N218711	001	Oct 23, 2024	Apr	DISC
-----	--------	--------------------	---------	-----	--------------	-----	------

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

@	INDICUS PHARMA	5MG	A201634	001	Jun 13, 2012	Apr	DISC
@		10MG	A201634	002	Jun 13, 2012	Apr	DISC

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB		AMNEAL	10MG;7MG	A208328	003	Feb 27, 2025	Feb	NFTG
AB			10MG;21MG	A208328	004	Feb 27, 2025	Feb	NEWA
>A>	AB	MACLEODS PHARMS LTD	10MG;14MG	A208672	001	Jul 15, 2025	Jul	NEWA
>A>	AB		10MG;28MG	A208672	002	Jul 15, 2025	Jul	NEWA
>A>	AB	XIAMEN LP PHARM CO	10MG;14MG	A216901	001	Jul 15, 2025	Jul	NEWA
>A>	AB		10MG;28MG	A216901	002	Jul 15, 2025	Jul	NEWA
		NAMZARIC						
AB	+	ABBVIE	10MG;7MG	N206439	003	Jul 18, 2016	Feb	CFTG

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT		SOMERSET THERAPS LLC	EQ 2% BASE	A215004	001	Feb 11, 2025	Jan	NEWA
----	--	----------------------	------------	---------	-----	--------------	-----	------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>D>	AT2	IDENTIRX	EQ 2% BASE;EQ 0.5% BASE	A216308	001	Feb 18, 2025	Jul	CAHN
	AT2		EQ 2% BASE;EQ 0.5% BASE	A216308	001	Feb 18, 2025	Feb	NEWA
>A>	AT2	NEW HEIGHTSRX	EQ 2% BASE;EQ 0.5% BASE	A216308	001	Feb 18, 2025	Jul	CAHN

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB		APPCO	EQ 1MG BASE	A209013	001	Apr 17, 2018	Mar	CAHN
AB			EQ 2MG BASE	A209013	002	Apr 17, 2018	Mar	CAHN
AB			EQ 4MG BASE	A209013	003	Apr 17, 2018	Mar	CAHN
AB			EQ 8MG BASE	A209013	004	Apr 17, 2018	Mar	CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

	@	ADAPTIS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Jan DISC
AB		PTS CONSULTING	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar CAHN
AB			EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar CAHN
AB			EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar CAHN
AB			EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar CAHN
AB			EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar CAHN
BX		ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar CTEC
BX			EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar CTEC
BX			EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar CTEC
BX			EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar CTEC
BX			EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar CTEC
BX			EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar CTEC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 3MG BASE	A216041	001	Jul 25, 2024	Jun CMFD
AB			EQ 6MG BASE	A216041	002	Jul 25, 2024	Jun CMFD
BX		MSN	EQ 3MG BASE	A214823	001	Apr 03, 2023	Mar CTEC
BX			EQ 6MG BASE	A214823	002	Apr 03, 2023	Mar CTEC
>A> AB		TARO	EQ 3MG BASE	A219058	001	Aug 06, 2025	Jul NEWA
>A> AB			EQ 6MG BASE	A219058	002	Aug 06, 2025	Jul NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB		ALEMBIC	20MG/10ML (2MG/ML)	A219199	001	Jun 27, 2025	Jun NEWA
AB			50MG/25ML (2MG/ML)	A219199	002	Jun 27, 2025	Jun NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB		MACLEODS PHARMS LTD	40MG	A210381	001	Mar 27, 2025	Mar NEWA
AB		PRINSTON INC	40MG	A217098	001	Jan 27, 2025	Jan NEWA

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

	@	BIONPHARMA	EQ 50MG BASE	A209393	001	Dec 10, 2020	Apr CAHN
	@		EQ 100MG BASE	A209393	002	Dec 10, 2020	Apr CAHN
AB	!	HIKMA INTL PHARMS	EQ 100MG BASE	A062396	001	May 07, 1984	Feb CHRS
>D>	@	STRIDES PHARMA	EQ 50MG BASE	A062337	001	Mar 29, 1982	Jul CMFD
>A> AB			EQ 50MG BASE	A062337	001	Mar 29, 1982	Jul CMFD
>D>	@		EQ 100MG BASE	A062337	002	Mar 29, 1982	Jul CMFD
>A> AB			EQ 100MG BASE	A062337	002	Mar 29, 1982	Jul CMFD

VIBRAMYCIN

@ + PFIZER

EQ 100MG BASE

N050007 002

Feb DISC

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

	@	AMNEAL	EQ 100MG BASE/VIAL	A217487	001	Dec 04, 2024	Jan DISC
>A> AP		ASPIRO	EQ 100MG BASE/VIAL	A218888	001	Aug 05, 2025	Jul NEWA
AP		DR REDDYS	EQ 100MG BASE/VIAL	A218753	001	Jul 01, 2025	Jun NEWA
AP		PRECISION DOSE INC	EQ 100MG BASE/VIAL	A217078	001	Feb 21, 2025	Feb NEWA

TABLET;ORAL

DOXYCYCLINE HYCLATE

@ AVIV PHARMA

EQ 100MG BASE

A209560 001

Apr 15, 2024

May CAHN

@ MYLAN

EQ 100MG BASE

A062432 001

Feb 15, 1983

Jun DISC

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

AB		JUBILANT CADISTA	100MG	A214391	001	Feb 18, 2021	Apr CAHN
AB			200MG	A214391	002	Feb 18, 2021	Apr CAHN
AB			300MG	A214391	003	Feb 18, 2021	Apr CAHN

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS; ORAL
DULOXETINE HYDROCHLORIDE

>D>	AB	TORRENT	EQ 20MG BASE	A090774	001	Dec 11, 2013	Jul DISC
>A>	@		EQ 20MG BASE	A090774	001	Dec 11, 2013	Jul DISC
>D>	AB		EQ 30MG BASE	A090774	002	Dec 11, 2013	Jul DISC
>A>	@		EQ 30MG BASE	A090774	002	Dec 11, 2013	Jul DISC
>D>	AB		EQ 60MG BASE	A090774	003	Dec 11, 2013	Jul DISC
>A>	@		EQ 60MG BASE	A090774	003	Dec 11, 2013	Jul DISC

DUTASTERIDECAPSULE; ORAL
DUTASTERIDE

>A>	@	AVIV PHARMA	0.5MG	A204705	001	Nov 20, 2015	May CAHN
>D>	@	PH HEALTH	0.5MG	A202421	001	Nov 20, 2015	Jul CAHN
>D>	@	VINTAGE	0.5MG	A202421	001	Nov 20, 2015	Jul CAHN

EDARAVONESOLUTION; INTRAVENOUS
EDARAVONE

	@	LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr DISC
SUSPENSION; ORAL							
RADICAVA ORS							
>A>	+	KK BCJ-94	105MG/5ML	N215446	001	May 12, 2022	Jul CAHN
>D>	+	mitsubishi tanabe	105MG/5ML	N215446	001	May 12, 2022	Jul CAHN

EFAVIRENZTABLET; ORAL
EFAVIRENZ

AB		NORVIUM BIOSCIENCE	600MG	A204869	001	Mar 12, 2018	May CAHN
----	--	--------------------	-------	---------	-----	--------------	----------

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@	CHARTWELL RX	600MG; 200MG; 300MG	A201802	001	Oct 03, 2023	Apr CAHN
---	--------------	---------------------	---------	-----	--------------	----------

EFLORNITHINE HYDROCHLORIDECREAM; TOPICAL
VANIQA

@ +	ABBVIE	13.9%	N021145	001	Jul 27, 2000	Feb CAHN
-----	--------	-------	---------	-----	--------------	----------

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

ELETRIPTAN HYDROBROMIDE

AB		ANNORA PHARMA	EQ 20MG BASE	A219143	001	Jul 07, 2025	Jun NEWA
AB			EQ 40MG BASE	A219143	002	Jul 07, 2025	Jun NEWA

ELIGLUSTAT TARTRATE

CAPSULE; ORAL

ELIGLUSTAT TARTRATE

@	APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024	Jan DISC
---	--------	--------------	---------	-----	--------------	----------

ELTROMBOPAG OLAMINE

TABLET; ORAL

ELTROMBOPAG OLAMINE

AB		HETERO LABS LTD V	EQ 12.5MG ACID	A206788	001	Jan 17, 2025	Jan NFTG
AB			EQ 25MG ACID	A206788	002	Jan 17, 2025	Jan NFTG
AB			EQ 50MG ACID	A206788	003	Jan 17, 2025	Jan NFTG
AB			EQ 75MG ACID	A206788	004	Jan 17, 2025	Jan NFTG
PROMACTA							
AB	+	NOVARTIS	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Jan CFTG
AB	+		EQ 25MG ACID	N022291	001	Nov 20, 2008	Jan CFTG
AB	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Jan CFTG
AB	+		EQ 75MG ACID	N022291	003	Sep 08, 2009	Jan CFTG

ELUXADOLINE

TABLET; ORAL

ELUXADOLINE

AB	ZYDUS PHARMS	75MG	A213522	001	Mar 14, 2025	Mar NFTG
AB		100MG	A213522	002	Mar 14, 2025	Mar NFTG
	VIBERZI					
AB	+ ABBVIE	75MG	N206940	001	May 27, 2015	Mar CFTG
AB	+!	100MG	N206940	002	May 27, 2015	Mar CFTG

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

AB	+! GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011	May CFTG
	EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE					
AB	MYLAN	200MG;EQ 25MG BASE;300MG	A208452	001	May 20, 2025	May NFTG

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	HETERO LABS LTD III	100MG;150MG	A201806	002	Mar 03, 2025	Feb NEWA
AB		133MG;200MG	A201806	003	Mar 03, 2025	Feb NEWA
AB		167MG;250MG	A201806	004	Mar 03, 2025	Feb NEWA

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

AB	SENORES PHARMS	2.5MG	A075483	001	Aug 22, 2000	Jun CAHN
AB		5MG	A075483	002	Aug 22, 2000	Jun CAHN
AB		10MG	A075483	003	Aug 22, 2000	Jun CAHN
AB		20MG	A075483	004	Aug 22, 2000	Jun CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@ MPP PHARMA 5MG;12.5MG
 @ 10MG;25MG

A076486	001	Oct 27, 2004	Jun CAHN
A076486	002	Oct 27, 2004	Jun CAHN

ENFUVIRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

@ + ROCHE 90MG/VIAL

N021481	001	Mar 13, 2003	Mar DISC
---------	-----	--------------	----------

ENTECAVIR

TABLET; ORAL

ENTECAVIR

@ BRECKENRIDGE 0.5MG
 @ 1MG

A208721	001	Mar 15, 2018	May DISC
A208721	002	Mar 15, 2018	May DISC

ENZALUTAMIDE

CAPSULE; ORAL

ENZALUTAMIDE

@ ZYDUS PHARMS 40MG
 XTANDI
 +! ASTELLAS 40MG

A209667	001	Sep 26, 2024	Feb DISC
N203415	001	Aug 31, 2012	Feb CTEC

EPHEDRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

REZIPRES

@ + DR REDDYS LABS SA 47MG/10ML (4.7MG/ML)

N213536	004	Dec 07, 2023	May DISC
---------	-----	--------------	----------

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOVAZ

AP3	+! EXELA PHARMA	25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021	Mar CTEC
	EMERPHED					
AP1	+! NEXUS	50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Mar CTEC
AP	+!	50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Jan CFTG
	EPHEDRINE SULFATE					
AP2	+! ENDO OPERATIONS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Mar CTEC
AP	+!	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Feb CFTG
AP2	+!	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Mar CTEC

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

AP	+	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Feb CFTG
AP2	FRESENIUS KABI USA	25MG/5ML (5MG/ML)	A218271	001	Mar 11, 2025	Mar CTEC
AP		25MG/5ML (5MG/ML)	A218271	001	Mar 11, 2025	Feb NFTG
AP2		50MG/10ML (5MG/ML)	A218271	002	Mar 11, 2025	Mar CTEC
AP		50MG/10ML (5MG/ML)	A218271	002	Mar 11, 2025	Feb NFTG
AP1	GLAND	50MG/10ML (5MG/ML)	A218211	001	Jan 16, 2025	Mar CTEC
AP		50MG/10ML (5MG/ML)	A218211	001	Jan 16, 2025	Jan NFTG
AP3	HIKMA	25MG/5ML (5MG/ML)	A217721	001	Oct 11, 2024	Mar CTEC

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

EPINASTINE HYDROCHLORIDE

@	RENOVA PHARMS	0.05%	A090870	001	Mar 14, 2011	Feb CAHN
---	---------------	-------	---------	-----	--------------	----------

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR

EPI E Z PEN JR

@	VIATRIS	0.15MG/DELIVERY	N019430	004	Aug 03, 1995	May CAHN
---	---------	-----------------	---------	-----	--------------	----------

EPIPEN E Z PEN

@	VIATRIS	0.3MG/DELIVERY	N019430	003	Aug 03, 1995	May CAHN
---	---------	----------------	---------	-----	--------------	----------

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

EPIPEN

AB	+	VIATRIS	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	May CAHN
----	---	---------	----------------	---------	-----	--------------	----------

EPIPEN JR.

AB	+	VIATRIS	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	May CAHN
----	---	---------	-----------------	---------	-----	--------------	----------

TWINJECT

@	IMPAX	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	May CTNA
---	-------	--------------------	---------	-----	--------------	----------

@		EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	May CTNA
---	--	-------------------	---------	-----	--------------	----------

SOLUTION;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

EPINEPHRINE

AP	GLAND PHARMA LTD	10MG/10ML (1MG/ML)	A219239	001	Feb 06, 2025	Jan NFTG
----	------------------	--------------------	---------	-----	--------------	----------

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

EPINEPHRINE

AP	+	BPI LABS	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022	Jan CFTG
----	---	----------	--------------------	---------	-----	--------------	----------

	+	FRESENIUS KABI USA	30MG/30ML (1MG/ML)	N215425	001	Mar 13, 2025	Mar NEWA
--	---	--------------------	--------------------	---------	-----	--------------	----------

AP	GLAND	10MG/10ML (1MG/ML)	A219239	001	Feb 06, 2025	Mar CDFR
----	-------	--------------------	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS

ADRENALIN

>D>	+	ENDO OPERATIONS	2MG/250ML (8MCG/ML)	N215875	001	Apr 21, 2023	Jul CAHN
-----	---	-----------------	---------------------	---------	-----	--------------	----------

>D>	+		4MG/250ML (16MCG/ML)	N215875	002	Apr 21, 2023	Jul CAHN
-----	---	--	----------------------	---------	-----	--------------	----------

>D>	+		5MG/250ML (20MCG/ML)	N215875	003	Apr 21, 2023	Jul CAHN
-----	---	--	----------------------	---------	-----	--------------	----------

>D>	+		8MG/250ML (32MCG/ML)	N215875	004	Apr 21, 2023	Jul CAHN
-----	---	--	----------------------	---------	-----	--------------	----------

>D>	+		10MG/250ML (40MCG/ML)	N215875	005	Apr 21, 2023	Jul CAHN
-----	---	--	-----------------------	---------	-----	--------------	----------

>A>	+	PH HEALTH	2MG/250ML (8MCG/ML)	N215875	001	Apr 21, 2023	Jul CAHN
-----	---	-----------	---------------------	---------	-----	--------------	----------

>A>	+		4MG/250ML (16MCG/ML)	N215875	002	Apr 21, 2023	Jul CAHN
-----	---	--	----------------------	---------	-----	--------------	----------

>A>	+		5MG/250ML (20MCG/ML)	N215875	003	Apr 21, 2023	Jul CAHN
-----	---	--	----------------------	---------	-----	--------------	----------

>A>	+		8MG/250ML (32MCG/ML)	N215875	004	Apr 21, 2023	Jul CAHN
-----	---	--	----------------------	---------	-----	--------------	----------

>A>	+		10MG/250ML (40MCG/ML)	N215875	005	Apr 21, 2023	Jul CAHN
-----	---	--	-----------------------	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

AP	GLAND	1MG/ML (1MG/ML)	A218144	001	Jun 03, 2025	May NEWA
----	-------	-----------------	---------	-----	--------------	----------

SPRAY;NASAL

NEFFY

+	ARS PHARMS OPERATION	1MG/SPRAY	N214697	002	Mar 05, 2025	Apr CHRS
---	----------------------	-----------	---------	-----	--------------	----------

+		1MG/SPRAY	N214697	002	Mar 05, 2025	Mar NEWA
---	--	-----------	---------	-----	--------------	----------

EPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+	BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N218475	001	Feb 28, 2025	Feb NEWA
---	----------------------	---------------------------------------	---------	-----	--------------	----------

EPLERENONE

TABLET;ORAL

EPLERENONE

@	THINKRX	25MG	A203896	001	Feb 02, 2017	Mar CAHN
---	---------	------	---------	-----	--------------	----------

@		50MG	A203896	002	Feb 02, 2017	Mar CAHN
---	--	------	---------	-----	--------------	----------

EPTIFIBATIDEINJECTABLE; INJECTION
EPTIFIBATIDE

AP	MEITHEAL	2MG/ML	A213599	001	May 09, 2024	Apr CAHN
AP		75MG/100ML	A213599	002	May 09, 2024	Apr CAHN

ERGOCALCIFEROLCAPSULE; ORAL
ERGOCALCIFEROL

AA	! ONESOURCE SPECIALTY	50,000 IU	A090455	001	Aug 03, 2010	Jun CAHN
----	-----------------------	-----------	---------	-----	--------------	----------

ERIBULIN MESYLATESOLUTION; INTRAVENOUS
ERIBULIN MESYLATE

AP	CHIA TAI TIANQING	1MG/2ML (0.5MG/ML)	A218743	001	Mar 04, 2025	Feb NEWA
AP	DR REDDYS	1MG/2ML (0.5MG/ML)	A217473	001	Jul 03, 2025	Jun NEWA
AP	JIANGXI KVVIT PHARM	1MG/2ML (0.5MG/ML)	A218281	001	Jun 28, 2024	Apr CAHN
AP	SANDOZ	1MG/2ML (0.5MG/ML)	A214310	001	Jun 09, 2025	May NEWA
>A> AP	XILING LAB	1MG/2ML (0.5MG/ML)	A218142	001	Aug 05, 2025	Jul NEWA

ERLOTINIB HYDROCHLORIDETABLET; ORAL
ERLOTINIB HYDROCHLORIDE

@	APOTEX	EQ 25MG BASE	A208396	001	Nov 05, 2019	Jan DISC
@		EQ 100MG BASE	A208396	002	Nov 05, 2019	Jan DISC
@		EQ 150MG BASE	A208396	003	Nov 05, 2019	Jan DISC
@	SUN PHARM	EQ 25MG BASE	A210300	001	Nov 05, 2019	Jan DISC
@		EQ 100MG BASE	A210300	002	Nov 05, 2019	Feb DISC
@		EQ 150MG BASE	A210300	003	Nov 05, 2019	Jan DISC

ERTUGLIFLOZINTABLET; ORAL
ERTUGLIFLOZIN

@	HETERO LABS LTD V	5MG	A217071	001	Sep 17, 2024	Apr DISC
@		15MG	A217071	002	Sep 17, 2024	Apr DISC
@	HIKMA	5MG	A216842	001	Jan 21, 2025	Feb DISC
AB		5MG	A216842	001	Jan 21, 2025	Jan NEWA
@		15MG	A216842	002	Jan 21, 2025	Feb DISC
AB		15MG	A216842	002	Jan 21, 2025	Jan NEWA
	STEGLATRO					
+	MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Apr CTEC
+!		15MG	N209803	002	Dec 19, 2017	Apr CTEC

ERYTHROMYCIN STEARATETABLET; ORAL
ERYTHROCIN STEARATE

@	AZURITY	EQ 250MG BASE	A060359	001		Apr DISC
---	---------	---------------	---------	-----	--	----------

ESCITALOPRAM OXALATETABLET; ORAL
ESCITALOPRAM OXALATE

>A> AB	ASCENT PHARMS INC	EQ 5MG BASE	A215177	001	Jul 15, 2025	Jul NEWA
>A> AB		EQ 10MG BASE	A215177	002	Jul 15, 2025	Jul NEWA
>A> AB		EQ 20MG BASE	A215177	003	Jul 15, 2025	Jul NEWA

ESLICARBAZEPINE ACETATETABLET; ORAL
ESLICARBAZEPINE ACETATE

AB	APOTEX	200MG	A211236	001	Dec 07, 2023	Apr CMFD
AB		400MG	A211236	002	Dec 07, 2023	Apr CMFD
AB		600MG	A211236	003	Dec 07, 2023	Apr CMFD
AB		800MG	A211236	004	Dec 07, 2023	Apr CMFD
>A> AB	JUBILANT GENERICS	200MG	A211219	001	Aug 04, 2025	Jul NEWA
>A> AB		400MG	A211219	002	Aug 04, 2025	Jul NEWA
>A> AB		600MG	A211219	003	Aug 04, 2025	Jul NEWA
>A> AB		800MG	A211219	004	Aug 04, 2025	Jul NEWA
AB	LUPIN LTD	200MG	A211246	001	Mar 27, 2024	Mar CMFD
AB		400MG	A211246	002	Mar 27, 2024	Mar CMFD
AB		600MG	A211246	003	Mar 27, 2024	Mar CMFD
AB		800MG	A211246	004	Mar 27, 2024	Mar CMFD
AB	TORRENT	200MG	A211227	001	Feb 27, 2024	May CMFD

TABLET;ORAL

ESLICARBAZEPINE ACETATE

AB		400MG	A211227	002	Feb 27, 2024	May CMFD
AB		600MG	A211227	003	Feb 27, 2024	May CMFD
AB		800MG	A211227	004	Feb 27, 2024	May CMFD

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		GUANGZHOU NOVAKEN	EQ 20MG BASE	A213859	001	Nov 18, 2020	Apr CAHN
AB			EQ 40MG BASE	A213859	002	Nov 18, 2020	Apr CAHN
	@	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Feb DISC
	@		EQ 40MG BASE	A078003	002	Jan 26, 2015	Feb DISC
	@	MACLEODS PHARMS LTD	EQ 20MG BASE	A208511	001	Oct 23, 2024	Jun DISC
	@		EQ 40MG BASE	A208511	002	Oct 23, 2024	Jun DISC
>D>	@	SUN PHARM	EQ 20MG BASE	A209735	001	Apr 30, 2018	Jul CMFD
>A> AB			EQ 20MG BASE	A209735	001	Apr 30, 2018	Jul CMFD
>D>	@		EQ 40MG BASE	A209735	002	Apr 30, 2018	Jul CMFD
>A> AB			EQ 40MG BASE	A209735	002	Apr 30, 2018	Jul CMFD

FOR SUSPENSION, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		AUROBINDO PHARMA LTD	EQ 5MG BASE/PACKET	A218948	001	Apr 15, 2025	Apr NEWA
AB			EQ 10MG BASE/PACKET	A219213	001	Apr 15, 2025	Apr NEWA
AB			EQ 20MG BASE/PACKET	A218948	002	Apr 15, 2025	Apr NEWA
AB			EQ 40MG BASE/PACKET	A218948	003	Apr 15, 2025	Apr NEWA
AB		TORRENT	EQ 2.5MG BASE/PACKET	A212651	001	Mar 05, 2025	Feb NEWA
AB			EQ 5MG BASE/PACKET	A212651	002	Mar 05, 2025	Feb NEWA
AB			EQ 10MG BASE/PACKET	A212652	001	Mar 05, 2025	Feb NEWA
AB			EQ 20MG BASE/PACKET	A212651	003	Mar 05, 2025	Feb NEWA
AB			EQ 40MG BASE/PACKET	A212651	004	Mar 05, 2025	Feb NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

	@	NORVIUM BIOSCIENCE	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021	Feb CAHN
	@		EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021	Feb CAHN

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

>A> AP		EPIC PHARMA LLC	EQ 40MG BASE/VIAL	A214046	001	Jan 08, 2025	Jul CAHN
>D> AP		EUGIA PHARMA	EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jul DISC
>A>	@		EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jul DISC
>D>	@	MYLAN	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	Jul CAHN
>D>	@		EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	Jul CAHN
>A>	@	PHARMOBEDIENT	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	Jul CAHN
>A>	@		EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	Jul CAHN
>D> AP		YANGTZE	EQ 40MG BASE/VIAL	A214046	001	Jan 08, 2025	Jul CAHN
AP			EQ 40MG BASE/VIAL	A214046	001	Jan 08, 2025	Jan NEWA

ESTRADIOL

CREAM;VAGINAL

ESTRADIOL

AB		ENCUBE	0.01%	A209767	001	Mar 05, 2018	Jan CAHN
----	--	--------	-------	---------	-----	--------------	----------

GEL;TRANSDERMAL

ESTRADIOL

AB		ENCUBE	0.1% (0.25GM/PACKET)	A218507	001	Mar 05, 2025	Feb NEWA
AB			0.1% (0.5GM/PACKET)	A218507	002	Mar 05, 2025	Feb NEWA
AB			0.1% (0.75GM/PACKET)	A218507	003	Mar 05, 2025	Feb NEWA
AB			0.1% (1.25GM/PACKET)	A218507	005	Mar 05, 2025	Feb NEWA
AB			0.1% (1GM/PACKET)	A218507	004	Mar 05, 2025	Feb NEWA

GEL, METERED;TRANSDERMAL

ELESTRIN

+! VIATRIS

0.06% (0.87GM/ACTIVATION)

N021813 001 Dec 15, 2006 Feb CAHN

TABLET;ORAL

ESTRADIOL

	@	RUBICON RESEARCH	0.5MG	A040114	003	Mar 14, 1996	Apr CAHN
	@		1MG	A040114	001	Mar 14, 1996	Apr CAHN
	@		2MG	A040114	002	Mar 14, 1996	Apr CAHN

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

@	AVIV PHARMA	1MG	A203087	001	May 08, 2019	May CAHN
@		2MG	A203087	002	May 08, 2019	May CAHN
@		3MG	A203087	003	May 08, 2019	May CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

GENCEPT 10/11-28

@	BARR LABS	0.035MG; 0.035MG; 0.5MG, 1MG	A072697	001	Feb 28, 1992	Mar CAHN
AB	BARR LABS	0.035MG; 0.5MG	A072695	001	Feb 28, 1992	Mar CAHN
AB	! BARR LABS	0.035MG; 1MG	A072696	001	Feb 28, 1992	Mar CAHN
TABLET, CHEWABLE; ORAL						
KAITLIB FE						
AB	! LUPIN LTD	0.025MG; 0.8MG	A203448	001	Dec 17, 2015	Apr CHRS
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
@ +	TEVA BRANDED PHARM	0.025MG; 0.8MG	N022573	001	Dec 22, 2010	Apr DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	BARR LABS	0.02MG; 1MG	A090938	001	Dec 01, 2014	Mar CAHN
TABLET; ORAL-21						
JUNEL 1/20						
AB	BARR LABS	0.02MG; 1MG	A076380	001	May 30, 2003	Mar CAHN
TABLET; ORAL-28						
BLISOVI FE 1.5/30						
AB	LUPIN LTD	0.03MG; 1.5MG	A201585	001	Nov 18, 2015	Apr CTEC

ETODOLAC

TABLET; ORAL

ETODOLAC

>A>	@	SENORES PHARMS	400MG	A074839	001	Jul 11, 1997	Jul CAHN
>D>	@	SHREE HARI INTL	400MG	A074839	001	Jul 11, 1997	Jul CAHN

ETOPOSIDE

CAPSULE; ORAL

VEPESID

@ +	ONESOURCE SPECIALTY	50MG	N019557	001	Dec 30, 1986	Jun CAHN
@ +		100MG	N019557	002	Dec 30, 1986	Jun CAHN

EVEROLIMUS

TABLET; ORAL

EVEROLIMUS

AB	BIOCON PHARMA	0.25MG	A216140	001	Apr 09, 2025	Mar NEWA
AB		0.5MG	A216140	002	Apr 09, 2025	Mar NEWA
AB		0.75MG	A216140	003	Apr 09, 2025	Mar NEWA
AB		1MG	A216140	004	Apr 09, 2025	Mar NEWA
@	MYLAN	2.5MG	A212936	001	Jun 08, 2020	Mar DISC
@		5MG	A212936	002	Jun 08, 2020	Mar DISC
@		7.5MG	A212936	003	Jun 08, 2020	Mar DISC
@		10MG	A212936	004	Jun 08, 2020	Mar DISC
TABLET, FOR SUSPENSION; ORAL						
EVEROLIMUS						
AB	AMNEAL	2MG	A218863	001	Jan 10, 2025	Jan NEWA
AB		3MG	A218863	002	Jan 10, 2025	Jan NEWA
AB		5MG	A218863	003	Jan 10, 2025	Jan NEWA
AB	NATCO	2MG	A217640	001	Jan 28, 2025	Jan NEWA
AB		3MG	A217640	002	Jan 28, 2025	Jan NEWA
AB		5MG	A217640	003	Jan 28, 2025	Jan NEWA

EXENATIDE SYNTHETIC

INJECTABLE; SUBCUTANEOUS

BYETTA

@ +	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Apr DISC
@ +		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Apr DISC

INJECTABLE;SUBCUTANEOUS
EXENATIDE SYNTHETIC

	!	AMNEAL	300MCG/1.2ML (250MCG/ML)	A206697	001	Nov 19, 2024	Apr CTEC
AP	!		300MCG/1.2ML (250MCG/ML)	A206697	001	Nov 19, 2024	Apr CHRS
	!		600MCG/2.4ML (250MCG/ML)	A206697	002	Nov 19, 2024	Apr CTEC
AP	!		600MCG/2.4ML (250MCG/ML)	A206697	002	Nov 19, 2024	Apr CHRS

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON BCISE

	@ +	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017	Mar DISC
--	-----	----------------	-------------------------	---------	-----	--------------	----------

EZETIMIBE

TABLET;ORAL
EZETIMIBE

	@	MACLEODS PHARMS LTD	10MG	A211159	001	Apr 29, 2024	Jun DISC
--	---	---------------------	------	---------	-----	--------------	----------

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

>D>	AB	AMNEAL PHARMS CO	10MG;10MG	A208831	001	Nov 21, 2017	Jul DISC
>A>	@		10MG;10MG	A208831	001	Nov 21, 2017	Jul DISC
>D>	AB		10MG;20MG	A208831	002	Nov 21, 2017	Jul DISC
>A>	@		10MG;20MG	A208831	002	Nov 21, 2017	Jul DISC
>D>	AB		10MG;40MG	A208831	003	Nov 21, 2017	Jul DISC
>A>	@		10MG;40MG	A208831	003	Nov 21, 2017	Jul DISC
>D>	AB		10MG;80MG	A208831	004	Nov 21, 2017	Jul DISC
>A>	@		10MG;80MG	A208831	004	Nov 21, 2017	Jul DISC
	@	SCIEGEN PHARMS INC	10MG;10MG	A211663	001	Dec 10, 2024	Jun DISC
	@		10MG;20MG	A211663	002	Dec 10, 2024	Jun DISC
	@		10MG;40MG	A211663	003	Dec 10, 2024	Jun DISC
	@		10MG;80MG	A211663	004	Dec 10, 2024	Jun DISC
	@	TORRENT	10MG;10MG	A209461	001	Jan 27, 2025	Jun DISC
AB			10MG;10MG	A209461	001	Jan 27, 2025	Jan NEWA
	@		10MG;20MG	A209461	002	Jan 27, 2025	Jun DISC
AB			10MG;20MG	A209461	002	Jan 27, 2025	Jan NEWA
	@		10MG;40MG	A209461	003	Jan 27, 2025	Jun DISC
AB			10MG;40MG	A209461	003	Jan 27, 2025	Jan NEWA
	@		10MG;80MG	A209461	004	Jan 27, 2025	Jun DISC
AB			10MG;80MG	A209461	004	Jan 27, 2025	Jan NEWA

FAMOTIDINE

FOR SUSPENSION;ORAL
FAMOTIDINE

AB		APPCO	40MG/5ML	A217655	001	Jun 16, 2023	Mar CAHN
AB		AUROBINDO PHARMA LTD	40MG/5ML	A219091	001	Jul 09, 2025	Jun NEWA
>D>	AB	BIONPHARMA	40MG/5ML	A219153	001	Jun 23, 2025	Jul DISC
>A>	@		40MG/5ML	A219153	001	Jun 23, 2025	Jul DISC
			40MG/5ML	A219153	001	Jun 23, 2025	Jun NEWA
AB		LANNETT CO INC	40MG/5ML	A217982	001	Jun 02, 2025	May NEWA
>A>	AB	MSN	40MG/5ML	A219863	001	Jul 24, 2025	Jul NEWA
AB		NOVITIUM PHARMA	40MG/5ML	A201995	001	May 30, 2014	Jun CAHN

>A>		SOLUTION;INTRAVENOUS					
>A>		FAMOTIDINE					
>A>	+	!	SAGENT	20MG/5ML (4MG/ML)	N219935	001	Jul 16, 2025
>A>	+	!		40MG/10ML (4MG/ML)	N219935	002	Jul 16, 2025
>A>	+	!		200MG/50ML (4MG/ML)	N219935	003	Jul 16, 2025

TABLET;ORAL

FAMOTIDINE

	@	APOTEX	20MG	A075611	001	Jul 23, 2001	Mar DISC
	@		40MG	A075611	002	Jul 23, 2001	Mar DISC
AB		BEXIMCO PHARMS USA	20MG	A218631	001	Mar 25, 2025	Mar NEWA
AB			40MG	A218631	002	Mar 25, 2025	Mar NEWA

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND FAMOTIDINE

AB		AUROBINDO PHARMA LTD	26.6MG;800MG	A219538	001	Jun 30, 2025	Jun NEWA
AB		ENDO OPERATIONS	26.6MG;800MG	A203658	001	Mar 22, 2024	Feb CTNA
	@	TORRENT	26.6MG;800MG	A215925	001	Mar 18, 2024	Feb CTNA
AB		ZYDUS PHARMS	26.6MG;800MG	A218684	001	Feb 20, 2025	Feb NEWA

FEBUXOSTATTABLET; ORAL
FEBUXOSTAT

AB	MSN	40MG	A210461	001	Dec 30, 2019	Jan CTEC
AB		80MG	A210461	002	Dec 30, 2019	Jan CTEC

FELBAMATETABLET; ORAL
FELBAMATE

@	ALVOGEN	400MG	A204595	001	Jan 11, 2016	May DISC
@		600MG	A204595	002	Jan 11, 2016	May DISC

FENOFIBRATECAPSULE; ORAL
FENOFIBRATE (MICRONIZED)

AB	CHARTWELL RX	43MG	A090859	001	Mar 01, 2012	Apr CAHN
AB		130MG	A090859	002	Mar 01, 2012	Apr CAHN

TABLET; ORAL
FENOFIBRATE

AB	CREEKWOOD PHARMS	40MG	A217732	001	Sep 07, 2023	Mar CTEC
AB		120MG	A217732	002	Sep 07, 2023	Mar CTEC
@	MYLAN	54MG	A076520	001	Oct 25, 2007	Feb DISC
@		160MG	A076520	003	Oct 25, 2007	Feb DISC
@	SUN PHARM	48MG	A200884	001	Sep 07, 2017	Jan DISC
@		145MG	A200884	002	Sep 07, 2017	Apr DISC

FENOFIBRIC ACIDTABLET; ORAL
FIBRICOR

+	ATHENA	105MG	N022418	002	Aug 14, 2009	Jun CMFD
---	--------	-------	---------	-----	--------------	----------

FIDAXOMICINTABLET; ORAL
DIFICID

>D>	+	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Jul CTEC
>A>	AB	+	200MG	N201699	001	May 27, 2011	Jul CTEC
		FIDAXOMICIN					
>D>	@	ACTAVIS LABS FL	200MG	A208443	001	Jan 16, 2024	Jul CMFD
>A>	AB		200MG	A208443	001	Jan 16, 2024	Jul CMFD

FINASTERIDE; TADALAFILCAPSULE; ORAL
FINASTERIDE AND TADALAFIL
NOVITIUM PHARMA

5MG; 5MG	A218499	001	Mar 19, 2025	Mar NEWA
----------	---------	-----	--------------	----------

FINERENONETABLET; ORAL
KERENDIA

>A>	+	BAYER HLTHCARE	40MG	N215341	003	Jul 11, 2025	Jul NEWA
-----	---	----------------	------	---------	-----	--------------	----------

FITUSIRAN SODIUMSOLUTION; SUBCUTANEOUS
QFITLIA

+	GENZYME CORP	EQ 20MG BASE/0.2ML (EQ 20MG BASE/0.2ML)	N219019	001	Mar 28, 2025	Mar NEWA
+		EQ 50MG BASE/0.5ML (EQ 50MG BASE/0.5ML)	N219019	002	Mar 28, 2025	Mar NEWA

FLUCYTOSINECAPSULE; ORAL
FLUCYTOSINE

>A>	AB	LAURUS	250MG	A218005	001	Jul 23, 2025	Jul NEWA
>A>	AB		500MG	A218005	002	Jul 23, 2025	Jul NEWA

FLUDEOXYGLUCOSE F-18INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP	BAMF	20-400mCi/ML	A216125	001	Mar 11, 2025	Feb NEWA
AP	SOFIE	20-300mCi/ML	A204463	001	Oct 21, 2014	Mar CAHN

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

FLUCINOLONE ACETONIDE

>D>	AT	GLENMARK PHARMS LTD	0.01%	A210556	001	Oct 25, 2018	Jul DISC
>A>	@		0.01%	A210556	001	Oct 25, 2018	Jul DISC

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

AB1		ENCUBE	0.05%	A211410	001	Oct 16, 2018	Feb CMFD
-----	--	--------	-------	---------	-----	--------------	----------

GEL; TOPICAL

FLUOCINONIDE

AB		PADAGIS US	0.05%	A209030	001	Jun 19, 2018	Feb CMFD
----	--	------------	-------	---------	-----	--------------	----------

SOLUTION; TOPICAL

FLUOCINONIDE

AT		QUAGEN	0.05%	A216389	001	Feb 26, 2025	Feb NEWA
	@	SAPTALIS PHARMS	0.05%	A207554	001	Mar 18, 2019	Feb CAHN

FLUORESCCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 25%

@ + LONG GROVE PHARMS

EQ 500MG BASE/2ML (EQ 250MG BASE/ML)

N022186	002	Aug 08, 2008	May DISC
---------	-----	--------------	----------

FLUORESCCEIN SODIUM

AP		NEXUS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A215709	001	Sep 25, 2023	Mar CAHN
----	--	-------	--------------------------------------	---------	-----	--------------	----------

!

EQ 500MG BASE/2ML (EQ 250MG BASE/ML)

A215709	002	Sep 25, 2023	May CTEC
---------	-----	--------------	----------

AP			EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Mar CAHN
----	--	--	--------------------------------------	---------	-----	--------------	----------

FLUORODOPA F-18

SOLUTION; INTRAVENOUS

FLUORODOPA F18

+! FEINSTEIN

1-40mCi/ML

N200655	001	Oct 10, 2019	Feb CPOT
---------	-----	--------------	----------

FLUOROURACIL

CREAM; TOPICAL

FLUOROURACIL

AB		ENCUBE	5%	A216942	001	Feb 12, 2025	Jan NEWA
----	--	--------	----	---------	-----	--------------	----------

INJECTABLE; INJECTION

FLUOROURACIL

>D>	AP	!	ACCORD HLTHCARE	500MG/10ML (50MG/ML)	A040743	002	Apr 26, 2007	Jul CHRS
>A>	AP			500MG/10ML (50MG/ML)	A040743	002	Apr 26, 2007	Jul CHRS
>D>	AP	!		1GM/20ML (50MG/ML)	A040743	001	Apr 26, 2007	Jul CHRS
>A>	AP			1GM/20ML (50MG/ML)	A040743	001	Apr 26, 2007	Jul CHRS
		@		2.5GM/50ML (50MG/ML)	A040798	002	Apr 26, 2007	May DISC
>D>	AP	!		5GM/100ML (50MG/ML)	A040798	001	Apr 26, 2007	Jul CHRS
>A>	AP			5GM/100ML (50MG/ML)	A040798	001	Apr 26, 2007	Jul CHRS
	AP	!	ALEMBIC	2.5GM/50ML (50MG/ML)	A217295	001	Mar 03, 2023	May CHRS
>D>	AP		FRESENIUS KABI USA	500MG/10ML (50MG/ML)	A040279	002	Sep 30, 1998	Jul CHRS
>A>	AP	!		500MG/10ML (50MG/ML)	A040279	002	Sep 30, 1998	Jul CHRS
>D>	AP			1GM/20ML (50MG/ML)	A040279	001	Sep 30, 1998	Jul CHRS
>A>	AP	!		1GM/20ML (50MG/ML)	A040279	001	Sep 30, 1998	Jul CHRS
>D>	AP			5GM/100ML (50MG/ML)	A040278	002	Sep 30, 1998	Jul CHRS
>A>	AP	!		5GM/100ML (50MG/ML)	A040278	002	Sep 30, 1998	Jul CHRS
	AP		KINDOS	5GM/100ML (50MG/ML)	A215699	001	Feb 06, 2025	Jan NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

>A>	@	CHARTWELL RX	EQ 10MG BASE	A078143	001	Jan 16, 2008	Jul CAHN
>A>	@		EQ 20MG BASE	A078143	002	Jan 16, 2008	Jul CAHN
>A>	@		EQ 40MG BASE	A078143	003	Jan 16, 2008	Jul CAHN
>D>	@	GRANULES	EQ 10MG BASE	A078143	001	Jan 16, 2008	Jul CAHN
>D>	@		EQ 20MG BASE	A078143	002	Jan 16, 2008	Jul CAHN
>D>	@		EQ 40MG BASE	A078143	003	Jan 16, 2008	Jul CAHN

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

AA		SCIEGEN PHARMS INC	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002	Jun CMFD
AA		SOLIS PHARMS	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Apr CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE							
	@	APPCO	EQ 10MG BASE	A211696	001	Jan 30, 2019	Feb CAHN
	@		EQ 20MG BASE	A211696	002	Jan 30, 2019	Feb CAHN
AB			EQ 60MG BASE	A211477	001	Nov 21, 2018	Jun CAHN
AB	!	AUROBINDO PHARMA LTD	EQ 20MG BASE	A213286	002	Apr 08, 2020	Jun CHRS
AB	!		EQ 60MG BASE	A213265	001	Jun 10, 2020	Apr CHRS
	@	CHARTWELL RX	EQ 10MG BASE	A211444	001	Sep 13, 2022	Mar CAHN
	@		EQ 20MG BASE	A211444	002	Sep 13, 2022	Mar CAHN
AB		DR REDDYS	EQ 20MG BASE	A076006	002	Apr 23, 2018	Jun CHRS
	@ +	TWI PHARMS	EQ 60MG BASE	N202133	001	Oct 06, 2011	Apr DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE							
AB	!	TEVA PHARMS	EQ 50MG BASE;EQ 6MG BASE	A077528	003	Jun 19, 2012	Jun CHRS
		SYMBYAX					
	@ +	LILLY	EQ 25MG BASE;EQ 3MG BASE	N021520	001	Apr 09, 2007	Feb DISC
	@ +		EQ 25MG BASE;EQ 6MG BASE	N021520	002	Dec 24, 2003	Feb DISC
	@ +		EQ 25MG BASE;EQ 12MG BASE	N021520	004	Dec 24, 2003	Feb DISC
	@ +		EQ 50MG BASE;EQ 6MG BASE	N021520	003	Dec 24, 2003	Feb DISC
	@ +		EQ 50MG BASE;EQ 12MG BASE	N021520	005	Dec 24, 2003	Feb DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE							
>D>	AB	TWI PHARMS	1MG	A215848	004	Dec 14, 2022	Jul DISC
>A>		@	1MG	A215848	004	Dec 14, 2022	Jul DISC
>D>	AB		2.5MG	A215848	001	Apr 01, 2022	Jul DISC
>A>		@	2.5MG	A215848	001	Apr 01, 2022	Jul DISC
>D>	AB		5MG	A215848	002	Apr 01, 2022	Jul DISC
>A>		@	5MG	A215848	002	Apr 01, 2022	Jul DISC
>D>	AB		10MG	A215848	003	Apr 01, 2022	Jul DISC
>A>		@	10MG	A215848	003	Apr 01, 2022	Jul DISC
	AB	ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Feb CAHN
	AB		2.5MG	A215141	002	Oct 20, 2021	Feb CAHN
	AB		5MG	A215141	003	Oct 20, 2021	Feb CAHN
	AB		10MG	A215141	004	Oct 20, 2021	Feb CAHN

FLURANDRENOLIDE

CREAM;TOPICAL

CORDRAN SP							
	@ +	INA PHARMS	0.025%	N012806	003		May CAHN
	@ +		0.05%	N012806	002		May CAHN

LOTION;TOPICAL

CORDRAN							
	@ +	INA PHARMS	0.05%	N013790	001		May CAHN

OINTMENT;TOPICAL

CORDRAN							
	@ +	INA PHARMS	0.025%	N012806	004		May CAHN
	@ +		0.05%	N012806	001		May CAHN

FLURBIPROFEN

TABLET;ORAL

FLURBIPROFEN							
>D>	!	GENUS	100MG	A074431	001	May 31, 1995	Jul CAHN
>A>	!	NEW HEIGHTSRX	100MG	A074431	001	May 31, 1995	Jul CAHN

FLUTICASONE PROPIONATE

OINTMENT;TOPICAL

FLUTICASONE PROPIONATE							
	@	CHARTWELL RX	0.005%	A076300	001	May 14, 2004	Mar CAHN

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE							
AB		RUBICON RESEARCH	0.05MG/SPRAY	A218321	001	Jun 05, 2025	May NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE							
>A>	AB	ANNORA PHARMA	100MG	A217024	001	Jul 30, 2025	Jul NEWA
>A>	AB		150MG	A217024	002	Jul 30, 2025	Jul NEWA

TABLET;ORAL

FLUVOXAMINE MALEATE

>A>	AB	AIPING PHARM INC	25MG	A075888	001	Nov 29, 2000	Jul CAHN
>A>	AB		50MG	A075888	002	Nov 29, 2000	Jul CAHN
>A>	AB	!	100MG	A075888	003	Nov 29, 2000	Jul CAHN
>D>	AB	UPSHER SMITH LABS	25MG	A075888	001	Nov 29, 2000	Jul CAHN
>D>	AB		50MG	A075888	002	Nov 29, 2000	Jul CAHN
>D>	AB	!	100MG	A075888	003	Nov 29, 2000	Jul CAHN

FOLIC ACID

TABLET;ORAL

FOLIC ACID

AA		AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Mar CAHN
----	--	------------------	-----	---------	-----	--------------	----------

FONDAPARINUX SODIUM

INJECTABLE;SUBCUTANEOUS

FONDAPARINUX SODIUM

>D>	AP	HANGZHOU ZHONGMEI	2.5MG/0.5ML	A216493	001	Aug 19, 2024	Jul DISC
>A>		@	2.5MG/0.5ML	A216493	001	Aug 19, 2024	Jul DISC
>D>	AP		5MG/0.4ML	A216493	002	Aug 19, 2024	Jul DISC
>A>		@	5MG/0.4ML	A216493	002	Aug 19, 2024	Jul DISC
>D>	AP		7.5MG/0.6ML	A216493	003	Aug 19, 2024	Jul DISC
>A>		@	7.5MG/0.6ML	A216493	003	Aug 19, 2024	Jul DISC
>D>	AP		10MG/0.8ML	A216493	004	Aug 19, 2024	Jul DISC
>A>		@	10MG/0.8ML	A216493	004	Aug 19, 2024	Jul DISC

FORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

AN		DEVA HOLDING AS	0.02MG/2ML	A218308	001	Feb 11, 2025	Jan NEWA
AN		DR REDDYS	0.02MG/2ML	A215907	001	Jan 30, 2025	Jan NEWA
		PERFOROMIST					
AN		+! VIATRIS SPECIALTY	0.02MG/2ML	N022007	001	May 11, 2007	Feb CAHN

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

@	PIRAMAL CRITICAL	EQ 150MG BASE/VIAL	A214683	001	May 16, 2023	Apr DISC
@	PRAXGEN	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Jan CAHN

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL

FOSFOMYCIN TROMETHAMINE

AA		PRECISION DOSE INC	EQ 3GM BASE/PACKET	A217187	001	Jun 03, 2025	May NEWA
----	--	--------------------	--------------------	---------	-----	--------------	----------

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

@	APOTEX	10MG	A076906	001	May 17, 2005	Mar DISC
@		20MG	A076906	002	May 17, 2005	Mar DISC
@		40MG	A076906	003	May 17, 2005	Mar DISC

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVATRIPTAN SUCCINATE

AB		LEADING	EQ 2.5MG BASE	A216998	001	Apr 16, 2025	Apr NEWA
----	--	---------	---------------	---------	-----	--------------	----------

FUROSEMIDE

TABLET;ORAL

FUROSEMIDE

>A>	AB	AUROBINDO PHARMA LTD	20MG	A218831	001	Jul 17, 2025	Jul NEWA
>A>	AB		40MG	A218831	002	Jul 17, 2025	Jul NEWA
>A>	AB		80MG	A218831	003	Jul 17, 2025	Jul NEWA
	AB	HIKMA	20MG	N018823	001	Nov 10, 1983	Jun CAHN
	AB		40MG	N018823	002	Nov 10, 1983	Jun CAHN
	@	NORVIUM BIOSCIENCE	80MG	A070082	001	Oct 29, 1986	Feb CAHN

GABAPENTINSOLUTION; ORAL
GABAPENTIN

AA		AJENAT PHARMS	250MG/5ML	A091286	001	Mar 14, 2016	Jan CAHN
AA		PAI HOLDINGS PHARM	250MG/5ML	A211330	001	Dec 03, 2019	Apr CMFD

TABLET; ORAL
GABAPENTIN

>D>	AB1	ACTAVIS ELIZABETH	600MG	A075694	001	Oct 21, 2004	Jul DISC
>A>	@		600MG	A075694	001	Oct 21, 2004	Jul DISC
>D>	AB1		800MG	A075694	002	Oct 21, 2004	Jul DISC
>A>	@		800MG	A075694	002	Oct 21, 2004	Jul DISC
>A>	@	ALLIED	600MG	A076877	001	Jul 06, 2006	Jul CAHN
>A>	@		800MG	A076877	002	Jul 06, 2006	Jul CAHN
	@	APOTEX	100MG	A077894	001	Oct 10, 2006	Mar DISC
	@		300MG	A077894	002	Oct 10, 2006	Mar DISC
	@		400MG	A077894	003	Oct 10, 2006	Mar DISC
>D>	@	INVATECH	600MG	A076877	001	Jul 06, 2006	Jul CAHN
>D>	@		800MG	A076877	002	Jul 06, 2006	Jul CAHN
		IVAX SUB TEVA PHARMS	300MG	A076017	002	Apr 28, 2004	Mar CTEC

GADOBUTROLSOLUTION; INTRAVENOUS
GADOBUTROL

AP		HAINAN POLY PHARM	1.20944GM/2ML (604.72MG/ML)	A217480	003	Apr 16, 2025	Apr NEWA
AP			6.0472GM/10ML (604.72MG/ML)	A217480	004	Apr 16, 2025	Apr NEWA
AP			18.1416GM/30ML (604.72MG/ML)	A217480	005	Apr 16, 2025	Apr NEWA
AP			39.3068GM/65ML (604.72MG/ML)	A217480	006	Apr 16, 2025	Apr NEWA

GADOTERIDOLINJECTABLE; INJECTION
GADOTERIDOL

AP		HAINAN POLY	279.3MG/ML	A218749	001	Feb 11, 2025	Jan NFTG
		PROHANCE					
AP		+! BRACCO	279.3MG/ML	N020131	001	Nov 16, 1992	Jan CFTG

GALLIUM GA-68 GOZETOTIDEPOWDER; INTRAVENOUS
GOZELLIX

	+!	TELIx INNOVATIONS	N/A	N219592	001	Mar 20, 2025	Mar NEWA
--	----	-------------------	-----	---------	-----	--------------	----------

GANCICLOVIRSOLUTION; INTRAVENOUS
GANZYK-RTU

@ +	EXELA PHARMA	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Apr DISC
-----	--------------	----------------------	---------	-----	--------------	----------

GANIRELIX ACETATEINJECTABLE; INJECTION
GANIRELIX ACETATE

AP		QILU	250MCG/0.5ML	A218855	001	Apr 23, 2025	Apr NEWA
AP		TRIS PHARMA INC	250MCG/0.5ML	A219454	001	Jun 27, 2025	Jun NEWA

GATIFLOXACINSOLUTION/DROPS; OPHTHALMIC
GATIFLOXACIN

@	CAPLIN	0.5%	A213542	001	Nov 03, 2021	May CAHN
---	--------	------	---------	-----	--------------	----------

GEFITINIBTABLET; ORAL
GEFITINIB

AB		CIPLA	250MG	A211826	001	May 16, 2025	May NEWA
----	--	-------	-------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

@	HIKMA INTL PHARMS	EQ 200MG BASE/VIAL	A206617	001	Jun 25, 2021	May DISC
@		EQ 1GM BASE/VIAL	A206617	002	Jun 25, 2021	May DISC

SOLUTION; INTRAVENOUS
AVGEMSI

+!	AVYXA HOLDINGS	EQ 200MG BASE/5.26ML (EQ 38MG BASE/ML)	N219920	001	Jun 27, 2025	Jun NEWA
+!		EQ 1GM BASE/26.3ML (EQ 38MG BASE/ML)	N219920	002	Jun 27, 2025	Jun NEWA

SOLUTION; INTRAVENOUS							
AVGEMSI							
	+	BASE/ML)					
		EQ 2GM BASE/52.6ML (EQ 38MG	N219920	003	Jun 27, 2025	Jun	NEWA
		BASE/ML)					
<u>GEMFIBROZIL</u>							
TABLET; ORAL							
GEMFIBROZIL							
@	APOTEX	600MG	A075034	001	Jul 20, 1998	Mar	DISC
<u>GENTAMICIN SULFATE</u>							
OINTMENT; TOPICAL							
GENTAMICIN SULFATE							
>D> AT	TARO	EQ 0.1% BASE	A062477	001	Dec 23, 1983	Jul	DISC
>A>	@	EQ 0.1% BASE	A062477	001	Dec 23, 1983	Jul	DISC
<u>GEPOTIDACIN MESYLATE</u>							
TABLET; ORAL							
BLUJEPA							
	+! GLAXOSMITHKLINE	EQ 750MG BASE	N218230	001	Mar 25, 2025	Mar	NEWA
<u>GLATIRAMER ACETATE</u>							
INJECTABLE; SUBCUTANEOUS							
GLATIRAMER ACETATE							
AP	CHEMI SPA	20MG/ML	A208468	001	May 07, 2025	Apr	NEWA
AP		40MG/ML	A208468	002	May 07, 2025	Apr	NEWA
<u>GLIMEPIRIDE</u>							
TABLET; ORAL							
AMARYL							
@ +	SANOFI AVENTIS US	1MG	N020496	001	Nov 30, 1995	Feb	DISC
@ +		2MG	N020496	002	Nov 30, 1995	Feb	DISC
@ +		4MG	N020496	003	Nov 30, 1995	Feb	DISC
GLIMEPIRIDE							
AB	! DR REDDYS LABS LTD	1MG	A077091	001	Oct 06, 2005	Feb	CHRS
<u>GLIPIZIDE</u>							
TABLET; ORAL							
GLIPIZIDE							
@	AIPING PHARM INC	5MG	A074305	001	Apr 07, 1995	Jan	CAHN
@		10MG	A074305	002	Apr 07, 1995	Jan	CAHN
AB	OXFORD PHARMS	5MG	A074378	001	Nov 28, 1994	Apr	CMFD
AB		10MG	A074378	002	Nov 28, 1994	Apr	CMFD
TABLET, EXTENDED RELEASE; ORAL							
GLUCOTROL XL							
@ +	PFIZER	2.5MG	N020329	003	Aug 10, 1999	Apr	DISC
AB	+	5MG	N020329	001	Apr 26, 1994	Apr	CMFD
AB	+	10MG	N020329	002	Apr 26, 1994	Apr	CHRS
<u>GLUCAGON</u>							
INJECTABLE; INJECTION							
GLUCAGON							
>A> AP	LUPIN LTD	1MG/VIAL	A214457	001	Jul 22, 2025	Jul	NEWA
SOLUTION; INTRAVENOUS							
GVOKE VIALDX							
	+! XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	006	Mar 14, 2025	Mar	NEWA
<u>GLYCOPYRROLATE</u>							
INJECTABLE; INJECTION							
GLYCOPYRROLATE							
@	XIROMED	0.2MG/ML	A212227	001	Mar 04, 2021	Jan	DISC
POWDER; INHALATION							
SEEBRI NEOHALER							
@ +	NOVARTIS	15.6MCG/INH	N207923	001	Oct 29, 2015	May	CTNA
SOLUTION; ORAL							
GLYCOPYRROLATE							
AA	MSN	1MG/5ML	A216084	001	Apr 08, 2025	Mar	NEWA
TABLET; ORAL							
GLYCOPYRROLATE							
AA	CHARTWELL RX	1MG	A040847	001	Mar 21, 2008	Feb	CAHN

TABLET;ORAL
GLYCOPYRROLATE

AA 2MG A040847 002 Mar 21, 2008 Feb CAHN

GLYCOPYRROLATE; INDACATEROL MALEATE

POWDER; INHALATION
UTIBRON NEOHALER
@ + NOVARTIS

15.6MCG/INH; 27.5MCG/INH

N207930 001 Oct 29, 2015 May CTNA

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT SAPTALIS PHARMS 0.025MG/ML; EQ 1.75MG
BASE/ML; 10,000 UNITS/ML

A065187 001 Oct 28, 2005 Feb CAHN

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL
GRANISETRON HYDROCHLORIDE
INTRA SANA LABS

EQ 2MG BASE/10ML

A219282 001 Mar 17, 2025 Mar NEWA

TABLET; ORAL
GRANISETRON HYDROCHLORIDE
@ APOTEX INC

EQ 1MG BASE

A078843 001 Feb 27, 2008 Mar DISC

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HYDROCHLORIDE

>A> AB AIPING PHARM INC EQ 1MG BASE
>A> AB EQ 2MG BASE
BX RUBICON EQ 1MG BASE
BX EQ 2MG BASE
>D> AB TWI PHARMS EQ 1MG BASE
>D> AB EQ 2MG BASE

A216399 001 Jun 08, 2022 Jul CAHN
A216399 002 Jun 08, 2022 Jul CAHN
A216762 001 Oct 17, 2023 Mar CTEC
A216762 002 Oct 17, 2023 Mar CTEC
A216399 001 Jun 08, 2022 Jul CAHN
A216399 002 Jun 08, 2022 Jul CAHN

TABLET, EXTENDED RELEASE; ORAL
GUANFACINE HYDROCHLORIDE

AB FOSUN WANBANG EQ 1MG BASE
@ EQ 1MG BASE
AB EQ 2MG BASE
@ EQ 2MG BASE
AB EQ 3MG BASE
@ EQ 3MG BASE
AB EQ 4MG BASE
@ EQ 4MG BASE
AB RUBICON EQ 1MG BASE
AB EQ 2MG BASE
AB EQ 3MG BASE
AB EQ 4MG BASE

A217638 001 Jun 12, 2024 Mar CMFD
A217638 001 Jun 12, 2024 Jan CAHN
A217638 002 Jun 12, 2024 Mar CMFD
A217638 002 Jun 12, 2024 Jan CAHN
A217638 003 Jun 12, 2024 Mar CMFD
A217638 003 Jun 12, 2024 Jan CAHN
A217638 004 Jun 12, 2024 Mar CMFD
A217638 004 Jun 12, 2024 Jan CAHN
A219689 001 Apr 15, 2025 Apr NEWA
A219689 002 Apr 15, 2025 Apr NEWA
A219689 003 Apr 15, 2025 Apr NEWA
A219689 004 Apr 15, 2025 Apr NEWA

HALCINONIDE

SOLUTION; TOPICAL
HALCINONIDE

! ENCUBE 0.1%
@ 0.1%

A217671 001 May 29, 2024 Mar CMFD
A217671 001 May 29, 2024 Jan DISC

HALOBETASOL PROPIONATE

LOTION; TOPICAL
ULTRAVATE

+! LACER PHARMA 0.05%
@ + 0.05%

N208183 001 Nov 06, 2015 Apr CMFD
N208183 001 Nov 06, 2015 Jan CAHN

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION; TOPICAL
DUOBRII

AB +! BAUSCH 0.01%; 0.045%
HALOBETASOL PROPIONATE AND TAZAROTENE
AB TARO 0.01%; 0.045%

N209354 001 Apr 25, 2019 Apr CFTG
A217190 001 May 02, 2025 Apr NFTG

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

AB APPCO 0.5MG
AB 1MG
AB 2MG

A211061 001 Jan 08, 2020 Feb CAHN
A211061 002 Jan 08, 2020 Feb CAHN
A211061 003 Jan 08, 2020 Feb CAHN

TABLET;ORAL
HALOPERIDOL

AB		5MG	A211061	004	Jan 08, 2020	Feb CAHN
AB		10MG	A211061	005	Jan 08, 2020	Feb CAHN
AB		20MG	A211061	006	Jan 08, 2020	Feb CAHN

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

AO	CAPLIN	EQ 50MG BASE/ML	A219168	001	May 13, 2025	May NEWA
AO		EQ 100MG BASE/ML	A219168	002	May 13, 2025	May NEWA

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

HALOPERIDOL

@	FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Feb DISC
---	--------------------	----------------	---------	-----	--------------	----------

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

@	B BRAUN MEDICAL	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Jan DISC
	HIKMA	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jan CTEC
AP	NORVIUM BIOSCIENCE	1,000 UNITS/ML	A203851	001	Nov 30, 2017	May CAHN
AP		5,000 UNITS/ML	A203851	002	Nov 30, 2017	May CAHN
AP		10,000 UNITS/ML	A203851	003	Nov 30, 2017	May CAHN
AP		20,000 UNITS/ML	A203852	001	Nov 30, 2017	May CAHN
AP	PLANO PHARMS	1,000 UNITS/ML	A091682	001	Jun 08, 2011	Mar CAHN
AP		5,000 UNITS/ML	A091682	002	Jun 08, 2011	Mar CAHN
AP		10,000 UNITS/ML	A201002	001	Jun 08, 2011	Mar CAHN
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	+! B BRAUN	5,000 UNITS/100ML	N019953	003	Mar 25, 2025	Mar NEWA
	+!	10,000 UNITS/100ML	N019953	004	Mar 25, 2025	Mar NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

@	APOZEAL PHARMS	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Apr CAHN
@	SANKALP LIFECARE	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	Apr CAHN
AA	XTTRIUM LABS INC	1.5MG/5ML;5MG/5ML	A088008	001	Mar 03, 1983	Feb CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

>A>	AP	@ ADRASTEIA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Jun DISC
	AP	BAXTER HLTHCARE CORP	20MG/ML	A219797	001	Jul 17, 2025	Jul NEWA
	AP	KINDOS	20MG/ML	A217501	001	Jun 02, 2025	May NEWA

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

@	MACLEODS PHARMS LTD	10MG	A211010	001	Aug 21, 2024	Jun DISC
@		25MG	A211010	002	Aug 21, 2024	Jun DISC
@		50MG	A211010	003	Aug 21, 2024	Jun DISC
@		100MG	A211010	004	Aug 21, 2024	Jun DISC

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

MICROZIDE

AB	+! TEVA BRANDED PHARM	12.5MG	N020504	001	Dec 27, 1996	Apr CAHN
----	-----------------------	--------	---------	-----	--------------	----------

FOR SUSPENSION;ORAL

INZIRQO

+!	NOVITIUM PHARMA	10MG/ML	N219141	001	Jan 28, 2025	Jan NEWA
----	-----------------	---------	---------	-----	--------------	----------

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB	UNICHEM	12.5MG	A040907	003	Apr 03, 2025	Mar NEWA
----	---------	--------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	SENORES PHARMS	25MG;50MG	A215789	001	Jan 08, 2025	Jan NEWA
AB		25MG;100MG	A215789	002	Jan 08, 2025	Jan NEWA

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

HYDROCHLOROTHIAZIDE AND OLMESARTAN MEDOXOMIL

>A>	AB	HETERO LABS LTD V	12.5MG; 20MG	A209199	001	Jul 25, 2025	Jul NEWA
>A>	AB		12.5MG; 40MG	A209199	002	Jul 25, 2025	Jul NEWA
>A>	AB		25MG; 40MG	A209199	003	Jul 25, 2025	Jul NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	APOTEX	12.5MG; EQ 10MG BASE	A091524	001	Mar 12, 2013	Jan DISC
@		12.5MG; EQ 20MG BASE	A091524	002	Mar 12, 2013	Jan DISC
@		25MG; EQ 20MG BASE	A091524	003	Mar 12, 2013	Jan DISC

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB	MANKIND PHARMA	12.5MG; 40MG	A218406	001	Mar 03, 2025	Feb NEWA
AB		12.5MG; 80MG	A218406	002	Mar 03, 2025	Feb NEWA
AB		25MG; 80MG	A218406	003	Mar 03, 2025	Feb NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@	MACLEODS PHARMS LTD	25MG; 37.5MG	A214611	001	Jan 28, 2025	Jun DISC
AB		25MG; 37.5MG	A214611	001	Jan 28, 2025	Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE

@	STRIDES PHARMA	5MG; 200MG	A077723	003	Nov 06, 2006	Apr CAHN
---	----------------	------------	---------	-----	--------------	----------

HYDROCODONE BITARTRATE AND IBUPROFEN

@	STRIDES PHARMA	7.5MG; 200MG	A077723	001	Nov 06, 2006	Apr CAHN
@		10MG; 200MG	A077723	002	Nov 06, 2006	Apr CAHN

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	APOZEAL PHARMS	5MG/5ML; 60MG/5ML	A206661	001	Jan 23, 2019	Apr CAHN
---	----------------	-------------------	---------	-----	--------------	----------

HYDROCORTISONE

LOTION; TOPICAL

ALA-SCALP

+	LEGACY PHARMA	2%	A083231	001		Mar CRLD
---	---------------	----	---------	-----	--	----------

SOLUTION; ORAL

KHINDIVI

+	ETON	1MG/ML	N218980	001	May 28, 2025	May NEWA
---	------	--------	---------	-----	--------------	----------

TABLET; ORAL

HYDROCORTISONE

AB	NOVITIUM PHARMA	5MG	A217881	001	May 02, 2025	Apr NEWA
AB		10MG	A217881	002	May 02, 2025	Apr NEWA
AB		20MG	A217881	003	May 02, 2025	Apr NEWA

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

CORTIFOAM

+	VIATRIS	10%	N017351	001	Feb 10, 1982	Feb CAHN
---	---------	-----	---------	-----	--------------	----------

CREAM; TOPICAL

MICORT-HC

@	LEGACY PHARMA	2%	A040398	001	Mar 29, 2002	Jan CAHN
---	---------------	----	---------	-----	--------------	----------

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

>D>	AB	GLENMARK PHARMS LTD	0.2%	A211129	001	Oct 12, 2018	Jul DISC
>A>		@	0.2%	A211129	001	Oct 12, 2018	Jul DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

@	SAPTALIS PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005	Feb CAHN
---	-----------------	-------------------------------------	---------	-----	--------------	----------

SUSPENSION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	SAPTALIS PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006	Feb CAHN
----	-----------------	-------------------------------------	---------	-----	--------------	----------

HYDROMORPHONE HYDROCHLORIDE

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

@	MPP PHARMA	8MG	A076723	001	Oct 18, 2005	Jun CAHN
---	------------	-----	---------	-----	--------------	----------

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

AA	BIONPHARMA	10MG/5ML	A219289	001	Apr 28, 2025	Apr NEWA
----	------------	----------	---------	-----	--------------	----------

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

@	APPCO	10MG	A040812	001	Mar 12, 2008	Apr CAHN
@		25MG	A040812	002	Mar 12, 2008	Apr CAHN
@		50MG	A040812	003	Mar 12, 2008	Apr CAHN
AB	! GRAVITI PHARMS	50MG	A217652	003	Aug 17, 2023	Mar CHRS
AB	+ PLIVA	50MG	A088619	001	Jan 10, 1986	Mar CHRS
@ +	STRIDES PHARMA	50MG	A087604	001	Jan 22, 1982	Mar CRLD

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB	BARR LABS	EQ 50MG HYDROCHLORIDE	A088487	001	Jun 15, 1984	Mar CAHN
		EQ 100MG HYDROCHLORIDE	A088488	001	Jun 15, 1984	Mar CAHN

SUSPENSION;ORAL

VISTARIL

>D>	@ PFIZER	EQ 25MG HYDROCHLORIDE/5ML	N011795	001		Jul CRLD
>A>	@ +	EQ 25MG HYDROCHLORIDE/5ML	N011795	001		Jul CRLD

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

ICATIBANT ACETATE

@	CAPLIN	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213054	001	Oct 05, 2020	Apr CAHN
---	--------	------------------------------------	---------	-----	--------------	----------

ICODEXTRIN

SOLUTION;INTRAPERITONEAL

EXTRANEAL

+!	VANTIVE US HLTHCARE	7.5GM/100ML	N021321	001	Dec 20, 2002	Feb CAHN
----	---------------------	-------------	---------	-----	--------------	----------

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

>A> AB	XIAMEN LP PHARM CO	1GM	A219156	001	Aug 06, 2025	Jul NEWA
--------	--------------------	-----	---------	-----	--------------	----------

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB	CSPC OUYI	EQ 100MG BASE	A212193	001	Apr 21, 2025	Apr NEWA
AB		EQ 400MG BASE	A212193	002	Apr 21, 2025	Apr NEWA
AB	HETERO LABS LTD V	EQ 100MG BASE	A212975	001	Apr 14, 2025	Apr NEWA
AB		EQ 400MG BASE	A212975	002	Apr 14, 2025	Apr NEWA

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

@	APOTEX INC	5%	A091308	001	Apr 06, 2012	Mar DISC
---	------------	----	---------	-----	--------------	----------

IOVERSOL

INJECTABLE; INJECTION
OPTIRAY 300

>D>	+!	LIEBEL-FLARSHEIM	64%	N020923	004	May 13, 1999	Jul DISC
>A>	@ +		64%	N020923	004	May 13, 1999	Jul DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE

	@	PHARMOBEDIANT	0.02%	A074755	001	Jan 10, 1997	Jun CAHN
		SPRAY, METERED; NASAL					
		IPRATROPIUM BROMIDE					
AB		LUPIN	0.021MG/SPRAY	A217912	001	Feb 07, 2025	Jan NEWA
AB			0.042MG/SPRAY	A217886	001	Jan 27, 2025	Jan NEWA
AB		RUBICON	0.021MG/SPRAY	A219222	001	Jan 14, 2025	Jan NEWA

ISOCARBOXAZID

TABLET; ORAL
MARPLAN

	+!	LIFSA DRUGS	10MG	N011961	001		Jun CAHN
--	----	-------------	------	---------	-----	--	----------

ISONIAZID

SYRUP; ORAL
ISONIAZID

AA		CHARTWELL RX	50MG/5ML	A081118	001	Jul 21, 1997	Feb CMFD
AA	+!	CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983	Feb CTEC

ISOSORBIDE DINITRATE

TABLET; ORAL
ISOSORBIDE DINITRATE

>A>	AB	HIKMA INTL PHARMS	5MG	A088088	003	Oct 29, 1987	Jul CMS1
>A>	AB		10MG	A088088	002	Oct 29, 1987	Jul CMS1

TABLET; SUBLINGUAL
ISOSORBIDE DINITRATE

>A>	@	HIKMA INTL PHARMS	2.5MG	A086055	002	Oct 29, 1987	Jul CMS1
-----	---	-------------------	-------	---------	-----	--------------	----------

ISOSULFAN BLUE

SOLUTION; SUBCUTANEOUS
ISOSULFAN BLUE

	@	SABA ILAY SANAYI	50MG/5ML (10MG/ML)	A210714	001	Jan 16, 2019	Jun CAHN
--	---	------------------	--------------------	---------	-----	--------------	----------

ISOTRETINOIN

CAPSULE; ORAL
AMNESTEEM

AB1		MYLAN PHARMS INC	30MG	A075945	004	Mar 17, 2025	Mar NEWA
		ISOTRETINOIN					
AB2		ZYDUS PHARMS	10MG	A216633	001	May 22, 2025	May NEWA
AB2			20MG	A216633	002	May 22, 2025	May NEWA
AB2			25MG	A216633	003	May 22, 2025	May NEWA
AB2			30MG	A216633	004	May 22, 2025	May NEWA
AB2			35MG	A216633	005	May 22, 2025	May NEWA
AB2			40MG	A216633	006	May 22, 2025	May NEWA

ITRACONAZOLE

CAPSULE; ORAL
ITRACONAZOLE

AB		RISING	100MG	A205724	001	Dec 13, 2016	Feb CMFD
----	--	--------	-------	---------	-----	--------------	----------

IVABRADINE HYDROCHLORIDE

TABLET; ORAL
IVABRADINE HYDROCHLORIDE

AB		MSN	EQ 5MG BASE	A213483	001	Apr 28, 2025	Apr NEWA
AB			EQ 7.5MG BASE	A213483	002	Apr 28, 2025	Apr NEWA

IVERMECTIN

TABLET; ORAL
IVERMECTIN

AB		RUBICON	3MG	A215922	001	Jan 22, 2025	Jan NEWA
			6MG	A215922	002	Jan 22, 2025	Jan NFTG

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETAMINE HYDROCHLORIDE

AP FRESenius KABI USA EQ 100MG BASE/ML A215808 003 Apr 18, 2025 Apr NEWA

KETOCONAZOLE

GEL; TOPICAL
XOLEGEL

@ + INA PHARMS

2%

N021946 001 Jul 28, 2006 May CAHN

SHAMPOO; TOPICAL
KETOCONAZOLE

AB ZYDUS LIFESCIENCES

2%

A218559 001 Mar 07, 2025 Feb NEWA

TABLET; ORAL

KETOCONAZOLE

AB ESJAY PHARMA

200MG

A219129 001 Jul 03, 2025 Jun NEWA

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

>D> AP FRESenius KABI USA

15MG/ML

A203242 001 Oct 07, 2015 Jul DISC

>A> @

15MG/ML

A203242 001 Oct 07, 2015 Jul DISC

>D> AP HOSPIRA

30MG/ML

A074993 002 Jan 27, 1999 Jul DISC

>A> @

30MG/ML

A074993 002 Jan 27, 1999 Jul DISC

>D> AP SUN PHARM

15MG/ML

A078737 001 Oct 06, 2008 Jul DISC

>A> @

15MG/ML

A078737 001 Oct 06, 2008 Jul DISC

>D> AP

30MG/ML

A078737 002 Oct 06, 2008 Jul DISC

>A> @

30MG/ML

A078737 002 Oct 06, 2008 Jul DISC

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HYDROCHLORIDE

>D> AB RUBICON

100MG

A211953 001 Aug 18, 2021 Jul CAHN

>D> AB

200MG

A211953 002 Aug 18, 2021 Jul CAHN

>D> AB

300MG

A211953 003 Aug 18, 2021 Jul CAHN

>A> AB RUBICON RESEARCH

100MG

A211953 001 Aug 18, 2021 Jul CAHN

>A> AB

200MG

A211953 002 Aug 18, 2021 Jul CAHN

>A> AB

300MG

A211953 003 Aug 18, 2021 Jul CAHN

LACOSAMIDE

SOLUTION; INTRAVENOUS
LACOSAMIDE

AP WESTMINSTER PHARMS

200MG/20ML (10MG/ML)

A218706 001 May 23, 2025 May NEWA

SOLUTION; ORAL

LACOSAMIDE

AA AJENAT PHARMS

10MG/ML

A219699 001 Jun 26, 2025 Jun NEWA

AA APOTEX

10MG/ML

A206355 001 Sep 26, 2022 May CMFD

@

10MG/ML

A206355 001 Sep 26, 2022 Feb DISC

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

AA ! CUMBERLAND PHARMS

10GM/PACKET

A074712 001 Dec 10, 1997 Mar CTEC

AA !

20GM/PACKET

A074712 002 Dec 10, 1997 Mar CTEC

AA PAI HOLDINGS

10GM/PACKET

A217914 001 Mar 14, 2025 Mar NEWA

AA

20GM/PACKET

A217914 002 Mar 14, 2025 Mar NEWA

SOLUTION; ORAL

LACTULOSE

@ VISTAPHARM LLC

10GM/15ML

A074138 001 Sep 30, 1992 Jan CAHN

LAMIVUDINE

TABLET; ORAL

LAMIVUDINE

AB APPCO

150MG

A206974 001 Nov 21, 2016 Mar CAHN

AB

300MG

A206974 002 Nov 21, 2016 Mar CAHN

@ NORVIUM BIOSCIENCE

150MG

A078545 001 Mar 05, 2019 Feb CAHN

@

300MG

A078545 002 Mar 05, 2019 Feb CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	NORVIUM BIOSCIENCE	150MG;300MG	A079128	001	May 13, 2015	May CAHN
----	--------------------	-------------	---------	-----	--------------	----------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@ AIPING PHARM INC

@

@

@

@

25MG

100MG

150MG

200MG

A078645 001 Jan 27, 2009 Jan CAHN

A078645 002 Jan 27, 2009 Jan CAHN

A078645 003 Jan 27, 2009 Jan CAHN

A078645 004 Jan 27, 2009 Jan CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

@ MACLEODS PHARMS LTD

@

15MG

30MG

A208671 001 Nov 04, 2024 Jun DISC

A208671 002 Nov 04, 2024 Jun DISC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

LANTHANUM CARBONATE

AB ALKEM LABS LTD

AB

AB

EQ 500MG BASE

EQ 750MG BASE

EQ 1GM BASE

A202329 001 Mar 13, 2025 Mar NEWA

A202329 002 Mar 13, 2025 Mar NEWA

A202329 003 Mar 13, 2025 Mar NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

@ CARNEGIE

AT MICRO LABS

0.005%

0.005%

A202077 001 Feb 11, 2013 Apr CAHN

A219306 001 Apr 14, 2025 Apr NEWA

LATANOPROSTENE BUNOD

SOLUTION/DROPS; OPHTHALMIC

LATANOPROSTENE BUNOD

AB GLAND

AB

AB

VYZULTA

+! BAUSCH AND LOMB

0.024%

0.024%

A217387 001 Apr 29, 2025 Apr NFTG

N207795 001 Nov 02, 2017 Apr CFTG

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

AB FOSUN WANBANG

AB

10MG

20MG

A077087 001 Sep 13, 2005 Jan CAHN

A077087 002 Sep 13, 2005 Jan CAHN

LENACAPAVIR SODIUM

SOLUTION; SUBCUTANEOUS

YEZTUGO

+! GILEAD SCIENCES INC

+! GILEAD SCIENCES INC

EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)

N220018 001 Jun 18, 2025 Jun NEWA

TABLET; ORAL

YEZTUGO

+! GILEAD SCIENCES INC

EQ 300MG BASE

N220020 001 Jun 18, 2025 Jun NEWA

LENALIDOMIDE

CAPSULE; ORAL

LENALIDOMIDE

@ AMNEAL

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

2.5MG

2.5MG

5MG

5MG

10MG

10MG

15MG

15MG

20MG

20MG

25MG

25MG

2.5MG

5MG

A216213 001 Jan 31, 2025 Jun DISC

A216213 001 Jan 31, 2025 Jan NEWA

A216213 002 Jan 31, 2025 Jun DISC

A216213 002 Jan 31, 2025 Jan NEWA

A216213 003 Jan 31, 2025 Jun DISC

A216213 003 Jan 31, 2025 Jan NEWA

A216213 004 Jan 31, 2025 Jun DISC

A216213 004 Jan 31, 2025 Jan NEWA

A216213 005 Jan 31, 2025 Jun DISC

A216213 005 Jan 31, 2025 Jan NEWA

A216213 006 Jan 31, 2025 Jun DISC

A216213 006 Jan 31, 2025 Jan NEWA

A215759 001 Mar 03, 2025 Feb NEWA

A215759 002 Mar 03, 2025 Feb NEWA

BIOCON PHARMA

CAPSULE; ORAL							
LENALIDOMIDE							
AB		10MG	A215759	003	Mar 03, 2025	Feb	NEWA
AB		15MG	A215759	004	Mar 03, 2025	Feb	NEWA
AB		20MG	A215759	005	Mar 03, 2025	Feb	NEWA
AB		25MG	A215759	006	Mar 03, 2025	Feb	NEWA
AB	DEVA HOLDING AS	2.5MG	A217554	001	May 22, 2025	May	NEWA
AB		5MG	A217554	002	May 22, 2025	May	NEWA
AB		10MG	A217554	003	May 22, 2025	May	NEWA
AB		15MG	A217554	004	May 22, 2025	May	NEWA
AB		20MG	A217554	005	May 22, 2025	May	NEWA
AB		25MG	A217554	006	May 22, 2025	May	NEWA
<u>LEUPROLIDE ACETATE</u>							
SOLUTION; SUBCUTANEOUS							
LEUPROLIDE ACETATE							
AP	ENDO OPERATIONS	14MG/2.8ML (1MG/0.2ML)	A217437	001	Jun 09, 2025	May	NEWA
<u>LEVALBUTEROL HYDROCHLORIDE</u>							
SOLUTION; INHALATION							
LEVALBUTEROL HYDROCHLORIDE							
@	MANKIND PHARMA	EQ 0.0103% BASE	A218770	001	Oct 21, 2024	Apr	DISC
@		EQ 0.021% BASE	A218770	002	Oct 21, 2024	Apr	DISC
@		EQ 0.042% BASE	A218770	003	Oct 21, 2024	Apr	DISC
<u>LEVETIRACETAM</u>							
INJECTABLE; INTRAVENOUS							
LEVETIRACETAM IN SODIUM CHLORIDE							
AP	CAPLIN	500MG/100ML (5MG/ML)	A219562	001	Jan 16, 2025	Jan	NEWA
AP		1GM/100ML (10MG/ML)	A219562	002	Jan 16, 2025	Jan	NEWA
AP		1.5GM/100ML (15MG/ML)	A219562	003	Jan 16, 2025	Jan	NEWA
SOLUTION; ORAL							
LEVETIRACETAM							
AA	AJENAT PHARMS	100MG/ML	A090461	001	Sep 30, 2010	Jan	CAHN
AA	BIONPHARMA	100MG/ML	A079120	001	Jan 16, 2009	May	CMFD
TABLET; ORAL							
LEVETIRACETAM							
@	CHINA RESOURCES	500MG	A205102	004	Dec 16, 2015	Jan	CAHN
@		1GM	A205102	003	Dec 16, 2015	Jan	CAHN
@	MPP PHARMA	250MG	A090511	001	Aug 18, 2011	Jun	CAHN
@		500MG	A090511	002	Aug 18, 2011	Jun	CAHN
@		750MG	A090511	003	Aug 18, 2011	Jun	CAHN
@		1GM	A090511	004	Aug 18, 2011	Jun	CAHN
TABLET, EXTENDED RELEASE; ORAL							
LEVETIRACETAM							
@	APOTEX	1GM	A202958	001	Feb 25, 2015	Mar	DISC
TABLET, FOR SUSPENSION; ORAL							
SPRITAM							
+	APRECIA PHARMS	500MG	N207958	002	Jul 31, 2015	Apr	CHRS
@ +		750MG	N207958	003	Jul 31, 2015	Apr	DISC
@ +		1GM	N207958	004	Jul 31, 2015	Apr	DISC
<u>LEVOCARNITINE</u>							
INJECTABLE; INJECTION							
LEVOCARNITINE							
AP	DEVA HOLDING AS	200MG/ML	A217430	001	Jun 30, 2025	Jun	NEWA
<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>							
TABLET; ORAL							
LEVOCETIRIZINE DIHYDROCHLORIDE							
AB	SYNTHON BV	5MG	A090229	001	Nov 26, 2010	Feb	CAHN
<u>LEVODOPA</u>							
POWDER; INHALATION							
INBRIJA							
+	MERZ	42MG	N209184	001	Dec 21, 2018	Feb	CAHN

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

@	APOTEX INC	250MG	A090787	001	Sep 29, 2011	Mar	DISC
@		500MG	A090787	002	Sep 29, 2011	Mar	DISC
@		750MG	A090787	003	Sep 29, 2011	Mar	DISC

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

AB	ACERTIS PHARMS	2MG	A211484	001	Dec 13, 2018	Apr	CAHN
BX	NOVITIUM PHARMA	1MG	A213479	003	Jul 20, 2021	Mar	CTEC
BX		2MG	A213479	001	Jul 01, 2020	Mar	CTEC
BX		3MG	A213479	002	Jan 12, 2021	Mar	CTEC
AB		3MG	A213479	002	Jan 12, 2021	Mar	CHRS
	! SUN PHARM INDS INC	3MG	A213906	002	Apr 25, 2023	Mar	CTEC
AB	!	3MG	A213906	002	Apr 25, 2023	Mar	CHRS

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

LEVOTHYROXINE SODIUM

@	ANI PHARMS	0.075MG	A211369	001	Oct 28, 2020	Jun	CAHN
@		0.088MG	A213256	001	Jan 06, 2021	Jun	CAHN
@		0.1MG	A213256	002	Jan 06, 2021	Jun	CAHN
@		0.112MG	A211369	003	Apr 16, 2021	Jun	CAHN
@		0.125MG	A213256	003	Jan 06, 2021	Jun	CAHN
@		0.137MG	A211369	005	May 02, 2023	Jun	CAHN
@		0.15MG	A211369	002	Oct 28, 2020	Jun	CAHN
@		0.175MG	A211369	006	May 02, 2023	Jun	CAHN
@		0.2MG	A211369	004	Nov 09, 2022	Jun	CAHN

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	ONESOURCE SPECIALTY	100MCG/VIAL	A216729	001	Mar 05, 2025	May	CAHN
AP		200MCG/VIAL	A216729	002	Mar 05, 2025	May	CAHN
AP		500MCG/VIAL	A216729	003	Mar 05, 2025	May	CAHN
AP	STERISCIENCE	100MCG/VIAL	A216729	001	Mar 05, 2025	Feb	NEWA
AP		200MCG/VIAL	A216729	002	Mar 05, 2025	Feb	NEWA
AP		500MCG/VIAL	A216729	003	Mar 05, 2025	Feb	NEWA

SOLUTION; ORAL

THYQUIDITY

+!	STEVENS J	100MCG/5ML	N214047	001	Nov 30, 2020	Apr	CAHN
----	-----------	------------	---------	-----	--------------	-----	------

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

EUTHYROX

AB2	EMD SERONO INC	0.025MG	N021292	001	May 31, 2002	Apr	CAHN
AB2		0.05MG	N021292	002	May 31, 2002	Apr	CAHN
AB2		0.075MG	N021292	003	May 31, 2002	Apr	CAHN
AB2		0.088MG	N021292	004	May 31, 2002	Apr	CAHN
AB2		0.1MG	N021292	005	May 31, 2002	Apr	CAHN
AB2		0.112MG	N021292	006	May 31, 2002	Apr	CAHN
AB2		0.125MG	N021292	007	May 31, 2002	Apr	CAHN
AB2		0.137MG	N021292	008	May 31, 2002	Apr	CAHN
AB2		0.15MG	N021292	009	May 31, 2002	Apr	CAHN
AB2		0.175MG	N021292	010	May 31, 2002	Apr	CAHN
AB2		0.2MG	N021292	011	May 31, 2002	Apr	CAHN
@		0.3MG	N021292	012	May 31, 2002	Apr	CAHN
	LEVOTHYROXINE SODIUM						
@	AUROBINDO PHARMA	0.137MG	A216414	001	Jul 16, 2024	Jan	DISC
@		0.15MG	A216414	002	Jul 16, 2024	Jan	DISC
@		0.175MG	A216414	003	Jul 16, 2024	Jan	DISC
@		0.2MG	A216414	004	Jul 16, 2024	Jan	DISC
@		0.3MG	A216414	005	Jul 16, 2024	Jan	DISC
AB1, AB2,	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Feb	CTEC
AB3, AB4							
AB1, AB2,		0.025MG	A211417	001	Dec 21, 2022	Feb	CTEC
AB4							
AB1, AB2,		0.05MG	A211417	002	Dec 21, 2022	Feb	CTEC
AB3, AB4							
AB1, AB2,		0.05MG	A211417	002	Dec 21, 2022	Feb	CTEC
AB4							
AB1, AB2,		0.075MG	A211417	003	Dec 21, 2022	Feb	CTEC

TABLET;ORAL

LEVOTHYROXINE SODIUM

AB3,AB4							
AB1,AB2,	0.075MG	A211417	003	Dec 21, 2022	Feb	CTEC	
AB4							
AB1,AB2,	0.088MG	A211417	004	Dec 21, 2022	Feb	CTEC	
AB3,AB4							
AB1,AB2,	0.088MG	A211417	004	Dec 21, 2022	Feb	CTEC	
AB4							
AB1,AB2,	0.1MG	A211417	005	Dec 21, 2022	Feb	CTEC	
AB3,AB4							
AB1,AB2,	0.1MG	A211417	005	Dec 21, 2022	Feb	CTEC	
AB4							
AB1,AB2,	0.112MG	A211417	006	Dec 21, 2022	Feb	CTEC	
AB3,AB4							
AB1,AB2,	0.112MG	A211417	006	Dec 21, 2022	Feb	CTEC	
AB4							
AB1,AB2,	0.125MG	A211417	007	Dec 21, 2022	Feb	CTEC	
AB3,AB4							
AB1,AB2,	0.125MG	A211417	007	Dec 21, 2022	Feb	CTEC	
AB4							
AB1,AB2,	0.137MG	A211417	008	Dec 21, 2022	Feb	CTEC	
AB3,AB4							
AB1,AB2,	0.137MG	A211417	008	Dec 21, 2022	Feb	CTEC	
AB4							
AB1,AB2,	0.15MG	A211417	009	Dec 21, 2022	Feb	CTEC	
AB3,AB4							
AB1,AB2,	0.15MG	A211417	009	Dec 21, 2022	Feb	CTEC	
AB4							
AB1,AB2,	0.175MG	A211417	010	Dec 21, 2022	Feb	CTEC	
AB3,AB4							
AB1,AB2,	0.175MG	A211417	010	Dec 21, 2022	Feb	CTEC	
AB4							
AB1,AB2,	0.2MG	A211417	011	Dec 21, 2022	Feb	CTEC	
AB3,AB4							
AB1,AB2,	0.2MG	A211417	011	Dec 21, 2022	Feb	CTEC	
AB4							
AB1,AB2,	0.3MG	A211417	012	Dec 21, 2022	Feb	CTEC	
AB3,AB4							
AB1,AB2,	0.3MG	A211417	012	Dec 21, 2022	Feb	CTEC	
AB4							

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

BX	ALEMBIC	5%	A211469	001	Nov 23, 2018	Mar	CTEC
AT	CHARTWELL RX	5%	A208660	001	Jan 05, 2021	Apr	CAHN

PATCH;TOPICAL

LIDOCAINE

AB	AVEVA	1.8%	A217221	001	Mar 25, 2025	Mar	NFTG
AB	ZTLIDO						
AB	+! SCILEX PHARMS	1.8%	N207962	001	Feb 28, 2018	Mar	CFTG

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

>D>	AP	AFAXYS	1%	A215132	001	Jun 09, 2022	Jul	DISC
>A>	@		1%	A215132	001	Jun 09, 2022	Jul	DISC
	AP	ANTHEA PHARMA	1%	A219535	001	Apr 02, 2025	Mar	NEWA
		LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
>D>	AP	EUGIA PHARMA	1%	A203040	001	Mar 14, 2013	Jul	DISC
>A>	@		1%	A203040	001	Mar 14, 2013	Jul	DISC
>D>	AP		2%	A203040	002	Mar 14, 2013	Jul	DISC
>A>	@		2%	A203040	002	Mar 14, 2013	Jul	DISC

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE

>A>	AT	AUROBINDO PHARMA LTD	2%	A219759	001	Jul 29, 2025	Jul	NEWA
	AT	XTTRIUM LABS INC	2%	A087872	001	Nov 18, 1982	Feb	CAHN

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	XTTRIUM LABS INC	4%	A087881	001	Nov 18, 1982	Feb	CAHN
----	------------------	----	---------	-----	--------------	-----	------

LINEZOLIDSOLUTION; INTRAVENOUS
LINEZOLID

AP	NORVIUM BIOSCIENCE	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	Feb CAHN
AP		600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	Feb CAHN

TABLET; ORAL
LINEZOLID

@	MACLEODS PHARMS LTD	600MG	A210378	001	Oct 10, 2024	Jun DISC
---	---------------------	-------	---------	-----	--------------	----------

LIOTHYRONINE SODIUMINJECTABLE; INJECTION
TRIOSTAT

>D>	@ +	ENDO OPERATIONS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Jul CAHN
>A>	@ +	PH HEALTH	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Jul CAHN

LIRAGLUTIDESOLUTION; SUBCUTANEOUS
LIRAGLUTIDE

>A>	AP	LUPIN LTD	18MG/3ML (6MG/ML)	A215421	001	Jul 22, 2025	Jul NEWA
	AP	NANJING KING-FRIEND	18MG/3ML (6MG/ML)	A218115	001	Apr 02, 2025	Mar NEWA

LISDEXAMFETAMINE DIMESYLATECAPSULE; ORAL
LISDEXAMFETAMINE DIMESYLATE

AB	GRANULES	10MG	A218987	001	Jan 29, 2025	Jan NEWA
AB		20MG	A218987	002	Jan 29, 2025	Jan NEWA
AB		30MG	A218987	003	Jan 29, 2025	Jan NEWA
AB		40MG	A218987	004	Jan 29, 2025	Jan NEWA
AB		50MG	A218987	005	Jan 29, 2025	Jan NEWA
AB		60MG	A218987	006	Jan 29, 2025	Jan NEWA
AB		70MG	A218987	007	Jan 29, 2025	Jan NEWA
AB	SANDOZ	20MG	A202836	001	Jul 26, 2024	Jan CMFD
AB		30MG	A202836	002	Jul 26, 2024	Jan CMFD
AB		40MG	A202836	003	Jul 26, 2024	Jan CMFD
AB		50MG	A202836	004	Jul 26, 2024	Jan CMFD
AB		60MG	A202836	005	Jul 26, 2024	Jan CMFD
AB		70MG	A202836	006	Jul 26, 2024	Jan CMFD

SOLUTION; ORAL
ARYNTA

+	!	AZURITY	10MG/ML	N219847	001	Jun 16, 2025	Jun NEWA
---	---	---------	---------	---------	-----	--------------	----------

LITHIUM CARBONATETABLET, EXTENDED RELEASE; ORAL
LITHIUM CARBONATE

>D>	AB	NORVIUM BIOSCIENCE	300MG	A202288	001	Jun 29, 2012	Jul DISC
>A>	@		300MG	A202288	001	Jun 29, 2012	Jul DISC
	@		450MG	A202219	001	Aug 08, 2012	Mar DISC
	AB		450MG	A202219	001	Aug 08, 2012	Feb CAHN

LODOXAMIDE TROMETHAMINESOLUTION/DROPS; OPHTHALMIC
ALOMIDE

@ +	NOVARTIS	EQ 0.1% BASE	N020191	001	Sep 23, 1993	May DISC
-----	----------	--------------	---------	-----	--------------	----------

LOFEXIDINE HYDROCHLORIDETABLET; ORAL
LOFEXIDINE HYDROCHLORIDE

AB	MSN	EQ 0.18MG BASE	A218699	001	Feb 24, 2025	Feb NEWA		
	LUCEMYRA							
AB	+	!	BIOCORRX PHARMS	EQ 0.18MG BASE	N209229	001	May 16, 2018	May CAHN

LORAZEPAMINJECTABLE; INJECTION
LORAZEPAM

@	AVIV PHARMA	1MG/0.5ML	A074551	003	Sep 12, 1996	May CAHN
@		2MG/ML	A074535	001	Sep 12, 1996	Apr CAHN
@		2MG/ML	A074551	001	Sep 12, 1996	May CAHN
@		4MG/ML	A074535	002	Sep 12, 1996	Apr CAHN
@		4MG/ML	A074551	002	Sep 12, 1996	May CAHN
@	HOSPIRA	2MG/ML	A074282	001	May 27, 1994	Apr DISC
@		4MG/ML	A074282	002	May 27, 1994	Apr DISC

TABLET;ORAL

LORAZEPAM

>A>	AB	GRAVITI PHARMS	0.5MG	A218597	001	Jul 24, 2025	Jul NEWA
>A>	AB		1MG	A218597	002	Jul 24, 2025	Jul NEWA
>A>	AB		2MG	A218597	003	Jul 24, 2025	Jul NEWA

LOSARTAN POTASSIUM

SUSPENSION;ORAL

ARBLI

+	!	SCIENTURE	10MG/ML	N218772	001	Mar 13, 2025	Mar NEWA
---	---	-----------	---------	---------	-----	--------------	----------

TABLET;ORAL

LOSARTAN POTASSIUM

>D>	@	AIPING PHARM INC	25MG	A090544	001	Oct 06, 2010	Jul CMFD
>A>	AB		25MG	A090544	001	Oct 06, 2010	Jul CMFD
>D>	@		50MG	A090544	002	Oct 06, 2010	Jul CMFD
>A>	AB		50MG	A090544	002	Oct 06, 2010	Jul CMFD
>D>	@		100MG	A090544	003	Oct 06, 2010	Jul CMFD
>A>	AB		100MG	A090544	003	Oct 06, 2010	Jul CMFD
	@	APOTEX	25MG	A218551	001	Jun 04, 2024	Jan DISC
	@		50MG	A218551	002	Jun 04, 2024	Jan DISC
	@		100MG	A218551	003	Jun 04, 2024	Jan DISC

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEMAX SM

AB	+	!	BAUSCH AND LOMB INC	0.38%	N208219	001	Feb 22, 2019	Jun CFTG
----	---	---	---------------------	-------	---------	-----	--------------	----------

LOTEPREDNOL ETABONATE

AB			LUPIN LTD	0.38%	A218087	001	Jun 30, 2025	Jun NFTG
----	--	--	-----------	-------	---------	-----	--------------	----------

SUSPENSION/DROPS;OPHTHALMIC

LOTEPREDNOL ETABONATE

AB			AMNEAL	0.5%	A217484	001	May 20, 2025	May NEWA
AB			PADAGIS US	0.5%	A215204	001	Jan 29, 2025	Jan NEWA

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

@	+	COVIS	20MG	N021316	002	Jun 26, 2002	May DISC
@	+		40MG	N021316	003	Jun 26, 2002	May DISC
@	+		60MG	N021316	004	Jun 26, 2002	May DISC

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB			CHARTWELL RX	20MG	A212091	001	Dec 28, 2020	Mar CAHN
AB				40MG	A212091	002	Dec 28, 2020	Mar CAHN
AB				60MG	A212091	003	Dec 28, 2020	Mar CAHN
AB				80MG	A212091	004	Dec 28, 2020	Mar CAHN
AB				120MG	A212091	005	Dec 28, 2020	Mar CAHN
AB			TORRENT	60MG	A208055	005	Jan 13, 2025	Jan NEWA

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

@		FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Jun DISC
---	--	--------------------	---	---------	-----	--------------	----------

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017378	001		Jun CTEC
---	---	-----------------	---	---------	-----	--	----------

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP		ASPIRO	1GM/2ML (500MG/ML)	A219777	001	May 28, 2025	May NFTG
AP			5GM/10ML (500MG/ML)	A219777	002	May 28, 2025	May NEWA
AP			10GM/20ML (500MG/ML)	A219777	003	May 28, 2025	May NEWA
AP			25GM/50ML (500MG/ML)	A219777	004	May 28, 2025	May NFTG
AP	+	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	May CFTG
AP	+		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	May CFTG

MANGANESE CHLORIDEINJECTABLE; INJECTION
MANGANESE CHLORIDE

AP	FRESENIUS KABI USA	EQ 0.1MG MANGANESE/ML	A217583	001	Jul 07, 2025	Jun NFTG
	MANGANESE CHLORIDE IN PLASTIC CONTAINER					
AP	+! HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986	Jun CFTG

MARALIXIBAT CHLORIDETABLET; ORAL
LIVMARLI

+	MIRUM	EQ 10MG BASE	N219485	001	Apr 10, 2025	Apr NEWA
+		EQ 15MG BASE	N219485	002	Apr 10, 2025	Apr NEWA
+		EQ 20MG BASE	N219485	003	Apr 10, 2025	Apr NEWA
+!		EQ 30MG BASE	N219485	004	Apr 10, 2025	Apr NEWA

MARAVIROCTABLET; ORAL
MARAVIROC

AB	NAVINTA LLC	150MG	A217880	001	May 13, 2025	May NEWA
AB		300MG	A217880	002	May 13, 2025	May NEWA

MECLIZINE HYDROCHLORIDETABLET; ORAL
MECLIZINE HYDROCHLORIDE

>A>	AA	ALLIED	25MG	A084092	003	May 22, 1989	Jul CAHN
>A>	@	HERITAGE	12.5MG	A205136	001	Feb 22, 2019	Jul CAHN
>A>	@		25MG	A205136	002	Feb 22, 2019	Jul CAHN
>A>	@		50MG	A205136	003	Feb 22, 2019	Jul CAHN
>D>	@	INDICUS PHARMA	12.5MG	A205136	001	Feb 22, 2019	Jul CAHN
	@		12.5MG	A205136	001	Feb 22, 2019	Jun CAHN
>D>	@		25MG	A205136	002	Feb 22, 2019	Jul CAHN
	@		25MG	A205136	002	Feb 22, 2019	Jun CAHN
>D>	@		50MG	A205136	003	Feb 22, 2019	Jul CAHN
	@		50MG	A205136	003	Feb 22, 2019	Jun CAHN
>D>	AA	INVATECH	25MG	A084092	003	May 22, 1989	Jul CAHN

MEFENAMIC ACIDCAPSULE; ORAL
MEFENAMIC ACID

AB	AJENAT PHARMS	250MG	A091608	001	Jun 02, 2014	Jan CAHN
	@ MPP PHARMA	250MG	A090359	001	Feb 05, 2013	Jun CAHN

MEFLOQUINE HYDROCHLORIDETABLET; ORAL
MEFLOQUINE HYDROCHLORIDE

AB	CHARTWELL RX	250MG	A076175	001	Feb 20, 2002	Jun CMFD
----	--------------	-------	---------	-----	--------------	----------

MEGESTROL ACETATESUSPENSION; ORAL
MEGACE ES

@ +	ENDO OPERATIONS	125MG/ML	N021778	001	Jul 05, 2005	Feb DISC
	MEGESTROL ACETATE					
!	TWI PHARMS	125MG/ML	A203139	001	Aug 27, 2014	Feb CTEC
AB	!	125MG/ML	A203139	001	Aug 27, 2014	Feb CHRS
AB	XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004	Apr CMFD

MELOXICAMSOLUTION; INTRAVENOUS
QAMZOVA

+	NANJING DELOVA	30MG/ML (30MG/ML)	N217593	001	Apr 22, 2025	Apr NEWA
	XIFYRM					
+	AZURITY	30MG/ML (30MG/ML)	N218395	001	Jun 05, 2025	Jun NEWA
	TABLET; ORAL					
	MELOXICAM					
AB	GRAVITI PHARMS	7.5MG	A077931	001	Jul 25, 2006	Feb CAHN
AB		15MG	A077931	002	Jul 25, 2006	Feb CAHN

MELOXICAM; RIZATRIPTAN BENZOATE

TABLET; ORAL

SYMBRAVO

+! AXSOME

20MG;EQ 10MG BASE

N215431 001 Jan 30, 2025 Jan NEWA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

@ APOTEX

7MG

A206135 001 Nov 22, 2016 Mar DISC

@

14MG

A206135 002 Nov 22, 2016 Mar DISC

@

21MG

A206135 003 Nov 22, 2016 Mar DISC

@

28MG

A206135 004 Nov 22, 2016 Mar DISC

AB RISING

7MG

A206032 001 Sep 28, 2016 May CMFD

AB

14MG

A206032 002 Sep 28, 2016 May CMFD

AB

21MG

A206032 003 Sep 28, 2016 May CMFD

AB

28MG

A206032 004 Sep 28, 2016 May CMFD

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

@ APOZEAL PHARMS

2MG/ML

A205446 001 Dec 07, 2015 Apr CAHN

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

@ POINTVIEW HLDINGS

5MG

A090073 001 Sep 04, 2015 Apr CAHN

@

10MG

A090073 002 Sep 04, 2015 Apr CAHN

AB YILING

5MG

A212947 001 Apr 03, 2020 Apr CMFD

AB

10MG

A212947 002 Apr 03, 2020 Apr CMFD

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

>D>

>D> AP +! HOSPIRA

1%

N012250 001 Jul DISC

>A> @ +

1%

N012250 001 Jul DISC

>D> AP +!

1.5%

N012250 005 Jul DISC

>A> @ +

1.5%

N012250 005 Jul DISC

>D> AP +!

2%

N012250 002 Jul DISC

>A> @ +

2%

N012250 002 Jul DISC

POLOCAINE

>D> AP FRESENIUS KABI USA

1%

A089407 001 Dec 01, 1986 Jul CTEC

>A>

1%

A089407 001 Dec 01, 1986 Jul CTEC

>D> AP

2%

A089410 001 Dec 01, 1986 Jul CTEC

>A>

2%

A089410 001 Dec 01, 1986 Jul CTEC

POLOCAINE-MPF

>D> AP FRESENIUS KABI USA

1%

A089406 001 Dec 01, 1986 Jul CTEC

>A>

1%

A089406 001 Dec 01, 1986 Jul CTEC

>D> AP

1.5%

A089408 001 Dec 01, 1986 Jul CTEC

>A>

1.5%

A089408 001 Dec 01, 1986 Jul CTEC

>D> AP

2%

A089409 001 Dec 01, 1986 Jul CTEC

>A>

2%

A089409 001 Dec 01, 1986 Jul CTEC

MERCAPTOPURINE

SUSPENSION; ORAL

MERCAPTOPURINE

AB HIKMA

20MG/ML

A216418 001 Feb 26, 2025 Feb NFTG

PURIXAN

AB +! NOVA LABS LTD

20MG/ML

N205919 001 Apr 28, 2014 Feb CFTG

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP ! ACS DOBFAR

500MG/VIAL

A091404 001 Oct 26, 2011 Apr CHRS

AP !

1GM/VIAL

A091404 002 Oct 26, 2011 Apr CHRS

MERREM IV

@ + PFIZER

500MG/VIAL

N050706 003 Jun 21, 1996 Apr DISC

@ +

1GM/VIAL

N050706 001 Jun 21, 1996 Apr DISC

POWDER; INTRAVENOUS

MEROPENEM

AP BROOKS STERISCIENCE

2GM/VIAL

A219084 001 Jun 23, 2025 Jun NFTG

AP +! HQ SPCLT PHARMA

2GM/VIAL

N215212 001 Jul 26, 2023 Jun CFTG

MESALAMINE

ENEMA; RECTAL
MESALAMINE

AB	NOVITIUM PHARMA	4GM/60ML	A215269	001	Apr 16, 2025	Apr NEWA
	SUPPOSITORY; RECTAL MESALAMINE					
AB	NORVIUM BIOSCIENCE	1GM	A204354	001	Nov 24, 2015	May CAHN
AB	RISING	1GM	A219028	001	Apr 14, 2025	Apr NEWA
	TABLET, DELAYED RELEASE; ORAL MESALAMINE					
AB	AMNEAL	800MG	A215067	001	Feb 18, 2025	Feb NEWA

MESNA

TABLET; ORAL
MESNA

AB	RICONPHARMA LLC	400MG	A218871	001	Jan 13, 2025	Jan NFTG
	MESNEX					
AB	+! BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002	Jan CFTG

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL
METFORMIN HYDROCHLORIDE

AB	ANNORA PHARMA	500MG/5ML	A215008	001	Mar 13, 2025	Mar NEWA
AB	BIONPHARMA	500MG/5ML	A219151	001	Apr 14, 2025	Apr NEWA
AB	VISTAPHARM LLC	500MG/5ML	A212677	001	Aug 19, 2022	Jan CAHN

TABLET; ORAL
METFORMIN HYDROCHLORIDE

@	APOTEX	500MG	A075984	001	Apr 23, 2002	Mar DISC
@		500MG	A090666	001	Dec 07, 2011	Mar DISC
@		850MG	A075984	002	Apr 23, 2002	Mar DISC
@		850MG	A090666	002	Dec 07, 2011	Mar DISC
@		1GM	A075984	003	Apr 23, 2002	Mar DISC
@		1GM	A090666	003	Dec 07, 2011	Mar DISC

TABLET, EXTENDED RELEASE; ORAL
FORTAMET

>D> AB2	+ ANDRX LABS LLC	1GM	N021574	002	Apr 27, 2004	Jul DISC
>A>	@ +	1GM	N021574	002	Apr 27, 2004	Jul DISC
	METFORMIN HYDROCHLORIDE					
AB1	MEDICAP LABS	500MG	A202306	001	Feb 23, 2017	Feb CAHN
AB		750MG	A202306	002	Feb 23, 2017	Feb CAHN
AB2	MPP PHARMA	500MG	A203832	001	Dec 26, 2017	May CAHN
AB2		1GM	A203832	002	Dec 26, 2017	May CAHN
	@ SUN PHARM	500MG	A202917	001	Aug 01, 2016	Jan DISC
	@	1GM	A202917	002	Aug 01, 2016	Jan DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	May CMFD
AB		850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	May CMFD

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB	DR REDDYS LABS SA	500MG;EQ 5MG BASE	A207678	001	Aug 09, 2023	Jan CTNA
AB		1GM;EQ 2.5MG BASE	A207678	002	Aug 09, 2023	Jan CTNA
AB	!	1GM;EQ 5MG BASE	A207678	003	Aug 09, 2023	Jan CTNA
>D> AB	SUN PHARM	500MG;EQ 5MG BASE	A206081	001	Jul 31, 2023	Jul DISC
>A>	@	500MG;EQ 5MG BASE	A206081	001	Jul 31, 2023	Jul DISC
>D> AB		1GM;EQ 2.5MG BASE	A206081	002	Jul 31, 2023	Jul DISC
>A>	@	1GM;EQ 2.5MG BASE	A206081	002	Jul 31, 2023	Jul DISC
>D> AB		1GM;EQ 5MG BASE	A206081	003	Jul 31, 2023	Jul DISC
>A>	@	1GM;EQ 5MG BASE	A206081	003	Jul 31, 2023	Jul DISC

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL
JANUMET XR

	+ MSD SUB MERCK	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Jun CTEC
AB	+	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	May CFTG
	+	1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Jun CTEC
AB	+	1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	May CFTG

TABLET, EXTENDED RELEASE;ORAL
JANUMET XR

	+	1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Jun CTEC	
AB	+	1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	May CFTG	
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE							
	@	ENDO OPERATIONS	500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	Jun DISC
AB			500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	May NFTG
	@		1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	Jun DISC
AB			1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	May NFTG
	@		1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	Jun DISC
AB			1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	May NFTG

METHADONE HYDROCHLORIDE

INJECTABLE;INJECTION
METHADONE HYDROCHLORIDE

AP		HIKMA	10MG/ML	A218609	001	May 05, 2025	Apr NEWA
TABLET;ORAL							
METHADONE HYDROCHLORIDE							
>A>	AA	HIKMA	5MG	A088109	002	Mar 08, 1983	Jul CMS1
TABLET, FOR SUSPENSION;ORAL							
METHADONE HYDROCHLORIDE							
AA		VISTAPHARM LLC	40MG	A075082	001	Mar 25, 1998	Jan CAHN

METHENAMINE HIPPURATE

TABLET;ORAL
HIPREX

>D>	@	+	ESJAY PHARMA	1GM	N017681	001	Jul CMFD
>A>	AB		+	1GM	N017681	001	Jul CMFD
	@	+		1GM	N017681	001	May DISC
METHENAMINE HIPPURATE							
AB		ZYDUS LIFESCIENCES	1GM	A219661	001	Mar 10, 2025	Feb NEWA
UREX							
>D>	AB	ALVOGEN	1GM	N016151	001		Jul CAHN
>A>	AB	QUAGEN	1GM	N016151	001		Jul CAHN

METHIMAZOLE

TABLET;ORAL
METHIMAZOLE

AB		AIPING PHARM INC	5MG	A040547	001	Feb 18, 2005	Mar CAHN
AB			10MG	A040547	002	Feb 18, 2005	Mar CAHN
	@		20MG	A040547	004	Feb 18, 2005	Mar CAHN
>D>	AB	SQUARE PHARMS PLC	5MG	A218830	001	Feb 05, 2025	Jul DISC
>A>	@		5MG	A218830	001	Feb 05, 2025	Jul DISC
AB			5MG	A218830	001	Feb 05, 2025	Jan NEWA
>D>	AB		10MG	A218830	002	Feb 05, 2025	Jul DISC
>A>	@		10MG	A218830	002	Feb 05, 2025	Jul DISC
AB			10MG	A218830	002	Feb 05, 2025	Jan NEWA

METHOCARBAMOL

SOLUTION;IM-IV
METHOCARBAMOL

	@	PHARMOBEDIANT	1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Jun CAHN
>A>	SUSPENSION;ORAL						
>A>	ATMEKSI						
>A>	+	ROSEMONT PHARMS	750MG/5ML	N219843	001	Jul 30, 2025	Jul NEWA
TABLET;ORAL							
METHOCARBAMOL							
AA		BOSTAL	500MG	A200958	001	Oct 21, 2011	May CAHN
AA			750MG	A200958	002	Oct 21, 2011	May CAHN
AB	!		1GM	A200958	003	Dec 06, 2021	May CAHN
AA		POINTVIEW HLDINGS	500MG	A212623	001	Apr 30, 2021	Apr CAHN
AA			750MG	A212623	002	Apr 30, 2021	Apr CAHN

METHOTREXATE

SOLUTION;SUBCUTANEOUS
OTREXUP

>D>	+	OTTER PHARMS	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Jul DISC
>A>	@	+	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Jul DISC
>D>	+		12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	Jul DISC
>A>	@	+	12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	Jul DISC
>D>	+		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Jul DISC
>A>	@	+	15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Jul DISC

SOLUTION;SUBCUTANEOUS

>D>	OTREXUP								
>D>	+	17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	Jul	DISC		
>A>	@ +	17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	Jul	DISC		
>D>	+	20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Jul	DISC		
>A>	@ +	20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Jul	DISC		
>D>	+	22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	Jul	DISC		
>A>	@ +	22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	Jul	DISC		
>D>	+	25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013	Jul	DISC		
>A>	@ +	25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013	Jul	DISC		

METHYLENE BLUE

SOLUTION;INTRAVENOUS

METHYLENE BLUE

AP	HIKMA	50MG/10ML (5MG/ML)	A216959	001	Dec 17, 2024	Jan	CAHN		
AP	MEITHEAL	50MG/10ML (5MG/ML)	A217380	001	Jan 23, 2025	Jan	CAHN		
AP	NANJING KING-FRIEND	50MG/10ML (5MG/ML)	A217380	001	Jan 23, 2025	Jan	NEWA		
>A> AP	XIROMED	50MG/10ML (5MG/ML)	A219363	001	Jul 30, 2025	Jul	NEWA		

METHYLNALTREXONE BROMIDE

SOLUTION;SUBCUTANEOUS

METHYLNALTREXONE BROMIDE

	@	ACTAVIS LLC	8MG/0.4ML (8MG/0.4ML)	A208112	001	Aug 26, 2024	Mar	DISC	
			12MG/0.6ML (12MG/0.6ML)	A208112	002	Aug 26, 2024	Mar	DISC	
	@	MYLAN LABS LTD	12MG/0.6ML (12MG/0.6ML)	A208592	001	May 28, 2025	Jun	DISC	
AP			12MG/0.6ML (12MG/0.6ML)	A208592	001	May 28, 2025	May	NFTG	
		RELISTOR							
	+	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Mar	CTEC	
	+		12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008	Jun	CTEC	
AP	+		12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008	May	CFTG	
	+		12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Mar	CTEC	

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

COTEMPLA XR-ODT

@ +	NEOS THERAPS INC	34.6MG	N205489	004	Aug 19, 2024	Jun	DISC		
+		34.6MG	N205489	004	Aug 19, 2024	Apr	CMFD		

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@	ESJAY PHARMA	5MG/5ML	A201466	001	Nov 12, 2013	Feb	CAHN		
@		10MG/5ML	A201466	002	Nov 12, 2013	Feb	CAHN		

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@	MPP PHARMA	5MG	A207587	001	Mar 03, 2017	Jun	CAHN		
@		10MG	A207587	002	Mar 03, 2017	Jun	CAHN		
@		20MG	A207587	003	Mar 03, 2017	Jun	CAHN		

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@	STRIDES PHARMA	2.5MG	A204954	001	Jan 26, 2017	Apr	CAHN		
@		5MG	A204954	002	Jan 26, 2017	Apr	CAHN		
@		10MG	A204954	003	Jan 26, 2017	Apr	CAHN		

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB	HIKMA	80MG/ML	A219145	001	Apr 16, 2025	Apr	NEWA		
----	-------	---------	---------	-----	--------------	-----	------	--	--

METHYLTESTOSTERONE

TABLET;ORAL

ANDROID 25

@	BAUSCH	25MG	A087147	001		Apr	DISC		
BP		25MG	A087147	001		Mar	CAHN		

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

>D> AP	FRESENIUS KABI USA	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013	Jul	DISC		
>A>	@	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013	Jul	DISC		

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@ VISTAPHARM LLC EQ 5MG BASE/5ML

A075051 001 Jan 26, 2001 Jan CAHN

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>D> AB IMPAX LABS INC EQ 5MG BASE

A071250 002 Dec 28, 1995 Jul DISC

>A> @ EQ 5MG BASE

A071250 002 Dec 28, 1995 Jul DISC

>D> AB EQ 10MG BASE

A071250 001 Feb 03, 1988 Jul DISC

>A> @ EQ 10MG BASE

A071250 001 Feb 03, 1988 Jul DISC

METOLAZONE

TABLET;ORAL

METOLAZONE

AB LEADING 2.5MG

A218606 001 Apr 17, 2024 Jun CAHN

AB 5MG

A218606 002 Apr 17, 2024 Jun CAHN

AB 10MG

A218606 003 Apr 17, 2024 Jun CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB IPCA LABS LTD EQ 25MG TARTRATE

A206980 001 Jun 25, 2025 Jun NEWA

AB EQ 50MG TARTRATE

A206980 002 Jun 25, 2025 Jun NEWA

AB EQ 100MG TARTRATE

A206980 003 Jun 25, 2025 Jun NEWA

AB EQ 200MG TARTRATE

A206980 004 Jun 25, 2025 Jun NEWA

METOPROLOL TARTRATE

SOLUTION;ORAL

LOPRESSOR

+! RUBICON 10MG/ML

N219373 001 Apr 10, 2025 Apr NEWA

TABLET;ORAL

METOPROLOL TARTRATE

@ PHARMOBEDIANT 50MG

A073666 001 Dec 21, 1993 Jun CAHN

@ 100MG

A073666 002 Dec 21, 1993 Jun CAHN

AB SCIEGEN PHARMS INC 25MG

A208955 001 Feb 05, 2020 Jan CAHN

AB 50MG

A208955 002 Feb 05, 2020 Jan CAHN

AB 100MG

A208955 003 Feb 05, 2020 Jan CAHN

@ SUN PHARM INDS INC 25MG

A076670 001 Jan 15, 2004 Apr DISC

METRONIDAZOLE

CREAM;TOPICAL

METROCREAM

AB + GALDERMA LABS LP 0.75%

N020531 001 Sep 20, 1995 Jun CHRS

METRONIDAZOLE

AB AUROBINDO PHARMA LTD 0.75%

A219295 001 Jul 09, 2025 Jun NEWA

AB ! FOUGERA PHARMS 0.75%

A076408 001 May 28, 2004 Jun CHRS

BX ZYDUS LIFESCIENCES 0.75%

A217128 001 Apr 21, 2023 Mar CTEC

GEL;VAGINAL

METRONIDAZOLE

@ ENCUBE 1.3%

A216795 001 Mar 18, 2024 Jan DISC

NUVESSA

+! CHEMO RESEARCH SL 1.3%

N205223 001 Mar 24, 2014 Jan CTEC

METYRAPONE

CAPSULE;ORAL

METOPIRONE

>A> +! ESTEVE 250MG

N012911 002 Aug 09, 1996 Jul CAHN

>D> +! HRA PHARMA 250MG

N012911 002 Aug 09, 1996 Jul CAHN

TABLET;ORAL

METOPIRONE

>A> @ ESTEVE 250MG

N012911 001 Jul CAHN

>D> @ HRA PHARMA 250MG

N012911 001 Jul CAHN

METYROSINE

CAPSULE;ORAL

METYROSINE

AB CEROVENE INC 250MG

A218620 001 Apr 09, 2025 Mar NEWA

MICAFUNGIN SODIUMINJECTABLE; INTRAVENOUS
MICAFUNGIN SODIUM

AP	QILU PHARM HAINAN	EQ 50MG BASE/VIAL	A219273	001	Apr 03, 2025	Mar	NEWA
AP		EQ 100MG BASE/VIAL	A219273	002	Apr 03, 2025	Mar	NEWA

MIDAZOLAMSOLUTION; INTRAVENOUS
MIDAZOLAM IN 0.8% SODIUM CHLORIDE

>D>	B BRAUN MEDICAL	50MG/50ML (1MG/ML)	A218454	001	May 01, 2025	Jul	CHRS
>A>	!	50MG/50ML (1MG/ML)	A218454	001	May 01, 2025	Jul	CHRS
		50MG/50ML (1MG/ML)	A218454	001	May 01, 2025	May	CAHN
>D>		100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	Jul	CHRS
>A>	!	100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	Jul	CHRS
		100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	May	CAHN
	STERINOVA INC	50MG/50ML (1MG/ML)	A218454	001	May 01, 2025	Apr	NFTG
		100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	Apr	NFTG

MIDAZOLAM HYDROCHLORIDEINJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

	@ EPIC PHARMA LLC	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Jun	CAHN
AP	HIKMA	EQ 1MG BASE/ML	A212847	001	Dec 11, 2020	Jun	CAHN
AP		EQ 5MG BASE/ML	A212847	002	Dec 11, 2020	Jun	CAHN
AP	RISING	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000	Jun	CAHN
AP		EQ 5MG BASE/ML	A075494	002	Jun 30, 2000	Jun	CAHN

SOLUTION; INTRAMUSCULAR

>D>	SEIZALAM						
>D>	+! MMT	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	N209566	001	Sep 14, 2018	Jul	DISC
>A>	@ +	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	N209566	001	Sep 14, 2018	Jul	DISC

MIDODRINE HYDROCHLORIDETABLET; ORAL
ORVATEN

AB	BEIJING YILING	2.5MG	A076725	001	Nov 03, 2004	Jun	CAHN
AB	!	5MG	A076725	002	Nov 03, 2004	Jun	CAHN
AB		10MG	A076725	003	Nov 03, 2004	Jun	CAHN

MIGLUSTATCAPSULE; ORAL
MIGLUSTAT

	@ CHARTWELL RX	100MG	A209325	001	Feb 03, 2022	Mar	CAHN
AB	NAVINTA LLC	100MG	A219111	001	Mar 14, 2025	Mar	NEWA
	@ VERANOVA	100MG	A209325	001	Feb 03, 2022	Feb	CAHN

MILNACIPRAN HYDROCHLORIDETABLET; ORAL
MILNACIPRAN HYDROCHLORIDE

@	HETERO LABS LTD V	12.5MG	A205147	001	Oct 03, 2024	Apr	DISC
@		25MG	A205147	002	Oct 03, 2024	Apr	DISC
@		50MG	A205147	003	Oct 03, 2024	Apr	DISC
@		100MG	A205147	004	Oct 03, 2024	Apr	DISC
	SAVELLA						
+	ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Apr	CTEC
+		25MG	N022256	002	Jan 14, 2009	Apr	CTEC
+	!	50MG	N022256	003	Jan 14, 2009	Apr	CTEC
+		100MG	N022256	004	Jan 14, 2009	Apr	CTEC

MINOCYCLINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
EMROSI

+	!	JOURNEY	EQ 40MG BASE	N219015	001	Nov 01, 2024	Mar	CPOT
---	---	---------	--------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

	MINOCIN							
+	!	REMPEX	EQ 100MG BASE/VIAL	N050444	001		May	CTEC
	MINOCYCLINE HYDROCHLORIDE							
AP	NEXUS	EQ 100MG BASE/VIAL	A214934	001	Oct 24, 2024	Mar	CAHN	

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL									
MIRABEGRON									
	@	APOTEX	25MG	A209434	001	Jan 02, 2025	May	DISC	
	@		50MG	A209434	002	Jan 02, 2025	May	DISC	
AB		QILU	25MG	A217989	001	Jun 30, 2025	Jun	NEWA	
AB			50MG	A217989	002	Jun 30, 2025	Jun	NEWA	
	@	SAWAI USA	50MG	A217061	001	May 06, 2025	Jun	DISC	
AB			50MG	A217061	001	May 06, 2025	Apr	NEWA	

MIRDAMETINIB

CAPSULE;ORAL									
GOMEKLI									
	+	SPRINGWORKS	1MG	N219389	001	Feb 11, 2025	Feb	NEWA	
	+	!	2MG	N219389	002	Feb 11, 2025	Feb	NEWA	
TABLET, FOR SUSPENSION;ORAL									
GOMEKLI									
	+	!	SPRINGWORKS	1MG	N219379	001	Feb 11, 2025	Feb	NEWA

MITOMYCIN

INJECTABLE;INJECTION									
MITOMYCIN									
AP		ACCORD HLTHCARE	20MG/VIAL	A064144	002	Apr 30, 1998	Apr	CMFD	
	@		20MG/VIAL	A064144	002	Apr 30, 1998	Jan	DISC	
AP	!	MEITHEAL	20MG/VIAL	A214505	002	Sep 08, 2022	Jan	CHRS	
POWDER;INTRAVESICAL									
ZUSDURI									
	+	!	UROGEN PHARMA	40MG/VIAL	N215793	001	Jun 12, 2025	Jun	NEWA

MITOTANE

TABLET;ORAL									
LYSODREN									
>A>		+	!	ESTEVE	500MG	N016885	001		Jul CAHN
>D>		+	!	HRA PHARMA	500MG	N016885	001		Jul CAHN

MODAFINIL

TABLET;ORAL									
MODAFINIL									
	@	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jun	DISC	
	@		200MG	A076715	002	Nov 01, 2012	Jun	DISC	
PROVIGIL									
AB	+	NUVO PHARMS	100MG	N020717	001	Dec 24, 1998	Jan	CAHN	
AB	+	!	200MG	N020717	002	Dec 24, 1998	Jan	CAHN	

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL									
MOEXIPRIL HYDROCHLORIDE									
	@	APOTEX INC	7.5MG	A078454	001	Jun 02, 2008	Mar	DISC	
	@		15MG	A078454	002	Jun 02, 2008	Mar	DISC	

MOMETASONE FUROATE

CREAM;TOPICAL									
MOMETASONE FUROATE									
	@	CHARTWELL MOLECULAR	0.1%	A076591	001	Apr 18, 2007	Feb	CAHN	
AB	!	COSETTE	0.1%	A077447	001	May 22, 2006	Jun	CHRS	
	@	GLENMARK PHARMS INC	0.1%	A078541	001	May 28, 2008	Jun	DISC	
LOTION;TOPICAL									
MOMETASONE FUROATE									
>D> AB		GLENMARK PHARMS LTD	0.1%	A090506	001	Aug 09, 2010	Jul	DISC	
>A>	@		0.1%	A090506	001	Aug 09, 2010	Jul	DISC	
OINTMENT;TOPICAL									
MOMETASONE FUROATE									
	@	GLENMARK PHARMS INC	0.1%	A078571	001	May 28, 2008	Jun	DISC	
AB	!	PADAGIS US	0.1%	A076067	001	Mar 18, 2002	Jun	CHRS	
SPRAY, METERED;NASAL									
MOMETASONE FUROATE									
AB		NASPRESS	0.05MG/SPRAY	A211706	001	May 15, 2025	May	NEWA	

MORPHINE SULFATE

SOLUTION;ORAL

MORPHINE SULFATE

AA	+	HIKMA	20MG/5ML	N022195	002	Mar 17, 2008	Apr CTEC
	+		20MG/5ML	N022195	002	Mar 17, 2008	Feb CTEC
AA		PHARM ASSOC	10MG/5ML	A206573	002	Sep 12, 2023	Jun CMFD
AA			100MG/5ML	A206573	001	Nov 14, 2016	Jun CMFD
	@	RHODES PHARMS	10MG/5ML	A206308	001	Jun 22, 2017	Jan DISC
	@		20MG/5ML	A206420	001	Jul 12, 2016	Jan DISC
	@		100MG/5ML	A206308	002	Jun 22, 2017	Jan DISC
	@	SANKALP LIFECARE	10MG/5ML	A201011	001	Feb 05, 2014	Apr CAHN
	@		20MG/5ML	A201011	002	Feb 05, 2014	Apr CAHN
	@		100MG/5ML	A201011	003	Oct 06, 2016	Apr CAHN
AA		WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Apr CMFD
	@		10MG/5ML	A211454	001	Feb 12, 2021	Feb DISC
AA			20MG/5ML	A211454	002	Feb 12, 2021	Apr CMFD
	@		20MG/5ML	A211454	002	Feb 12, 2021	Feb DISC
AA			100MG/5ML	A211454	003	Feb 12, 2021	Apr CMFD
	@		100MG/5ML	A211454	003	Feb 12, 2021	Feb DISC

TABLET;ORAL

MORPHINE SULFATE

AB	+	HIKMA	15MG	N022207	001	Mar 17, 2008	Jun CAHN
AB	+	!	30MG	N022207	002	Mar 17, 2008	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

	@	NOVEL LABS INC	15MG	A203602	001	Dec 16, 2015	Feb DISC
	@		30MG	A203602	002	Dec 16, 2015	Feb DISC
	@		60MG	A203602	003	Dec 16, 2015	Feb DISC
	@		100MG	A203602	004	Dec 16, 2015	Feb DISC
	@		200MG	A203602	005	Dec 16, 2015	Feb DISC

MOTIXAFORTIDE ACETATE

POWDER;SUBCUTANEOUS

APHEXDA

	+	!	AYRMID PHARMA	EQ 62MG BASE/VIAL	N217159	001	Sep 08, 2023	Mar CAHN
--	---	---	---------------	-------------------	---------	-----	--------------	----------

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

>A>	AT1	FDC LTD	EQ 0.5% BASE	A219475	001	Aug 04, 2025	Jul NEWA
	AT1	MANKIND PHARMA	EQ 0.5% BASE	A217988	001	Jan 27, 2025	Jan NEWA
	@	NORVIUM BIOSCIENCE	EQ 0.5% BASE	A206447	001	Mar 30, 2020	Feb CAHN

MUPIROCIN

OINTMENT;TOPICAL

MUPIROCIN

AB		ENCUBE	2%	A217943	001	May 13, 2025	May NEWA
----	--	--------	----	---------	-----	--------------	----------

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

BX		ALEMBIC	EQ 2% BASE	A213053	001	Nov 16, 2021	Mar CTEC
----	--	---------	------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL

FOR SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

	@	TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Apr DISC
AB		VISTAPHARM LLC	200MG/ML	A210370	001	Feb 12, 2019	Jan CAHN

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC SODIUM

>D>	AB	AMTA	EQ 180MG BASE	A214376	001	Feb 10, 2021	Jul CAHN
>D>	AB		EQ 360MG BASE	A214376	002	Feb 10, 2021	Jul CAHN
	AB	FOSUN WANBANG	EQ 180MG BASE	A216637	001	May 29, 2024	Jan CAHN
	AB		EQ 360MG BASE	A216637	002	May 29, 2024	Jan CAHN
>A>	AB	YICHANG HUMANWELL	EQ 180MG BASE	A214376	001	Feb 10, 2021	Jul CAHN
>A>	AB		EQ 360MG BASE	A214376	002	Feb 10, 2021	Jul CAHN

NABUMETONETABLET; ORAL
NABUMETONE

@	MPP PHARMA	500MG	A 090427	001	Dec 30, 2011	Jun	CAHN
@		750MG	A 090427	002	Dec 30, 2011	Jun	CAHN

NAFCILLIN SODIUMINJECTABLE; INJECTION
NAFCILLIN SODIUM

@	FRESENIUS	EQ 10GM BASE/VIAL	A 206761	001	Jun 02, 2020	Apr	DISC
---	-----------	-------------------	----------	-----	--------------	-----	------

NALBUPHINE HYDROCHLORIDESOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
NALBUPHINE

@	ABRAXIS PHARM	10MG/ML (10MG/ML)	A 070751	001	Jul 02, 1986	Mar	CPOT	
@		10MG/ML	A 070751	001	Jul 02, 1986	Mar	CDFR	
@		20MG/ML (20MG/ML)	A 070752	001	Sep 24, 1986	Mar	CPOT	
@		20MG/ML	A 070752	001	Sep 24, 1986	Mar	CDFR	
@		200MG/10ML (20MG/ML)	A 070752	002	Sep 24, 1986	Mar	NEWA	
	NALBUPHINE HYDROCHLORIDE							
@	ABBOTT	20MG/ML (20MG/ML)	A 070917	001	Feb 03, 1989	Mar	CPOT	
@		20MG/ML	A 070917	001	Feb 03, 1989	Mar	CDFR	
@	ABRAXIS PHARM	100MG/10ML (10MG/ML)	A 070751	002	Jul 02, 1986	Mar	NEWA	
@	DR REDDYS	10MG/ML	A 074471	001	Mar 19, 1998	Mar	CDFR	
@		20MG/ML	A 074471	002	Mar 19, 1998	Mar	CDFR	
@		100MG/10ML (10MG/ML)	A 074471	001	Mar 19, 1998	Mar	CPOT	
@		200MG/10ML (20MG/ML)	A 074471	002	Mar 19, 1998	Mar	CPOT	
AP	!	HOSPIRA	10MG/ML (10MG/ML)	A 070914	001	Feb 03, 1989	Mar	CPOT
AP	!		10MG/ML	A 070914	001	Feb 03, 1989	Mar	CDFR
AP	!		10MG/ML	A 070915	001	Feb 03, 1989	Mar	CDFR
AP	!		20MG/ML (20MG/ML)	A 070916	001	Feb 03, 1989	Mar	CPOT
AP	!		20MG/ML	A 070916	001	Feb 03, 1989	Mar	CDFR
AP	!		20MG/ML	A 070918	001	Feb 03, 1989	Mar	CDFR
AP	!		100MG/10ML (10MG/ML)	A 070915	001	Feb 03, 1989	Mar	CPOT
AP	!		200MG/10ML (20MG/ML)	A 070918	001	Feb 03, 1989	Mar	CPOT
@	IGI LABS INC	10MG/ML (10MG/ML)	A 072070	001	Apr 10, 1989	Mar	CPOT	
@		10MG/ML	A 072070	001	Apr 10, 1989	Mar	CDFR	
@		10MG/ML (10MG/ML)	A 072071	001	Apr 10, 1989	Mar	CPOT	
@		10MG/ML	A 072071	001	Apr 10, 1989	Mar	CDFR	
@		10MG/ML (10MG/ML)	A 072072	001	Apr 10, 1989	Mar	CPOT	
@		10MG/ML	A 072072	001	Apr 10, 1989	Mar	CDFR	
@		20MG/ML (20MG/ML)	A 072073	001	Apr 10, 1989	Mar	CPOT	
@		20MG/ML	A 072073	001	Apr 10, 1989	Mar	CDFR	
@		20MG/ML (20MG/ML)	A 072074	001	Apr 10, 1989	Mar	CPOT	
@		20MG/ML	A 072074	001	Apr 10, 1989	Mar	CDFR	
@		20MG/ML (20MG/ML)	A 072075	001	Apr 10, 1989	Mar	CPOT	
@		20MG/ML	A 072075	001	Apr 10, 1989	Mar	CDFR	
@		100MG/10ML (10MG/ML)	A 072070	002	Apr 10, 1989	Mar	NEWA	
@		200MG/10ML (20MG/ML)	A 072073	002	Apr 10, 1989	Mar	NEWA	
@	RISING	10MG/ML	A 206506	001	Feb 06, 2019	Mar	CDFR	
@		10MG/ML (10MG/ML)	A 207595	001	Jan 11, 2019	Mar	CPOT	
@		10MG/ML	A 207595	001	Jan 11, 2019	Mar	CDFR	
@		20MG/ML	A 206506	002	Feb 06, 2019	Mar	CDFR	
@		20MG/ML (20MG/ML)	A 207595	002	Jan 11, 2019	Mar	CPOT	
@		20MG/ML	A 207595	002	Jan 11, 2019	Mar	CDFR	
@		100MG/10ML (10MG/ML)	A 206506	001	Feb 06, 2019	Mar	CPOT	
@		200MG/10ML (20MG/ML)	A 206506	002	Feb 06, 2019	Mar	CPOT	
AP	SOMERSET THERAPS LLC	10MG/ML	A 216049	001	Sep 19, 2024	Mar	CDFR	
AP		10MG/ML (10MG/ML)	A 216050	001	Sep 19, 2024	Mar	CPOT	
AP		10MG/ML	A 216050	001	Sep 19, 2024	Mar	CDFR	
AP		20MG/ML	A 216049	002	Sep 19, 2024	Mar	CDFR	
AP		20MG/ML (20MG/ML)	A 216050	002	Sep 19, 2024	Mar	CPOT	
AP		20MG/ML	A 216050	002	Sep 19, 2024	Mar	CDFR	
AP		100MG/10ML (10MG/ML)	A 216049	001	Sep 19, 2024	Mar	CPOT	
AP		200MG/10ML (20MG/ML)	A 216049	002	Sep 19, 2024	Mar	CPOT	
	NUBAIN							
>D>	@ +	ENDO OPERATIONS	10MG/ML (10MG/ML)	N 018024	001		Jul	CAHN
	@ +		10MG/ML	N 018024	001		Mar	CDFR
	@ +		10MG/ML (10MG/ML)	N 018024	001		Mar	CPOT
>D>	@ +		20MG/ML (20MG/ML)	N 018024	002	May 27, 1982	Jul	CAHN
	@ +		20MG/ML	N 018024	002	May 27, 1982	Mar	CDFR
	@ +		20MG/ML (20MG/ML)	N 018024	002	May 27, 1982	Mar	CPOT

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
NUBAIN

>D>	@ +	20MG/2ML (10MG/ML)	N018024	004		Jul CAHN
	@ +	20MG/2ML (10MG/ML)	N018024	004		Mar NEWA
>D>	@ +	100MG/10ML (10MG/ML)	N018024	003		Jul CAHN
	@ +	100MG/10ML (10MG/ML)	N018024	003		Mar NEWA
>D>	@ +	200MG/10ML (20MG/ML)	N018024	005	Mar 02, 1984	Jul CAHN
	@ +	200MG/10ML (20MG/ML)	N018024	005	Mar 02, 1984	Mar NEWA
>A>	@ + PH HEALTH	10MG/ML (10MG/ML)	N018024	001		Jul CAHN
>A>	@ +	20MG/ML (20MG/ML)	N018024	002	May 27, 1982	Jul CAHN
>A>	@ +	20MG/2ML (10MG/ML)	N018024	004		Jul CAHN
>A>	@ +	100MG/10ML (10MG/ML)	N018024	003		Jul CAHN
>A>	@ +	200MG/10ML (20MG/ML)	N018024	005	Mar 02, 1984	Jul CAHN

NALMEFENE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
ZURNAI (AUTOINJECTOR)

@ +	PURDUE PHARMA LP	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Jan DISC
-----	------------------	---	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

AP		BAXTER HLTHCARE CORP	1MG/ML	A214785	002	Jun 03, 2025	May NEWA
>D>	@	PAR STERILE PRODUCTS	0.4MG/ML	A211286	001	Jan 17, 2020	Jul CAHN
>A>	@	PH HEALTH	0.4MG/ML	A211286	001	Jan 17, 2020	Jul CAHN

SPRAY;NASAL

KLOXXADO

	+	!	HIKMA	8MG/SPRAY	N212045	001	Apr 29, 2021	May CTEC
AB		+		8MG/SPRAY	N212045	001	Apr 29, 2021	Apr CFTG
			NALOXONE HYDROCHLORIDE					
	@		PADAGIS ISRAEL	8MG/SPRAY	A216719	001	Apr 24, 2025	May DISC
AB				8MG/SPRAY	A216719	001	Apr 24, 2025	Apr NFTG
			REZENOPY					
>D>	+	!	SUMMIT BIOSCI	10MG/SPRAY	N215487	001	Apr 19, 2024	Jul DISC
>A>	@ +			10MG/SPRAY	N215487	001	Apr 19, 2024	Jul DISC

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

>A>	@	ALLIED	50MG	A075434	001	Mar 08, 2000	Jul CAHN
>A>	@	ESJAY PHARMA	50MG	A075434	001	Mar 08, 2000	Jul CAHN
>D>	@	FOSUN PHARMA	50MG	A075434	001	Mar 08, 2000	Jul CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	EQ 2.5MG BASE	A212661	001	Jan 28, 2025	Jan NEWA
AB			EQ 5MG BASE	A212661	002	Jan 28, 2025	Jan NEWA
AB			EQ 10MG BASE	A212661	003	Jan 28, 2025	Jan NEWA
AB			EQ 20MG BASE	A212661	004	Jan 28, 2025	Jan NEWA

NELARABINE

INJECTABLE;INTRAVENOUS

NELARABINE

>A>	!	SHORLA	375MG/75ML (5MG/ML)	A214809	002	Jul 16, 2025	Jul NFTG
-----	---	--------	---------------------	---------	-----	--------------	----------

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

@	AVIV PHARMA	500MG	A065468	001	Mar 29, 2010	May CAHN
---	-------------	-------	---------	-----	--------------	----------

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP		AVET LIFESCIENCES	5MG/10ML (0.5MG/ML)	A208230	001	Nov 25, 2022	May CTNA
AP			10MG/10ML (1MG/ML)	A208230	002	Nov 25, 2022	May CTNA

NIACINTABLET, EXTENDED RELEASE;ORAL
NIACIN

>A>	AB	MPP PHARMA	500MG	A207726	001	Jul 25, 2025	Jul NEWA
>A>	AB		750MG	A207726	002	Jul 25, 2025	Jul NEWA
>A>	AB		1GM	A207726	003	Jul 25, 2025	Jul NEWA
	AB	ZYDUS PHARMS	500MG	A203285	001	Apr 28, 2025	Apr NEWA
	AB		750MG	A203285	002	Apr 28, 2025	Apr NEWA
	AB		1GM	A203285	003	Apr 28, 2025	Apr NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB		NAVINTA LLC	20MG	A218638	001	Jun 25, 2025	Jun NEWA
AB			30MG	A218638	002	Jun 25, 2025	Jun NEWA

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

	@	AMNEAL	25MG/10ML (2.5MG/ML)	A215406	001	Oct 31, 2024	Jan DISC
AP		MANKIND PHARMA	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009	Jun CAHN

NILOTINIB D-TARTRATE

CAPSULE;ORAL

NILOTINIB D-TARTRATE

	+	CIPLA	EQ 50MG BASE	N218922	001	Feb 19, 2025	Feb NEWA
	+		EQ 150MG BASE	N218922	002	Feb 19, 2025	Feb NEWA
	+	!	EQ 200MG BASE	N218922	003	Feb 19, 2025	Feb NEWA

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

NILOTINIB HYDROCHLORIDE

AB		APOTEX	EQ 50MG BASE	A203640	001	Jan 05, 2024	Apr CMFD
AB			EQ 150MG BASE	A203640	002	Jan 05, 2024	Apr CMFD
AB			EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr CMFD
		TASIGNA					
AB	+	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr CTEC
AB	+		EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr CTEC
AB	+	!	EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr CTEC

NIMODIPINE

SOLUTION;ORAL

NIMODIPINE

AB		ALKEM LABS LTD	6MG/ML	A213409	001	Jan 22, 2025	Jan NFTG
		NYMALIZE					
AB	+	!	AZURITY	N203340	002	Apr 08, 2020	Jan CFTG

NITAZOXANIDE

TABLET;ORAL

NITAZOXANIDE

AB		ANI PHARMS	500MG	A214844	001	Feb 03, 2025	Apr CAHN
AB		ANNORA PHARMA	500MG	A218701	001	Apr 15, 2025	Apr NEWA
AB	!	RISING	500MG	A213820	001	Nov 27, 2020	Jan CTEC
AB		ZENARA	500MG	A214844	001	Feb 03, 2025	Jan NEWA

NITISINONE

TABLET;ORAL

HARLIKU

>A>							
>A>		+	!	CYCLE	2MG	N209449	004 Jun 10, 2025 Jul NEWA

NITRIC OXIDE

GAS;INHALATION

INOMAX

>D>	@	+	MALLINCKRODT HOSP	100PPM	N020845	002	Dec 23, 1999	Jul CAHN
>D>	AA		+	!	800PPM	N020845	003	Dec 23, 1999
>D>			+	!	4880PPM	N020845	004	Jan 17, 2023
>A>	@	+	MALLINCKRODT IRELAND	100PPM	N020845	002	Dec 23, 1999	Jul CAHN
>A>	AA		+	!	800PPM	N020845	003	Dec 23, 1999
>A>			+	!	4880PPM	N020845	004	Jan 17, 2023
			NOXIVENT					
	@		LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	Apr DISC

NITROFURANTOINSUSPENSION;ORAL
NITROFURANTOIN

AB	ANNORA PHARMA	25MG/5ML	A219495	001	Jul 02, 2025	Jun NEWA
AB	APPCO	25MG/5ML	A208909	001	Jan 14, 2025	Jan NEWA
AB	STRIDES PHARMA	25MG/5ML	A201355	001	Aug 14, 2013	Apr CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>D>	AB	AMNEAL PHARMS	75MG;25MG	A207372	001	May 15, 2017	Jul DISC
>A>	@		75MG;25MG	A207372	001	May 15, 2017	Jul DISC

NITROGLYCERIN

OINTMENT;TRANSDERMAL

NITROGLYCERIN

AB	ENCUBE	2%	A218235	001	Apr 15, 2025	Apr NFTG
AB	+! FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	Apr CFTG

TABLET;SUBLINGUAL

NITROGLYCERIN

>D>	AB	RUBICON	0.3MG	A209779	001	May 03, 2021	Jul CAHN
>D>	AB		0.4MG	A209779	002	May 03, 2021	Jul CAHN
>D>	AB		0.6MG	A209779	003	May 03, 2021	Jul CAHN
>A>	AB	RUBICON RESEARCH	0.3MG	A209779	001	May 03, 2021	Jul CAHN
>A>	AB		0.4MG	A209779	002	May 03, 2021	Jul CAHN
>A>	AB		0.6MG	A209779	003	May 03, 2021	Jul CAHN

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE

>D>	AB	GLENMARK PHARMS INC	150MG	A090618	001	Jul 15, 2011	Jul DISC
>A>	@		150MG	A090618	001	Jul 15, 2011	Jul DISC
>D>	AB		300MG	A090618	002	Jul 15, 2011	Jul DISC
>A>	@		300MG	A090618	002	Jul 15, 2011	Jul DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP	ASPIRO	EQ 1MG BASE/ML	A219163	001	Jan 31, 2025	Jan NEWA
AP	BIOCON PHARMA	EQ 1MG BASE/ML	A219443	001	Mar 21, 2025	Mar NEWA

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT	AUROBINDO PHARMA	100,000 UNITS/GM	A219527	001	Mar 21, 2025	Mar NEWA
	@ CHARTWELL RX	100,000 UNITS/GM	A065315	001	May 31, 2006	Apr CAHN

POWDER;TOPICAL

NYSTATIN

@	ADRASTEIA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Jun DISC
---	------------------	------------------	---------	-----	--------------	----------

SUSPENSION;ORAL

NYSTATIN

AA	XTTRIUM LABS INC	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jan CAHN
----	------------------	------------------	---------	-----	--------------	----------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	CHARTWELL RX	100,000 UNITS/GM;0.1%	A208326	001	Oct 26, 2016	Apr CAHN	
>D>	AT	GLENMARK PHARMS LTD	100,000 UNITS/GM;0.1%	A208136	001	Oct 24, 2016	Jul DISC
>A>	@		100,000 UNITS/GM;0.1%	A208136	001	Oct 24, 2016	Jul DISC

OINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

>D>	AT	GLENMARK PHARMS LTD	100,000 UNITS/GM;0.1%	A208300	001	Jun 23, 2016	Jul DISC
>A>	@		100,000 UNITS/GM;0.1%	A208300	001	Jun 23, 2016	Jul DISC

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

@	AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb DISC
---	--------	------	---------	-----	--------------	----------

OLANZAPINE

INJECTABLE; INTRAMUSCULAR
OLANZAPINE

AP	QILU	10MG/VIAL	A218116	001	May 16, 2025	May NEWA
AP	UBI	10MG/VIAL	A211072	001	Jun 11, 2025	May NEWA

OLICERIDINE

SOLUTION; INTRAVENOUS
OLINVYK

@ +	TREVENA	1MG/ML (1MG/ML)	N210730	001	Oct 30, 2020	Jan DISC
@ +		2MG/2ML (1MG/ML)	N210730	002	Oct 30, 2020	Jan DISC

OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS
CLINOLIPID 20%

+	!	BAXTER HLTHCARE CORP	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun CMFD
---	---	----------------------	--------------------------------------	---------	-----	--------------	----------

OLMESARTAN MEDOXOMIL

TABLET; ORAL
OLMESARTAN MEDOXOMIL

AB	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Mar CMFD
AB		20MG	A205482	002	Apr 24, 2017	Mar CMFD
AB		40MG	A205482	003	Apr 24, 2017	Mar CMFD

OMAVELOXOLONE

CAPSULE; ORAL
SKYCLARYS

+	!	BIOGEN US	50MG	N216718	001	Feb 28, 2023	Jan CAHN
---	---	-----------	------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL
LOVAZA

AB	+	!	WAYLIS THERAP	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Feb CAHN
----	---	---	---------------	--	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

>D>	AB	SUN PHARM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210834	001	Jan 09, 2020	Jul DISC
-----	----	-----------	--	---------	-----	--------------	----------

>A>	@		1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210834	001	Jan 09, 2020	Jul DISC
-----	---	--	--	---------	-----	--------------	----------

OMIDENEPAG ISOPROPYL

SOLUTION; OPHTHALMIC
OMLONTI

+	!	OCUVEX THERAP	0.002%	N215092	001	Sep 22, 2022	Jun CMFD
---	---	---------------	--------	---------	-----	--------------	----------

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ONDANSETRON

AB	IPCA LABS LTD	4MG	A209389	001	Oct 30, 2023	May CMFD
AB		8MG	A209389	002	Oct 30, 2023	May CMFD
@	NORVIUM BIOSCIENCE	4MG	A078139	001	Jun 25, 2007	Feb CAHN
@		8MG	A078139	002	Jun 25, 2007	Feb CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

@	HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076781	001	Dec 26, 2006	Mar DISC
---	--------------------	----------------	---------	-----	--------------	----------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

@	APOTEX	EQ 4MG BASE	A077306	001	Jun 25, 2007	Mar DISC
@		EQ 8MG BASE	A077306	002	Jun 25, 2007	Mar DISC
AB	IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	May CMFD
AB		EQ 8MG BASE	A203761	002	Jan 23, 2014	May CMFD

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	SHANDONG	EQ 30MG BASE	A217274	001	Jul 09, 2025	Jun NEWA
AB		EQ 45MG BASE	A217274	002	Jul 09, 2025	Jun NEWA
AB		EQ 75MG BASE	A217274	003	Jul 09, 2025	Jun NEWA
AB	ZHEJIANG POLY PHARM	EQ 75MG BASE	A218009	001	Nov 24, 2023	Mar CAHN

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	JUBILANT GENERICS	EQ 6MG BASE/ML	A213695	001	Mar 03, 2025	Feb NEWA
----	-------------------	----------------	---------	-----	--------------	----------

OSPEMIFENE

TABLET;ORAL

OSPEMIFENE

@ HETERO LABS LTD V

OSPHERA

+! DUCHESNAY

60MG

60MG

A215574 001 Feb 13, 2024 Apr DISC

N203505 001 Feb 26, 2013 Apr CTEC

OXALIPLATIN

INJECTABLE;INTRAVENOUS

OXALIPLATIN

AP	HETERO LABS LTD VI	50MG/10ML (5MG/ML)	A217925	001	Jan 27, 2025	Jan NEWA
AP		100MG/20ML (5MG/ML)	A217925	002	Jan 27, 2025	Jan NEWA

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

>A>	AB	EPIC PHARMA LLC	10MG	A071756	002	Apr 19, 1988	Jul CMS1
>A>	AB		30MG	A071756	003	Apr 19, 1988	Jul CMS1
	AB	LEADING	10MG	A218261	001	Mar 03, 2025	Feb NEWA
	AB		15MG	A218261	002	Mar 03, 2025	Feb NEWA
	AB		30MG	A218261	003	Mar 03, 2025	Feb NEWA

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

>A>	AB	MACLEODS PHARMS LTD	300MG/5ML	A207300	001	Jul 11, 2025	Jul NEWA
>A>	@	PAI HOLDINGS	300MG/5ML	A211420	001	Jul 09, 2021	Jul CAHN
>D>	@	RENEW PHARMS	300MG/5ML	A211420	001	Jul 09, 2021	Jul CAHN

TABLET, EXTENDED RELEASE;ORAL

OXCARBAZEPINE

AB	AJANTA PHARMA LTD	150MG	A217659	001	Feb 22, 2024	Apr CMFD
AB		300MG	A217659	002	Feb 22, 2024	Apr CMFD
AB		600MG	A217659	003	Feb 22, 2024	Apr CMFD
@	AUROBINDO PHARMA LTD	150MG	A219241	001	Apr 30, 2025	May DISC
AB		150MG	A219241	001	Apr 30, 2025	Apr NEWA
@		300MG	A219241	002	Apr 30, 2025	May DISC
AB		300MG	A219241	002	Apr 30, 2025	Apr NEWA
@		600MG	A219241	003	Apr 30, 2025	May DISC
AB		600MG	A219241	003	Apr 30, 2025	Apr NEWA
AB	RICONPHARMA LLC	150MG	A215796	001	Nov 22, 2024	Apr CMFD
AB		300MG	A215796	002	Nov 22, 2024	Apr CMFD
AB		600MG	A215796	003	Nov 22, 2024	Apr CMFD

OXYBUTYNIN CHLORIDE

TABLET;ORAL

OXYBUTYNIN CHLORIDE

>A>	AB	AIPING PHARM INC	5MG	A074625	001	Jul 31, 1996	Jul CAHN
>D>	AB	UPSHER SMITH LABS	5MG	A074625	001	Jul 31, 1996	Jul CAHN

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

@ PHARM ASSOC

@ VISTAPHARM LLC

100MG/5ML

100MG/5ML

A206822 001 Aug 15, 2017 Apr DISC

A202537 001 Jul 30, 2012 Jan CAHN

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

@ NOVEL LABS INC

@

@

@

5MG

10MG

15MG

20MG

A204021 001 Jun 12, 2017 Feb DISC

A204021 002 Jun 12, 2017 Feb DISC

A204021 003 Jun 12, 2017 Feb DISC

A204021 004 Jun 12, 2017 Feb DISC

TABLET;ORAL
 OXYCODONE HYDROCHLORIDE
 @

30MG

A204021 005 Jun 12, 2017 Feb DISC

PACLITAXEL

POWDER;INTRAVENOUS
 PACLITAXEL

AB CIPLA 100MG/VIAL
 AB SHUANGCHENG 100MG/VIAL

A209657 001 Apr 10, 2025 Mar NEWA
 A216355 001 May 15, 2025 May NEWA

PALBOCICLIB

TABLET;ORAL
 PALBOCICLIB

@ ZYDUS LIFESCIENCES 75MG
 @ 100MG
 @ 125MG

A215570 001 Jun 05, 2024 Apr CAHN
 A215570 002 Jun 05, 2024 Apr CAHN
 A215570 003 Jun 05, 2024 Apr CAHN

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL
 PALIPERIDONE

AB DR REDDYS 3MG
 AB 6MG
 AB 9MG

A205559 001 Feb 19, 2025 Feb NEWA
 A205559 002 Feb 19, 2025 Feb NEWA
 A205559 003 Feb 19, 2025 Feb NEWA

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL
 PANTOPRAZOLE SODIUM

AB AUROBINDO PHARMA LTD EQ 40MG BASE
 AB CIPLA EQ 40MG BASE

A217923 001 Mar 31, 2025 Mar NEWA
 A217458 001 Mar 31, 2025 Mar NEWA

INJECTABLE;INTRAVENOUS
 PANTOPRAZOLE SODIUM

AP ALEMBIC EQ 40MG BASE/VIAL
 AP DEVA HOLDING AS EQ 40MG BASE/VIAL

A219230 001 Mar 31, 2025 Mar NEWA
 A215074 001 May 16, 2025 May NEWA

POWDER;INTRAVENOUS
 PANTOPRAZOLE SODIUM

AP FRESENIUS KABI USA EQ 40MG BASE/VIAL
 @ EQ 40MG BASE/VIAL
 AP +! HIKMA EQ 40MG BASE/VIAL
 +! EQ 40MG BASE/VIAL

A216021 001 Aug 01, 2024 May CMFD
 A216021 001 Aug 01, 2024 Feb DISC
 N209463 001 Jun 30, 2017 May CTEC
 N209463 001 Jun 30, 2017 Feb CTEC

TABLET, DELAYED RELEASE;ORAL
 PANTOPRAZOLE SODIUM

AB GRAVITI PHARMS EQ 20MG BASE
 AB EQ 40MG BASE
 @ INGENUS PHARMS LLC EQ 40MG BASE

A219087 001 Jan 16, 2025 Jan NEWA
 A219087 002 Jan 16, 2025 Jan NEWA
 A211368 001 Mar 01, 2019 Jan DISC

PARICALCITOL

CAPSULE;ORAL
 PARICALCITOL

AB CHARTWELL RX 1MCG
 AB 2MCG
 AB 4MCG

A091412 001 Jun 24, 2014 Apr CAHN
 A091412 002 Jun 24, 2014 Apr CAHN
 A091412 003 Jun 24, 2014 Apr CAHN

SOLUTION;INTRAVENOUS
 PARICALCITOL

AP CAPLIN 0.002MG/ML (0.002MG/ML)
 AP 0.005MG/ML (0.005MG/ML)
 AP 0.01MG/2ML (0.005MG/ML)
 >D> AP HIKMA PHARMS 0.002MG/ML (0.002MG/ML)
 >A> @ 0.002MG/ML (0.002MG/ML)
 >D> AP 0.005MG/ML (0.005MG/ML)
 >A> @ 0.005MG/ML (0.005MG/ML)
 >D> AP 0.01MG/2ML (0.005MG/ML)
 >A> @ 0.01MG/2ML (0.005MG/ML)

A204910 001 Aug 17, 2016 Apr CAHN
 A204910 002 Aug 17, 2016 Apr CAHN
 A204910 003 Aug 17, 2016 Apr CAHN
 N205917 001 Nov 18, 2014 Jul DISC
 N205917 001 Nov 18, 2014 Jul DISC
 N205917 002 Nov 18, 2014 Jul DISC
 N205917 002 Nov 18, 2014 Jul DISC
 N205917 003 Nov 18, 2014 Jul DISC
 N205917 003 Nov 18, 2014 Jul DISC

PEMETREXED DISODIUM

POWDER;INTRAVENOUS
 PEMETREXED DISODIUM

@ BAXTER HLTHCARE CORP EQ 100MG BASE/VIAL
 @ EQ 500MG BASE/VIAL

A214436 001 Aug 18, 2022 May DISC
 A214436 002 Aug 18, 2022 May DISC

SOLUTION;INTRAVENOUS
 PEMETREXED DISODIUM

@ + ACCORD HLTHCARE EQ 100MG BASE/4ML (EQ 25MG
 BASE/ML)

N214408 001 Jul 19, 2022 Jun DISC

SOLUTION; INTRAVENOUS
PEMETREXED DISODIUM

@ +	EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214408	002	Jul 19, 2022	Jun DISC
@ +	EQ 850MG BASE/34ML (EQ 25MG BASE/ML)	N214408	003	Jul 19, 2022	Jun DISC
@ +	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214408	004	Jul 19, 2022	Jun DISC

PENCICLOVIR

CREAM; TOPICAL
PENCICLOVIR

BX	TORRENT	1%	A216981	001	Aug 07, 2023	Mar CTEC
----	---------	----	---------	-----	--------------	----------

PERAMPANEL

SUSPENSION; ORAL
FYCOMPA

>D>	+! CATALYST PHARMS	0.5MG/ML	N208277	001	Apr 29, 2016	Jul CFTG
>A> AB	+!	0.5MG/ML	N208277	001	Apr 29, 2016	Jul CFTG
>A>	PERAMPANEL					
>A> AB	MSN	0.5MG/ML	A218152	001	Jul 11, 2025	Jul NFTG

TABLET; ORAL
FYCOMPA

AB	+ CATALYST PHARMS	2MG	N202834	001	Oct 22, 2012	May CFTG
AB	+	4MG	N202834	002	Oct 22, 2012	May CFTG
AB	+	6MG	N202834	003	Oct 22, 2012	May CFTG
AB	+	8MG	N202834	004	Oct 22, 2012	May CFTG
AB	+	10MG	N202834	005	Oct 22, 2012	May CFTG
AB	+!	12MG	N202834	006	Oct 22, 2012	May CFTG

PERAMPANEL

AB	TEVA PHARMS USA INC	2MG	A209801	001	May 23, 2025	May NFTG
AB		4MG	A209801	002	May 23, 2025	May NFTG
AB		6MG	A209801	003	May 23, 2025	May NFTG
AB		8MG	A209801	004	May 23, 2025	May NFTG
AB		10MG	A209801	005	May 23, 2025	May NFTG
AB		12MG	A209801	006	May 23, 2025	May NFTG

PERPHENAZINE

TABLET; ORAL
PERPHENAZINE

AB	JUBILANT GENERICS	2MG	A213694	001	Mar 18, 2025	Mar NEWA
AB		4MG	A213694	002	Mar 18, 2025	Mar NEWA
AB		8MG	A213694	003	Mar 18, 2025	Mar NEWA
AB		16MG	A213694	004	Mar 18, 2025	Mar NEWA

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE

	+! ACERTIS PHARMS	105MG	N018074	001		May CAHN
	TABLET; ORAL					
	BONTRIL PDM					
AA	+! BAUSCH	35MG	A085272	001		Mar CAHN
	PHENDIMETRAZINE TARTRATE					
AA	ACERTIS PHARMS	35MG	A085588	001		May CAHN
@	MPP PHARMA	35MG	A203600	001	Dec 27, 2017	May CAHN

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE

AB	DR REDDYS LABS SA	EQ 7.5MG BASE; 46MG	A208175	002	Jun 12, 2025	Jun NEWA
AB		EQ 11.25MG BASE; 69MG	A208175	003	Jun 12, 2025	Jun NEWA
AB		EQ 15MG BASE; 92MG	A208175	004	Jun 12, 2025	Jun NEWA
AB		EQ 3.75MG BASE; 23MG	A208175	001	Jun 12, 2025	Jun NEWA

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS
BIORPHEN

AP	+! DR REDDYS LABS SA	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Feb CFTG
	PHENYLEPHRINE HYDROCHLORIDE					
AP	SOMERSET THERAPS LLC	0.5MG/5ML (0.1MG/ML)	A215617	001	Feb 14, 2025	Feb NFTG
	PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE					
	+! DR REDDYS LABS SA	20MG/250ML (0.08MG/ML)	N216830	001	May 30, 2025	Jun CAHN

SOLUTION;INTRAVENOUS							
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE							
	+!	SINTETICA SA	20MG/250ML (0.08MG/ML)	N216830	001	May 30, 2025	May NEWA
<u>PHENYTOIN</u>							
SUSPENSION;ORAL							
PHENYTOIN							
	@	VISTAPHARM LLC	125MG/5ML	A040342	001	Jan 31, 2001	Jan CAHN
	@		125MG/5ML	A040342	002	Aug 18, 2005	Jan CAHN
<u>PHYTONADIONE</u>							
INJECTABLE;INJECTION							
PHYTONADIONE							
AB1		CAPLIN	10MG/ML	A219212	001	Apr 17, 2025	Apr NEWA
TABLET;ORAL							
PHYTONADIONE							
	@	HIKMA	5MG	A212112	001	Dec 19, 2024	Feb DISC
<u>PILOCARPINE HYDROCHLORIDE</u>							
SOLUTION;OPHTHALMIC							
PILOCARPINE HYDROCHLORIDE							
AB		AMNEAL	1.25%	A217733	001	Apr 28, 2025	Apr NFTG
VUITY							
AB	+!	ABBVIE	1.25%	N214028	001	Oct 28, 2021	Apr CFTG
<u>PINDOLOL</u>							
TABLET;ORAL							
PINDOLOL							
AB		MPP PHARMA	5MG	A205415	001	Jan 13, 2016	May CAHN
AB			10MG	A205415	002	Jan 13, 2016	May CAHN
<u>PIOGLITAZONE HYDROCHLORIDE</u>							
TABLET;ORAL							
PIOGLITAZONE HYDROCHLORIDE							
	@	AVIV PHARMA	EQ 15MG BASE	A078472	001	Feb 13, 2013	May CAHN
	@		EQ 30MG BASE	A078472	002	Feb 13, 2013	May CAHN
	@		EQ 45MG BASE	A078472	003	Feb 13, 2013	May CAHN
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM</u>							
POWDER;INTRAVENOUS							
PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER							
	+!	B BRAUN MEDICAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N206056	001	Apr 03, 2025	Apr NEWA
	+!		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N206056	002	Apr 03, 2025	Apr NEWA
	+!		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N206056	003	Apr 03, 2025	Apr NEWA
<u>PIROXICAM</u>							
CAPSULE;ORAL							
PIROXICAM							
AB		SOLIS PHARMS	10MG	A074118	002	Jun 15, 1993	Apr CAHN
AB			20MG	A074118	001	Jun 15, 1993	Apr CAHN
<u>PITOLISANT HYDROCHLORIDE</u>							
TABLET;ORAL							
WAKIX							
	+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Feb CAHN
	+!		EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Feb CAHN
<u>PLERIXAFOR</u>							
SOLUTION;SUBCUTANEOUS							
PLERIXAFOR							
AP		HETERO LABS LTD VI	24MG/1.2ML (20MG/ML)	A217560	001	Jun 16, 2025	Jun NEWA
<u>POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE</u>							
FOR SOLUTION;ORAL							
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE							
	@	SOLIS PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BO T;11.2GM/BOT	A202060	001	Mar 08, 2017	Apr CAHN

POLYMYXIN B SULFATEINJECTABLE;INJECTION
POLYMYXIN B SULFATE

@	ADRASTEIA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Jun DISC
---	------------------	----------------------------	---------	-----	--------------	----------

POMALIDOMIDECAPSULE;ORAL
POMALIDOMIDE

@	APOTEX	1MG	A210164	001	Jun 11, 2024	Jan DISC
@		2MG	A210164	002	Jun 11, 2024	Jan DISC
@		3MG	A210164	003	Jun 11, 2024	Jan DISC
@		4MG	A210164	004	Jun 11, 2024	Jan DISC
@	HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Apr DISC
@		2MG	A210236	002	Sep 26, 2024	Apr DISC
@		3MG	A210236	003	Sep 26, 2024	Apr DISC
@		4MG	A210236	004	Sep 26, 2024	Apr DISC

POMALYST

+	BRISTOL	1MG	N204026	001	Feb 08, 2013	Apr CTEC
+		2MG	N204026	002	Feb 08, 2013	Apr CTEC
+		3MG	N204026	003	Feb 08, 2013	Apr CTEC
+		4MG	N204026	004	Feb 08, 2013	Apr CTEC

POSACONAZOLETABLET, DELAYED RELEASE;ORAL
POSACONAZOLE

AB	MSN	100MG	A218434	001	Feb 24, 2025	Feb NEWA
AB	QILU PHARM HAINAN	100MG	A217720	001	Apr 23, 2025	Apr NEWA

POTASSIUM CHLORIDEFOR SOLUTION;ORAL
POTASSIUM CHLORIDE

AA	AJENAT PHARMS	20MEQ	A212183	001	May 06, 2019	Jan CAHN
AA	+! GENUS	20MEQ	N208019	001	Aug 19, 2015	Jan CHRS
	@ +	40MEQ	N208019	003	Aug 25, 2023	Jan DISC
>A> AA	GUARDIAN DRUG	20MEQ	A219009	001	Jul 11, 2025	Jul NEWA

INJECTABLE;INJECTION
POTASSIUM CHLORIDE

AP	NEXUS	2MEQ/ML	A217704	001	Aug 14, 2023	Mar CAHN
----	-------	---------	---------	-----	--------------	----------

SOLUTION;ORAL
POTASSIUM CHLORIDE

AA	AJENAT PHARMS	20MEQ/15ML	A216156	001	Mar 07, 2023	Jan CAHN
AA		40MEQ/15ML	A216156	002	Mar 07, 2023	Jan CAHN
AA	ASCENT PHARMS INC	20MEQ/15ML	A211992	001	Apr 09, 2025	Mar NEWA
AA		40MEQ/15ML	A211992	002	Apr 09, 2025	Mar NEWA
>A> AA	TARO	20MEQ/15ML	A218960	001	Jul 22, 2025	Jul NEWA

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB1	GUANGZHOU NOVAKEN	10MEQ	A214395	001	Jan 28, 2021	Apr CAHN
AB1		20MEQ	A214395	002	Jan 28, 2021	Apr CAHN
AB2	NORVIUM BIOSCIENCE	8MEQ	A204662	001	Aug 21, 2014	May CAHN
AB2		10MEQ	A204662	002	Aug 21, 2014	May CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE;INJECTION
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	OTSUKA ICU MEDCL	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	May CAHN
----	------------------	-------------------------	---------	-----	--------------	----------

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASICSOLUTION;INTRAVENOUS
POTASSIUM PHOSPHATES

AP	CIPLA	1.18GM/5ML (236MG/ML) ;	A217892	001	Jan 24, 2025	Jan NEWA
		1.12GM/5ML (224MG/ML)				
AP		3.54GM/15ML (236MG/ML) ;	A217892	002	Jan 24, 2025	Jan NEWA
		3.36GM/15ML (224MG/ML)				
AP		11.8GM/50ML (236MG/ML) ;	A217892	003	Jan 24, 2025	Jan NEWA
		11.2GM/50ML (224MG/ML)				
	POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE					
	+! FRESSENIUS KABI USA	1.18GM/100ML (11.8MG/ML) ;	N212832	004	May 09, 2025	May NEWA
		1.12GM/100ML (11.2MG/ML)				
	+!	1.18GM/250ML (4.72MG/ML) ;	N212832	005	May 09, 2025	May NEWA
		1.12GM/250ML (4.48MG/ML)				

PRALATREXATESOLUTION; INTRAVENOUS
FOLOTYN

AP	+	ACROTECH BIOPHARMA	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Feb CFTG
AP	+	!	40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Feb CFTG
PRALATREXATE							
AP		DR REDDYS	20MG/ML (20MG/ML)	A206183	001	Mar 10, 2025	Feb NFTG
AP			40MG/2ML (20MG/ML)	A206183	002	Mar 10, 2025	Feb NFTG

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

@	AVIV PHARMA	0.125MG	A091450	001	Oct 08, 2010	May CAHN
@		0.25MG	A091450	002	Oct 08, 2010	May CAHN
@		0.5MG	A091450	003	Oct 08, 2010	May CAHN
@		1MG	A091450	004	Oct 08, 2010	May CAHN
@		1.5MG	A091450	005	Oct 08, 2010	May CAHN

PREDNISOLONE

SOLUTION; ORAL

PREDNISOLONE

AA	!	CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Jun CDFR
	@	HIKMA	15MG/5ML	A040401	001	Feb 27, 2003	Jun CDFR
	@	IVAX SUB TEVA PHARMS	15MG/5ML	A040287	001	May 28, 1999	Jun CDFR
AA		LANNETT CO INC	15MG/5ML	A040775	001	Sep 21, 2007	Jun CDFR
	@	NESHER PHARMS	15MG/5ML	A040364	001	Apr 10, 2002	Jun CDFR
	@	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	Jun CDFR
AA			15MG/5ML	A040571	001	Aug 25, 2005	Jun CDFR
	@	PHARMOBEDIENT CNSLTG	15MG/5ML	A040313	001	Sep 10, 2003	Jun CDFR
	@	TEVA PHARMS	15MG/5ML	A040322	001	Jan 19, 2000	Jun CDFR
AA		TULEX PHARMS INC	15MG/5ML	A219509	001	Jun 23, 2025	Jun NEWA
	@	WE PHARMS	15MG/5ML	A040192	001	May 28, 1998	Jun CDFR
PRELONE							
AA		TEVA	15MG/5ML	A089081	001	Feb 04, 1986	Jun CDFR

PREDNISOLONE ACETATESUSPENSION/DROPS; OPHTHALMIC
PREDNISOLONE ACETATE

AB		AMNEAL	1%	A218256	001	Jun 11, 2025	May NEWA
----	--	--------	----	---------	-----	--------------	----------

PREDNISONE

TABLET; ORAL

PREDNISONE

	@	AIPING PHARM INC	5MG	A080336	002		Jan CAHN
AB	+	!	HIKMA	1MG	A080352	002	Apr 22, 1982
AB	+	!		2.5MG	A080352	003	Apr 22, 1982
AB	+	!		10MG	A080352	004	Apr CMS1
AB	+	!		20MG	A080352	005	Apr CMS1
AB	+	!		50MG	A080352	006	Apr CMS1
AB		POINTVIEW HLDINGS	5MG	A212629	001	Dec 05, 2023	Apr CAHN
AB			10MG	A212629	002	Dec 05, 2023	Apr CAHN
AB			20MG	A212629	003	Dec 05, 2023	Apr CAHN

PREGABALIN

CAPSULE; ORAL

PREGABALIN

@	ACTAVIS ELIZABETH	25MG	A091025	001	Jul 09, 2020	Apr DISC
@		50MG	A091025	002	Jul 09, 2020	Apr DISC
@		75MG	A091025	003	Jul 09, 2020	Apr DISC
@		100MG	A091025	004	Jul 09, 2020	Apr DISC
@		150MG	A091025	005	Jul 09, 2020	Apr DISC
@		200MG	A091025	006	Jul 09, 2020	Apr DISC
@		225MG	A091025	007	Jul 09, 2020	Apr DISC
@		300MG	A091025	008	Jul 09, 2020	Apr DISC
@	APOTEX	25MG	A211685	001	Jul 07, 2021	Apr DISC
@		50MG	A211685	002	Jul 07, 2021	Apr DISC
@		75MG	A211685	003	Jul 07, 2021	Apr DISC
@		100MG	A211685	004	Jul 07, 2021	Apr DISC
@		150MG	A211685	005	Jul 07, 2021	Apr DISC
@		200MG	A211685	006	Jul 07, 2021	Apr DISC
@		225MG	A211685	007	Jul 07, 2021	Apr DISC
@		300MG	A211685	008	Jul 07, 2021	Apr DISC

CAPSULE;ORAL							
PREGABALIN							
AB	HLTHCARE	25MG	A091222	001	Feb 21, 2025	Feb	NEWA
AB		50MG	A091222	002	Feb 21, 2025	Feb	NEWA
AB		75MG	A091222	003	Feb 21, 2025	Feb	NEWA
AB		100MG	A091222	004	Feb 21, 2025	Feb	NEWA
AB		150MG	A091222	005	Feb 21, 2025	Feb	NEWA
AB		200MG	A091222	006	Feb 21, 2025	Feb	NEWA
AB		225MG	A091222	007	Feb 21, 2025	Feb	NEWA
AB		300MG	A091222	008	Feb 21, 2025	Feb	NEWA
AB	JUBILANT GENERICS	25MG	A209530	001	May 20, 2025	May	NEWA
AB		50MG	A209530	002	May 20, 2025	May	NEWA
AB		75MG	A209530	003	May 20, 2025	May	NEWA
AB		100MG	A209530	004	May 20, 2025	May	NEWA
AB		150MG	A209530	005	May 20, 2025	May	NEWA
AB		200MG	A209530	006	May 20, 2025	May	NEWA
AB		225MG	A209530	007	May 20, 2025	May	NEWA
AB		300MG	A209530	008	May 20, 2025	May	NEWA
	@ MACLEODS PHARMS LTD	25MG	A205924	001	Nov 12, 2024	Jun	DISC
	@	50MG	A205924	002	Nov 12, 2024	Jun	DISC
	@	75MG	A205924	003	Nov 12, 2024	Jun	DISC
	@	100MG	A205924	004	Nov 12, 2024	Jun	DISC
	@	150MG	A205924	005	Nov 12, 2024	Jun	DISC
	@	200MG	A205924	006	Nov 12, 2024	Jun	DISC
	@	225MG	A205924	007	Nov 12, 2024	Jun	DISC
	@	300MG	A205924	008	Nov 12, 2024	Jun	DISC
AB	TORRENT	25MG	A206942	001	Feb 21, 2025	Feb	NEWA
AB		50MG	A206942	002	Feb 21, 2025	Feb	NEWA
AB		75MG	A206942	003	Feb 21, 2025	Feb	NEWA
AB		100MG	A206942	004	Feb 21, 2025	Feb	NEWA
AB		150MG	A206942	005	Feb 21, 2025	Feb	NEWA
AB		200MG	A206942	006	Feb 21, 2025	Feb	NEWA
AB		225MG	A206942	007	Feb 21, 2025	Feb	NEWA
AB		300MG	A206942	008	Feb 21, 2025	Feb	NEWA
TABLET, EXTENDED RELEASE;ORAL							
PREGABALIN							
	@ ALVOGEN	82.5MG	A211593	001	Apr 13, 2021	Feb	DISC
	@	165MG	A211593	002	Apr 13, 2021	Feb	DISC
	@	330MG	A211593	003	Apr 13, 2021	Feb	DISC
	@ APOTEX	165MG	A213313	001	Apr 13, 2021	Jan	DISC
	@	330MG	A213313	002	Apr 13, 2021	Jan	DISC
AB	HQ PHARMA	330MG	A217857	001	Jan 28, 2025	Jan	NEWA
<u>PRIMIDONE</u>							
TABLET;ORAL							
PRIMIDONE							
	@ CHARTWELL RX	50MG	A040862	001	Oct 03, 2008	Apr	CAHN
	@	250MG	A040862	002	Oct 03, 2008	Apr	CAHN
<u>PROBENECID; SULOPENEM ETZADROXIL</u>							
TABLET;ORAL							
ORLYNVAH							
	@ + ITERUM THERAP	500MG;500MG	N213972	001	Oct 25, 2024	Apr	DISC
<u>PROCAINAMIDE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
PROCAINAMIDE HYDROCHLORIDE							
AP	CAPLIN	100MG/ML	A218674	001	Feb 04, 2025	Jan	NEWA
AP		500MG/ML	A218674	002	Feb 04, 2025	Jan	NEWA
<u>PROCHLORPERAZINE</u>							
SUPPOSITORY;RECTAL							
COMPAZINE							
	@ + GLAXOSMITHKLINE	2.5MG	N011127	003		Mar	CRLD
	@ +	5MG	N011127	001		Mar	CMS1
	@ +	5MG	N011127	001		Mar	CRLD
	@ +	25MG	N011127	002		Mar	CMS1
	@ +	25MG	N011127	002		Mar	CRLD

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

@ NEXUS EQ 5MG BASE/ML A204860 001 Feb 15, 2019 Apr DISC

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB CEROVENE INC EQ 5MG BASE A217847 001 May 19, 2025 May NEWA
AB EQ 10MG BASE A217847 002 May 19, 2025 May NEWA

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM

AB + ACERTIS PHARMS 100MG N019781 001 May 14, 1998 May CAHN
AB +! 200MG N019781 002 Oct 15, 1999 May CAHN
@ 300MG N019781 003 Oct 15, 1999 May CAHN

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE

AA COSETTE 6.25MG/5ML A091675 001 Jun 28, 2012 Jun CAHN
AA STRIDES PHARMA 6.25MG/5ML A040891 001 Mar 13, 2009 Apr CAHN
PROMETHAZINE PLAIN
AA +! XTTRIUM LABS INC 6.25MG/5ML A087953 001 Nov 15, 1982 Feb CAHN

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
PROPARACAINE HYDROCHLORIDE

AT MANKIND PHARMA 0.5% A219136 001 May 21, 2025 May NEWA

PROTAMINE SULFATE

SOLUTION; INTRAVENOUS
PROTAMINE SULFATE

@ HIKMA 50MG/5ML (10MG/ML) A089475 002 Jun 07, 1988 May NEWA

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
PROTRIPTYLINE HYDROCHLORIDE

AB ! EPIC PHARMA LLC 10MG A202220 002 Nov 19, 2012 Apr CHRS
@ HIKMA 5MG A078913 001 Sep 16, 2008 Apr DISC
@ 10MG A078913 002 Sep 16, 2008 Apr DISC

PRUCALOPRIDE SUCCINATE

TABLET; ORAL
PRUCALOPRIDE SUCCINATE

AB AGGREGA EQ 1MG BASE A219193 001 Jun 24, 2025 Jun NEWA
AB EQ 2MG BASE A219193 002 Jun 24, 2025 Jun NEWA
AB ALKEM LABS LTD EQ 1MG BASE A218295 001 Jun 24, 2025 Jun NEWA
AB EQ 2MG BASE A218295 002 Jun 24, 2025 Jun NEWA
AB ANNORA PHARMA EQ 1MG BASE A219160 001 Jun 24, 2025 Jun NEWA
AB EQ 2MG BASE A219160 002 Jun 24, 2025 Jun NEWA
AB APOTEX EQ 1MG BASE A218977 001 Jun 24, 2025 Jun NEWA
AB EQ 2MG BASE A218977 002 Jun 24, 2025 Jun NEWA
AB APPCO EQ 1MG BASE A218963 001 Jun 24, 2025 Jun NEWA
AB EQ 2MG BASE A218963 002 Jun 24, 2025 Jun NEWA
AB H2-PHARMA EQ 1MG BASE A219216 001 Jun 24, 2025 Jun NEWA
AB EQ 2MG BASE A219216 002 Jun 24, 2025 Jun NEWA
AB HIKMA EQ 1MG BASE A217662 001 Jun 24, 2025 Jun NEWA
AB EQ 2MG BASE A217662 002 Jun 24, 2025 Jun NEWA
AB LUPIN LTD EQ 1MG BASE A218847 001 Jun 24, 2025 Jun NEWA
AB EQ 2MG BASE A218847 002 Jun 24, 2025 Jun NEWA
AB MSN EQ 1MG BASE A218177 001 Jun 24, 2025 Jun NEWA
AB EQ 2MG BASE A218177 002 Jun 24, 2025 Jun NEWA
AB SKG PHARMA EQ 1MG BASE A218812 001 Jun 24, 2025 Jun NEWA
AB EQ 2MG BASE A218812 002 Jun 24, 2025 Jun NEWA
AB SOMERSET THERAP EQ 1MG BASE A219078 001 Jun 24, 2025 Jun NEWA
AB EQ 2MG BASE A219078 002 Jun 24, 2025 Jun NEWA
>D> AB TORRENT EQ 1MG BASE A218778 001 Jun 24, 2025 Jul DISC
>A> @ EQ 1MG BASE A218778 001 Jun 24, 2025 Jul DISC
AB EQ 1MG BASE A218778 001 Jun 24, 2025 Jun NEWA

TABLET;ORAL

PRUCALOPRIDE SUCCINATE

>D>	AB		EQ 2MG BASE	A218778	002	Jun 24, 2025	Jul DISC
>A>	@		EQ 2MG BASE	A218778	002	Jun 24, 2025	Jul DISC
	AB		EQ 2MG BASE	A218778	002	Jun 24, 2025	Jun NEWA
	AB	ZENARA	EQ 1MG BASE	A218795	001	Jun 24, 2025	Jun NEWA
	AB		EQ 2MG BASE	A218795	002	Jun 24, 2025	Jun NEWA

PYRIMETHAMINE

TABLET;ORAL

PYRIMETHAMINE

@	ALVOGEN	25MG	A211271	001	Jul 27, 2021	May DISC
---	---------	------	---------	-----	--------------	----------

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB	GRAVITI PHARMS	EQ 25MG BASE	A077380	001	Mar 27, 2012	Feb CAHN
AB		EQ 50MG BASE	A077380	002	Mar 27, 2012	Feb CAHN
AB		EQ 100MG BASE	A077380	003	Mar 27, 2012	Feb CAHN
AB		EQ 150MG BASE	A077380	004	Mar 27, 2012	Feb CAHN
AB		EQ 200MG BASE	A077380	005	Mar 27, 2012	Feb CAHN
AB		EQ 300MG BASE	A077380	006	Mar 27, 2012	Feb CAHN
AB		EQ 400MG BASE	A077380	007	Mar 27, 2012	Feb CAHN

SEROQUEL

AB	+! CHEPLAPHARM	EQ 25MG BASE	N020639	001	Sep 26, 1997	Mar CAHN
AB	+	EQ 50MG BASE	N020639	007	Oct 04, 2005	Mar CAHN
AB	+	EQ 100MG BASE	N020639	002	Sep 26, 1997	Mar CAHN
	@ +	EQ 150MG BASE	N020639	004	Dec 20, 1998	Mar CAHN
AB	+	EQ 200MG BASE	N020639	003	Sep 26, 1997	Mar CAHN
AB	+!	EQ 300MG BASE	N020639	005	Jul 26, 2000	Mar CAHN
AB	+	EQ 400MG BASE	N020639	006	Oct 04, 2005	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB	MEDICAP LABS	EQ 50MG BASE	A202939	001	May 09, 2017	Feb CAHN
AB		EQ 150MG BASE	A202939	002	May 09, 2017	Feb CAHN
AB		EQ 200MG BASE	A202939	003	May 09, 2017	Feb CAHN
AB		EQ 300MG BASE	A202939	004	May 09, 2017	Feb CAHN
AB		EQ 400MG BASE	A202939	005	May 09, 2017	Feb CAHN

SEROQUEL XR

AB	+ CHEPLAPHARM	EQ 50MG BASE	N022047	001	May 17, 2007	Mar CAHN
AB	+	EQ 150MG BASE	N022047	005	Aug 11, 2008	Mar CAHN
AB	+!	EQ 200MG BASE	N022047	002	May 17, 2007	Mar CAHN
AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Mar CAHN
AB	+	EQ 400MG BASE	N022047	004	May 17, 2007	Mar CAHN

RALTEGRAVIR POTASSIUM

TABLET;ORAL

ISENTRESS

	+! MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007	Jan CTEC
	ISENTRESS HD					
AB	+! MSD SUB MERCK	EQ 600MG BASE	N022145	002	May 26, 2017	Apr CFTG
	RALTEGRAVIR POTASSIUM					
	@ HETERO LABS LTD III	EQ 400MG BASE	A203540	001	Dec 19, 2024	Jan DISC
AB	LUPIN LTD	EQ 600MG BASE	A217990	001	May 06, 2025	Apr NFTG

RAMELTEON

TABLET;ORAL

RAMELTEON

AB	APPCO	8MG	A213815	001	Oct 26, 2020	Mar CAHN
BX	AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Mar CTEC
BX	I3 PHARMS	8MG	A212650	001	Apr 10, 2020	Mar CTEC
BX	XIROMED	8MG	A216209	001	Nov 25, 2022	Mar CTEC

RAMIPRIL

CAPSULE;ORAL

ALTACE

>D>	AB	+ KING PHARMS LLC	1.25MG	N019901	001	Jan 28, 1991	Jul DISC
>A>	@ +		1.25MG	N019901	001	Jan 28, 1991	Jul DISC
>D>	AB	+	2.5MG	N019901	002	Jan 28, 1991	Jul DISC
>A>	@ +		2.5MG	N019901	002	Jan 28, 1991	Jul DISC
>D>	AB	+	5MG	N019901	003	Jan 28, 1991	Jul DISC
>A>	@ +		5MG	N019901	003	Jan 28, 1991	Jul DISC

		CAPSULE;ORAL					
>D>		ALTACE					
>D>	AB	+!	10MG	N019901	004	Jan 28, 1991	Jul DISC
>A>		@ +	10MG	N019901	004	Jan 28, 1991	Jul DISC
		RAMIPRIL					
>D>	AB	LUPIN	10MG	A077626	004	Jun 09, 2008	Jul CHRS
>A>	AB	!	10MG	A077626	004	Jun 09, 2008	Jul CHRS
		SOLUTION;ORAL					
		VOSTALLY					
>A>		+! ROSEMONT PHARMS	1MG/ML	N219757	001	Jul 23, 2025	Jul NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@	APOTEX	EQ 150MG BASE	A074680	001	Sep 12, 1997	Mar DISC
@		EQ 300MG BASE	A074680	002	Sep 12, 1997	Mar DISC
@	MPP PHARMA	EQ 150MG BASE	A203694	001	Nov 30, 2017	Jun CAHN
@		EQ 300MG BASE	A203694	002	Nov 30, 2017	Jun CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB		ARTHUR GRP	500MG	A212781	001	Mar 23, 2020	Jan CAHN
AB			1GM	A212781	002	Mar 23, 2020	Jan CAHN
AB	!	CADILA	1GM	A210188	002	Aug 19, 2019	Mar CHRS
AB		JUBILANT GENERICS	500MG	A211361	001	Apr 15, 2025	Apr NEWA
AB			1GM	A211361	002	Apr 15, 2025	Apr NEWA
	@	SUN PHARM	500MG	A211707	001	May 28, 2019	Mar DISC
	@		1GM	A211707	002	May 28, 2019	Mar DISC
	@	TORRENT	500MG	A210407	001	Feb 04, 2025	Jun DISC
AB			500MG	A210407	001	Feb 04, 2025	Jan NEWA
	@		1GM	A210407	002	Feb 04, 2025	Jun DISC
AB			1GM	A210407	002	Feb 04, 2025	Jan NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

@	CARNEGIE	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Apr CAHN	
@		EQ 1MG BASE	A201942	002	Nov 18, 2021	Apr CAHN	
AB		TORRENT	EQ 0.5MG BASE	A210150	001	May 05, 2025	Apr NEWA
AB			EQ 1MG BASE	A210150	002	May 05, 2025	Apr NEWA

REGORAFENIB

TABLET;ORAL

REGORAFENIB

>D>		REGORAFENIB					
>D>	AB	ACTAVIS LABS FL	40MG	A209728	001	Jan 13, 2025	Jul DISC
>A>		@	40MG	A209728	001	Jan 13, 2025	Jul DISC
	AB		40MG	A209728	001	Jan 13, 2025	Jan NFTG
		STIVARGA					
>D>	AB	+! BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012	Jul CTEC
>A>		+!	40MG	N203085	001	Sep 27, 2012	Jul CTEC
	AB	+!	40MG	N203085	001	Sep 27, 2012	Jan CFTG

REMDESIVIR

SOLUTION;INTRAVENOUS

VEKLURY

@ +	GILEAD SCIENCES INC	100MG/20ML (5MG/ML)	N214787	002	Oct 22, 2020	Jun DISC
-----	---------------------	---------------------	---------	-----	--------------	----------

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

@	SUN PHARM INDS INC	1MG	A077571	002	Jul 11, 2013	Feb DISC
@		2MG	A077571	003	Jul 11, 2013	Feb DISC

REPOTRECTINIB

CAPSULE;ORAL

AUGTYRO

>D>		+ BRISTOL	160MG	N218213	002	Jun 11, 2024	Jul CHRS
>A>		+!	160MG	N218213	002	Jun 11, 2024	Jul CHRS

RIFAMPIN

CAPSULE;ORAL

RIFADIN

@ +	SANOFI AVENTIS US	150MG	N050420	002		Apr	CMS1
-----	-------------------	-------	---------	-----	--	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET, FOR SUSPENSION;ORAL

EDURANT PED

+!	JANSSEN PRODS	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	May	CMFD
----	---------------	---------------	---------	-----	--------------	-----	------

RILUZOLE

TABLET;ORAL

RILUZOLE

AB	NORVIUM BIOSCIENCE	50MG	A203042	001	Jul 01, 2013	Feb	CAHN
----	--------------------	------	---------	-----	--------------	-----	------

RISDIPLAM

TABLET;ORAL

EVRYSDI

+!	GENENTECH INC	5MG	N219285	001	Feb 11, 2025	Feb	NEWA
----	---------------	-----	---------	-----	--------------	-----	------

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE;ORAL

RISEDRONATE SODIUM

@	SUN PHARM	35MG	A203925	001	Jul 09, 2019	Apr	DISC
---	-----------	------	---------	-----	--------------	-----	------

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RYKINDO

>D>	+	SHANDONG LUYE	12.5MG	N212849	001	Jan 13, 2023	Jul	DISC
-----	---	---------------	--------	---------	-----	--------------	-----	------

>A>	@ +		12.5MG	N212849	001	Jan 13, 2023	Jul	DISC
-----	-----	--	--------	---------	-----	--------------	-----	------

SOLUTION;ORAL

RISPERIDONE

>D>	@	APOZEAL PHARMS	1MG/ML	A078909	001	Jul 29, 2009	Jul	CMFD
-----	---	----------------	--------	---------	-----	--------------	-----	------

>A>	AA		1MG/ML	A078909	001	Jul 29, 2009	Jul	CMFD
-----	----	--	--------	---------	-----	--------------	-----	------

@			1MG/ML	A078909	001	Jul 29, 2009	Apr	CAHN
---	--	--	--------	---------	-----	--------------	-----	------

@	LANNETT CO INC		1MG/ML	A079158	001	Dec 03, 2010	Feb	DISC
---	----------------	--	--------	---------	-----	--------------	-----	------

>D>	AA	TARO	1MG/ML	A090347	001	Feb 07, 2011	Jul	DISC
-----	----	------	--------	---------	-----	--------------	-----	------

>A>			1MG/ML	A090347	001	Feb 07, 2011	Jul	DISC
-----	--	--	--------	---------	-----	--------------	-----	------

TABLET;ORAL

RISPERIDONE

@	APOTEX INC	0.25MG	A077953	001	Sep 15, 2008	Mar	DISC
---	------------	--------	---------	-----	--------------	-----	------

@		0.5MG	A077953	002	Sep 15, 2008	Mar	DISC
---	--	-------	---------	-----	--------------	-----	------

@		1MG	A077953	003	Sep 15, 2008	Mar	DISC
---	--	-----	---------	-----	--------------	-----	------

@		2MG	A077953	004	Sep 15, 2008	Mar	DISC
---	--	-----	---------	-----	--------------	-----	------

@		3MG	A077953	005	Sep 15, 2008	Mar	DISC
---	--	-----	---------	-----	--------------	-----	------

@		4MG	A077953	006	Sep 15, 2008	Mar	DISC
---	--	-----	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

>D>	AB	SUN PHARM INDS LTD	0.5MG	A078464	001	Apr 08, 2013	Jul	DISC
-----	----	--------------------	-------	---------	-----	--------------	-----	------

>A>		@	0.5MG	A078464	001	Apr 08, 2013	Jul	DISC
-----	--	---	-------	---------	-----	--------------	-----	------

>D>	AB		1MG	A078464	002	Apr 08, 2013	Jul	DISC
-----	----	--	-----	---------	-----	--------------	-----	------

>A>		@	1MG	A078464	002	Apr 08, 2013	Jul	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

>D>	AB		2MG	A078464	003	Apr 08, 2013	Jul	DISC
-----	----	--	-----	---------	-----	--------------	-----	------

>A>		@	2MG	A078464	003	Apr 08, 2013	Jul	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

>D>	AB		3MG	A078464	004	Apr 08, 2013	Jul	DISC
-----	----	--	-----	---------	-----	--------------	-----	------

>A>		@	3MG	A078464	004	Apr 08, 2013	Jul	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

>D>	AB		4MG	A078464	005	Apr 08, 2013	Jul	DISC
-----	----	--	-----	---------	-----	--------------	-----	------

>A>		@	4MG	A078464	005	Apr 08, 2013	Jul	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

RIVAROXABAN

FOR SUSPENSION;ORAL

RIVAROXABAN

AB	ALKEM LABS LTD	1MG/ML	A218502	001	Jun 26, 2025	Jun	NFTG
----	----------------	--------	---------	-----	--------------	-----	------

XARELTO

AB	+!	JANSSEN PHARMS	1MG/ML	N215859	001	Dec 20, 2021	Jun	CFTG
----	----	----------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

RIVAROXABAN

AB	ALEMBIC	2.5MG	A210301	001	May 14, 2025	May	NEWA
----	---------	-------	---------	-----	--------------	-----	------

AB		10MG	A210301	002	May 14, 2025	May	NFTG
----	--	------	---------	-----	--------------	-----	------

AB		15MG	A210301	003	May 14, 2025	May	NFTG
----	--	------	---------	-----	--------------	-----	------

AB		20MG	A210301	004	May 14, 2025	May	NFTG
----	--	------	---------	-----	--------------	-----	------

TABLET;ORAL

RIVAROXABAN

AB	APOTEX	2.5MG	A217810	001	May 02, 2025	Apr	NEWA	
AB	ASCENT PHARMS INC	2.5MG	A219332	001	May 14, 2025	May	NEWA	
AB		10MG	A219332	002	May 14, 2025	May	NFTG	
AB		15MG	A219332	003	May 14, 2025	May	NFTG	
AB		20MG	A219332	004	May 14, 2025	May	NFTG	
AB	AUROBINDO PHARMA LTD	2.5MG	A208544	001	Apr 10, 2025	Apr	NEWA	
AB		10MG	A208544	002	May 15, 2025	May	NEWA	
AB		15MG	A208544	003	May 15, 2025	May	NEWA	
AB		20MG	A208544	004	May 15, 2025	May	NEWA	
AB	BIOCON PHARMA	2.5MG	A218107	001	May 14, 2025	May	NEWA	
AB		10MG	A218107	002	May 14, 2025	May	NFTG	
AB		15MG	A218107	003	May 14, 2025	May	NFTG	
AB		20MG	A218107	004	May 14, 2025	May	NFTG	
AB	BRECKENRIDGE	10MG	A208220	001	May 15, 2025	May	NEWA	
AB		15MG	A208220	002	May 15, 2025	May	NEWA	
AB		20MG	A208220	003	May 15, 2025	May	NEWA	
AB	CHANGZHOU PHARM	10MG	A216995	001	May 14, 2025	May	NFTG	
AB		15MG	A216995	002	May 14, 2025	May	NFTG	
AB		20MG	A216995	003	May 14, 2025	May	NFTG	
AB	DR REDDYS	2.5MG	A208534	001	May 14, 2025	May	NEWA	
AB		10MG	A208534	002	May 14, 2025	May	NFTG	
AB		15MG	A208534	003	May 14, 2025	May	NFTG	
AB		20MG	A208534	004	May 14, 2025	May	NFTG	
AB	INVAGEN PHARMS	10MG	A208543	001	May 14, 2025	May	NFTG	
AB		15MG	A208543	002	May 14, 2025	May	NFTG	
AB		20MG	A208543	003	May 14, 2025	May	NFTG	
AB	LUPIN LTD	2.5MG	A208555	001	Mar 03, 2025	Feb	NFTG	
AB		10MG	A208555	002	May 14, 2025	May	NFTG	
AB		15MG	A208555	003	May 14, 2025	May	NFTG	
AB		20MG	A208555	004	May 14, 2025	May	NFTG	
AB	MACLEODS PHARMS LTD	2.5MG	A213114	001	May 14, 2025	May	NEWA	
AB		10MG	A213114	002	May 14, 2025	May	NFTG	
AB		15MG	A213114	003	May 14, 2025	May	NFTG	
AB		20MG	A213114	004	May 14, 2025	May	NFTG	
>A> AB	SCIEGEN PHARMS INC	2.5MG	A218117	001	Jul 31, 2025	Jul	NEWA	
>A> AB		10MG	A218117	002	Jul 31, 2025	Jul	NEWA	
>A> AB		15MG	A218117	003	Jul 31, 2025	Jul	NEWA	
>A> AB		20MG	A218117	004	Jul 31, 2025	Jul	NEWA	
AB	SUNSHINE	10MG	A213348	001	May 14, 2025	May	NFTG	
AB		15MG	A213348	002	May 14, 2025	May	NFTG	
AB		20MG	A213348	003	May 14, 2025	May	NFTG	
AB	TARO	2.5MG	A208557	001	Mar 03, 2025	Feb	NFTG	
XARELTO								
AB	+	JANSSEN PHARMS	2.5MG	N022406	004	Oct 11, 2018	Feb	CFTG
AB	+		10MG	N022406	001	Jul 01, 2011	May	CFTG
AB	+		15MG	N022406	002	Nov 04, 2011	May	CFTG
AB	+		20MG	N022406	003	Nov 04, 2011	May	CFTG

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

@	ALVOGEN	4.6MG/24HR	A204403	001	Sep 03, 2015	Mar	DISC
@		9.5MG/24HR	A204403	002	Sep 03, 2015	Mar	DISC
@		13.3MG/24HR	A204403	003	Aug 31, 2015	Mar	DISC

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB	NORVIUM BIOSCIENCE	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb	CAHN
AB		EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb	CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
RIZATRIPTAN BENZOATE							
@	NATCO PHARMA LTD	EQ 5MG BASE	A203478	001	Jul 01, 2013	Jun	DISC
@		EQ 10MG BASE	A203478	002	Jul 01, 2013	Jun	DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP	MANKIND PHARMA	50MG/5ML (10MG/ML)	A219674	001	May 29, 2025	May	NEWA
AP		100MG/10ML (10MG/ML)	A219674	002	May 29, 2025	May	NEWA

SOLUTION;INTRAVENOUS

ROCURONIUM BROMIDE

+! FRESENIUS KABI USA
+!

50MG/5ML (10MG/ML)
100MG/10ML (10MG/ML)

N217472 001 Jun 09, 2025 Jun NEWA
N217472 002 Jun 09, 2025 Jun NEWA

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

AB AUROBINDO PHARMA LTD 250MCG
@ SENORES PHARMS 250MCG
@ 500MCG

A213298 002 Jan 31, 2025 Jan NEWA
A208236 002 Oct 19, 2023 Feb CAHN
A208236 001 Oct 03, 2018 Feb CAHN

ROIIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROIIVACAINE HYDROCHLORIDE

AP ANTHEA PHARMA 40MG/20ML (2MG/ML)
AP 150MG/30ML (5MG/ML)
AP 200MG/20ML (10MG/ML)

A219883 001 Mar 21, 2025 Mar NEWA
A219883 002 Mar 21, 2025 Mar NEWA
A219883 003 Mar 21, 2025 Mar NEWA

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

AB + ASTRAZENECA EQ 5MG BASE
AB + EQ 10MG BASE
AB + EQ 20MG BASE
AB +! EQ 40MG BASE

N021366 002 Aug 12, 2003 Jan CAHN
N021366 003 Aug 12, 2003 Jan CAHN
N021366 004 Aug 12, 2003 Jan CAHN
N021366 005 Aug 12, 2003 Jan CAHN

ROSUVASTATIN CALCIUM

@ MACLEODS PHARMS LTD EQ 5MG BASE
@ EQ 10MG BASE
@ EQ 20MG BASE
@ EQ 40MG BASE
AB MANKIND PHARMA EQ 5MG BASE
AB EQ 10MG BASE
AB EQ 20MG BASE
AB EQ 40MG BASE
AB ZHEJIANG JINGXIN EQ 5MG BASE
AB EQ 10MG BASE
AB EQ 20MG BASE
AB EQ 40MG BASE

A207296 001 Nov 06, 2024 Jun DISC
A207296 002 Nov 06, 2024 Jun DISC
A207296 003 Nov 06, 2024 Jun DISC
A207296 004 Nov 06, 2024 Jun DISC
A206603 001 May 16, 2025 May NEWA
A206603 002 May 16, 2025 May NEWA
A206603 003 May 16, 2025 May NEWA
A206603 004 May 16, 2025 May NEWA
A206513 001 Mar 01, 2019 May CMFD
A206513 002 Mar 01, 2019 May CMFD
A206513 003 Mar 01, 2019 May CMFD
A206513 004 Mar 01, 2019 May CMFD

RUFINAMIDE

SUSPENSION;ORAL

RUFINAMIDE

AB HIKMA 40MG/ML
AB MSN 40MG/ML

A207363 001 Apr 23, 2019 Jun CAHN
A214817 001 Apr 15, 2025 Apr NEWA

SACUBITRIL; VALSARTAN

TABLET;ORAL

SACUBITRIL AND VALSARTAN

AB DR REDDYS 24MG;26MG
AB 49MG;51MG
AB 97MG;103MG
>A> AB HETERO LABS LTD III 24MG;26MG
>A> AB 49MG;51MG
>A> AB 97MG;103MG
AB LUPIN 24MG;26MG
AB 49MG;51MG
AB 97MG;103MG
>A> AB MSN 24MG;26MG
>A> AB 49MG;51MG
>A> AB 97MG;103MG
>A> AB NOVUGEN PHARMA SDN 24MG;26MG
>A> AB 49MG;51MG
>A> AB 97MG;103MG

A213627 001 Jan 13, 2025 Jan NEWA
A213627 002 Jan 13, 2025 Jan NEWA
A213627 003 Jan 13, 2025 Jan NEWA
A213668 001 Jul 17, 2025 Jul NEWA
A213668 002 Jul 17, 2025 Jul NEWA
A213668 003 Jul 17, 2025 Jul NEWA
A213808 001 Jan 08, 2025 Jan NEWA
A213808 002 Jan 08, 2025 Jan NEWA
A213808 003 Jan 08, 2025 Jan NEWA
A213748 001 Jul 16, 2025 Jul NEWA
A213748 002 Jul 16, 2025 Jul NEWA
A213748 003 Jul 16, 2025 Jul NEWA
A213611 001 Jul 16, 2025 Jul NEWA
A213611 002 Jul 16, 2025 Jul NEWA
A213611 003 Jul 16, 2025 Jul NEWA

SAFINAMIDE MESYLATE

TABLET;ORAL

SAFINAMIDE MESYLATE

AB ZENARA EQ 50MG BASE
AB EQ 100MG BASE

A215913 001 Jun 13, 2025 Jun NEWA
A215913 002 Jun 13, 2025 Jun NEWA

SAPROPTERIN DIHYDROCHLORIDEPOWDER; ORAL
ZELVYSIA

AB	AUCTA	100MG/PACKET	A218645	001	Apr 29, 2025	Jun CAHN
AB		500MG/PACKET	A218645	002	Apr 29, 2025	Jun CAHN
AB	SHANGHAI AUCYUN	100MG/PACKET	A218645	001	Apr 29, 2025	Apr NEWA
AB		500MG/PACKET	A218645	002	Apr 29, 2025	Apr NEWA

TABLET; ORAL

SAPROPTERIN DIHYDROCHLORIDE

AB	AUROBINDO PHARMA	100MG	A216797	001	Jun 09, 2025	May NEWA
AB	ZENARA	100MG	A218797	001	Jun 11, 2025	May NEWA

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

SAXAGLIPTIN

>D> AB	SUN PHARM	EQ 2.5MG BASE	A206078	001	Jul 31, 2023	Jul DISC
>A>	@	EQ 2.5MG BASE	A206078	001	Jul 31, 2023	Jul DISC
>D> AB		EQ 5MG BASE	A206078	002	Jul 31, 2023	Jul DISC
>A>	@	EQ 5MG BASE	A206078	002	Jul 31, 2023	Jul DISC

SCOPOLAMINESYSTEM; TRANSDERMAL
SCOPOLAMINE

AB	AMNEALS PHARMS	1MG/72HR	A218384	001	Jun 09, 2025	May NEWA
AB	! RICONPHARMA LLC	1MG/72HR	A212342	001	Nov 24, 2020	Apr CHRS
AB	+ BAXTER HLTHCARE CORP	1MG/72HR	N017874	001		Apr CHRS

>A> SEBETRALSTAT>A> TABLET; ORAL
>A> EKTERLY

>A>	+! KALVISTA	300MG	N219301	001	Jul 03, 2025	Jul NEWA
-----	-------------	-------	---------	-----	--------------	----------

SELENIOS ACID

SOLUTION; INTRAVENOUS

SELENIOS ACID

AP	+! AM REGENT	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	N209379	003	Aug 30, 2021	May CFTG
	+!	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Feb CTEC
AP	+!	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Jan CFTG
AP	+!	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	N209379	001	Apr 30, 2019	Feb CFTG
AP	ASPIRO	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A219633	001	Jun 11, 2025	May NFTG
AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219633	002	Jun 11, 2025	May NEWA
>A> AP	CIPLA	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A218661	001	Jul 21, 2025	Jul NEWA
>A> AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218661	002	Jul 21, 2025	Jul NEWA
AP	FRESENIUS KABI USA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Jan NFTG
>D> AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Jul DISC
>A>	@	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Jul DISC
AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Feb CMS1
AP	GLAND	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219629	001	Jul 08, 2025	Jun NEWA
AP	SUN PHARM	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219547	001	Feb 20, 2025	Feb NEWA

SELINEXOR

TABLET; ORAL

XPOVIO

	+ KARYOPHARM THERAPS	10MG	N212306	005	Mar 10, 2025	Mar NEWA
--	----------------------	------	---------	-----	--------------	----------

SELPERCATINIB

CAPSULE;ORAL

RETEVMO

+ ELI LILLY AND CO

40MG

N213246 001 May 08, 2020 Jan CAHN

+!

80MG

N213246 002 May 08, 2020 Jan CAHN

TABLET;ORAL

RETEVMO

+ ELI LILLY AND CO

40MG

N218160 001 Apr 10, 2024 Jan CAHN

+

80MG

N218160 002 Apr 10, 2024 Jan CAHN

+

120MG

N218160 003 Apr 10, 2024 Jan CAHN

+!

160MG

N218160 004 Apr 10, 2024 Jan CAHN

>A> SEPIAPTERIN

>A> POWDER;ORAL

>A> SEPHIENCE

>A> + PTC THERAP

250MG/PACKET

N219666 001 Jul 28, 2025 Jul NEWA

>A> +!

1GM/PACKET

N219666 002 Jul 28, 2025 Jul NEWA

SERTRALINE HYDROCHLORIDE

CAPSULE;ORAL

SERTRALINE HYDROCHLORIDE

>D> +! ALMATICA

EQ 150MG BASE

N215133 001 Oct 04, 2021 Jul CFTG

>A> AB +!

EQ 150MG BASE

N215133 001 Oct 04, 2021 Jul CFTG

>D> +

EQ 200MG BASE

N215133 002 Oct 04, 2021 Jul CFTG

>A> AB +

EQ 200MG BASE

N215133 002 Oct 04, 2021 Jul CFTG

>A> AB ZENARA

EQ 150MG BASE

A218853 001 Jul 16, 2025 Jul NFTG

>A> AB

EQ 200MG BASE

A218853 002 Jul 16, 2025 Jul NFTG

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

@ INVAGEN PHARMS

800MG/PACKET

A206234 001 Jul 12, 2024 Jan DISC

@

2.4GM/PACKET

A206234 002 Jul 12, 2024 Jan DISC

@ TORRENT

800MG/PACKET

A215909 001 Feb 27, 2025 Jun DISC

AB @

800MG/PACKET

A215909 001 Feb 27, 2025 Feb NEWA

AB @

2.4GM/PACKET

A215909 002 Feb 27, 2025 Jun DISC

AB @

2.4GM/PACKET

A215909 002 Feb 27, 2025 Feb NEWA

TABLET;ORAL

SEVELAMER CARBONATE

@ EPIC PHARMA LLC

800MG

A212970 001 Apr 09, 2020 Jun CAHN

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

SEVELAMER HYDROCHLORIDE

BX AUROBINDO PHARMA LTD 400MG

A212599 001 Jul 11, 2023 Mar CTEC

BX 800MG

A212599 002 Jul 11, 2023 Mar CTEC

AB NAVINTA LLC 800MG

A218966 001 Feb 03, 2025 Jan NEWA

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

SILDENAFIL CITRATE

AB APPCO EQ 10MG BASE/ML

A213814 001 Apr 29, 2021 Feb CAHN

AB CHARTWELL RX EQ 10MG BASE/ML

A213814 001 Apr 29, 2021 Feb CAHN

TABLET;ORAL

SILDENAFIL CITRATE

AB JUBILANT GENERICS EQ 20MG BASE

A202954 001 Mar 06, 2025 Feb NEWA

SILODOSIN

CAPSULE;ORAL

>D> RAPAFLO

>D> AB +! ABBVIE

4MG

N022206 001 Oct 08, 2008 Jul DISC

>A> @ +

4MG

N022206 001 Oct 08, 2008 Jul DISC

>D> AB +

8MG

N022206 002 Oct 08, 2008 Jul DISC

>A> @ +

8MG

N022206 002 Oct 08, 2008 Jul DISC

SILODOSIN

>D> AB LUPIN LTD 4MG

A206541 001 Dec 03, 2018 Jul CHRS

>A> AB ! 4MG

A206541 001 Dec 03, 2018 Jul CHRS

@ TORRENT 4MG

A210396 001 Feb 10, 2025 Jun DISC

AB 4MG

A210396 001 Feb 10, 2025 Jan NEWA

@ 8MG

A210396 002 Feb 10, 2025 Jun DISC

AB 8MG

A210396 002 Feb 10, 2025 Jan NEWA

SIMVASTATINTABLET; ORAL
SIMVASTATIN

AB	GRAVITI PHARMS	5MG	A077752	005	Jan 23, 2008	Feb CAHN
AB		10MG	A077752	001	Dec 20, 2006	Feb CAHN
AB		20MG	A077752	002	Dec 20, 2006	Feb CAHN
AB		40MG	A077752	003	Dec 20, 2006	Feb CAHN
AB		80MG	A077752	004	Dec 20, 2006	Feb CAHN

SIPONIMODTABLET; ORAL
MAYZENT

	+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	May CTEC
AB	+		EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr CFTG
	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	May CTEC
AB	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Apr CFTG
	+		EQ 2MG BASE	N209884	002	Mar 26, 2019	May CTEC
AB	+		EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr CFTG

SIPONIMOD

	@	RICONPHARMA LLC	EQ 0.25MG BASE	A218444	001	Apr 22, 2025	May DISC
AB			EQ 0.25MG BASE	A218444	001	Apr 22, 2025	Apr NFTG
	@		EQ 1MG BASE	A218444	002	Apr 22, 2025	May DISC
AB			EQ 1MG BASE	A218444	002	Apr 22, 2025	Apr NFTG
	@		EQ 2MG BASE	A218444	003	Apr 22, 2025	May DISC
AB			EQ 2MG BASE	A218444	003	Apr 22, 2025	Apr NFTG

SIROLIMUSPOWDER; INTRAVENOUS
FYARRO

	+	AADI SUB	100MG/VIAL	N213312	001	Nov 22, 2021	Mar CAHN
--	---	----------	------------	---------	-----	--------------	----------

SOLUTION; ORAL
SIROLIMUS

>A> AA		RISING	1MG/ML	A215116	001	Jul 15, 2025	Jul NEWA
--------	--	--------	--------	---------	-----	--------------	----------

SITAGLIPTIN HYDROCHLORIDESOLUTION; ORAL
BRYNOVIN

	+	AZURITY	EQ 25MG BASE/ML	N219122	001	Jan 16, 2025	Jan NEWA
--	---	---------	-----------------	---------	-----	--------------	----------

SODIUM BICARBONATEINJECTABLE; INJECTION
SODIUM BICARBONATE

AP		ANTHEA PHARMA	1MEQ/ML	A219701	001	Jun 26, 2025	Jun NEWA
----	--	---------------	---------	---------	-----	--------------	----------

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		+	OTSUKA ICU MEDCL	900MG/100ML	N016366	001	May CAHN
----	--	---	------------------	-------------	---------	-----	----------

SOLUTION; INJECTION
SODIUM CHLORIDE 0.9%

AP		NEXUS	90MG/10ML (9MG/ML)	A217535	001	Aug 23, 2023	Mar CAHN
AP			180MG/20ML (9MG/ML)	A217535	002	Aug 23, 2023	Mar CAHN

SODIUM IODIDE I-131SOLUTION; ORAL
SODIUM IODIDE I 131

AA		CARDINAL HLTH 414	250-1000mCi	A213615	001	Jun 12, 2025	Jun NEWA
----	--	-------------------	-------------	---------	-----	--------------	----------

SODIUM NITROPRUSSIDEINJECTABLE; INJECTION
SODIUM NITROPRUSSIDE

	@	XIROMED	25MG/ML	A211277	001	Oct 29, 2020	Jan DISC
--	---	---------	---------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATEPOWDER; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

AA		AJENAT PHARMS	454GM/BOT	A205727	001	Feb 23, 2016	Jan CAHN
----	--	---------------	-----------	---------	-----	--------------	----------

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

AA		LYNE	15GM/60ML	A214912	001	Jun 10, 2025	May NEWA
----	--	------	-----------	---------	-----	--------------	----------

SOLIFENACIN SUCCINATE

>D>	SUSPENSION;ORAL							
>D>	VESICARE LS							
>D>	+! ASTELLAS	1MG/ML	N209529	001	May 26, 2020	Jul	DISC	
>A>	@ +	1MG/ML	N209529	001	May 26, 2020	Jul	DISC	
	TABLET;ORAL							
	SOLIFENACIN SUCCINATE							
	@ TORRENT	5MG	A209424	001	Mar 04, 2025	Jun	DISC	
AB		5MG	A209424	001	Mar 04, 2025	Feb	NEWA	
	@	10MG	A209424	002	Mar 04, 2025	Jun	DISC	
AB		10MG	A209424	002	Mar 04, 2025	Feb	NEWA	

SORAFENIB TOSYLATE

	TABLET;ORAL							
	SORAFENIB TOSYLATE							
	@ APOTEX	EQ 200MG BASE	A212228	001	Jan 27, 2025	Mar	DISC	
AB		EQ 200MG BASE	A212228	001	Jan 27, 2025	Jan	NEWA	

SPIRONOLACTONE

	SUSPENSION;ORAL							
	SPIRONOLACTONE							
AB	HETERO LABS LTD III	25MG/5ML	A218085	001	Feb 21, 2025	Feb	NEWA	
	TABLET;ORAL							
	SPIRONOLACTONE							
>A> AB	ANNORA PHARMA	25MG	A217761	001	Jul 25, 2025	Jul	NEWA	
>A> AB		50MG	A217761	002	Jul 25, 2025	Jul	NEWA	
>A> AB		100MG	A217761	003	Jul 25, 2025	Jul	NEWA	
AB	GRAVITI PHARMS	25MG	A219494	001	Jan 23, 2025	Jan	NEWA	
AB		50MG	A219494	002	Jan 23, 2025	Jan	NEWA	
AB		100MG	A219494	003	Jan 23, 2025	Jan	NEWA	

STREPTOZOCIN

	INJECTABLE;INJECTION							
	ZANOSAR							
	@ + TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982	Feb	DISC	

SUCCINYLCHOLINE CHLORIDE

	INJECTABLE;INJECTION							
	SUCCINYLCHOLINE CHLORIDE							
AP	FRESENIUS KABI USA	20MG/ML	A217885	001	Feb 21, 2025	Feb	NEWA	
	SOLUTION;INTRAMUSCULAR, INTRAVENOUS							
	SUCCINYLCHOLINE CHLORIDE							
AP	FRESENIUS KABI USA	100MG/5ML (20MG/ML)	A217884	001	Feb 11, 2025	Jan	NEWA	

SUCRALFATE

	SUSPENSION;ORAL							
	SUCRALFATE							
AB	PADAGIS US	1GM/10ML	A211780	001	Apr 14, 2025	Apr	NEWA	
	TABLET;ORAL							
	SUCRALFATE							
AB	CHARTWELL RX	1GM	A074415	001	Jun 08, 1998	Apr	CAHN	

SUGAMMADEX SODIUM

	SOLUTION;INTRAVENOUS							
	SUGAMMADEX SODIUM							
>A> AP	FISIOPHARMA	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214279	001	Aug 05, 2025	Jul	NEWA	

SULFACETAMIDE SODIUM

	LOTION;TOPICAL							
	SULFACETAMIDE SODIUM							
>D> AB	TARO	10%	A078668	001	May 20, 2009	Jul	DISC	
>A>	@	10%	A078668	001	May 20, 2009	Jul	DISC	

SULINDAC

	TABLET;ORAL							
	SULINDAC							
AB	EPIC PHARMA	150MG	A072711	002	Mar 25, 1991	Mar	CMS1	

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

AB	SUN PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001	Jun 21, 2011	Jun CMFD
----	-----------	-------------------------------------	---------	-----	--------------	----------

TABLET;ORAL

SUMATRIPTAN SUCCINATE

>A>	AB	IPCA LABS LTD	EQ 25MG BASE	A206019	001	Jul 15, 2025	Jul NEWA
>A>	AB		EQ 50MG BASE	A206019	002	Jul 15, 2025	Jul NEWA
>A>	AB		EQ 100MG BASE	A206019	003	Jul 15, 2025	Jul NEWA
>D>	AB	SUN PHARM INDS	EQ 25MG BASE	A078295	001	Aug 10, 2009	Jul DISC
>A>	@		EQ 25MG BASE	A078295	001	Aug 10, 2009	Jul DISC
>D>	AB		EQ 50MG BASE	A078295	002	Aug 10, 2009	Jul DISC
>A>	@		EQ 50MG BASE	A078295	002	Aug 10, 2009	Jul DISC
>D>	AB		EQ 100MG BASE	A078295	003	Aug 10, 2009	Jul DISC
>A>	@		EQ 100MG BASE	A078295	003	Aug 10, 2009	Jul DISC

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB	FOSUN WANBANG	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Jan CAHN
AB		EQ 25MG BASE	A218012	002	Aug 21, 2023	Jan CAHN
AB		EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Jan CAHN
AB		EQ 50MG BASE	A218012	004	Aug 21, 2023	Jan CAHN
AB	MSN	EQ 12.5MG BASE	A214824	001	Feb 14, 2025	Feb NEWA
AB		EQ 25MG BASE	A214824	002	Feb 14, 2025	Feb NEWA
AB		EQ 37.5MG BASE	A214824	003	Feb 14, 2025	Feb NEWA
AB		EQ 50MG BASE	A214824	004	Feb 14, 2025	Feb NEWA

>A> SUNVOZERTINIB

>A> TABLET;ORAL

>A> ZEGFROVY

>A>	+	DIZAL JIANGSU	150MG	N219839	001	Jul 02, 2025	Jul NEWA
>A>	+	!	200MG	N219839	002	Jul 02, 2025	Jul NEWA

SUZETRIGINE

TABLET;ORAL

JOURNAVX

+	!	VERTEX PHARMS INC	50MG	N219209	001	Jan 30, 2025	Jan NEWA
---	---	-------------------	------	---------	-----	--------------	----------

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS

AB	AJENAT PHARMS	EQ 0.5MG BASE	A206651	001	Nov 30, 2017	Jan CAHN	
AB		EQ 1MG BASE	A206651	002	Nov 30, 2017	Jan CAHN	
AB		EQ 5MG BASE	A206651	003	Nov 30, 2017	Jan CAHN	
>D>	AB	HANGZHOU ZHONGMEI	EQ 0.5MG BASE	A210929	001	Apr 17, 2023	Jul DISC
>A>	@		EQ 0.5MG BASE	A210929	001	Apr 17, 2023	Jul DISC
>D>	AB		EQ 1MG BASE	A210929	002	Apr 17, 2023	Jul DISC
>A>	@		EQ 1MG BASE	A210929	002	Apr 17, 2023	Jul DISC
>D>	AB		EQ 5MG BASE	A210929	003	Apr 17, 2023	Jul DISC
>A>	@		EQ 5MG BASE	A210929	003	Apr 17, 2023	Jul DISC

INJECTABLE;INJECTION

PROGRAF

AP	+	!	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Jan CTEC
----	---	---	----------	----------------	---------	-----	--------------	----------

TACROLIMUS

AP	NEXUS	EQ 5MG BASE/ML	A217108	001	Feb 12, 2025	Jan NEWA
----	-------	----------------	---------	-----	--------------	----------

OINTMENT;TOPICAL

TACROLIMUS

BX	ENCUBE	0.1%	A212387	001	Oct 10, 2023	Mar CTEC
----	--------	------	---------	-----	--------------	----------

TALAZOPARIB TOSYLATE

CAPSULE;ORAL

TALZENNA

@ + PFIZER

@	+		EQ 0.1MG BASE	N211651	005	Jun 20, 2023	Feb DISC
@	+		EQ 0.25MG BASE	N211651	001	Oct 16, 2018	Feb DISC
@	+		EQ 0.35MG BASE	N211651	006	Jun 20, 2023	Feb DISC
@	+		EQ 0.5MG BASE	N211651	003	Sep 20, 2021	Feb DISC
@	+		EQ 0.75MG BASE	N211651	004	Sep 20, 2021	Feb DISC
@	+		EQ 1MG BASE	N211651	002	Oct 16, 2018	Feb DISC

TALETRECTINIB ADIPATE

CAPSULE;ORAL

IBTROZI

+! NUVATION

EQ 200MG BASE

N219713 001 Jun 11, 2025 Jun NEWA

TAMOXIFEN CITRATE

TABLET;ORAL

TAMOXIFEN CITRATE

@ APOTEX

EQ 10MG BASE

A090878 001 Sep 23, 2011 Mar DISC

@

EQ 20MG BASE

A090878 002 Sep 23, 2011 Mar DISC

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

FLOMAX

@ + SANOFI

0.4MG

N020579 001 Apr 15, 1997 Feb DISC

TAMSULOSIN HYDROCHLORIDE

AB ASCENT PHARMS INC

0.4MG

A214730 001 May 04, 2022 Feb CMFD

AB GRAVITI PHARMS

0.4MG

A219767 001 May 01, 2025 Apr NEWA

AB ! ZYDUS PHARMS USA INC

0.4MG

A078225 001 Apr 27, 2010 Feb CHRS

TAPINAROF

CREAM;TOPICAL

VTAMA

+! ORGANON LLC

1%

N215272 001 May 23, 2022 May CAHN

TAVABOROLE

SOLUTION;TOPICAL

TAVABOROLE

>D> AB AMNEAL

5%

A212256 001 Nov 25, 2020 Jul DISC

>A> @

5%

A212256 001 Nov 25, 2020 Jul DISC

>D> AB TARO

5%

A212215 001 May 07, 2021 Jul DISC

>A> @

5%

A212215 001 May 07, 2021 Jul DISC

TAZAROTENE

CREAM;TOPICAL

TAZAROTENE

AB COSETTE

0.05%

A208662 002 Mar 10, 2025 Feb NEWA

LOTION;TOPICAL

ARAZLO

>D> +! BAUSCH

0.045%

N211882 001 Dec 18, 2019 Jul CFTG

>A> AB +!

0.045%

N211882 001 Dec 18, 2019 Jul CFTG

>A> TAZAROTENE

>A> AB PADAGIS ISRAEL

0.045%

A215393 001 Jul 29, 2025 Jul NFTG

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION

OSTEOLITE

@ SUN PHARM INDS INC

N/A

N017972 001 Feb CAHN

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE;INJECTION

DRAXIMAGE DTPA

AP +! JUBILANT

N/A

N018511 001 Dec 29, 1989 Mar CFTG

TECHNETIUM TC-99M PENTETATE KIT

AP CURIUM

N/A

A215146 001 Mar 26, 2025 Mar NFTG

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE;INJECTION

TECHNETIUM TC 99M SESTAMIBI

@ SUN PHARM INDS INC

10-30mCi

A079157 001 Jul 10, 2009 May DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION;INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

@ SUN PHARM INDS INC

12mCi/ML

N017321 001 May CAHN

@

24mCi/ML

N017321 002 May CAHN

@

48mCi/ML

N017321 003 May CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS

ULTRA-TECHNEKOW V4

+! CURIUM

1-19 CI/GENERATOR

N017243 003 Feb 18, 2014 Jun CTNA

@

0.25-3 CI/GENERATOR

N017243 002 Jun CTNA

SOLUTION;INTRAVENOUS, ORAL

DRYTEC

@ + GE HEALTHCARE

68-2703mCi/GENERATOR

N017693 002 Dec 13, 2013 Jun CTNA

@

830-16600mCi/GENERATOR

N017693 001 Jun CTNA

TELMISARTAN

TABLET;ORAL

MICARDIS

>D> AB + BOEHRINGER INGELHEIM

80MG

N020850 002 Nov 10, 1998 Jul DISC

>A>

@ +

80MG

N020850 002 Nov 10, 1998 Jul DISC

AB

+

80MG

N020850 002 Nov 10, 1998 Feb CHRS

TELMISARTAN

AB

!

INVENTIA

80MG

A205150 003 Oct 30, 2015 Feb CHRS

AB

MACLEODS PHARMS LTD

20MG

A203986 001 Jan 15, 2025 Jan NEWA

AB

40MG

A203986 002 Jan 15, 2025 Jan NEWA

AB

80MG

A203986 003 Jan 15, 2025 Jan NEWA

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

@ SUN PHARM INDUSTRIES

7.5MG

A078581 001 Sep 08, 2009 Mar DISC

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

@ NEXTSOURCE

5MG

A203898 001 Feb 10, 2016 Mar CAHN

@

20MG

A203898 002 Feb 10, 2016 Mar CAHN

@

100MG

A203898 003 Feb 10, 2016 Mar CAHN

AB

100MG

A203898 003 Feb 10, 2016 Mar CMFD

@

140MG

A203898 004 Feb 10, 2016 Mar CAHN

AB

140MG

A203898 004 Feb 10, 2016 Mar CMFD

@

180MG

A203898 005 Feb 10, 2016 Mar CAHN

AB

180MG

A203898 005 Feb 10, 2016 Mar CMFD

@

250MG

A203898 006 Feb 10, 2016 Mar CAHN

AB

250MG

A203898 006 Feb 10, 2016 Mar CMFD

@

TRI-SOURCE PHARMA

5MG

A203898 001 Feb 10, 2016 Apr CAHN

@

20MG

A203898 002 Feb 10, 2016 Apr CAHN

AB

100MG

A203898 003 Feb 10, 2016 Apr CAHN

AB

140MG

A203898 004 Feb 10, 2016 Apr CAHN

AB

180MG

A203898 005 Feb 10, 2016 Apr CAHN

AB

250MG

A203898 006 Feb 10, 2016 Apr CAHN

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB AJANTA PHARMA LTD

EQ 1MG BASE

A219482 001 May 12, 2025 May NEWA

AB

EQ 2MG BASE

A219482 002 May 12, 2025 May NEWA

AB

EQ 5MG BASE

A219482 003 May 12, 2025 May NEWA

AB

EQ 10MG BASE

A219482 004 May 12, 2025 May NEWA

@

HIKMA

EQ 1MG BASE

A075498 001 Apr 12, 2001 Jun CAHN

@

EQ 2MG BASE

A075498 002 Apr 12, 2001 Jun CAHN

@

EQ 5MG BASE

A075498 003 Apr 12, 2001 Jun CAHN

@

EQ 10MG BASE

A075498 004 Apr 12, 2001 Jun CAHN

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

@ BRECKENRIDGE PHARM

EQ 250MG BASE

A077714 001 Jun 04, 2010 Mar DISC

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

@ APOTEX

7MG

A209601 001 Nov 02, 2018 Feb DISC

@

14MG

A209601 002 Nov 02, 2018 Feb DISC

AB

CONCORD BIOTECH LTD

7MG

A218663 001 Apr 07, 2025 Mar NEWA

AB

14MG

A218663 002 Apr 07, 2025 Mar NEWA

TABLET;ORAL

TERIFLUNOMIDE

@ WELDING

7MG

A209702 001 Feb 28, 2020 Jun CAHN

@

14MG

A209702 002 Feb 28, 2020 Jun CAHN

TERIPARATIDE

SOLUTION;SUBCUTANEOUS

BONSITY

ALVOGEN

0.56MG/2.24ML (0.25MG/ML)

N211939 001 Oct 04, 2019 Feb CPOT

FORTEO

AP +! LILLY

0.56MG/2.24ML (0.25MG/ML)

N021318 002 Jun 25, 2008 Feb CPOT

TERIPARATIDE

AP +! ALMAJECT

0.56MG/2.24ML (0.25MG/ML)

N218771 001 Jun 04, 2024 Feb CPOT

AP +!

0.6MG/2.4ML (0.25MG/ML)

N218771 001 Jun 04, 2024 Feb CTEC

AP APOTEX

0.56MG/2.24ML (0.25MG/ML)

A211097 001 Nov 16, 2023 Feb CPOT

AP TEVA PHARMS USA

0.56MG/2.24ML (0.25MG/ML)

A208569 001 Nov 16, 2023 Feb CPOT

TESTOSTERONE

SOLUTION, METERED;TRANSDERMAL

TESTOSTERONE

@ ENCUBE

30MG/1.5ML ACTUATION

A212301 001 Jan 11, 2021 Jan DISC

@ TWI PHARMS

30MG/1.5ML ACTUATION

A209836 001 Sep 03, 2021 Jun DISC

THEOPHYLLINE

SOLUTION, ELIXIR;ORAL

ELIXOPHYLLIN

AA +! SOLIS PHARMS

80MG/15ML

A085186 001

Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

>D> AB AJANTA PHARMA LTD

300MG

A218401 002 Mar 26, 2025 Jul DISC

>A> @

300MG

A218401 002 Mar 26, 2025 Jul DISC

AB

300MG

A218401 002 Mar 26, 2025 Mar NEWA

>D> AB

450MG

A218401 001 Jan 13, 2025 Jul DISC

>A> @

450MG

A218401 001 Jan 13, 2025 Jul DISC

AB

450MG

A218401 001 Jan 13, 2025 Jan NEWA

AB MPP PHARMA

400MG

A040560 003 Apr 21, 2006 Jun CAHN

AB !

600MG

A040560 002 Apr 21, 2006 Jun CAHN

@ RHODES PHARMS

300MG

A214113 001 May 11, 2023 Jan DISC

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

AP GLAND

100MG/ML

A217800 001 Feb 24, 2025 Feb NEWA

THIOTEPA

POWDER;INTRAVENOUS

TEPADINA AND SODIUM CHLORIDE

+! ADIENNE SA

200MG

N208264 003 Apr 10, 2025 May NEWA

SOLUTION;INTRAVENOUS

TEPYLUTE

+! SHORLA

100MG/10ML (10MG/ML)

N216984 002 Feb 26, 2025 Mar NEWA

TIAGABINE HYDROCHLORIDE

TABLET;ORAL

TIAGABINE HYDROCHLORIDE

@ SUN PHARM INDS

2MG

A077555 001 Nov 04, 2011 Jun DISC

@

4MG

A077555 002 Nov 04, 2011 Jun DISC

TICAGRELOR

TABLET;ORAL

BRILINTA

AB + ASTRAZENECA

60MG

N022433 002 Sep 03, 2015 Mar CTEC

TICAGRELOR

AB ALEMBIC

90MG

A208576 001 May 01, 2025 Apr NEWA

AB APOTEX

90MG

A208584 001 May 01, 2025 Apr NEWA

AB INVAGEN PHARMS

90MG

A208537 001 May 05, 2025 Apr NEWA

AB MSN

90MG

A208596 001 Apr 07, 2020 Mar CMFD

@

90MG

A208596 001 Apr 07, 2020 Feb CAHN

>D> @ MYLAN

60MG

A208597 001 Jul 09, 2021 Jul CMFD

>A> AB

60MG

A208597 001 Jul 09, 2021 Jul CMFD

>D> @

90MG

A208597 002 Jul 09, 2021 Jul CMFD

>A> AB

90MG

A208597 002 Jul 09, 2021 Jul CMFD

TABLET;ORAL

TICAGRELOR

AB	SUNSHINE	90MG	A208508	001	Apr 06, 2020	Mar CMFD
AB	WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Mar CMFD
AB		90MG	A208390	002	Sep 04, 2018	Mar CMFD

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL

TICLOPIDINE HYDROCHLORIDE

@	APOTEX	250MG	A075089	001	Jul 01, 1999	Mar DISC
---	--------	-------	---------	-----	--------------	----------

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC

BETIMOL

@ +	THEA PHARMA	0.25%	N020439	001	Mar 31, 1995	Jun DISC
-----	-------------	-------	---------	-----	--------------	----------

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

@	APOTEX	EQ 0.5% BASE	A204936	001	Apr 17, 2015	May DISC
---	--------	--------------	---------	-----	--------------	----------

TOBRAMYCIN

POWDER;INHALATION

TOBI PODHALER

+!	VIATRIS	28MG	N201688	001	Mar 22, 2013	Feb CAHN
----	---------	------	---------	-----	--------------	----------

SOLUTION;INHALATION

TOBI

AN	+!	VIATRIS	300MG/5ML	N050753	001	Dec 22, 1997	Feb CAHN
----	----	---------	-----------	---------	-----	--------------	----------

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB CITRATE

@	DEXCEL	EQ 11MG BASE	A218668	001	Dec 16, 2024	Apr DISC
---	--------	--------------	---------	-----	--------------	----------

XELJANZ XR

+	PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Apr CTEC
---	--------	--------------	---------	-----	--------------	----------

TOLTERODINE TARTRATE

TABLET;ORAL

TOLTERODINE TARTRATE

>D>	AB	ELYSIUM	1MG	A210775	001	Dec 30, 2019	Jul CAHN
>D>	AB		2MG	A210775	002	Dec 30, 2019	Jul CAHN
	AB	PTS CONSULTING	1MG	A204721	001	Jan 24, 2020	Mar CAHN
	AB		2MG	A204721	002	Jan 24, 2020	Mar CAHN
>A>	AB	RISING	1MG	A210775	001	Dec 30, 2019	Jul CAHN
>A>	AB		2MG	A210775	002	Dec 30, 2019	Jul CAHN

TOLVAPTAN

TABLET;ORAL

JYNARQUE

AB2	+	OTSUKA	15MG	N204441	001	Apr 23, 2018	Apr CFTG
AB2	+		30MG	N204441	002	Apr 23, 2018	Apr CFTG
AB	+!		45MG	N204441	003	Apr 23, 2018	Apr CFTG
AB2	+		60MG	N204441	004	Apr 23, 2018	Apr CFTG
AB	+		90MG	N204441	005	Apr 23, 2018	Apr CFTG

SAMSCA

AB1	+	OTSUKA	15MG	N022275	001	May 19, 2009	Apr CTEC
AB1	+!		30MG	N022275	002	May 19, 2009	Apr CTEC

TOLVAPTAN

AB1		ALKEM LABS LTD	15MG	A211891	003	Sep 06, 2022	Apr CTEC
AB1			30MG	A211891	001	May 19, 2020	Apr CTEC
AB1		APOTEX	15MG	A207605	002	Sep 06, 2022	Apr CTEC
AB1			30MG	A207605	001	May 19, 2020	Apr CTEC
AB1		ENDO OPERATIONS	15MG	A206119	001	Feb 15, 2022	Apr CTEC
AB1			30MG	A206119	002	Feb 15, 2022	Apr CTEC
AB1		HETERO LABS LTD V	15MG	A205646	002	Sep 06, 2022	Apr CTEC
AB1			30MG	A205646	001	Jul 16, 2021	Apr CTEC
AB2		LUPIN LTD	15MG	A216063	001	Apr 23, 2025	Apr NFTG
AB2			30MG	A216063	002	Apr 23, 2025	Apr NFTG
AB			45MG	A216063	003	Apr 23, 2025	Apr NFTG
AB2			60MG	A216063	004	Apr 23, 2025	Apr NFTG
AB			90MG	A216063	005	Apr 23, 2025	Apr NFTG
AB1		MSN	15MG	A216949	001	Jun 21, 2023	Apr CTEC

TABLET;ORAL							
TOLVAPTAN							
AB1		30MG	A216949	002	Jun 21, 2023	Apr	CTEC
<u>TOPIRAMATE</u>							
CAPSULE;ORAL							
TOPIRAMATE							
AB	RUBICON	15MG	A216683	001	May 27, 2025	May	NEWA
AB		25MG	A216683	002	May 27, 2025	May	NEWA
AB		50MG	A216683	003	May 27, 2025	May	NEWA
AB	ZYDUS PHARMS USA INC	50MG	A078877	003	Oct 23, 2024	May	CTEC
TABLET;ORAL							
TOPIRAMATE							
@	SENORES PHARMS	25MG	A090353	001	Sep 01, 2010	May	CAHN
@		50MG	A090353	002	Sep 01, 2010	May	CAHN
@		100MG	A090353	003	Sep 01, 2010	May	CAHN
@		200MG	A090353	004	Sep 01, 2010	May	CAHN
@	SUN PHARM	200MG	A090278	004	Mar 27, 2009	May	DISC
<u>TORSEMIDE</u>							
TABLET;ORAL							
TORSEMIDE							
AB	COREPHARMA	5MG	A076894	001	May 31, 2005	Apr	CAHN
AB		10MG	A076894	002	May 31, 2005	Apr	CAHN
AB		20MG	A076894	003	May 31, 2005	Apr	CAHN
AB		100MG	A076894	004	May 31, 2005	Apr	CAHN
<u>TRAMADOL HYDROCHLORIDE</u>							
TABLET;ORAL							
TRAMADOL HYDROCHLORIDE							
AB	APDM PHARMS	50MG	A090404	001	Jan 31, 2011	Feb	CAHN
@	APOTEX	50MG	A075981	001	Jul 10, 2002	Mar	DISC
@	MERRO PHARM USA	50MG	A206706	001	Jul 02, 2019	Feb	DISC
AB	SENORES PHARMS	50MG	A090404	001	Jan 31, 2011	Jun	CAHN
TABLET, EXTENDED RELEASE;ORAL							
TRAMADOL HYDROCHLORIDE							
AB1	! LUPIN LTD	100MG	A200503	001	Aug 29, 2011	Jan	CTEC
AB1		200MG	A200503	002	Aug 29, 2011	Jan	CTEC
AB1		300MG	A200503	003	Aug 29, 2011	Jan	CTEC
AB1	MACLEODS PHARMS LTD	100MG	A209404	001	Jan 31, 2025	Jan	NEWA
AB1		200MG	A209404	002	Jan 31, 2025	Jan	NEWA
AB1		300MG	A209404	003	Jan 31, 2025	Jan	NEWA
<u>TRAMETINIB DIMETHYL SULFOXIDE</u>							
TABLET;ORAL							
TRAMETINIB DIMETHYL SULFOXIDE							
@	HIKMA	EQ 0.5MG	A219002	001	Aug 06, 2024	Feb	CAHN
@		EQ 2MG	A219002	002	Aug 06, 2024	Feb	CAHN
<u>TRANEXAMIC ACID</u>							
INJECTABLE;INJECTION							
TRANEXAMIC ACID							
@	FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Jan	DISC
SOLUTION;INTRAVENOUS							
TRANEXAMIC ACID							
AP	RTU PHARMA SA	1GM/100ML (10MG/ML)	A218896	001	Jun 02, 2025	May	NEWA
TABLET;ORAL							
TRANEXAMIC ACID							
AB	APPCO	650MG	A218729	001	Jun 11, 2025	May	NEWA
<u>TRAVOPROST</u>							
SOLUTION/DROPS;OPHTHALMIC							
TRAVATAN Z							
AT2	+! SANDOZ	0.004%	N021994	001	Sep 21, 2006	Feb	CTEC
TRAVOPROST							
@	ALEMBIC	0.004%	A210458	001	Dec 20, 2019	Feb	DISC
AT2	APOTEX	0.004%	A203431	001	Jul 10, 2015	Feb	CTEC
!	CHARTWELL RX	0.004%	A091340	001	Mar 01, 2013	Feb	CTEC
AT2	GLAND	0.004%	A218159	001	Jul 12, 2024	Feb	CTEC
AT2	MICRO LABS	0.004%	A203767	001	Mar 19, 2021	Feb	CTEC
AT2	MYLAN	0.004%	A205050	001	Jul 07, 2017	Feb	CTEC
AT2	SOMERSET THERAPS LLC	0.004%	A217228	001	Sep 23, 2024	Feb	CTEC

TREOSULFANPOWDER; INTRAVENOUS
GRAFAPEX

+	!	MEDEXUS	1GM/VIAL	N214759	001	Jan 21, 2025	Jan CAHN
+	!		5GM/VIAL	N214759	002	Jan 21, 2025	Jan CAHN
+	!	MGFKSMB	1GM/VIAL	N214759	001	Jan 21, 2025	Jan NEWA
+	!		5GM/VIAL	N214759	002	Jan 21, 2025	Jan NEWA

TREPROSTINILINJECTABLE; INTRAVENOUS, SUBCUTANEOUS
REMODULIN

@	+	UNITED THERAP	0.1MG/ML	N021272	006	Sep 28, 2023	Jun DISC
@	+		0.2MG/ML	N021272	007	Sep 28, 2023	Jun DISC
@	+		20MG/ML	N021272	005	Jul 30, 2021	Jun DISC

POWDER; INHALATION

TYVASO DPI

+	!	UNITED THERAP	0.032MG/INH	N214324	002	May 23, 2022	Jan CHRS
+	!		0.048MG/INH	N214324	003	May 23, 2022	Jan CHRS
+	!		0.08MG/INH	N214324	005	Oct 24, 2024	Jan CHRS

TREPROSTINIL SODIUMPOWDER; INHALATION
YUTREPIA

+	!	LIQUIDIA TECH	EQ 0.0265MG BASE/INH	N213005	001	May 23, 2025	May NEWA
+	!		EQ 0.053MG BASE/INH	N213005	002	May 23, 2025	May NEWA
+	!		EQ 0.0795MG BASE/INH	N213005	003	May 23, 2025	May NEWA
+	!		EQ 0.106MG BASE/INH	N213005	004	May 23, 2025	May NEWA

TRETINOIN

CAPSULE; ORAL

TRETINOIN

	@	BARR LABS INC	10MG	A077684	001	Jun 22, 2007	Feb DISC
AB	!	ENDO OPERATIONS	10MG	A201687	001	Oct 24, 2012	Feb CHRS

CREAM; TOPICAL

TRETINOIN

>A>	AB	ENCUBE	0.025%	A217831	001	Jul 10, 2025	Jul NEWA
-----	----	--------	--------	---------	-----	--------------	----------

GEL; TOPICAL

RETIN-A

AB	+	!	BAUSCH	0.01%	N017955	001	Jan CAHN
----	---	---	--------	-------	---------	-----	----------

TRETINOIN

AB		AUROBINDO PHARMA LTD	0.01%	A218246	001	Jan 13, 2025	Jan NEWA
AB			0.025%	A218245	001	Feb 27, 2025	Feb NEWA
AB		ENCUBE	0.01%	A217588	001	Mar 03, 2025	Feb NEWA
AB			0.025%	A217587	001	Mar 03, 2025	Feb NEWA

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

>D>	AT	GLENMARK PHARMS LTD	0.1%	A207117	001	Aug 05, 2016	Jul DISC
>A>		@	0.1%	A207117	001	Aug 05, 2016	Jul DISC

GEL; TOPICAL

ARISTOGEL

@	+	ASTELLAS	0.1%	A083380	001		Feb CRLD
---	---	----------	------	---------	-----	--	----------

INJECTABLE; INJECTION

KENALOG-10

AB	+	APOTHECON	10MG/ML	N012041	001		Feb CTEC
----	---	-----------	---------	---------	-----	--	----------

TRIAMCINOLONE ACETONIDE

AB		DR REDDYS	10MG/ML	A218773	001	Mar 12, 2025	Feb NEWA
AB			40MG/ML	A218421	001	Apr 11, 2025	Apr NEWA

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

	@	BEACH PRODS	0.025%	A204608	001	Jul 07, 2016	May CAHN
AT	!	XTTRIUM LABS INC	0.025%	A088450	001	Apr 01, 1985	Feb CAHN
AT	!		0.1%	A088451	001	Apr 03, 1985	Feb CAHN

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

>D>	AT	GLENMARK PHARMS LTD	0.5%	A206379	001	Jul 22, 2016	Jul DISC
>A>		@	0.5%	A206379	001	Jul 22, 2016	Jul DISC
>D>	AT	GLENMARK SPECLT	0.1%	A208320	001	Aug 22, 2017	Jul DISC
>A>		@	0.1%	A208320	001	Aug 22, 2017	Jul DISC

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

@ + ETHYPHARM INC

5MG/ML

N016466 001

May CAHN

@ +

20MG/ML

N016466 002

May CAHN

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

@ + TEVA WOMENS

EQ 25MG BASE

N016792 001

Jun CAHN

@ +

EQ 50MG BASE

N016792 002

Jun CAHN

@ +

EQ 100MG BASE

N016792 003 Sep 15, 1982

Jun CAHN

TROSPIMUM CHLORIDE

TABLET; ORAL

TROSPIMUM CHLORIDE

AB ZAMEER PHARMS

20MG

A215781 001 Feb 16, 2022 Feb CAHN

URSODIOL

TABLET; ORAL

URSO 250

@ + ABBVIE

250MG

N020675 001 Dec 10, 1997

Jun DISC

AB

+

250MG

N020675 001 Dec 10, 1997

Jun CAHN

URSO FORTE

@ + ABBVIE

500MG

N020675 002 Jul 21, 2004

Jun DISC

AB

+!

500MG

N020675 002 Jul 21, 2004

Jun CAHN

URSODIOL

AB ! ZYDUS LIFESCIENCES

500MG

A211145 002 Oct 30, 2018

Jun CHRS

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

@ APOTEX

EQ 500MG BASE

A090500 001 Apr 04, 2014 Mar DISC

VALBENAZINE TOSYLATE

CAPSULE; ORAL

INGREZZA

+ NEUROCRINE

EQ 60MG BASE

N209241 003 Apr 23, 2021

Feb CTEC

VALBENAZINE TOSYLATE

@ ZYDUS LIFESCIENCES

EQ 40MG BASE

A216137 001 Aug 07, 2024

Feb DISC

@

EQ 60MG BASE

A216137 002 Aug 07, 2024

Feb DISC

@

EQ 80MG BASE

A216137 003 Aug 07, 2024

Feb DISC

VALGANCICLOVIR HYDROCHLORIDE

TABLET; ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB SPH ZHONGXI PHARM

EQ 450MG BASE

A218027 001 Apr 16, 2025 Apr NEWA

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

@ PAI HOLDINGS

250MG/5ML

A077105 001 Jul 29, 2005

Apr CAHN

VALSARTAN

SOLUTION; ORAL

PREXXARTAN

@ + CARMEL BIOSCIENCES

4MG/ML

N209139 001 Dec 19, 2017

May CPOT

VALSARTAN

AB ! NOVITIUM PHARMA

4MG/ML

A214102 001 Nov 02, 2021

May CTEC

!

4MG/ML

A214102 001 Nov 02, 2021

May CPOT

AB

RUBICON

4MG/ML

A216460 001 Jun 05, 2025

May NEWA

TABLET; ORAL

VALSARTAN

@ RENATA

40MG

A218169 001 Aug 05, 2024

Feb DISC

AB

@

40MG

A218169 001 Aug 05, 2024

Jan CAHN

@

80MG

A218169 002 Aug 05, 2024

Feb DISC

AB

@

80MG

A218169 002 Aug 05, 2024

Jan CAHN

@

160MG

A218169 003 Aug 05, 2024

Feb DISC

AB

@

160MG

A218169 003 Aug 05, 2024

Jan CAHN

@

320MG

A218169 004 Aug 05, 2024

Feb DISC

AB

@

320MG

A218169 004 Aug 05, 2024

Jan CAHN

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

>A>	@	ABON PHARMS LLC	EQ 125MG BASE	A065478	001	Apr 09, 2012	Jul CAHN
>A>	@		EQ 250MG BASE	A065478	002	Apr 09, 2012	Jul CAHN
>D>	@	PAI HOLDINGS PHARM	EQ 125MG BASE	A065478	001	Apr 09, 2012	Jul CAHN
>D>	@		EQ 250MG BASE	A065478	002	Apr 09, 2012	Jul CAHN

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE

@	STERISCIENCE	EQ 500MG BASE/VIAL	A060180	001		Apr CAHN
@		EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Apr CAHN
@		EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Apr CAHN
@		EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Apr CAHN
@		EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Apr CAHN
@		EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Apr CAHN
@		EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Apr CAHN
@		EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Apr CAHN
@		EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Apr CAHN

VANCOMYCIN HYDROCHLORIDE

>D>	AP	HOSPIRA INC	EQ 10GM BASE/VIAL	A065455	001	Apr 29, 2009	Jul DISC
>A>	@		EQ 10GM BASE/VIAL	A065455	001	Apr 29, 2009	Jul DISC
	AP	MEDIMETRIKS PHARMS	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan CMFD
	AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan CMFD
	@	PLANO PHARMS	EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010	Mar CAHN
	@		EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010	Mar CAHN
	@		EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Mar CAHN
	@		EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Mar CAHN

POWDER; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

AP	GLAND	EQ 750MG BASE/VIAL	A218140	001	Mar 21, 2025	Mar NEWA	
AP		EQ 1.25GM BASE/VIAL	A218140	002	Mar 21, 2025	Mar NEWA	
AP		EQ 1.5GM BASE/VIAL	A218140	003	Mar 21, 2025	Mar NEWA	
AP	+!	MYLAN LABS LTD	EQ 750MG BASE/VIAL	N209481	002	Jul 10, 2018	Mar CFTG

SOLUTION; INTRAVENOUS

TYZAVAN

>A>	+!	HIKMA	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019	Jul CTNA
>A>	+!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020	Jul CTNA
>A>	+!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019	Jul CTNA
>A>	+!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020	Jul CTNA
>A>	+!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019	Jul CTNA
>A>	+!		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020	Jul CTNA
>A>	+!		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019	Jul CTNA

VANCOMYCIN HYDROCHLORIDE

>D>	+!	HIKMA	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019	Jul CTNA
>D>	+!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020	Jul CTNA
>D>	+!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019	Jul CTNA
>D>	+!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020	Jul CTNA
>D>	+!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019	Jul CTNA
>D>	+!		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020	Jul CTNA
>D>	+!		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019	Jul CTNA

VARENICLINE TARTRATE

TABLET; ORAL

VARENICLINE TARTRATE

AB	AUROBINDO PHARMA	EQ 0.5MG BASE	A214595	001	May 02, 2025	Apr NEWA	
AB		EQ 1MG BASE	A214595	002	May 02, 2025	Apr NEWA	
>D>	AB	HANDA PHARMS LLC	EQ 0.5MG BASE	A213268	001	May 21, 2025	Jul CAHN
	AB		EQ 0.5MG BASE	A213268	001	May 21, 2025	May NEWA
>D>	AB		EQ 1MG BASE	A213268	002	May 21, 2025	Jul CAHN
	AB		EQ 1MG BASE	A213268	002	May 21, 2025	May NEWA
>D>	AB	NORVIUM BIOSCIENCE	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Jul CAHN

TABLET;ORAL

VARENICLINE TARTRATE

	AB		EQ 0.5MG BASE	A202019	001	Feb 28, 2024	May CAHN
>D>	AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	Jul CAHN
	AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	May CAHN
>A>	AB	PHARMOBEDIENT	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Jul CAHN
>A>	AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	Jul CAHN
	@	PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Feb DISC
	@		EQ 1MG BASE	A217115	002	Jul 23, 2024	Feb DISC
>A>	AB	RHODES PHARMS	EQ 0.5MG BASE	A213268	001	May 21, 2025	Jul CAHN
>A>	AB		EQ 1MG BASE	A213268	002	May 21, 2025	Jul CAHN
	AB	SHILPA	EQ 0.5MG BASE	A216615	001	Apr 08, 2025	Mar NEWA
	AB		EQ 1MG BASE	A216615	002	Apr 08, 2025	Mar NEWA
	AB	VIWIT PHARM	EQ 0.5MG BASE	A212879	001	May 06, 2025	Apr NEWA
	AB		EQ 1MG BASE	A212879	002	May 06, 2025	Apr NEWA

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOPRESSIN IN SODIUM CHLORIDE 0.9%

@ +	LONG GROVE PHARMS	50UNITS/50ML (1UNIT/ML)	N217766	003	Jul 11, 2024	May DISC
-----	-------------------	-------------------------	---------	-----	--------------	----------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

	AB	MEDICAP LABS	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Feb CAHN
	AB		EQ 75MG BASE	A201272	002	Nov 23, 2018	Feb CAHN
	AB		EQ 150MG BASE	A201272	003	Nov 23, 2018	Feb CAHN
>A>	AB	SCIEGEN PHARMS INC	EQ 37.5MG BASE	A078865	001	Apr 14, 2011	Jul CAHN
>A>	AB		EQ 75MG BASE	A078865	002	Apr 14, 2011	Jul CAHN
>A>	AB		EQ 150MG BASE	A078865	003	Apr 14, 2011	Jul CAHN
>D>	AB	WOCKHARDT BIO AG	EQ 37.5MG BASE	A078865	001	Apr 14, 2011	Jul CAHN
>D>	AB		EQ 75MG BASE	A078865	002	Apr 14, 2011	Jul CAHN
>D>	AB		EQ 150MG BASE	A078865	003	Apr 14, 2011	Jul CAHN

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		ABON PHARMS LLC	EQ 150MG BASE	A217841	001	Feb 07, 2025	Jan NEWA
AB			EQ 225MG BASE	A217841	002	Feb 07, 2025	Jan NEWA
AB		MPP PHARMA	EQ 150MG BASE	A205468	002	Mar 24, 2017	May CAHN
AB			EQ 225MG BASE	A205468	003	Mar 24, 2017	May CAHN
	@	TORRENT	EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jun DISC
AB			EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jan NEWA
	@		EQ 75MG BASE	A218180	002	Jan 28, 2025	Jun DISC
AB			EQ 75MG BASE	A218180	002	Jan 28, 2025	Jan NEWA
	@		EQ 150MG BASE	A218180	003	Jan 28, 2025	Jun DISC
AB			EQ 150MG BASE	A218180	003	Jan 28, 2025	Jan NEWA
	@		EQ 225MG BASE	A218180	004	Jan 28, 2025	Jun DISC
AB			EQ 225MG BASE	A218180	004	Jan 28, 2025	Jan NEWA

VIGABATRIN

TABLET;ORAL

VIGABATRIN

@	AMNEAL PHARMS	500MG	A210042	001	Jun 22, 2022	Feb DISC
@	CARNEGIE	500MG	A215519	001	Apr 28, 2023	May CAHN
@	RYAN LABS	500MG	A215519	001	Apr 28, 2023	Jan DISC

VIMSELTINIB

CAPSULE;ORAL

ROMVIMZA

+	DECIPHERA PHARMS	14MG	N219304	001	Feb 14, 2025	Feb NEWA
+		20MG	N219304	002	Feb 14, 2025	Feb NEWA
+	!	30MG	N219304	003	Feb 14, 2025	Feb NEWA

VORICONAZOLE

FOR SUSPENSION;ORAL

VORICONAZOLE

AB	ZHEJIANG POLY PHARM	200MG/5ML	A216805	001	Jan 02, 2024	Mar CAHN
----	---------------------	-----------	---------	-----	--------------	----------

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

>A>	@	AIPING PHARM INC	1MG	A200104	001	Jun 27, 2013	Jul CAHN
>A>	@		2MG	A200104	002	Jun 27, 2013	Jul CAHN
>A>	@		2.5MG	A200104	003	Jun 27, 2013	Jul CAHN
>A>	@		3MG	A200104	004	Jun 27, 2013	Jul CAHN
>A>	@		4MG	A200104	005	Jun 27, 2013	Jul CAHN
>A>	@		5MG	A200104	006	Jun 27, 2013	Jul CAHN
>A>	@		6MG	A200104	007	Jun 27, 2013	Jul CAHN
>A>	@		7.5MG	A200104	008	Jun 27, 2013	Jul CAHN
>A>	@		10MG	A200104	009	Jun 27, 2013	Jul CAHN
>D>	@	IPCA LABS LTD	1MG	A200104	001	Jun 27, 2013	Jul CAHN
>D>	@		2MG	A200104	002	Jun 27, 2013	Jul CAHN
>D>	@		2.5MG	A200104	003	Jun 27, 2013	Jul CAHN
>D>	@		3MG	A200104	004	Jun 27, 2013	Jul CAHN
>D>	@		4MG	A200104	005	Jun 27, 2013	Jul CAHN
>D>	@		5MG	A200104	006	Jun 27, 2013	Jul CAHN
>D>	@		6MG	A200104	007	Jun 27, 2013	Jul CAHN
>D>	@		7.5MG	A200104	008	Jun 27, 2013	Jul CAHN
>D>	@		10MG	A200104	009	Jun 27, 2013	Jul CAHN

ZANUBRUTINIB

CAPSULE; ORAL

BRUKINSA

+	!	BEONE MEDICINES USA	80MG	N213217	001	Nov 14, 2019	Apr CAHN
---	---	---------------------	------	---------	-----	--------------	----------

TABLET; ORAL

BRUKINSA

+	!	BEONE MEDICINES USA	160MG	N218785	001	Jun 10, 2025	Jun NEWA
---	---	---------------------	-------	---------	-----	--------------	----------

ZINC ACETATE

CAPSULE; ORAL

GALZIN

+		ETON	EQ 25MG ZINC	N020458	001	Jan 28, 1997	Jan CAHN
+	!		EQ 50MG ZINC	N020458	002	Jan 28, 1997	Jan CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE

AP		RK PHARMA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	May CAHN
AP		STIRA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	Apr NEWA

ZINC SULFATE

SOLUTION; INTRAVENOUS

ZINC SULFATE

AP		ASPIRO	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A219585	001	May 01, 2025	Apr NEWA
AP			EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A219585	002	May 01, 2025	Apr NEWA
AP			EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A219585	003	May 01, 2025	Apr NEWA
AP		STIRA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217624	001	Jun 10, 2025	May NEWA
AP			EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217624	002	Jun 10, 2025	May NEWA
AP			EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A217624	003	Jun 10, 2025	May NEWA

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

ZOLEDRONIC ACID

@		APOTEX	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar DISC
---	--	--------	-------------------	---------	-----	--------------	----------

ZOLMITRIPTAN

SPRAY; NASAL

ZOLMITRIPTAN

AB		PADAGIS ISRAEL	5MG/SPRAY	A212469	002	Sep 30, 2021	Apr CHRS
AB		ZOMIG					
AB		+	!	AMNEAL	2.5MG/SPRAY	N021450	003 Sep 16, 2013 Apr CHRS

ZOLPIDEM TARTRATE

TABLET;ORAL

AMBIEN

AB	+	COSETTE	5MG	N019908	001	Dec 16, 1992	Jan CAHN
AB	+	!	10MG	N019908	002	Dec 16, 1992	Jan CAHN

ZOLPIDEM TARTRATE

@	APOTEX INC	5MG	A077884	001	Apr 23, 2007	Mar DISC
@		10MG	A077884	002	Apr 23, 2007	Mar DISC

TABLET;SUBLINGUAL

EDLUAR

AB	+	VIATRIS	5MG	N021997	001	Mar 13, 2009	Feb CAHN
AB	+	!	10MG	N021997	002	Mar 13, 2009	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

AMBIEN CR

AB	+	COSETTE	6.25MG	N021774	002	Sep 02, 2005	Jan CAHN
AB	+	!	12.5MG	N021774	001	Sep 02, 2005	Jan CAHN

ZOLPIDEM TARTRATE

@	APOTEX	6.25MG	A200266	001	Sep 10, 2013	Mar DISC
@		12.5MG	A200266	002	Sep 10, 2013	Mar DISC

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

	@	APOTEX	25MG	A077642	001	Dec 22, 2005	Mar DISC
	@		50MG	A077642	002	Dec 22, 2005	Mar DISC
	@		100MG	A077642	003	Dec 22, 2005	Mar DISC
>D> AB		MACLEODS PHARMS LTD	25MG	A219507	001	May 12, 2025	Jul DISC
>A>	@		25MG	A219507	001	May 12, 2025	Jul DISC
AB			25MG	A219507	001	May 12, 2025	May NEWA
>D> AB			50MG	A219507	002	May 12, 2025	Jul DISC
>A>	@		50MG	A219507	002	May 12, 2025	Jul DISC
AB			50MG	A219507	002	May 12, 2025	May NEWA
>D> AB			100MG	A219507	003	May 12, 2025	Jul DISC
>A>	@		100MG	A219507	003	May 12, 2025	Jul DISC
AB			100MG	A219507	003	May 12, 2025	May NEWA
>D> AB		SUN PHARM INDS (IN)	25MG	A077634	001	Mar 17, 2006	Jul DISC
>A>	@		25MG	A077634	001	Mar 17, 2006	Jul DISC
>D> AB			50MG	A077634	002	Mar 17, 2006	Jul DISC
>A>	@		50MG	A077634	002	Mar 17, 2006	Jul DISC
>D> AB			100MG	A077634	003	Mar 17, 2006	Jul DISC
>A>	@		100MG	A077634	003	Mar 17, 2006	Jul DISC

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL

ACETAMINOPHEN AND IBUPROFEN

>D>	STRIDES PHARMA	250MG;125MG	A217241	001	Jan 17, 2025	Jul DISC
>A>	@	250MG;125MG	A217241	001	Jan 17, 2025	Jul DISC
		250MG;125MG	A217241	001	Jan 17, 2025	Jan NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA	0.2055MG/SPRAY	A216561	001	Jan 27, 2025	Jan NEWA
------------------	----------------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	@	AIPING PHARM INC	5MG	A202277	002	Mar 11, 2014	Jul CAHN
>A>	@		10MG	A202277	004	Mar 11, 2014	Jul CAHN
>D>	@	IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014	Jul CAHN
>D>	@		10MG	A202277	004	Mar 11, 2014	Jul CAHN

CETIRIZINE HYDROCHLORIDE HIVES

>A>	@	AIPING PHARM INC	5MG	A202277	001	Mar 11, 2014	Jul CAHN
>A>	@		10MG	A202277	003	Mar 11, 2014	Jul CAHN
>D>	@	IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014	Jul CAHN
>D>	@		10MG	A202277	003	Mar 11, 2014	Jul CAHN

Zyrtec Allergy

+	KENVUE BRANDS	5MG	N019835	003	Nov 16, 2007	Apr CMFD
---	---------------	-----	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	UNICHEM	5MG;120MG	A210507	001	Sep 10, 2024	Jun DISC
---	---------	-----------	---------	-----	--------------	----------

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@	APOTEX	100MG	A074948	001	Jun 19, 1998	Mar DISC
@		200MG	A074948	002	Jul 26, 2002	Mar DISC

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

GUARDIAN DRUG	EQ 20MG BASE	A216149	001	Mar 15, 2023	May CAHN
---------------	--------------	---------	-----	--------------	----------

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

CONTRACT PHARMACAL	60MG	A219032	001	Feb 28, 2025	Feb NEWA
	180MG	A219032	002	Feb 28, 2025	Feb NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	180MG;240MG	A215232	001	Apr 17, 2025	Apr NEWA
----------------------	-------------	---------	-----	--------------	----------

IBUPROFEN

SUSPENSION/DROPS; ORAL

IBUPROFEN

AUROBINDO PHARMA LTD	40MG/ML	A213506	001	Apr 08, 2024	May CMFD
----------------------	---------	---------	-----	--------------	----------

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

STRIDES PHARMA	200MG;30MG	A077628	001	Aug 14, 2006	Apr CAHN
----------------	------------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	@	APOTEX	5MG	A211443	001	Apr 21, 2021	Jan DISC
>D>		MICRO LABS	5MG	A211551	001	Nov 20, 2018	Jul CAHN
>A>		SANKALP LIFECARE	5MG	A211551	001	Nov 20, 2018	Jul CAHN

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM A-D

	@ +	KENVUE BRANDS	1MG/5ML	N019487	001	Mar 01, 1988	Apr DISC
--	-----	---------------	---------	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE

	@	PAI HOLDINGS	1MG/5ML	A074352	001	Nov 17, 1995	Feb CAHN
--	---	--------------	---------	---------	-----	--------------	----------

	@	WOCKHARDT BIO AG	1MG/5ML	A074730	001	Aug 28, 1997	Apr DISC
--	---	------------------	---------	---------	-----	--------------	----------

LORATADINE

CAPSULE; ORAL

LORATADINE

		AUROBINDO PHARMA	10MG	A211900	001	Mar 24, 2023	Jun CMFD
--	--	------------------	------	---------	-----	--------------	----------

	@	CATALENT PHARMA	10MG	A215127	001	Feb 28, 2025	Jun DISC
--	---	-----------------	------	---------	-----	--------------	----------

			10MG	A215127	001	Feb 28, 2025	Feb NEWA
--	--	--	------	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

LORATADINE

		SUN PHARM	10MG	A210088	002	Apr 25, 2025	Apr NEWA
--	--	-----------	------	---------	-----	--------------	----------

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

		TARO	5%	A217998	001	Jun 30, 2025	Jun NEWA
--	--	------	----	---------	-----	--------------	----------

MOMETASONE FUROATE

SPRAY, METERED; NASAL

MOMETASONE FUROATE

	@	AUROBINDO PHARMA	0.05MG/SPRAY	A217498	001	Nov 22, 2024	May DISC
--	---	------------------	--------------	---------	-----	--------------	----------

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

	@	NOVELGENIX THERAPS	220MG	A207612	001	Nov 16, 2018	Apr DISC
--	---	--------------------	-------	---------	-----	--------------	----------

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL

NICOTINE POLACRILEX

>A>		DR REDDYS LABS SA	EQ 2MG BASE	A215276	001	Jul 17, 2025	Jul NEWA
-----	--	-------------------	-------------	---------	-----	--------------	----------

>A>			EQ 4MG BASE	A215276	002	Jul 17, 2025	Jul NEWA
-----	--	--	-------------	---------	-----	--------------	----------

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

		BAUSCH AND LOMB INC	EQ 0.1% BASE	A206046	001	Jul 26, 2017	May CMFD
--	--	---------------------	--------------	---------	-----	--------------	----------

			EQ 0.2% BASE	A206087	001	Dec 05, 2017	Feb CMFD
--	--	--	--------------	---------	-----	--------------	----------

>A>		FDC LTD	EQ 0.2% BASE	A217051	001	Jul 14, 2025	Jul NEWA
-----	--	---------	--------------	---------	-----	--------------	----------

		GLENMARK PHARMS INC	EQ 0.2% BASE	A219557	001	Feb 28, 2025	Feb NEWA
--	--	---------------------	--------------	---------	-----	--------------	----------

		RISING	EQ 0.1% BASE	A204392	001	Mar 21, 2018	May CMFD
--	--	--------	--------------	---------	-----	--------------	----------

			EQ 0.2% BASE	A204620	001	Jun 16, 2020	Apr CMFD
--	--	--	--------------	---------	-----	--------------	----------

OMEPRAZOLE

TABLET, DELAYED RELEASE; ORAL

OMEPRAZOLE

	@	APOTEX	20MG	A210070	001	Feb 11, 2019	Jan DISC
--	---	--------	------	---------	-----	--------------	----------

POTASSIUM IODIDE

TABLET; ORAL

THYROSAFE

		BTG INTL	130MG	A076350	002	Apr 02, 2025	Mar NFTG
--	--	----------	-------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 7 JULY 2025

NO JULY 2025 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2025 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	10167291	Jul 01, 2036	DP U-2145		I-960	Jan 16, 2028
	10167291	Jul 01, 2036	DP U-2519			
	10167291	Jul 01, 2036	DP U-2666			
	10167291	Jul 01, 2036	DP U-2667			
	10167291	Jul 01, 2036	DP U-2668			
	10167291	Jul 01, 2036	DP U-2669			
	10167291	Jul 01, 2036	DP U-2670			
	10167291	Jul 01, 2036	DP U-2671			
	10167291	Jul 01, 2036	DP U-2682			
	10167291	Jul 01, 2036	DP U-2683			
	10167291	Jul 01, 2036	DP U-2684			
	10167291	Jul 01, 2036	DP U-2685			
	10167291	Jul 01, 2036	DP U-2686			
	10167291	Jul 01, 2036	DP U-2687			
	10167291	Jul 01, 2036	DP U-4109			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
	9796721	Jul 01, 2036	DS DP U-2145			
	9796721	Jul 01, 2036	DS DP U-2666			
	9796721	Jul 01, 2036	DS DP U-2667			
	9796721	Jul 01, 2036	DS DP U-2668			
	9796721	Jul 01, 2036	DS DP U-2669			
	9796721	Jul 01, 2036	DS DP U-2670			
	9796721	Jul 01, 2036	DS DP U-2671			
	9796721	Jul 01, 2036	DS DP U-4108			
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	10272083	Jan 21, 2035	U-2519		I-960	Jan 16, 2028
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	11059829	Jul 01, 2036	DS DP U-2145			
	11059829	Jul 01, 2036	DS DP U-2666			
	11059829	Jul 01, 2036	DS DP U-2667			
	11059829	Jul 01, 2036	DS DP U-2668			
	11059829	Jul 01, 2036	DS DP U-2669			
	11059829	Jul 01, 2036	DS DP U-2670			
	11059829	Jul 01, 2036	DS DP U-2671			
	11059829	Jul 01, 2036	DS DP U-4108			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
<u>ACETAMINOPHEN - ACETAMINOPHEN</u>						
A 214331 002					>A> PC	Jan 07, 2026
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 002	8748413	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 003	8748413	Jul 01, 2030	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACOLTREMONE - TRYPTER</u>						
N 217370 001	10028920	Sep 08, 2031	U-1900		NCE	May 28, 2030
	11850221	Dec 16, 2042	DP U-1900			
>A>	12336971	Dec 16, 2042	U-1900			
	9095609	Sep 08, 2031	DP U-1900			
	9433679	Sep 08, 2031	U-1900			
<u>ACORAMIDIS HYDROCHLORIDE - ATTRUBY</u>						
N 216540 001	9913826	May 05, 2031	U-4046		ODE-506	Nov 22, 2031
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	12281113	Sep 10, 2041	DS DP			
>A>	12336995	Feb 05, 2041	U-3953			
<u>AFAMELANOTIDE - SCENESSE</u>						
N 210797 001	>A> 8334265	Jan 20, 2033	U-2638			
<u>ALBUMIN HUMAN - OPTISON</u>						
N 020899 001					NPP	May 09, 2028
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	7396341	Oct 10, 2026	DP	Y		
	7837235	Mar 13, 2028	DP	Y		
	8733341	Oct 16, 2030	DP	Y		
	9027967	Mar 31, 2027	DP	Y		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	12233033	Aug 23, 2038	U-2106			
	12233033	Aug 23, 2038	U-2224			
	12233033	Aug 23, 2038	U-3180			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	12233033	Aug 23, 2038	U-2106			
	12233033	Aug 23, 2038	U-2224			
	12233033	Aug 23, 2038	U-3180			
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	12168021	May 15, 2035	U-2414			
	12168022	May 15, 2035	U-2414			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	11179574	Oct 13, 2036	U-804			
	11446512	Jan 17, 2037	U-804			
	11697028	Oct 13, 2036	U-804			
	12290700	Oct 13, 2036	U-804			
	12296011	Jan 12, 2038	U-3163			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	12280146	Dec 08, 2043	DP			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			
	12329740	Feb 09, 2038	U-2754			
	12329740	Feb 09, 2038	U-3467			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	12329740	Feb 09, 2038	U-2754			
	12329740	Feb 09, 2038	U-3467			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	12336984	Oct 06, 2037	U-3447			
	12336984	Oct 06, 2037	U-3448			
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	12005141	Feb 24, 2041	DP U-3309			
	12005141	Feb 24, 2041	DP U-3310			
	12005141	Feb 24, 2041	DP U-3311			
	12226528	Feb 24, 2041	DP U-3309			
	12226528	Feb 24, 2041	DP U-3310			
	12226528	Feb 24, 2041	DP U-3311			
<u>AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK</u>						
N 219423 001	10322117	Jan 23, 2038	DP		>A> NP	Jun 05, 2028
	10799487	Jan 23, 2038	DP U-3448			
<u>AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK</u>						
N 219423 002	10322117	Jan 23, 2038	DP		>A> NP	Jun 05, 2028
	10799487	Jan 23, 2038	DP U-3448			
<u>AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK</u>						
N 219423 003	10322117	Jan 23, 2038	DP		>A> NP	Jun 05, 2028
	10799487	Jan 23, 2038	DP U-3448			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	12303493	Dec 03, 2035	DP			
	12303497	Jan 30, 2040	U-4201			
	12303497	Jan 30, 2040	U-4202			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	12303493	Dec 03, 2035	DP			
	12303497	Jan 30, 2040	U-4201			
	12303497	Jan 30, 2040	U-4202			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Nov 21, 2026	DS DP U-1167		NPP	Apr 17, 2028
	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-1501			
	6967208	Nov 21, 2026	DS DP U-1502			
	6967208	Nov 21, 2026	DS DP U-1729			
	6967208	Nov 21, 2026	DS DP U-1730			
	6967208	Nov 21, 2026	DS DP U-4178			
	6967208*PED	May 21, 2027				
	9326945	Feb 24, 2031	DP			
	9326945*PED	Aug 24, 2031				
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6967208	Nov 21, 2026	DS DP U-1200		NPP	Apr 17, 2028
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-4178			
	6967208*PED	May 21, 2027				
	9326945	Feb 24, 2031	DP			
	9326945*PED	Aug 24, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 003	6967208	Nov 21, 2026	DS DP U-4179		NS	Apr 17, 2028
	6967208*PED	May 21, 2027			PED	Oct 17, 2028
	9326945	Feb 24, 2031	DP			
	9326945*PED	Aug 24, 2031				
<u>APIXABAN - ELIQUIS SPRINKLE</u>						
N 220073 001	11896586	Nov 22, 2040	DP U-4180		NP	Apr 17, 2028
	11896586*PED	May 22, 2041			PED	Oct 17, 2028
	6967208	Nov 21, 2026	DS DP U-4180			
	6967208*PED	May 21, 2027				
<u>APOMORPHINE HYDROCHLORIDE - ONAPGO</u>						
N 214056 001					NP	Feb 03, 2028
<u>APREPITANT - CINVANTI</u>						
N 209296 001	12290520	Sep 18, 2035	DP			
<u>APREPITANT - APONVIE</u>						
N 216457 001	12290520	Sep 18, 2035	DP			
<u>APROCITENTAN - TRVIO</u>						
N 217686 001	12297189	Feb 26, 2038	DP			
<u>ARIPIRAZOLE - MEZOXY</u>						
N 211448 001	9694008	Aug 07, 2033	DP			
<u>ARIPIRAZOLE - MEZOXY</u>						
N 211448 002	9694008	Aug 07, 2033	DP			
<u>ARIPIRAZOLE - MEZOXY</u>						
N 211448 003	9694008	Aug 07, 2033	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	>A> 11969469	Oct 24, 2033	DP			
	>A> 12251381	Apr 06, 2039	U-543			
	>A> 12311027	Sep 19, 2033	DP U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	>A> 11969469	Oct 24, 2033	DP			
	>A> 12251381	Apr 06, 2039	U-543			
	>A> 12311027	Sep 19, 2033	DP U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	>A> 11969469	Oct 24, 2033	DP			
	>A> 12251381	Apr 06, 2039	U-543			
	>A> 12311027	Sep 19, 2033	DP U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	>A> 11969469	Oct 24, 2033	DP			
	12251381	Apr 06, 2039	U-543			
	>A> 12311027	Sep 19, 2033	DP U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	12251381	Apr 06, 2039	U-543			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
<u>ATOGEPAANT - OULIPTA</u>						
N 215206 001 >A>	12350259	Feb 27, 2043	U-4234			
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001 >A>	12370136	Jun 07, 2037	DP			
<u>ATRASENTAN HYDROCHLORIDE - VANRAFIA</u>						
N 219208 001	10016393	Jul 07, 2034	DP		NCE	Apr 02, 2030
	11491137	Dec 16, 2040	U-3980			
	11874283	Feb 18, 2032	U-3980			
	11998526	Dec 16, 2040	U-3980			
	12121509	Dec 16, 2040	U-3980			
	8623819	Aug 22, 2028	U-3980			
	9364458	Jul 07, 2034	DP U-3980			
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	7579456	Feb 14, 2026	DS			
	9617546	Feb 14, 2026	DS U-3673			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	12252494	Apr 10, 2040	U-3506			
<u>AVIBACTAM SODIUM; AZTREONAM - EMBLAVEO</u>						
N 217906 001	7112592	Jan 07, 2026	DS DP U-4147		NP	Feb 07, 2028
	7612087	Nov 12, 2026	DP		GAIN	Feb 07, 2033
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS DP			
<u>AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)</u>						
N 219616 001	11400090	Oct 29, 2038	U-4196		NCE	May 08, 2030
	11517573	Sep 11, 2040	U-4196			
	11517573	Sep 11, 2040	U-4205			
	11873296	Dec 29, 2042	DP U-4196			
	7897792	Feb 09, 2027	DS DP			
	7928109	Aug 21, 2029	DS DP			
	8247411	Apr 17, 2028	DS DP			
<u>BACLOFEN - BACLOFEN</u>						
A 214445 001					PC	Jul 14, 2025
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001					M-187	Dec 19, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 002	10392406	Apr 27, 2036	DS			
	10633397	Apr 27, 2036			U-2816	
	10633397	Apr 27, 2036			U-3000	
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037			U-2816	
	11306106	Aug 09, 2037			U-3000	
	11925648	Apr 21, 2041	DP			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 003	10392406	Apr 27, 2036	DS			
	10633397	Apr 27, 2036			U-2816	
	10633397	Apr 27, 2036			U-3000	
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037			U-2816	
	11306106	Aug 09, 2037			U-3000	
	11925648	Apr 21, 2041	DP			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	9463289	May 18, 2031	DP		Y	
	9808587	May 18, 2031	DP		Y	
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	9463289	May 18, 2031	DP		Y	
	9808587	May 18, 2031	DP		Y	
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	10561808	Jan 01, 2032	DP		Y	
	11395889	May 18, 2031	DP		Y	
	12296089	Jan 26, 2038	DP			
	8132712	Sep 07, 2028	DP		Y	
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	10561808	Jan 01, 2032	DP		Y	
	11395889	May 18, 2031	DP		Y	
	12296089	Jan 26, 2038	DP			
	8132712	Sep 07, 2028	DP		Y	
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002					ODE*	Aug 09, 2026
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001 >A>	12358870	Jun 30, 2042	DP		I-968	May 14, 2028
	9908845	Sep 05, 2034	DS DP		U-3201	
	9908845	Sep 05, 2034	DS DP		U-4176	
	9908845	Sep 05, 2034	DS DP		U-4195	
	RE49948	Sep 05, 2034	DS DP		U-3201	
	RE49948	Sep 05, 2034	DS DP		U-4176	
	RE49948	Sep 05, 2034	DS DP		U-4195	
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	12138248	Jan 28, 2031	DP			
	>A> 12350257	Jan 28, 2031	DP		U-1542	
	>A> 12350257	Jan 28, 2031	DP		U-1971	
	>A> 12350257	Jan 28, 2031	DP		U-1972	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	12138248	Jan 28, 2031	DP			
	>A> 12350257	Jan 28, 2031	DP U-1542			
	>A> 12350257	Jan 28, 2031	DP U-1971			
	>A> 12350257	Jan 28, 2031	DP U-1972			
<u>BENDAMUSTINE HYDROCHLORIDE - VIVIMUSTA</u>						
N 212209 001	12208086	Jul 29, 2042	DP			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	12208167	Feb 26, 2044	DP U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	12208167	Feb 26, 2044	DP U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	12208167	Feb 26, 2044	DP U-713			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	12257348	May 23, 2041	DP U-3947			
	12295935	Dec 27, 2040	U-3356			
	12350382	Feb 03, 2028	DP			
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902 001	12257348	May 23, 2041	DP U-3987			
	12295935	Dec 27, 2040	U-3987			
	>A> 12357602	Jul 12, 2038	DP U-3987			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	>A> 12344585	Nov 01, 2039	U-3010			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	>A> 12344585	Nov 01, 2039	U-3010			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2026	DS DP			
<u>BIRCH TRITERPENES - FILSUEVZ</u>						
N 215064 001	12268695	Jan 04, 2039	U-3811			
	8828444	Jun 21, 2026	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001					M-315	May 09, 2028
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002					M-315	May 09, 2028
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003					M-315	May 09, 2028
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004					M-315	May 09, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	005				M-315	May 09, 2028
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	006				M-315	May 09, 2028
<u>BUDESONIDE - TARPEYO</u>						
N 215935	001	12171882	Jan 23, 2043	U-4085		
		12171882	Jan 23, 2043	U-4086		
		12171883	Jan 23, 2043	DP		
		12311057	Jan 23, 2043	DP U-4085		
		12311057	Jan 23, 2043	DP U-4086		
		12311057	Jan 23, 2043	DP U-4204		
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	001	12226610	Feb 02, 2043	U-4148		
		12226610	Feb 02, 2043	U-4149		
		12226610	Feb 02, 2043	U-4150		
		12251468	Jul 02, 2044	DP U-4152		
		12296047	Jan 22, 2041	DP U-4184		
		12318483	Jul 02, 2044	U-4152		
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	002	12226610	Feb 02, 2043	U-4148		
		12226610	Feb 02, 2043	U-4149		
		12226610	Feb 02, 2043	U-4150		
		12251468	Jul 02, 2044	DP U-4152		
		12296047	Jan 22, 2041	DP U-4184		
		12318483	Jul 02, 2044	U-4152		
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819	001				M-314	Feb 21, 2028
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819	002				M-314	Feb 21, 2028
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136	001	12161640	Jul 26, 2032	DP U-4100		
	>A>	12318379	Jul 26, 2032	DP U-4100		
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136	002	12161640	Jul 26, 2032	DP U-4100		
	>A>	12318379	Jul 26, 2032	DP U-4100		
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136	003	12161640	Jul 26, 2032	DP U-4100		
	>A>	12318379	Jul 26, 2032	DP U-4100		
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136	004	12161640	Jul 26, 2032	DP U-4100		
	>A>	12318379	Jul 26, 2032	DP U-4100		
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136	005	12161640	Jul 26, 2032	DP U-4100		
	>A>	12318379	Jul 26, 2032	DP U-4100		
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136	006	12161640	Jul 26, 2032	DP U-4100		
	>A>	12318379	Jul 26, 2032	DP U-4100		
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136	007	12161640	Jul 26, 2032	DP U-4100		
	>A>	12318379	Jul 26, 2032	DP U-4100		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	12310961	Jan 20, 2043	U-3419			
	>A> 12357697	Jan 20, 2043	U-3419			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	11389448	Apr 13, 2032	DP			
	12178815	Jul 18, 2038	U-3348			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	11389448	Apr 13, 2032	DP			
	12178815	Jul 18, 2038	U-3348			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					NPP PED	Dec 18, 2027 Jun 18, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	002				NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	003				NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	004				NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	001				NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	002				NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	003				NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	004				NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANTHARIDIN - YCANTH</u>						
N 212905	001	12233042	Aug 22, 2038	DP U-3663		
		12290651	Feb 19, 2041	DP		
<u>CAPIVASERTIB - TRUQAP</u>						
N 218197	001	12252495	Oct 10, 2028	U-3762		
<u>CAPIVASERTIB - TRUQAP</u>						
N 218197	002	12252495	Oct 10, 2028	U-3762		
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591	001	10596178	Jul 22, 2035	DP		
		12208101	Jul 22, 2035	DP		
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591	002	10596178	Jul 22, 2035	DP		
		12208101	Jul 22, 2035	DP		
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186	001	12194150	Dec 21, 2041	U-219		
		12201596	Dec 21, 2041	U-1649		
		12201596	Dec 21, 2041	U-4004		
		12201596	Dec 21, 2041	U-4005		
		12263148	Dec 21, 2041	U-1649		
		12263148	Dec 21, 2041	U-219		
		12263148	Dec 21, 2041	U-4004		
		12263148	Dec 21, 2041	U-4005		
		12263149	Dec 21, 2041	U-1649		
		12263149	Dec 21, 2041	U-219		
		12263149	Dec 21, 2041	U-4004		
		12263149	Dec 21, 2041	U-4005		
		12274793	Oct 07, 2034	DP		
		12295931	Dec 21, 2041	U-1649		
		12295931	Dec 21, 2041	U-219		
		12295931	Dec 21, 2041	U-4004		
		12295931	Dec 21, 2041	U-4005		
		12303481	Dec 21, 2041	U-1649		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 001	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 002	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	7417042	Jul 20, 2026	DS DP		>A> M-14	May 22, 2028
	7417042*PED	Jan 20, 2027			>A> PED	Nov 22, 2028
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	7417042	Jul 20, 2026	DS DP		>A> M-14	May 22, 2028
	7417042*PED	Jan 20, 2027			>A> PED	Nov 22, 2028
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	7417042	Jul 20, 2026	DS DP		>A> M-14	May 22, 2028
	7417042*PED	Jan 20, 2027			>A> PED	Nov 22, 2028
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	RE48960	Feb 16, 2029	DS DP U-3087			
	RE48960	Feb 16, 2029	DS DP U-3088			
<u>CEDAZURIDINE; DECITABINE - INQOVI</u>						
N 212576 001	12195496	Oct 07, 2040	DP			
	12239653	Feb 24, 2041	U-2865			
	12239653	Feb 24, 2041	U-2866			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CERITINIB - ZYKADIA</u>						
N 211225 001	>A> 12357630	Dec 13, 2037	U-3096			
<u>CHENODIOL - CTEXLI</u>						
N 219488 001					NP	Feb 21, 2028
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001	11969403	May 14, 2039	DP			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	>A> 12337002	Jul 24, 2028	DP U-3280			
	>A> 8865690	Dec 27, 2025	U-2942			
<u>CLINDAMYCIN PHOSPHATE - XACIATO</u>						
N 215650 001	12303563	Sep 22, 2036	DP			
<u>COBICISTAT - TYBOST</u>						
N 203094 002	>A> 10039718	Oct 06, 2032	DP			
	>A> 10039718*PED	Apr 06, 2033				
	>A> 8148374	Sep 03, 2029	DS DP U-1279			
	>A> 8148374*PED	Mar 03, 2030				
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	8148374	Sep 03, 2029	DS DP U-1279			
	8148374	Sep 03, 2029	DS DP U-2939			
	8148374	Sep 03, 2029	DS DP U-4162			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 002	10039718	Oct 06, 2032	DP			
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-4162			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	12274751	Nov 22, 2036	U-2814			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	12233035	Nov 01, 2033	U-4132			
	12280025	Nov 01, 2033	U-4168			
	>A> 12364675	Nov 01, 2033	U-3639			
<u>COPPER - MIUDELLA</u>						
N 218201 001	10022264	Mar 22, 2034	DP		NP	Feb 24, 2028
	10159596	Aug 14, 2032	DP			
	10166141	Jun 13, 2034	DP			
	10188546	Aug 14, 2032	DP			
	10398588	Feb 24, 2034	DP U-4155			
	10918516	Jan 23, 2037	DP			
	11207209	Aug 16, 2034	DP			
	11850181	Aug 14, 2032	DP			
	12138199	Oct 18, 2033	DP			
	9089418	Apr 09, 2033	DP			
	9265652	Apr 28, 2034	U-4155			
	9427351	Aug 14, 2032	DP			
	9610191	Feb 24, 2034	U-4155			
<u>COPPER CU-64 DOTATATE - DETECTNET</u>						
N 213227 001	10383961	Jul 02, 2033	U-2951			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 003	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 004	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL</u>						
N 008372 008	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	12233105	Oct 27, 2043	U-3904			
	12233105	Oct 27, 2043	U-3905			
	12233105	Oct 27, 2043	U-3906			
	12233105	Oct 27, 2043	U-3907			
	12233105	Oct 27, 2043	U-3908			
	12233105	Oct 27, 2043	U-3909			
	12233105	Oct 27, 2043	U-3910			
	12233105	Oct 27, 2043	U-3911			
	12233105	Oct 27, 2043	U-3912			
	12233105	Oct 27, 2043	U-3913			
	12233105	Oct 27, 2043	U-3914			
	12233105	Oct 27, 2043	U-3915			
	12233105	Oct 27, 2043	U-3916			
	12233105	Oct 27, 2043	U-3917			
	12233105	Oct 27, 2043	U-3918			
	12233105	Oct 27, 2043	U-3919			
	12233105	Oct 27, 2043	U-3920			
	12233105	Oct 27, 2043	U-3921			
	12233105	Oct 27, 2043	U-3922			
	12233105	Oct 27, 2043	U-3923			
	12233105	Oct 27, 2043	U-3924			
	12233105	Oct 27, 2043	U-3925			
	12233105	Oct 27, 2043	U-3926			
	12324787	Oct 27, 2043	DP			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 002	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 003	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218820 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 001	>A> 12329767	Feb 15, 2036	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 002	>A> 12329767	Feb 15, 2036	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 003	>A> 12329767	Feb 15, 2036	DP			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8292129	Feb 25, 2031	DP	Y		
	8561859	Apr 16, 2032	DP	Y		
	9669974	May 11, 2034	DP	Y		
	9676525	Feb 07, 2034	DP	Y		
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 001	7772243	May 05, 2028	DS DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 002	7772243	May 05, 2028	DS DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 003	7772243	May 05, 2028	DS DP			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	12213988	Apr 01, 2041	U-4140			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 001					M-200	Sep 30, 2027
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 002					M-200	Sep 30, 2027
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	10835515	Jan 28, 2036	DP U-2605			
	10835515	Jan 28, 2036	DP U-4208			
	10835515	Jan 28, 2036	DP U-4209			
	10835515	Jan 28, 2036	DP U-4210			
	12329742	May 14, 2042	DP			
	8975254	Mar 25, 2033	DS DP U-4208			
	8975254	Mar 25, 2033	DS DP U-4209			
	8975254	Mar 25, 2033	DS DP U-4210			
	9657003	Oct 27, 2030	DS DP U-4208			
	9657003	Oct 27, 2030	DS DP U-4209			
	9657003	Oct 27, 2030	DS DP U-4210			
<u>DELGOCITINIB - ANZUPGO</u>						
N 219155 001					>A> NCE	Jul 23, 2030
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	12161653	Feb 17, 2032	U-1940			
<u>DEURUXOLITINIB PHOSPHATE - LEQSELVI</u>						
N 217900 001	12247034	May 10, 2044	DS DP			
	12285432	Aug 11, 2042	U-3976			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 001	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10081621	Mar 25, 2031	DP U-4087			
	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 001	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			
	RE50453	May 01, 2027	DS DP			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
>A>	10058546	Jul 15, 2033	U-4218			
	10081621	Mar 25, 2031	DP U-4087			
	10206877	Apr 14, 2035	DP U-4092			
	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	11951212	Apr 14, 2035	DP U-4089			
	12186306	Jan 10, 2043	U-4088			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9012496	Jul 15, 2033	U-4097			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			
	RE50453	May 01, 2027	DS DP			
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001					NPP	Apr 07, 2028
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	12324852	Oct 16, 2032	U-4173			
	12337061	Jun 13, 2032	U-4173			
	8927497	Jul 21, 2025	DP U-4173			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	12324852	Oct 16, 2032	U-4173			
	12337061	Jun 13, 2032	U-4173			
	8927497	Jul 21, 2025	DP U-4173			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	12324852	Oct 16, 2032	U-4173			
	12337061	Jun 13, 2032	U-4173			
	8927497	Jul 21, 2025	DP U-4173			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	12324852	Oct 16, 2032	U-4173			
	12337061	Jun 13, 2032	U-4173			
	8927497	Jul 21, 2025	DP U-4173			
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 001	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
	12343348	Nov 12, 2035	U-4211			
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 002	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
	12343348	Nov 12, 2035	U-4211			
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 003	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
	12343348	Nov 12, 2035	U-4211			
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
<u>DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR)</u>						
N 215400 001	10532049	Feb 26, 2039	DP			
	11304942	Feb 26, 2039	DP			
	11819501	Feb 26, 2039	U-4188			
	11819501	Feb 26, 2039	U-848			
<u>DIHYDROERGOTAMINE MESYLATE - ATZUMI</u>						
N 217901 001	10758532	Dec 11, 2039	DP		NP	Apr 30, 2028
	10792253	Aug 04, 2037	DP			
	11744967	Oct 12, 2041	DP			
	11872314	Aug 04, 2037	DP			
	12102754	Oct 12, 2041	DP			
	12263162	Dec 11, 2039	DP			
<u>DIROXIMEL FUMARATE - VUMERITY</u>						
N 211855 001	8669281	Oct 29, 2033	DS DP			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 001	12161767	Dec 30, 2036	DS DP U-3334			
	12168075	Dec 30, 2036	U-3334			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 002	12161767	Dec 30, 2036	DS DP U-3334			
	12168075	Dec 30, 2036	U-3334			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE</u>						
A 208328 001					PC	Jul 15, 2025
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE</u>						
A 208328 002					PC	Jul 15, 2025
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 001					M-14	Jun 11, 2028
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 002					M-14	Jun 11, 2028
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 003					M-14	Jun 11, 2028
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	12280151	Jun 28, 2031	DP			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	12233074	Feb 09, 2043	DP U-3152			
	7732430	Jan 15, 2028	DP U-3152			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	12171742	Apr 13, 2037	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001	12213983	Apr 26, 2035	U-2412			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002	12213983	Apr 26, 2035	U-2412			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	12194025	Nov 12, 2041	U-4111			
	12285409	Nov 01, 2039	DP			
	12310946	Nov 12, 2041	U-4111			
<u>ELACESTRANT HYDROCHLORIDE - ORSERDU</u>						
N 217639 001	>A> 11819480	Feb 28, 2037	U-3523			
<u>ELACESTRANT HYDROCHLORIDE - ORSERDU</u>						
N 217639 002	>A> 11819480	Feb 28, 2037	U-3523			
<u>ELAFIBRANOR - IQIRVO</u>						
N 218860 001	12233038	Mar 30, 2037	U-1854			
	12295927	Mar 30, 2037	U-1854			
	12295928	Mar 30, 2037	U-1854			
	12310935	Mar 30, 2037	U-1854			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10081621	Mar 25, 2031	DP U-3032		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-3157		ODE-512	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4075			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10239867	Apr 09, 2027	DS DP U-4056			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4067			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
>A>	12350262	Jul 17, 2038	U-4221			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
>A>	RE50453	May 01, 2027	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10081621	Mar 25, 2031	DP U-3157		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4075		ODE*	Oct 21, 2026
	10239867	Apr 09, 2027	DS DP U-3158		ODE*	Dec 21, 2027
	10239867	Apr 09, 2027	DS DP U-4056		ODE-512	Dec 20, 2031
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4069			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
>A>	12350262	Jul 17, 2038	U-4222			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3144			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
>A>	RE50453	May 01, 2027	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	10081621	Mar 25, 2031	DP U-3600		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4065		ODE-512	Dec 20, 2031
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
>A>	RE50453	May 01, 2027	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	10081621	Mar 25, 2031	DP U-3600		ODE-512	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4065			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
>A>	12350262	Jul 17, 2038	U-4220			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
>A>	RE50453	May 01, 2027	DS DP			
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 001					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 002					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 003					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 004					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 216620 001					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 216620 002					PC	Nov 09, 2025
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	12263153	Apr 03, 2034	U-4171			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	12263153	Apr 03, 2034	U-4171			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	12178819	May 04, 2027	DP			
>A>	12364700	Jun 08, 2037	U-4224			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	12178819	May 04, 2027	DP			
	>A> 12364700	Jun 08, 2037	U-4224			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	>A> 12364700	Jun 08, 2037	U-4224			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	>A> 12364700	Jun 08, 2037	U-4224			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	>A> 12364700	Jun 08, 2037	U-4224			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	>A> 12364700	Jun 08, 2037	U-4224			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 208452 001					PC	Nov 23, 2025
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001					I-957	Dec 20, 2027
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-957	Dec 20, 2027
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10005761	Aug 27, 2030	U-3738			
	10005761	Aug 27, 2030	U-4051			
	10258622	Nov 21, 2032	U-2802			
	10258622	Nov 21, 2032	U-4051			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8541575	Feb 26, 2030	DS DP U-3738			
	8541575	Feb 26, 2030	DS DP U-4051			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9314464	Jul 04, 2031	U-3738			
	9314464	Jul 04, 2031	U-4051			
	9474754	Aug 05, 2033	U-2802			
	9474754	Aug 05, 2033	U-4051			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
	9850230	Aug 27, 2030	U-3738			
	9850230	Aug 27, 2030	U-4051			
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 001	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS U-4099			
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 002	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS U-4099			
<u>ENSIFENTRINE - OHTUVAYRE</u>						
N 217389 001	12251384	Jun 25, 2044	DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	8299057	Mar 10, 2032	DS DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	8299057	Mar 10, 2032	DS DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 218550 001					ODE*	Aug 15, 2026
					ODE*	Aug 15, 2026
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 001	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 002	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
<u>EPINEPHRINE - EPINEPHRINE</u>						
A 213708 001					PC	Jun 03, 2025
<u>EPINEPHRINE - EPINEPHRINE</u>						
A 219239 001					CGT	Sep 03, 2025
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	12280024	Mar 13, 2035	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	12280024	Mar 13, 2035	DP			
<u>EPINEPHRINE - NEFFY</u>						
N 214697 001	12324838	Feb 06, 2039	DP			
<u>EPINEPHRINE - NEFFY</u>						
N 214697 002	10576156	Feb 06, 2038	DP			
	10682414	Feb 06, 2039	U-3979			
	11173209	Feb 06, 2038	U-3979			
	11191838	Feb 06, 2039	DP U-3979			
	11717571	Feb 06, 2039	U-3979			
	11744895	Feb 06, 2039	U-3979			
	11918655	Feb 06, 2039	U-3979			
	12324838	Feb 06, 2039	DP			
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	8101743	Apr 01, 2026	DS DP			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034		I-959	Jan 17, 2028
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
	10869844	Sep 10, 2035	U-4113			
	10869844	Sep 10, 2035	U-4114			
	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
	11173134	Sep 10, 2035	U-4115			
	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	11311500	Sep 10, 2035	U-4116			
	11311500	Sep 10, 2035	U-4117			
	11446260	Mar 14, 2034	U-3444			
	11446260	Mar 14, 2034	U-3445			
	11446260	Mar 14, 2034	U-3446			
	11446260	Mar 14, 2034	U-4118			
	11446260	Mar 14, 2034	U-4119			
	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
	11883526	Feb 18, 2040	U-4120			
	8785500	Mar 05, 2033	U-2502			
	8785500	Mar 05, 2033	U-4112			
	9592207	Mar 20, 2027	U-2502			
	9592207	Mar 20, 2027	U-4112			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034		I-959	Jan 17, 2028
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
	10869844	Sep 10, 2035	U-4113			
	10869844	Sep 10, 2035	U-4114			
	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
	11173134	Sep 10, 2035	U-4115			
	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	11311500	Sep 10, 2035	U-4116			
	11311500	Sep 10, 2035	U-4117			
	11446260	Mar 14, 2034	U-3444			
	11446260	Mar 14, 2034	U-3445			
	11446260	Mar 14, 2034	U-3446			
	11446260	Mar 14, 2034	U-4118			
	11446260	Mar 14, 2034	U-4119			
	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
	11883526	Feb 18, 2040	U-4120			
	8785500	Mar 05, 2033	U-2502			
	8785500	Mar 05, 2033	U-4112			
	9592207	Mar 20, 2027	U-2502			
	9592207	Mar 20, 2027	U-4112			
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 001					PC	Nov 02, 2025
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 002					PC	Nov 02, 2025
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 003					PC	Nov 02, 2025
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 004					PC	Nov 02, 2025
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	12325714	Sep 27, 2033	DS DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMLYV</u>						
N 218718 001	12178824	Jun 24, 2041	DP			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	12303518	Jun 21, 2039	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2026	DS DP			
<u>FINERENONE - KERENDIA</u>						
N 215341 001					>A> I-970	Jul 11, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FINERENONE - KERENDIA</u>						
N 215341 002					>A> I-970	Jul 11, 2028
<u>FINERENONE - KERENDIA</u>						
N 215341 003	>A> 8436180	Apr 12, 2029	DS DP		>A> NCE	Jul 09, 2026
	>A> RE49826	Jul 29, 2035	DS		>A> NS	Jul 11, 2028
<u>FITUSIRAN SODIUM - QFITLIA</u>						
N 219019 001	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
	9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
	9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032
<u>FITUSIRAN SODIUM - QFITLIA</u>						
N 219019 002	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
	9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
	9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677 001	>A> 9308284	Jul 14, 2032	DP			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 001	>A> 8506929	Apr 30, 2027	DS DP U-4217			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 002	>A> 8506929	Apr 30, 2027	DS DP U-4217			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 003	>A> 8506929	Apr 30, 2027	DS DP U-4217			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 004	>A> 7687052	Apr 30, 2027	DS DP U-4217			
	>A> 8506929	Apr 30, 2027	DS DP U-4217			
<u>FLUOCINOLONE ACETONIDE - ILUVIEN</u>						
N 201923 001	9849027	Nov 07, 2028	DP U-4157			
	9849027	Nov 07, 2028	DP U-708			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
<u>FOSCARBIDOPA; FOSLEVODOPA - VYALEV</u>						
N 216962 001	12251365	Jun 10, 2040	U-4030		NP	Oct 16, 2027
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	12208109	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	12208109	Jun 02, 2037	DP			
<u>GALLIUM GA-68 GOZETOTIDE - GOZELLIX</u>						
N 219592 001	11027031	Jul 28, 2035	U-3317			
<u>GEPOTIDACIN MESYLATE - BLUJEPÄ</u>						
N 218230 001	8389524	Feb 12, 2029	DS DP U-4166		NCE GAIN	Mar 25, 2030 Mar 25, 2035
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	>A> 10028937	Jun 10, 2030	U-2141		I-967	Jun 10, 2028
	>A> 10028937	Jun 10, 2030	U-3237			
	>A> 10028937	Jun 10, 2030	U-4206			
	>A> 10028937*PED	Dec 10, 2030				
	>A> 10039754	Jun 10, 2030	U-2141			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	>A> 10039754	Jun 10, 2030	U-3237			
	>A> 10039754	Jun 10, 2030	U-4206			
	>A> 10039754*PED	Dec 10, 2030				
	>A> 10286029	Mar 14, 2034	U-3237			
	>A> 10286029	Mar 14, 2034	U-4206			
	>A> 10286029*PED	Sep 14, 2034				
	>A> 11484534	Mar 14, 2034	U-3237			
	>A> 11484534	Mar 14, 2034	U-4206			
	>A> 11484534*PED	Sep 14, 2034				
	>A> 8648037	Jan 19, 2032	DS DP U-2141			
	>A> 8648037	Jan 19, 2032	DS DP U-3237			
	>A> 8648037	Jan 19, 2032	DS DP U-4206			
	>A> 8648037*PED	Jul 19, 2032				
	>A> 9586978	Nov 06, 2030	U-2141			
	>A> 9586978	Nov 06, 2030	U-3237			
	>A> 9586978	Nov 06, 2030	U-4206			
	>A> 9586978*PED	May 06, 2031				
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110 001	>A> 10028937	Jun 10, 2030	U-3238		I-967	Jun 10, 2028
	>A> 10028937	Jun 10, 2030	U-4206			
	>A> 10028937*PED	Dec 10, 2030				
	>A> 10039754	Jun 10, 2030	U-3238			
	>A> 10039754	Jun 10, 2030	U-4206			
	>A> 10039754*PED	Dec 10, 2030				
	>A> 10286029	Mar 14, 2034	U-3238			
	>A> 10286029	Mar 14, 2034	U-4206			
	>A> 10286029*PED	Sep 14, 2034				
	>A> 8648037	Jan 19, 2032	DS DP U-3238			
	>A> 8648037	Jan 19, 2032	DS DP U-4206			
	>A> 8648037*PED	Jul 19, 2032				
	>A> 9586978	Nov 06, 2030	U-3238			
	>A> 9586978	Nov 06, 2030	U-4206			
	>A> 9586978*PED	May 06, 2031				
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001	7696182	May 16, 2026	DS DP U-3774			
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002	7696182	May 16, 2026	DS DP U-3774			
<u>HYDROCHLOROTHIAZIDE - INZIRQO</u>						
N 219141 001	11878022	Jan 23, 2044	DP U-4138			
	11878022	Jan 23, 2044	DP U-4139			
<u>HYDROCORTISONE - KHINDIVI</u>						
N 218980 001	>A> 11904046	Feb 23, 2043	DP U-4216			
	>A> 12133914	Feb 23, 2043	U-4215			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	12201690	Jun 14, 2039	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	12171738	Feb 09, 2030	U-4105			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	12171738	Feb 09, 2030	U-4105			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	12171778	Jun 16, 2039	U-3956			
	9388415	Sep 09, 2025	U-3956			
	9388416	Sep 09, 2025	U-3956			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	12171778	Jun 16, 2039	U-3956			
	9388415	Sep 09, 2025	U-3956			
	9388416	Sep 09, 2025	U-3956			
<u>IOMEPROL - IOMERVU</u>						
N 216016 001					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 002					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 003					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 004					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 005					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 006					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 007					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 008					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 009					NCE	Nov 27, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IOMEPROL - IOMERVU</u> N 216016 010					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 011					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 012					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 013					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 001					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 002					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 003					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 004					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 005					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 006					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 007					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 008					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 009					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 010					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 011					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 012					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 013					NCE	Nov 27, 2029
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u> N 021527 001	8474447	Jan 17, 2030	DP	Y		
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u> N 218276 001	10093663 10093663 12285422	Jul 14, 2034 Jul 14, 2034 Aug 30, 2038	U-3980 U-4161 U-4181		I-963	Mar 20, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051	001				PC	Jan 11, 2025
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051	002				PC	Jan 11, 2025
<u>IVACAFITOR - KALYDECO</u>						
N 203188	001	10646481	Aug 13, 2029	DP	ODE-338	Dec 21, 2027
		10646481*PED	Feb 13, 2030		PED	Jun 21, 2028
		11564916	Aug 13, 2029	U-3530		
		11564916*PED	Feb 13, 2030			
		8354427	Jul 06, 2026	U-1311		
		8354427	Jul 06, 2026	U-1905		
		8354427*PED	Jan 06, 2027			
		8410274	Dec 28, 2026	DP		
		8410274*PED	Jun 28, 2027			
		8754224	Dec 28, 2026	DS DP		
		8754224*PED	Jun 28, 2027			
		9670163	Dec 28, 2026	DP U-1311		
		9670163*PED	Jun 28, 2027			
<u>IVACAFITOR - KALYDECO</u>						
N 207925	001	10272046	Feb 27, 2033	DP U-2531	>A> M-14	May 22, 2028
		10272046*PED	Aug 27, 2033		ODE-236	Apr 29, 2026
		10646481	Aug 13, 2029	DP	ODE-338	Dec 21, 2027
		10646481*PED	Feb 13, 2030		PED	Oct 29, 2026
		11147770	Feb 27, 2033	DP U-3339	PED	Jun 21, 2028
		11147770*PED	Aug 27, 2033		>A> PED	Nov 22, 2028
		11564916	Aug 13, 2029	U-3528		
		11564916*PED	Feb 13, 2030			
		11752106	Feb 27, 2033	DP U-3697		
		11752106*PED	Aug 27, 2033			
		12214083	Feb 27, 2033	DP U-4126		
		12214083*PED	Aug 27, 2033			
		7495103	May 20, 2027	DS DP		
		7495103*PED	Nov 20, 2027			
		8324242	Aug 05, 2027	U-1311		
		8324242	Aug 05, 2027	U-1906		
		8324242	Aug 05, 2027	U-2527		
		8324242*PED	Feb 05, 2028			
		8354427	Jul 06, 2026	U-1311		
		8354427	Jul 06, 2026	U-1905		
		8354427	Jul 06, 2026	U-2528		
		8354427*PED	Jan 06, 2027			
		8410274	Dec 28, 2026	DP		
		8410274*PED	Jun 28, 2027			
		8754224	Dec 28, 2026	DS DP		
		8754224*PED	Jun 28, 2027			
		8883206	Feb 27, 2033	DP		
		8883206*PED	Aug 27, 2033			
		9670163	Dec 28, 2026	DP U-1311		
		9670163	Dec 28, 2026	DP U-2530		
		9670163*PED	Jun 28, 2027			
<u>IVACAFITOR - KALYDECO</u>						
N 207925	002	10272046	Feb 27, 2033	DP U-2531	>A> M-14	May 22, 2028
		10272046*PED	Aug 27, 2033		ODE-236	Apr 29, 2026
		10646481	Aug 13, 2029	DP	ODE-338	Dec 21, 2027
		10646481*PED	Feb 13, 2030		PED	Oct 29, 2026
		11147770	Feb 27, 2033	DP U-3339	PED	Jun 21, 2028
		11147770*PED	Aug 27, 2033		>A> PED	Nov 22, 2028
		11564916	Aug 13, 2029	U-3528		
		11564916*PED	Feb 13, 2030			
		11752106	Feb 27, 2033	DP U-3697		
		11752106*PED	Aug 27, 2033			
		12214083	Feb 27, 2033	DP U-4126		
		12214083*PED	Aug 27, 2033			
		7495103	May 20, 2027	DS DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFITOR - KALYDECO</u>						
N 207925 002	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
	9670163*PED	Jun 28, 2027				
<u>IVACAFITOR - KALYDECO</u>						
N 207925 003	10272046	Feb 27, 2033	DP U-2967		>A> M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			ODE-236	Apr 29, 2026
	10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
	10646481*PED	Feb 13, 2030			PED	Oct 29, 2026
	11147770	Feb 27, 2033	DP U-3339		PED	Jun 21, 2028
	11147770*PED	Aug 27, 2033			>A> PED	Nov 22, 2028
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4128			
	12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2963			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2964			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2966			
	9670163*PED	Jun 28, 2027				
<u>IVACAFITOR - KALYDECO</u>						
N 207925 004	10272046	Feb 27, 2033	DP U-3605		>A> M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	10646481*PED	Feb 13, 2030			PED	Nov 03, 2026
	11147770	Feb 27, 2033	DP U-3604		>A> PED	Nov 22, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 03, 2030
	11564916	Aug 13, 2029	U-3603			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4127			
	12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 004	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-3608			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 005	10272046	Feb 27, 2033	DP U-3605		>A> M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	10646481*PED	Feb 13, 2030			PED	Nov 03, 2026
	11147770	Feb 27, 2033	DP U-3604		>A> PED	Nov 22, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 03, 2030
	11564916	Aug 13, 2029	U-3603			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4127			
	12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-3608			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	RE50453	May 01, 2027	DS DP			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	RE50453	May 01, 2027	DS DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	10076513	Dec 04, 2028	DP U-2411			
	10076513*PED	Jun 04, 2029				
	10597384	Dec 04, 2028	DS DP U-2777			
	10597384*PED	Jun 04, 2029				
	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11052075	Dec 04, 2028	DP U-3181			
	11052075*PED	Jun 04, 2029				
	11564916	Aug 13, 2029	U-3529			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3984			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-1973			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1911			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1717			
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-1912			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DS DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	10597384	Dec 04, 2028	DS DP U-2777			
	10597384*PED	Jun 04, 2029				
	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11052075	Dec 04, 2028	DP U-3181			
	11052075*PED	Jun 04, 2029				
	11564916	Aug 13, 2029	U-3529			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3984			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-1973			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-1911			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1910			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-1912			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	10597384	Dec 04, 2028	DS DP U-3430		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-3424			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-3424			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-3426			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-3424			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-3427			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-3427			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-3428			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-3429			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-3429			
	9931334*PED	Jun 28, 2027				
<u>IVERMECTIN - IVERMECTIN</u>						
A 215922 002					CGT	Oct 01, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACTULOSE - LACTULOSE</u>						
A 217914 001					CGT	Sep 13, 2025
<u>LACTULOSE - LACTULOSE</u>						
A 217914 002					CGT	Sep 13, 2025
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	8637512	Jan 07, 2029	DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	12257246	Jul 07, 2030	U-2718			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	12257246	Jul 07, 2030	U-2718			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 003	12257246	Jul 07, 2030	U-2718			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 001	12138351	Apr 13, 2041	DP			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 002	12138351	Apr 13, 2041	DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211672 001	8071643	Mar 25, 2033	DS DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211673 001	12121582	Jun 14, 2036	DP			
	8071643	Mar 25, 2033	DS DP			
<u>LENACAPAVIR SODIUM - YEZTUGO</u>						
N 220018 001	>A> 10071985	Aug 17, 2037	DS DP		>A> NCE	Dec 22, 2027
	>A> 11267799	Aug 16, 2038	DS		>A> NP	Jun 18, 2028
	>A> 11807625	Nov 25, 2040	U-4190			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENACAPAVIR SODIUM - YEZTUGO</u>						
N 220018 001	>A> 9951043	Feb 28, 2034	DS DP U-4190			
<u>LENACAPAVIR SODIUM - YEZTUGO</u>						
N 220020 001	>A> 10071985	Aug 17, 2037	DS DP		>A> NCE	Dec 22, 2027
	>A> 11267799	Aug 16, 2038	DS		>A> NP	Jun 18, 2028
	>A> 9951043	Feb 28, 2034	DS DP U-4190			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	12083112	Mar 03, 2036	U-3996			
	12083112	Mar 03, 2036	U-3997			
	12083112*PED	Sep 03, 2036				
	12226409	May 15, 2038	U-4146			
	12226409*PED	Nov 15, 2038				
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	12083112	Mar 03, 2036	U-3996			
	12083112	Mar 03, 2036	U-3997			
	12083112*PED	Sep 03, 2036				
	12226409	May 15, 2038	U-4146			
	12226409*PED	Nov 15, 2038				
<u>LEVACETYLLAUCINE - AONEURSA</u>						
N 219132 001	11400067	Aug 11, 2037	U-4170			
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	9918984	May 03, 2028	U-3283		NCE*	Dec 30, 2026
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	12178819	May 04, 2027	DP			
	>A> 12364700	Jun 08, 2037	U-4224			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	>A> 12364700	Jun 08, 2037	U-4224			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	>A> 12364700	Jun 08, 2037	U-4224			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	>A> 12364700	Jun 08, 2037	U-4224			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	>A> 12364700	Jun 08, 2037	U-4224			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	>A> 12364700	Jun 08, 2037	U-4224			
<u>LISDEXAMFETAMINE DIMESYLATE - ARYNIA</u>						
N 219847 001	11576878	Aug 30, 2040	DP			
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	12186360	Nov 06, 2035	DP			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2029	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2029	U-3070			
<u>LOSARTAN POTASSIUM - ARBLI</u>						
N 218772 001	11890273	Oct 07, 2041	DP			
	12156869	Oct 07, 2041	DP U-4158			
	12156869	Oct 07, 2041	DP U-4159			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOSARTAN POTASSIUM - ARBLI</u>						
N 218772 001	12156869	Oct 07, 2041	DP U-4160			
<u>LOTILANER - XDEMVI</u>						
N 217603 001	12171750	Dec 14, 2038	U-3674			
	12213964	Dec 14, 2038	DP			
>A>	12364685	Dec 14, 2038	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	11753419	Dec 10, 2040	DP	Y		
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	11753419	Dec 10, 2040	DP	Y		
	RE48825	Mar 12, 2029	DS			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	11753419	Dec 10, 2040	DP	Y		
	RE48825	Mar 12, 2029	DS			
<u>LURBINECTEDIN - ZEPZELCA</u>						
N 213702 001	12324806	May 29, 2040	U-4212			
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAKETAN - PLUVICTO</u>						
N 215833 001	10406240	Aug 15, 2028	DS DP U-4169		I-965	Mar 28, 2028
	11318121	Aug 15, 2028	DS DP U-4169			
	11951190	Nov 12, 2035	U-4169			
	12208102	Sep 18, 2041	U-4169			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001					M-187	Feb 28, 2028
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE</u>						
N 215344 001	12239659	Jun 14, 2044	U-4143			
	12290529	Aug 02, 2044	DP			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 002 >A>	12350267	Oct 26, 2032	U-3973			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 001	12296050	Oct 05, 2043	DP U-4186		I-938	Mar 13, 2027
	12296050	Oct 05, 2043	DP U-4187		NCE	Sep 29, 2026
>A>	12350267	Oct 26, 2032	U-3973			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 002	12296050	Oct 05, 2043	DP U-4186		I-938	Mar 13, 2027
	12296050	Oct 05, 2043	DP U-4187		NCE	Sep 29, 2026
>A>	12350267	Oct 26, 2032	U-3973			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 003	12296050	Oct 05, 2043	DP U-4186		I-938	Mar 13, 2027
	12296050	Oct 05, 2043	DP U-4187		NCE	Sep 29, 2026
>A>	12350267	Oct 26, 2032	U-3973			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 004	12296050	Oct 05, 2043	DP U-4186		I-938	Mar 13, 2027
	12296050	Oct 05, 2043	DP U-4187		NCE	Sep 29, 2026
>A>	12350267	Oct 26, 2032	U-3973			
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001	12213989	Nov 18, 2042	U-4137			
	12295940	Oct 11, 2043	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM - QAMZOVA</u>						
N 217593 001	12059423	Jul 19, 2040	DS DP			
<u>MELOXICAM - XIFYRM</u>						
N 218395 001	12263176	Jul 31, 2041	DP			
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	10029010	Apr 11, 2036	U-4133		NP	Jan 30, 2028
	10058614	Apr 11, 2036	DP			
	10137131	Apr 11, 2036	DP U-1719			
	10195278	Apr 11, 2036	U-1719			
	10265324	Apr 11, 2036	U-1719			
	10363312	Apr 11, 2036	U-1719			
	10369224	Apr 11, 2036	U-4134			
	10426839	Apr 11, 2036	U-4135			
	10463736	Apr 11, 2036	DP			
	10471014	Apr 11, 2036	U-1719			
	10471069	Apr 11, 2036	U-1719			
	10512692	Apr 11, 2036	U-1719			
	10512693	Apr 11, 2036	U-1719			
	10517950	Apr 11, 2036	U-1719			
	10532101	Apr 11, 2036	U-1719			
	10537642	Apr 11, 2036	U-1719			
	10561664	Apr 11, 2036	U-1719			
	10583144	Apr 11, 2036	U-1719			
	10653777	Apr 11, 2036	U-1719			
	10688102	Apr 11, 2036	U-1719			
	10688185	Apr 11, 2036	U-1719			
	10695429	Apr 11, 2036	U-1719			
	10695430	Apr 11, 2036	U-1719			
	10702535	Apr 11, 2036	U-4136			
	10702602	Apr 11, 2036	U-1719			
	10722583	Apr 11, 2036	U-1719			
	10729696	Apr 11, 2036	U-1719			
	10729697	Apr 11, 2036	U-1719			
	10729773	Apr 11, 2036	U-1719			
	10758617	Apr 11, 2036	U-1719			
	10758618	Apr 11, 2036	U-1719			
	10780165	Apr 11, 2036	U-1719			
	10780166	Apr 11, 2036	U-1719			
	10799588	Apr 11, 2036	U-1719			
	10821181	Apr 11, 2036	U-1719			
	10821182	Apr 11, 2036	U-1719			
	10894053	Apr 11, 2036	U-1719			
	10905693	Apr 11, 2036	U-1719			
	10918722	Apr 11, 2036	U-1719			
	10933136	Apr 11, 2036	U-1719			
	10933137	Apr 11, 2036	U-1719			
	10940153	Apr 11, 2036	U-1719			
	10987358	Apr 11, 2036	U-1719			
	11013805	Apr 11, 2036	U-1719			
	11013806	Apr 11, 2036	U-1719			
	11020483	Apr 11, 2036	U-1719			
	11045549	Apr 11, 2036	U-1719			
	11135295	Apr 11, 2036	U-1719			
	11207328	Apr 11, 2036	U-1719			
	11219626	Apr 11, 2036	U-1719			
	11285213	Apr 11, 2036	U-1719			
	11331323	Apr 11, 2036	U-1719			
	11369684	Apr 11, 2036	U-1719			
	11426414	Apr 11, 2036	U-1719			
	11471464	Apr 11, 2036	U-1719			
	11471465	Apr 11, 2036	U-1719			
	11504429	Apr 11, 2036	U-1719			
	11510927	Apr 11, 2036	U-1719			
	11571428	Apr 11, 2036	U-1719			
	11602563	Apr 11, 2036	U-1719			
	11607456	Apr 11, 2036	U-1719			
	11617755	Apr 11, 2036	U-1719			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	11617756	Apr 11, 2036	U-1719			
	11617791	Apr 11, 2036	U-1719			
	11628173	Apr 11, 2036	U-1719			
	11712441	Apr 11, 2036	U-1719			
	11738085	Apr 11, 2036	U-1719			
	11759522	Apr 11, 2036	U-1719			
	11801250	Apr 11, 2036	U-1719			
	11806354	Apr 11, 2036	U-1719			
	11826370	Apr 11, 2036	U-1719			
	11865117	Apr 11, 2036	U-1719			
	12128052	May 28, 2040	U-1719			
>A>	12370196	Dec 29, 2041	U-1719			
	9821075	Apr 11, 2036	DP U-1719			
<u>MERCAPTOPURINE - MERCAPTOPURINE</u>						
A 216418 001					CGT	Aug 25, 2025
<u>MESNA - MESNA</u>						
A 218871 001					CGT	Jul 13, 2025
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	12303592	Aug 03, 2027	DP U-4197			
	12303592	Aug 03, 2027	DP U-4198			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	12303592	Aug 03, 2027	DP U-4197			
	12303592	Aug 03, 2027	DP U-4198			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	12303592	Aug 03, 2027	DP U-4197			
	12303592	Aug 03, 2027	DP U-4198			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	12194008	Dec 22, 2029	U-2843			
	12194009	Dec 22, 2029	U-2843			
>A>	12377064	Nov 17, 2038	U-2843			
<u>METRONIDAZOLE - LIKMEZ</u>						
N 216755 001	12257236	Jan 16, 2039	DP U-3169			
	12257236	Jan 16, 2039	DP U-4163			
	12257236	Jan 16, 2039	DP U-4164			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	12280042	May 30, 2038	DS U-2371			
<u>MIGLUSTAT - OPFOLDA</u>						
N 215211 001	12246062	Sep 16, 2038	U-3726			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	12059409	Sep 28, 2029	DP			
	12059409*PED	Mar 28, 2030				
	12097189	Sep 28, 2029	U-2996			
	12097189	Sep 28, 2029	U-3670			
	12097189*PED	Mar 28, 2030				
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	12059409	Sep 28, 2029	DP			
	12059409*PED	Mar 28, 2030				
	12097189	Sep 28, 2029	U-2996			
	12097189	Sep 28, 2029	U-3670			
	12097189*PED	Mar 28, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219379 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041		U-4130		
	11571402	Feb 17, 2041	DP			
	11806321	Feb 17, 2041		U-4130		
>A>	11806322	Apr 09, 2043		U-4130		
	11819487	Feb 17, 2041		U-4130		
	11839595	Mar 16, 2043		U-4130		
	11883375	Mar 16, 2043		U-4130		
	12011424	Feb 17, 2041		U-4130		
	12029711	Mar 15, 2044	DP	U-4130		
	12037306	Feb 17, 2041		U-4130		
	12090128	Feb 17, 2041	DP	U-4130		
	12220390	Mar 16, 2043		U-4130		
	12257215	Mar 16, 2043		U-4130		
	12263146	Feb 17, 2041		U-4130		
	12295925	Feb 17, 2041		U-4130		
	12324791	Mar 16, 2043		U-4130		
>A>	12357597	Feb 17, 2041		U-4130		
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041		U-4130		
	11806321	Feb 17, 2041		U-4130		
>A>	11806322	Apr 09, 2043		U-4130		
	11819487	Feb 17, 2041		U-4130		
	11839595	Mar 16, 2043		U-4130		
	11883375	Mar 16, 2043		U-4130		
	12011424	Feb 17, 2041		U-4130		
	12029711	Mar 15, 2044	DP	U-4130		
	12037306	Feb 17, 2041		U-4130		
	12220390	Mar 16, 2043		U-4130		
	12257215	Mar 16, 2043		U-4130		
	12263146	Feb 17, 2041		U-4130		
	12275688	Feb 17, 2041	DP	U-4130		
	12295925	Feb 17, 2041		U-4130		
	12324791	Mar 16, 2043		U-4130		
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 002	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041		U-4130		
	11806321	Feb 17, 2041		U-4130		
>A>	11806322	Apr 09, 2043		U-4130		
	11819487	Feb 17, 2041		U-4130		
	11839595	Mar 16, 2043		U-4130		
	11883375	Mar 16, 2043		U-4130		
	12029711	Mar 15, 2044	DP	U-4130		
	12037306	Feb 17, 2041		U-4130		
	12220390	Mar 16, 2043		U-4130		
	12257215	Mar 16, 2043		U-4130		
	12263146	Feb 17, 2041		U-4130		
	12275688	Feb 17, 2041	DP	U-4130		
	12295925	Feb 17, 2041		U-4130		
	12324791	Mar 16, 2043		U-4130		
<u>MITOMYCIN - JELMYTO</u>						
N 211728 001	12268745	Jan 20, 2031		U-4172		
<u>MITOMYCIN - ZUSDURI</u>						
N 215793 001					NP	Jun 12, 2028
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	12303635	Apr 08, 2039	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10918615	Feb 27, 2035	DP U-1384			
	10918616	Feb 27, 2035	U-1384			
	10918617	Feb 27, 2035	DP			
	10945985	Feb 27, 2035	DP			
	11590095	Feb 27, 2035	U-1384			
<u>MOTIXAFORTIDE ACETATE - APHEXDA</u>						
N 217159 001	12257285	Dec 29, 2041	DP			
	12268725	Dec 29, 2041	DP			
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					NPP	Feb 07, 2028
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	12194143	Aug 16, 2039	DP U-1752			
	12226526	Aug 16, 2039	DP U-1752			
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	>A> 12350377	May 13, 2033	DP			
	>A> RE46365	Feb 24, 2031	DS DP			
<u>NALMEFENE HYDROCHLORIDE - OPVEE</u>						
N 217470 001	12290596	Aug 04, 2042	U-4182			
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 001					NPP	Mar 27, 2028
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 002					NPP	Mar 27, 2028
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 003					NPP	Mar 27, 2028
<u>NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE</u>						
A 203640 001					PC	Nov 19, 2025
<u>NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE</u>						
A 203640 002					PC	Nov 19, 2025
<u>NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE</u>						
A 203640 003					PC	Nov 19, 2025
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	12186308	Apr 16, 2038	DP U-2804			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 001	11730725	Jan 25, 2039	DP			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 002	11730725	Jan 25, 2039	DP			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 003	11730725	Jan 25, 2039	DP			
<u>NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)</u>						
N 217188 001					D-195	Jan 31, 2028
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
	12297177	Aug 09, 2039	DP			
	>A> 7795447	Aug 18, 2030	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	>A> 7951958	Mar 11, 2025	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
	12297177	Aug 09, 2039	DP			
	>A> 7795447	Aug 18, 2030	DS			
	>A> 7951958	Mar 11, 2025	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
	12297177	Aug 09, 2039	DP			
	>A> 7795447	Aug 18, 2030	DS			
	>A> 7951958	Mar 11, 2025	DS			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 001	12290494	Mar 08, 2041	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 002	12290494	Mar 08, 2041	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 001	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 002	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 003	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 001	RE49422	Feb 26, 2035	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 002	RE49422	Feb 26, 2035	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 003	10251848	Feb 26, 2035	DP			
	RE49422	Feb 26, 2035	DP			
	RE49443	Feb 26, 2035	DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	12246054	Feb 03, 2036	U-2857			
	12251418	Feb 03, 2036	U-2857			
<u>OCTREOTIDE ACETATE - BYNFEZIA PEN</u>						
N 213224 001	>A> 12350475	Dec 29, 2041	U-4007			
	>A> 12350475	Dec 29, 2041	U-4008			
	>A> 12350475	Dec 29, 2041	U-4009			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	10011633	Nov 08, 2031	U-3186			
	10011633	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	12187812	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	10011633	Nov 08, 2031	U-3186			
	10011633	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	10011633	Nov 08, 2031	U-3186			
	10011633	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	10011633	Nov 08, 2031	U-3186			
	10011633	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	12194035	Aug 23, 2031	U-3141			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	12178816	Oct 07, 2029	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	12178816	Oct 07, 2029	DP			
<u>OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)</u>						
N 218614 001	9127276	May 01, 2034	DS		>A> ODE-515	Dec 19, 2031
	9157082	Apr 27, 2032		U-4050		
	9163239	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
	9593333	Feb 14, 2034		U-4050		
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	7396341	Oct 10, 2026	DP	Y		
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP	Y		
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP	Y		
	9027967	Mar 31, 2027	DP	Y		
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	12275715	Sep 18, 2035	DS DP U-3684			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	9265740	Oct 24, 2030	DP U-1569			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	9265740	Mar 05, 2029	DP			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001					M-270	Dec 20, 2027
<u>OMEFRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	12329752	Jul 16, 2039	DP			
<u>OMIDENEPAG ISOPROPYL - OMLONTI</u>						
N 215092 001	>A> 12290511	Dec 27, 2038		U-3454		
	>A> 12295946	Jan 08, 2035	DP	U-3454		
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 001	10709691	Oct 12, 2035		U-2770		
	10709691	Oct 12, 2035		U-4177		
	8609862	Jan 13, 2031		U-2770		
	8609862	Jan 13, 2031		U-4177		
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 002	10709691	Oct 12, 2035		U-2770		
	10709691	Oct 12, 2035		U-4177		
	8609862	Jan 13, 2031		U-2770		
	8609862	Jan 13, 2031		U-4177		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001 >A>	12350255	Jun 11, 2035		U-3494		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	8481573	Mar 24, 2033	DS DP	U-2774		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	8481573	Mar 24, 2033	DS DP	U-2774		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	8481573	Mar 24, 2033	DS DP	U-2774		
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	12208100	May 07, 2041		U-3359		
	12208100	May 07, 2041		U-4110		
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	12208100	May 07, 2041		U-3359		
	12208100	May 07, 2041		U-4110		
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 001	12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 002	12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 003	12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	12201614	Jun 08, 2037	U-4031			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PATISIRAN SODIUM - ONPATTRO</u>						
N 210922 001	8168775	Aug 10, 2032	DS DP U-2378			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	12290566	Dec 14, 2038	DP U-4174			
	12290566	Dec 14, 2038	DP U-4175			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	11592396	Sep 01, 2030	DS			
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 001					PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 002					PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 003					PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 004					PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 005					PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 006					PC	Nov 25, 2025
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	12201615	Dec 25, 2039	U-3804			
	12201616	Oct 25, 2039	U-3804			
>A>	12350366	Jan 31, 2034	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826 004	12257342	Sep 26, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826 005	12257342	Sep 26, 2036	DP			
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214966 001					CGT	Sep 06, 2025
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
	12268666	Jul 29, 2039	DP			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
	12268666	Jul 29, 2039	DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 001	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 003	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE</u>						
N 212832 004	11813291	Oct 12, 2041	DP U-4185			
	11925661	Oct 12, 2041	DP U-4185			
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE</u>						
N 212832 005	11813291	Oct 12, 2041	DP U-4185			
	11925661	Oct 12, 2041	DP U-4185			
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
N 217604 001	12233166	Jun 18, 2038	DP			
<u>RAMIPRIL - VOSTALLY</u>						
N 219757 001 >A>	12343338	Aug 16, 2039	DP U-4233			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	12325714	Sep 27, 2033	DS DP			
	12336990	Sep 29, 2037	U-3020			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
	12310968	Jul 20, 2036	U-3755			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 002	12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
	12310968	Jul 20, 2036	U-3755			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	12285417	Aug 29, 2039	U-2440			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 001					ODE-504 ODE-505	Nov 15, 2031 Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 002					ODE-504 ODE-505	Nov 15, 2031 Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 003					ODE-504 ODE-505	Nov 15, 2031 Nov 15, 2031
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	8309569	Jul 18, 2029	U-1707	Y		
	8309569	Jul 18, 2029	U-1708	Y		
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	12213967	Dec 30, 2040	DP			
	12213968	Dec 30, 2040	DP			
	12226406	Dec 30, 2040	DP			
	12295944	Aug 12, 2040	U-4183			
	12318373	Aug 12, 2040	U-4191			
	12318374	Dec 30, 2040	DP			
<u>RISDIPLAM - EVRYSOI</u>						
N 213535 001 >A>	12350273	Oct 01, 2038	U-1943			
<u>RISDIPLAM - EVRYSOI</u>						
N 219285 001	11534444	Oct 04, 2038	U-1943		M-270	Oct 03, 2026
	11827646	Jan 25, 2036	U-1943		NCE	Aug 07, 2025
	12122789	Apr 15, 2041	DS DP			
>A>	12350273	Oct 01, 2038	U-1943			
	9586955	Feb 08, 2033	DS DP			
	9969754	May 11, 2035	DS DP U-1943			
<u>RISPERIDONE - UZEDY</u>						
N 213586 001 >A>	12329851	Mar 17, 2042	U-4214			
<u>RISPERIDONE - UZEDY</u>						
N 213586 002 >A>	12329851	Mar 17, 2042	U-4214			
<u>RISPERIDONE - UZEDY</u>						
N 213586 003 >A>	12329851	Mar 17, 2042	U-4214			
<u>RISPERIDONE - UZEDY</u>						
N 213586 004 >A>	12329851	Mar 17, 2042	U-4214			
<u>RISPERIDONE - UZEDY</u>						
N 213586 005 >A>	12329851	Mar 17, 2042	U-4214			
<u>RISPERIDONE - UZEDY</u>						
N 213586 006 >A>	12329851	Mar 17, 2042	U-4214			
<u>RISPERIDONE - UZEDY</u>						
N 213586 007 >A>	12329851	Mar 17, 2042	U-4214			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	12310956	Jun 07, 2037	U-3748			
>A>	12336983	Jun 07, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 002	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	12310956	Jun 07, 2037	U-3970			
>A>	12336983	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001	11129818	Aug 25, 2037	U-3773		>A> I-969	May 22, 2028
	11129818	Aug 25, 2037	U-4203			
	11819496	Jun 07, 2037	U-3773			
	11819496	Jun 07, 2037	U-4203			
	11992480	Jun 07, 2037	U-3773			
	11992480	Jun 07, 2037	U-4203			
	12005051	Jun 07, 2037	U-3773			
	12005051	Jun 07, 2037	U-4203			
	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	12310956	Jun 07, 2037	U-3773			
	12310956	Jun 07, 2037	U-4203			
>A>	12329751	Dec 03, 2041	U-3773			
>A>	12336983	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	U-3773			
	9907788	Jun 07, 2037	U-4203			
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	12226419	May 20, 2031	DP			
	12233067	Jul 28, 2040	U-4151			
<u>SEBETRALSTAT - EKTERLY</u>						
N 219301 001	>A> 10364238	Nov 26, 2035	DS DP		>A> NCE	Jul 03, 2030
	>A> 10611758	Nov 26, 2035	U-4223			
	>A> 11001578	Nov 26, 2035	DS DP			
	>A> 11084809	Nov 26, 2035	DS DP	U-4223		
	>A> 11198691	Nov 26, 2035	U-4223			
	>A> 11230537	Dec 25, 2037	DS DP			
	>A> 11234939	Jan 26, 2039	DP	U-4223		
	>A> 11739068	Jun 23, 2037	U-4223			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	12280037	Dec 11, 2041	U-3302			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 002	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 003	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 004	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 005	10519139	Aug 14, 2035	DS DP	U-2584	ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP	U-2855	ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP	U-3018	ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u>						
N 212306 005	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 001					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	Sep 21, 2029
					ODE*	Sep 21, 2029
					ODE*	May 29, 2031
					ODE*	May 29, 2031
					ODE*	May 29, 2031
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 002					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	Sep 21, 2029
					ODE*	Sep 21, 2029
					ODE*	May 29, 2031
					ODE*	May 29, 2031
					ODE*	May 29, 2031
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 003					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	Sep 21, 2029
					ODE*	Sep 21, 2029
					ODE*	May 29, 2031
					ODE*	May 29, 2031
					ODE*	May 29, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160	004				M-311	Sep 27, 2027
					M-312	Sep 27, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	Sep 21, 2029
					ODE*	Sep 21, 2029
					ODE*	May 29, 2031
					ODE*	May 29, 2031
					ODE*	May 29, 2031
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756	001	12220403	Mar 26, 2029	DP		
		12318367	Mar 26, 2029	DP		
		7425637	Mar 13, 2026	DS		
		8178693	Mar 13, 2026	DS DP		
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756	002	12220403	Mar 26, 2029	DP		
		12318367	Mar 26, 2029	DP		
		7425637	Mar 13, 2026	DS		
		8178693	Mar 13, 2026	DS DP		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	001	10220155	Jul 17, 2026	DP	Y	I-961 Jan 28, 2028
		10357616	Jan 20, 2026	DP	Y	
		10376652	Jan 20, 2026	DP	Y	
		11097063	Jul 17, 2026	DP	Y	
		8684969	Oct 20, 2025	DP	Y	
		8920383	Jul 17, 2026	DP	Y	
		9108002	Jan 20, 2026	DP	Y	
		9132239	Feb 01, 2032	DP	Y	
		9457154	Sep 27, 2027	DP	Y	
		9616180	Jan 20, 2026	DP	Y	
		9687611	Feb 27, 2027	DP	Y	
		9775953	Jul 17, 2026	DP	Y	
		9861757	Jan 20, 2026	DP	Y	
		RE46363	Aug 03, 2026	DP	Y	
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	002	10220155	Jul 17, 2026	DP	Y	I-961 Jan 28, 2028
		10357616	Jan 20, 2026	DP	Y	
		10376652	Jan 20, 2026	DP	Y	
		11097063	Jul 17, 2026	DP	Y	
		8684969	Oct 20, 2025	DP	Y	
		8920383	Jul 17, 2026	DP	Y	
		9108002	Jan 20, 2026	DP	Y	
		9132239	Feb 01, 2032	DP	Y	
		9457154	Sep 29, 2027	DP	Y	
		9616180	Jan 20, 2026	DP	Y	
		9687611	Feb 27, 2027	DP	Y	
		9775953	Jul 17, 2026	DP	Y	
		9861757	Jan 20, 2026	DP	Y	
		RE46363	Aug 03, 2026	DP	Y	
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	003	10220155	Jul 17, 2026	DP	Y	I-961 Jan 28, 2028
		10357616	Jan 20, 2026	DP	Y	
		10376652	Jan 20, 2026	DP	Y	
		11097063	Jul 17, 2026	DP	Y	
		12295988	Oct 10, 2038	U-2628		
		8684969	Oct 20, 2025	DP	Y	
		8920383	Jul 17, 2026	DP	Y	
		9108002	Jan 20, 2026	DP	Y	
		9132239	Feb 01, 2032	DP	Y	
		9457154	Sep 29, 2027	DP	Y	
		9616180	Jan 20, 2026	DP	Y	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 004	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10278923	May 02, 2034		U-2628		
	12239739	May 02, 2034	DS DP	U-2628		
	8536122	Mar 20, 2026	DS DP	U-2628		
	9278123	Dec 16, 2031	DP	U-2628		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10278923	May 02, 2034		U-2628		
	12239739	May 02, 2034	DS DP	U-2628		
	8536122	Mar 20, 2026	DS DP	U-2628		
	9278123	Dec 16, 2031	DP	U-2628		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10278923	May 02, 2034		U-2628		
	12239739	May 02, 2034	DS DP	U-2628		
	8536122	Mar 20, 2026	DS DP	U-2628		
	9278123	Dec 16, 2031	DP	U-2628		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 004	10278923	May 02, 2034	DS DP	U-2628		
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP	U-2628		
	8129343	Dec 05, 2031	DS DP	U-2628		
	8536122	Mar 20, 2026	DS DP	U-2628		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 005	10278923	May 02, 2034	DS DP	U-2628		
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP	U-2628		
	8129343	Dec 05, 2031	DS DP	U-2628		
	8536122	Mar 20, 2026	DS DP	U-2628		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 006	10278923	May 02, 2034	DS DP	U-2628		
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP	U-2628		
	8129343	Dec 05, 2031	DS DP	U-2628		
	8536122	Mar 20, 2026	DS DP	U-2628		
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	12214017	Aug 24, 2038	DP	U-3162		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12214017	Aug 24, 2038	DP U-3162			
<u>SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE</u>						
A 218853 001					>A> CGT	Jan 18, 2026
<u>SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE</u>						
A 218853 002					>A> CGT	Jan 18, 2026
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001	8039435	Aug 21, 2032	DS DP		NPP ODE-508 ODE-509	Dec 20, 2027 Dec 20, 2031 Dec 20, 2031
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	12186321	Dec 24, 2038	DP U-3582			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	11944602	Apr 23, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Apr 23, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	11944602	Apr 23, 2036	U-3889			
<u>SITAGLIPTIN HYDROCHLORIDE - BRYNOVIN</u>						
N 219122 001	11944621	Oct 23, 2040	DP			
	12295953	Oct 23, 2040	DP			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	12304813	Feb 10, 2030	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	12304813	Feb 10, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR - EPLUSA</u>						
N 214187 002					ODE*	Mar 19, 2027
<u>SOFPIRONIUM BROMIDE - SOFDRA</u>						
N 217347 001	12156865	May 22, 2034	DP U-2398			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
	12263145	Dec 30, 2042	U-3693			
	12318362	Mar 19, 2040	U-3765			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	12290495	Apr 01, 2034	U-2096			
	12290495	Apr 01, 2034	U-2494			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 003	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
<u>SUCCINYLCHOLINE CHLORIDE - SUCCINYLCHOLINE CHLORIDE</u>						
N 215143 001	12295932	Nov 02, 2041	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001					NPP	Dec 12, 2027
					PED	Jun 12, 2028
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002					NPP	Dec 12, 2027
					PED	Jun 12, 2028
<u>SUNVOZERTINIB - ZEGFROVY</u>						
N 219839 001	>A> 11007198	Jan 28, 2039	DS DP		>A> NCE	Jul 02, 2030
	>A> 11504375	Jan 28, 2039	DS DP U-3220			
	>A> 11896597	Jan 28, 2039	DS DP U-3220			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUNVOZERTINIB - ZEGFROVY</u>						
N 219839 002	>A> 11007198	Jan 28, 2039	DS DP		>A> NCE	Jul 02, 2030
	>A> 11504375	Jan 28, 2039	DS DP U-3220			
	>A> 11896597	Jan 28, 2039	DS DP U-3220			
<u>SUZETRIGINE - JOURNAVX</u>						
N 219209 001	11834441	Dec 04, 2040	DS DP U-4125		NCE	Jan 30, 2030
<u>TADALAFIL - TADLIO</u>						
N 214522 001	12186322	Dec 24, 2038	DP U-3397			
<u>TALETRECTINIB ADIPATE - IBTROZI</u>						
N 219713 001	9187489	Jun 03, 2033	DS DP U-4207		NCE	Jun 11, 2030
	9751887	Jun 03, 2033	DS DP U-4207			
<u>TAPINAROF - VTAMA</u>						
N 215272 001	10426743	May 19, 2036	U-2625		I-956	Dec 12, 2027
	10426743	May 19, 2036	U-4048			
	11497718	Nov 13, 2039	U-4048			
	11612573	May 19, 2036	U-2625			
	11612573	May 19, 2036	U-4048			
	11938099	Nov 13, 2039	U-4048			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	12201604	Jan 25, 2033	U-3003			
	12201604	Jan 25, 2033	U-3865			
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	12201604	Jan 25, 2033	U-3003			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	12161645	Sep 12, 2031	U-2853			
	12162865	May 21, 2034	U-2736			
	12168014	May 03, 2038	U-2736			
	12168014	May 03, 2038	U-2852			
	12168014	May 03, 2038	U-2853			
	12168015	Sep 12, 2031	DS DP			
	12168016	Sep 12, 2031	U-2736			
	12168016	Sep 12, 2031	U-2853			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001					NPP	Apr 04, 2028
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001					NPP	Apr 04, 2028
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	12310978	Feb 21, 2039	U-4194			
<u>TETRACAINE HYDROCHLORIDE - TETRACAINE HYDROCHLORIDE</u>						
A 217227 001					CGT	Jun 25, 2025
<u>THIOTEPA - TEPADINA AND SODIUM CHLORIDE</u>						
N 208264 003	9931458	May 31, 2037	DP			
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 002	11975013	Aug 16, 2041	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - TICAGRELOR</u>						
A 208390	001				PC	Oct 28, 2025
<u>TICAGRELOR - TICAGRELOR</u>						
A 208531	001				PC	Oct 28, 2025
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936	001	7396341	Oct 10, 2026	DP	Y	
		7396341*PED	Apr 10, 2027			
		7837235	Mar 13, 2028	DP	Y	
		7837235*PED	Sep 13, 2028			
		8733341	Oct 16, 2030	DP	Y	
		8733341*PED	Apr 16, 2031			
		9027967	Mar 31, 2027	DP	Y	
		9027967*PED	Sep 30, 2027			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936	002	7396341	Oct 10, 2026	DP	Y	
		7396341*PED	Apr 10, 2027			
		7837235	Mar 13, 2028	DP	Y	
		7837235*PED	Sep 13, 2028			
		8733341	Oct 16, 2030	DP	Y	
		8733341*PED	Apr 16, 2031			
		9027967	Mar 31, 2027	DP	Y	
		9027967*PED	Sep 30, 2027			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866	001	12295987	Dec 30, 2041	U-4192		
		12295987	Dec 30, 2041	U-4193		
	>A>	12343382	Jul 22, 2039	U-4229		
	>A>	12343382	Jul 22, 2039	U-4230		
	>A>	12343382	Jul 22, 2039	U-4231		
	>A>	12343382	Jul 22, 2039	U-4232		
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866	002	12295987	Dec 30, 2041	U-4192		
		12295987	Dec 30, 2041	U-4193		
	>A>	12343382	Jul 22, 2039	U-4229		
	>A>	12343382	Jul 22, 2039	U-4230		
	>A>	12343382	Jul 22, 2039	U-4231		
	>A>	12343382	Jul 22, 2039	U-4232		
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866	003	12295987	Dec 30, 2041	U-4192		
		12295987	Dec 30, 2041	U-4193		
	>A>	12343382	Jul 22, 2039	U-4229		
	>A>	12343382	Jul 22, 2039	U-4230		
	>A>	12343382	Jul 22, 2039	U-4231		
	>A>	12343382	Jul 22, 2039	U-4232		
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866	004	12295987	Dec 30, 2041	U-4192		
		12295987	Dec 30, 2041	U-4193		
	>A>	12343382	Jul 22, 2039	U-4229		
	>A>	12343382	Jul 22, 2039	U-4230		
	>A>	12343382	Jul 22, 2039	U-4231		
	>A>	12343382	Jul 22, 2039	U-4232		
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866	005	12295987	Dec 30, 2041	U-4192		
		12295987	Dec 30, 2041	U-4193		
	>A>	12343382	Jul 22, 2039	U-4229		
	>A>	12343382	Jul 22, 2039	U-4230		
	>A>	12343382	Jul 22, 2039	U-4231		
	>A>	12343382	Jul 22, 2039	U-4232		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 006	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	>A> 12343382	Jul 22, 2039	U-4229			
	>A> 12343382	Jul 22, 2039	U-4230			
	>A> 12343382	Jul 22, 2039	U-4231			
	>A> 12343382	Jul 22, 2039	U-4232			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	>A> 12343382	Jul 22, 2039	U-4229			
	>A> 12343382	Jul 22, 2039	U-4230			
	>A> 12343382	Jul 22, 2039	U-4231			
	>A> 12343382	Jul 22, 2039	U-4232			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	>A> 12343382	Jul 22, 2039	U-4229			
	>A> 12343382	Jul 22, 2039	U-4230			
	>A> 12343382	Jul 22, 2039	U-4231			
	>A> 12343382	Jul 22, 2039	U-4232			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	>A> 12343382	Jul 22, 2039	U-4229			
	>A> 12343382	Jul 22, 2039	U-4230			
	>A> 12343382	Jul 22, 2039	U-4231			
	>A> 12343382	Jul 22, 2039	U-4232			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	>A> 12343382	Jul 22, 2039	U-4229			
	>A> 12343382	Jul 22, 2039	U-4230			
	>A> 12343382	Jul 22, 2039	U-4231			
	>A> 12343382	Jul 22, 2039	U-4232			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	>A> 12343382	Jul 22, 2039	U-4229			
	>A> 12343382	Jul 22, 2039	U-4230			
	>A> 12343382	Jul 22, 2039	U-4231			
	>A> 12343382	Jul 22, 2039	U-4232			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	>A> 12343382	Jul 22, 2039	U-4229			
	>A> 12343382	Jul 22, 2039	U-4230			
	>A> 12343382	Jul 22, 2039	U-4231			
	>A> 12343382	Jul 22, 2039	U-4232			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	>A> 12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	>A> 12343382	Jul 22, 2039	U-4228			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	>A> 12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	>A> 12343382	Jul 22, 2039	U-4228			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	>A> 12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	>A> 12343382	Jul 22, 2039	U-4228			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	>A> 12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	>A> 12343382	Jul 22, 2039	U-4228			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	>A> 12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	>A> 12343382	Jul 22, 2039	U-4228			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	>A> 12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	>A> 12343382	Jul 22, 2039	U-4228			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	>A> 12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	>A> 12343382	Jul 22, 2039	U-4228			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	>A> 12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	>A> 12343382	Jul 22, 2039	U-4228			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	>A> 12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	>A> 12343382	Jul 22, 2039	U-4228			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	>A> 12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	>A> 12343382	Jul 22, 2039	U-4228			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	>A> 12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	>A> 12343382	Jul 22, 2039	U-4228			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	>A> 12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	>A> 12343382	Jul 22, 2039	U-4228			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	7166722	Nov 16, 2028	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	7166722	Nov 16, 2028	DS DP			
<u>TIZANIDINE HYDROCHLORIDE - ONTRALFY</u>						
N 216190 001	12263158	May 07, 2042	DP U-2779			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
	11253523*PED	Sep 14, 2034				
	9937181	Mar 14, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	9937181*PED	Sep 14, 2034	DS			
	RE41783	Dec 08, 2025				
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	10639309	Mar 14, 2034	DP			
	10639309*PED	Sep 14, 2034				
	11253523	Mar 14, 2034		U-3326		
	11253523	Mar 14, 2034		U-3327		
	11253523	Mar 14, 2034		U-3328		
	11253523	Mar 14, 2034		U-3329		
	11253523*PED	Sep 14, 2034	DS			
	RE41783	Dec 08, 2025				
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 213082 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 001					PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 002					PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 003					PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 004					PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 005					PC	Nov 08, 2025
<u>TOPIRAMATE - TOPIRAMATE</u>						
A 217795 001					>A> PC	Jan 05, 2026
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	12290503	Aug 21, 2040	DP U-3413			
	12290503	Aug 21, 2040	DP U-3414			
	12290503	Aug 21, 2040	DP U-3415			
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001	12201555	Feb 14, 2031	DS DP			
	12201557	Jun 18, 2030	DS DP U-4129			
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 001	7199162	Mar 21, 2026	U-4142		NCE ODE-513 ODE-514	Jan 21, 2030 Jan 21, 2032 Jan 21, 2032
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 002	7199162	Mar 21, 2026	U-4142		NCE ODE-513 ODE-514	Jan 21, 2030 Jan 21, 2032 Jan 21, 2032
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	11357782	May 14, 2027	U-1849			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	11357782	May 14, 2027	U-1849			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	11357782	May 14, 2027	U-1849			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	11357782	May 14, 2027	U-1849			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 005	11357782	May 14, 2027	U-1849			
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005 001	10898494	May 05, 2037	U-4200		>A> NP	May 23, 2028
	11660304	May 05, 2037	U-4200			
	>A> 11712442	May 05, 2037	U-4200			
	11744835	May 05, 2037	DP			
	11744836	May 05, 2037	DP			
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005 002	10898494	May 05, 2037	U-4200		>A> NP	May 23, 2028
	11660304	May 05, 2037	U-4200			
	>A> 11712442	May 05, 2037	U-4200			
	11744835	May 05, 2037	DP			
	11744836	May 05, 2037	DP			
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005 003	10898494	May 05, 2037	U-4200		>A> NP	May 23, 2028
	11660304	May 05, 2037	U-4200			
	>A> 11712442	May 05, 2037	U-4200			
	11744835	May 05, 2037	DP			
	11744836	May 05, 2037	DP			
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005 004	10898494	May 05, 2037	U-4200		>A> NP	May 23, 2028
	11660304	May 05, 2037	U-4200			
	>A> 11712442	May 05, 2037	U-4200			
	11744835	May 05, 2037	DP			
	11744836	May 05, 2037	DP			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	12168666	Nov 13, 2040	DS DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	7452895	Nov 16, 2025	DS DP U-2788			
	7452895	Nov 16, 2025	DS DP U-4153			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	7452895	Nov 16, 2025	DS DP U-2788			
	7452895	Nov 16, 2025	DS DP U-4153			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	12168004	Jan 30, 2035	DP			
	12194030	Dec 22, 2041	U-4121			
	12194030	Dec 22, 2041	U-4122			
	12220408	Jan 30, 2035	DP			
	12310953	Jan 30, 2035	DP			
	>A> 12329750	Dec 22, 2041	U-4213			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	12168004	Jan 30, 2035	DP			
	12220408	Jan 30, 2035	DP			
	12310953	Jan 30, 2035	DP			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001					I-966	Apr 28, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	12201639	Mar 17, 2040	DS DP U-3747			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 001	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 002	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 003	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 004	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 005	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 006	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 007	12161690	Nov 06, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 003	12186362	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 004	12186362	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	12186362	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 006	12186362	Jan 30, 2035	DP			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	12180219	Mar 12, 2034	DS DP		I-955	Dec 18, 2027
	>A> 12357636	May 04, 2042	U-4219			
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001	12290499	Oct 17, 2042	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	9662338	Apr 02, 2035	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	9662338	Apr 02, 2035	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9662338	Apr 02, 2035	DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 001	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	12285430	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 002	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	12285430	Dec 23, 2039	U-4145			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 002	9181223	Mar 14, 2034	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 003	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	12285430	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001					NCE GAIN	May 03, 2027 May 03, 2032
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 002					NCE GAIN	May 03, 2027 May 03, 2032
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	12233106	Jul 11, 2042	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	12233106	Jul 11, 2042	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	12233106	Jul 11, 2042	U-3927			
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001					I-964	Mar 20, 2028
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 218785 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2537		ODE*	Nov 14, 2026
	10570139	Apr 22, 2034	U-2666		ODE*	Aug 31, 2028
	10570139	Apr 22, 2034	U-3063		ODE*	Sep 14, 2028
	10570139	Apr 22, 2034	U-3486		ODE*	Jan 19, 2030
	10570139	Apr 22, 2034	U-3860		ODE*	Mar 07, 2031
	10927117	Aug 15, 2037	DS DP			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11142528	Apr 22, 2034	DP U-3860			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	11591340	Aug 15, 2037	U-3727			
	11591340	Aug 15, 2037	U-3728			
	11591340	Aug 15, 2037	U-3729			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 218785 001	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	12233069	Jun 10, 2040	DP			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Aug 23, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Aug 23, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Aug 23, 2037	U-2552			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 45TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm